Carm1 inhibitors and uses thereof

ABSTRACT

Provided herein are compounds of Formula (I):and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein X, R1, R1a, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula:wherein L2, R13, G8, G10, G11, and G12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

RELATED APPLICATIONS

This application is a Continuation of U.S. patent application Ser. No.16/149,519, filed Oct. 2, 2018, now issued U.S. Pat. No. 10,633,389,which is a Continuation of U.S. patent application Ser. No. 15/835,758,filed Dec. 8, 2017, now issued U.S. Pat. No. 10,118,931, which is aContinuation Application of U.S. patent application Ser. No. 15/648,701,filed Jul. 13, 2017, now issued U.S. Pat. No. 9,856,267, which is aContinuation of U.S. patent application Ser. No. 14/775,766, filed Sep.14, 2015, now issued U.S. Pat. No. 9,738,651, which is a national stagefiling under 35 U.S.C. § 371 of International PCT applicationPCT/US2014/028463, filed Mar. 14, 2014 which claims priority under 35U.S.C. § 119(e) to U.S. provisional patent application, U.S. Ser. No.61/794,442, filed Mar. 15, 2013, and to U.S. provisional patentapplication, U.S. Ser. No. 61/937,333, filed Feb. 7, 2014, the entirecontents of each of which is incorporated herein by reference.

BACKGROUND OF THE INVENTION

Epigenetic regulation of gene expression is an important biologicaldeterminant of protein production and cellular differentiation and playsa significant pathogenic role in a number of human diseases.

Epigenetic regulation involves heritable modification of geneticmaterial without changing its nucleotide sequence. Typically, epigeneticregulation is mediated by selective and reversible modification (e.g.,methylation) of DNA and proteins (e.g., histones) that control theconformational transition between transcriptionally active and inactivestates of chromatin. These covalent modifications can be controlled byenzymes such as methyltransferases (e.g., CARM1 (co-activator-associatedarginine methyltransferase 1; PRMT4)), many of which are associated withspecific genetic alterations that can cause human disease.

Disease-associated chromatin-modifying enzymes play a role in diseasessuch as proliferative disorders, autoimmune disorders, musculardisorders, and neurological disorders. Thus, there is a need for thedevelopment of small molecules that are capable of inhibiting theactivity of CARM1.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A and B show cell proliferation in response to the presence ofcompounds of the current invention. Human Multiple Myeloma cell linesNCI-H929 (FIG. 1A) and U266B1 (FIG. 1B) were treated with varying dosesof 304-1a (medium grey data points), 23-3 (light grey data points), and113-3 (black data points) in a 14-day proliferation assay. At the end ofthe experiment, total cell number was determined for each cell line fordifferent doses of 304-1a, 23-3, and 113-3. As shown below, allcompounds tested decreased the proliferation of these cell lines, atpotencies consistent with that seen for the biochemical and cell-based(PABP1me2a) ICW (In Cell Western) assays.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

CARM1 is an attractive target for modulation given its role in theregulation of diverse biological processes. It has now been found thatcompounds described herein, and pharmaceutically acceptable salts andcompositions thereof, are effective as inhibitors of CARM1. Suchcompounds have the general Formula (I):

and pharmaceutically acceptable salts thereof, and pharmaceuticalcompositions thereof; wherein X, R¹, R^(a), R^(2a), R^(2b), R^(2c),R^(2d), are as defined herein, and wherein Ring HET is a 6-memberedmonocyclic heteroaryl ring system of Formula:

wherein L², R¹³, G₈, G₁₀, G₁₁, and G₁₂ are as defined herein. In certainembodiments of Formula (I), R^(1a) is hydrogen. In certain embodimentsof Formula (I), R¹ is not hydrogen, and R^(1a) is hydrogen. In certainembodiments of Formula (I), each of R¹ and R^(1a) is not hydrogen. Incertain embodiments of Formula (I), each of R¹ and R^(1a) is hydrogen. Anon-hydrogen group, as used herein, refers to any group recited as apossibility for that particular group but excluding hydrogen.

In some embodiments, pharmaceutical compositions are provided whichcomprise a compound described herein (e.g., a compound of Formula (I),or a pharmaceutically acceptable salt thereof) and optionally apharmaceutically acceptable excipient.

In certain embodiments, compounds described herein inhibit the activityof CARM1. In certain embodiments, methods of inhibiting CARM1 areprovided which comprise contacting CARM1 with an effective amount of acompound of Formula (I), or a pharmaceutically acceptable salt thereof.The CARM1 may be purified or crude, and may be present in a cell,tissue, or a subject. Thus, such methods encompass inhibition of CARM1activity both in vitro and in vivo. In certain embodiments, the CARM1 iswild-type CARM1. In certain embodiments, the CARM1 is overexpressed. Incertain embodiments, the CARM1 is a mutant. In certain embodiments, theCARM1 is in a cell. In certain embodiments, the CARM1 is in a tissue. Incertain embodiments, the CARM1 is in a biological sample. In certainembodiments, the CARM1 is in an animal, e.g., a human. In someembodiments, the CARM1 is expressed at normal levels in a subject, butthe subject would benefit from CARM1 inhibition (e.g., because thesubject has one or more mutations in an CARM1 substrate that causes anincrease in methylation of the substrate with normal levels of CARM1).In some embodiments, the CARM1 is in a subject known or identified ashaving abnormal CARM1 activity (e.g., overexpression). In someembodiments, the CARM1 is in a subject known or identified as havingaberrant CARM1 activity. In some embodiments, a provided compound isselective for CARM1 over other methyltransferases. In certainembodiments, a provided compound is at least about 10-fold selective, atleast about 20-fold selective, at least about 30-fold selective, atleast about 40-fold selective, at least about 50-fold selective, atleast about 60-fold selective, at least about 70-fold selective, atleast about 80-fold selective, at least about 90-fold selective, or atleast about 100-fold selective relative to one or more othermethyltransferases.

In certain embodiments, methods of modulating gene expression oractivity in a cell are provided which comprise contacting a cell with aneffective amount of a compound of Formula (I), or a pharmaceuticallyacceptable salt thereof, or a pharmaceutical composition thereof. Incertain embodiments, the cell is cultured in vitro. In certainembodiments, cell is in an animal, e.g., a human.

In certain embodiments, methods of modulating transcription in a cellare provided which comprise contacting a cell with an effective amountof a compound of Formula (I), or a pharmaceutically acceptable saltthereof, or a pharmaceutical composition thereof. In certainembodiments, the cell is cultured in vitro. In certain embodiments, thecell is in an animal, e.g., a human.

In some embodiments, methods of treating a CARM1-mediated disorder areprovided which comprise administering to a subject suffering from aCARM1-mediated disorder an effective amount of a compound describedherein (e.g., a compound of Formula (I), or a pharmaceuticallyacceptable salt thereof), or a pharmaceutical composition thereof. Incertain embodiments, the CARM1-mediated disorder is a proliferativedisorder. In certain embodiments, compounds described herein are usefulfor treating cancer. In certain embodiments, compounds described hereinare useful for treating breast cancer or prostate cancer. In certainembodiments, the CARM1-mediated disorder is a metabolic disorder.

Compounds described herein are also useful for the study of CARM1 inbiological and pathological phenomena, the study of intracellular signaltransduction pathways mediated by CARM1, and the comparative evaluationof new CARM1 inhibitors.

This application refers to various issued patent, published patentapplications, journal articles, and other publications, all of which areincorporated herein by reference.

Definitions of specific functional groups and chemical terms aredescribed in more detail below. The chemical elements are identified inaccordance with the Periodic Table of the Elements, CAS version,Handbook of Chemistry and Physics, 75^(th) Ed., inside cover, andspecific functional groups are generally defined as described therein.Additionally, general principles of organic chemistry, as well asspecific functional moieties and reactivity, are described in ThomasSorrell, Organic Chemistry, University Science Books, Sausalito, 1999;Smith and March, March's Advanced Organic Chemistry, 5^(th) Edition,John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive OrganicTransformations, VCH Publishers, Inc., New York, 1989; and Carruthers,Some Modern Methods of Organic Synthesis, 3^(rd) Edition, CambridgeUniversity Press, Cambridge, 1987.

Compounds described herein can comprise one or more asymmetric centers,and thus can exist in various isomeric forms, e.g., enantiomers and/ordiastereomers. For example, the compounds described herein can be in theform of an individual enantiomer, diastereomer or geometric isomer, orcan be in the form of a mixture of stereoisomers, including racemicmixtures and mixtures enriched in one or more stereoisomer. Isomers canbe isolated from mixtures by methods known to those skilled in the art,including chiral high pressure liquid chromatography (HPLC) and theformation and crystallization of chiral salts; or preferred isomers canbe prepared by asymmetric syntheses. See, for example, Jacques et al.,Enantiomers, Racemates and Resolutions (Wiley Interscience, New York,1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistryof Carbon Compounds (McGraw-Hill, N Y, 1962); and Wilen, Tables ofResolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ.of Notre Dame Press, Notre Dame, Ind. 1972). The present disclosureadditionally encompasses compounds described herein as individualisomers substantially free of other isomers, and alternatively, asmixtures of various isomers.

Unless otherwise stated, structures depicted herein are also meant toinclude compounds that differ only in the presence of one or moreisotopically enriched atoms. For example, compounds having the presentstructures except for the replacement of hydrogen by deuterium ortritium, replacement of ¹⁹F with ¹⁸F, or the replacement of a carbon by¹³C or ¹⁴C are within the scope of the disclosure. Such compounds areuseful, for example, as analytical tools or probes in biological assays.

When a range of values is listed, it is intended to encompass each valueand sub-range within the range. For example “C₁₋₆ alkyl” is intended toencompass, C₁, C₂, C₃, C₄, C₅, C₆, C₁₋₆, C₁₋₅, C₁₋₄, C₁₋₃, C₁₋₂, C₂₋₆,C₂₋₅, C₂₋₄, C₂₋₃, C₃₋₆, C₃₋₅, C₃₋₄, C₄₋₆, C₄₋₅, and C₅₋₆ alkyl.

“Aliphatic” refers to alkyl, alkenyl, alkynyl, and carbocyclic groups.

“Alkyl” refers to a radical of a straight-chain or branched saturatedhydrocarbon group having from 1 to 20 carbon atoms (“C₁₋₂₀ alkyl”). Insome embodiments, an alkyl group has 1 to 10 carbon atoms (“C₁₋₁₀alkyl”). In some embodiments, an alkyl group has 1 to 9 carbon atoms(“C₁₋₉ alkyl”). In some embodiments, an alkyl group has 1 to 8 carbonatoms (“C₁₋₈ alkyl”). In some embodiments, an alkyl group has 1 to 7carbon atoms (“C₁₋₇ alkyl”). In some embodiments, an alkyl group has 1to 6 carbon atoms (“C₁₋₆ alkyl”). In some embodiments, an alkyl grouphas 1 to 5 carbon atoms (“C₁₋₅ alkyl”). In some embodiments, an alkylgroup has 1 to 4 carbon atoms (“C₁₋₄ alkyl”). In some embodiments, analkyl group has 1 to 3 carbon atoms (“C₁₋₃ alkyl”). In some embodiments,an alkyl group has 1 to 2 carbon atoms (“C₁₋₂ alkyl”). In someembodiments, an alkyl group has 1 carbon atom (“C₁ alkyl”). In someembodiments, an alkyl group has 2 to 6 carbon atoms (“C₂₋₆ alkyl”).Examples of C₁₋₆ alkyl groups include methyl (C₁), ethyl (C₂), n-propyl(C₃), isopropyl (C₃), n-butyl (C₄), tert-butyl (C₄), sec-butyl (C₄),iso-butyl (C₄), n-pentyl (C₅), 3-pentanyl (C₅), amyl (C₅), neopentyl(C₅), 3-methyl-2-butanyl (C₅), tertiary amyl (C₅), and n-hexyl (C₆).Additional examples of alkyl groups include n-heptyl (C₇), n-octyl (C₈)and the like. In certain embodiments, each instance of an alkyl group isindependently optionally substituted, e.g., unsubstituted (an“unsubstituted alkyl”) or substituted (a “substituted alkyl”) with oneor more substituents. In certain embodiments, the alkyl group isunsubstituted C₁₋₁₀ alkyl (e.g., —CH₃). In certain embodiments, thealkyl group is substituted C₁₋₁₀ alkyl.

“Haloalkyl” refers to an alkyl group substituted with one or morehalogen atoms, e.g., 1, 2, 3, 4, 5, or 6 halogen atoms. Haloalkylencompasses perhaloalkyl as defined herein.

“Perhaloalkyl” is a substituted alkyl group as defined herein whereinall of the hydrogen atoms are independently replaced by a halogen, e.g.,fluoro, bromo, chloro, or iodo. In some embodiments, the alkyl moietyhas 1 to 8 carbon atoms (“C₁₋₈ perhaloalkyl”). In some embodiments, thealkyl moiety has 1 to 6 carbon atoms (“C₁₋₆ perhaloalkyl”). In someembodiments, the alkyl moiety has 1 to 4 carbon atoms (“C₁₋₄perhaloalkyl”). In some embodiments, the alkyl moiety has 1 to 3 carbonatoms (“C₁₋₃ perhaloalkyl”). In some embodiments, the alkyl moiety has 1to 2 carbon atoms (“C₁₋₂ perhaloalkyl”). In some embodiments, all of thehydrogen atoms are replaced with fluoro. In some embodiments, all of thehydrogen atoms are replaced with chloro. Examples of perhaloalkyl groupsinclude —CF₃, —CF₂CF₃, —CF₂CF₂CF₃, —CCl₃, —CFCl₂, —CF₂Cl, and the like.

“Alkenyl” refers to a radical of a straight-chain or branchedhydrocarbon group having from 2 to 20 carbon atoms, one or morecarbon-carbon double bonds (e.g., 1, 2, 3, or 4 double bonds), andoptionally one or more triple bonds (e.g., 1, 2, 3, or 4 triple bonds)(“C₂₋₂₀ alkenyl”). In certain embodiments, alkenyl does not comprisetriple bonds. In some embodiments, an alkenyl group has 2 to 10 carbonatoms (“C₂₋₁₀ alkenyl”). In some embodiments, an alkenyl group has 2 to9 carbon atoms (“C₂₋₉ alkenyl”). In some embodiments, an alkenyl grouphas 2 to 8 carbon atoms (“C₂₋₈ alkenyl”). In some embodiments, analkenyl group has 2 to 7 carbon atoms (“C₂₋₇ alkenyl”). In someembodiments, an alkenyl group has 2 to 6 carbon atoms (“C₂₋₆ alkenyl”).In some embodiments, an alkenyl group has 2 to 5 carbon atoms (“C₂₋₅alkenyl”). In some embodiments, an alkenyl group has 2 to 4 carbon atoms(“C₂₋₄ alkenyl”). In some embodiments, an alkenyl group has 2 to 3carbon atoms (“C₂₋₃ alkenyl”). In some embodiments, an alkenyl group has2 carbon atoms (“C₂ alkenyl”). The one or more carbon-carbon doublebonds can be internal (such as in 2-butenyl) or terminal (such as in1-butenyl). Examples of C₂₋₄ alkenyl groups include ethenyl (C₂),1-propenyl (C₃), 2-propenyl (C₃), 1-butenyl (C₄), 2-butenyl (C₄),butadienyl (C₄), and the like. Examples of C₂₋₆ alkenyl groups includethe aforementioned C₂₋₄ alkenyl groups as well as pentenyl (C₅),pentadienyl (C₅), hexenyl (C₆), and the like. Additional examples ofalkenyl include heptenyl (C₇), octenyl (C₈), octatrienyl (C₈), and thelike. In certain embodiments, each instance of an alkenyl group isindependently optionally substituted, e.g., unsubstituted (an“unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) withone or more substituents. In certain embodiments, the alkenyl group isunsubstituted C₂₋₁₀ alkenyl. In certain embodiments, the alkenyl groupis substituted C₂₋₁₀ alkenyl.

“Alkynyl” refers to a radical of a straight-chain or branchedhydrocarbon group having from 2 to 20 carbon atoms and one or morecarbon-carbon triple bonds (e.g., 1, 2, 3, or 4 triple bonds), andoptionally one or more double bonds (e.g., 1, 2, 3, or 4 double bonds)(“C₂₋₂₀ alkynyl”). In certain embodiments, alkynyl does not comprisedouble bonds. In some embodiments, an alkynyl group has 2 to 10 carbonatoms (“C₂₋₁₀ alkynyl”). In some embodiments, an alkynyl group has 2 to9 carbon atoms (“C₂₋₉ alkynyl”). In some embodiments, an alkynyl grouphas 2 to 8 carbon atoms (“C₂₋₈ alkynyl”). In some embodiments, analkynyl group has 2 to 7 carbon atoms (“C₂₋₇ alkynyl”). In someembodiments, an alkynyl group has 2 to 6 carbon atoms (“C₂₋₆ alkynyl”).In some embodiments, an alkynyl group has 2 to 5 carbon atoms (“C₂₋₈alkynyl”). In some embodiments, an alkynyl group has 2 to 4 carbon atoms(“C₂₋₄ alkynyl”). In some embodiments, an alkynyl group has 2 to 3carbon atoms (“C₂₋₃ alkynyl”). In some embodiments, an alkynyl group has2 carbon atoms (“C₂ alkynyl”). The one or more carbon-carbon triplebonds can be internal (such as in 2-butynyl) or terminal (such as in1-butynyl). Examples of C₂₋₄ alkynyl groups include, without limitation,ethynyl (C₂), 1-propynyl (C₃), 2-propynyl (C₃), 1-butynyl (C₄),2-butynyl (C₄), and the like. Examples of C₂₋₆ alkenyl groups includethe aforementioned C₂₋₄ alkynyl groups as well as pentynyl (C₅), hexynyl(C₆), and the like. Additional examples of alkynyl include heptynyl(C₇), octynyl (C₈), and the like. In certain embodiments, each instanceof an alkynyl group is independently optionally substituted, e.g.,unsubstituted (an “unsubstituted alkynyl”) or substituted (a“substituted alkynyl”) with one or more substituents. In certainembodiments, the alkynyl group is unsubstituted C₂₋₁₀ alkynyl. Incertain embodiments, the alkynyl group is substituted C₂₋₁₀ alkynyl.

“Carbocyclyl” or “carbocyclic” refers to a radical of a non-aromaticcyclic hydrocarbon group having from 3 to 14 ring carbon atoms (“C₃₋₁₄carbocyclyl”) and zero heteroatoms in the non-aromatic ring system. Insome embodiments, a carbocyclyl group has 3 to 10 ring carbon atoms(“C₃₋₁₀ carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to8 ring carbon atoms (“C₃₋₈ carbocyclyl”). In some embodiments, acarbocyclyl group has 3 to 7 ring carbon atoms (“C₃₋₇ carbocyclyl”). Insome embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms(“C₃₋₆ carbocyclyl”). In some embodiments, a carbocyclyl group has 5 to10 ring carbon atoms (“C₅₋₁₀ carbocyclyl”). Exemplary C₃₋₆ carbocyclylgroups include, without limitation, cyclopropyl (C₃), cyclopropenyl(C₃), cyclobutyl (C₄), cyclobutenyl (C₄), cyclopentyl (C₅),cyclopentenyl (C₅), cyclohexyl (C₆), cyclohexenyl (C₆), cyclohexadienyl(C₆), and the like. Exemplary C₃₋₈ carbocyclyl groups include, withoutlimitation, the aforementioned C₃₋₆ carbocyclyl groups as well ascycloheptyl (C₇), cycloheptenyl (C₇), cycloheptadienyl (C₇),cycloheptatrienyl (C₇), cyclooctyl (C₈), cyclooctenyl (C₈),bicyclo[2.2.1]heptanyl (C₇), bicyclo[2.2.2]octanyl (C₈), and the like.Exemplary C₃₋₁₀ carbocyclyl groups include, without limitation, theaforementioned C₃₋₈ carbocyclyl groups as well as cyclononyl (C₉),cyclononenyl (C₉), cyclodecyl (C₁₀), cyclodecenyl (C₁₀),octahydro-1H-indenyl (C₉), decahydronaphthalenyl (C₁₀),spiro[4.5]decanyl (C₁₀), and the like. As the foregoing examplesillustrate, in certain embodiments, the carbocyclyl group is eithermonocyclic (“monocyclic carbocyclyl”) or contain a fused, bridged orspiro ring system such as a bicyclic system (“bicyclic carbocyclyl”) ortricyclic system (“tricyclic carbocyclyl”), and can be saturated or canbe partially unsaturated. “Carbocyclyl” also includes ring systemswherein the carbocyclyl ring, as defined above, is fused with one ormore aryl or heteroaryl groups wherein the point of attachment is on thecarbocyclyl ring, and in such instances, the number of carbons continueto designate the number of carbons in the carbocyclic ring system. Incertain embodiments, each instance of a carbocyclyl group isindependently optionally substituted, e.g., unsubstituted (an“unsubstituted carbocyclyl”) or substituted (a “substitutedcarbocyclyl”) with one or more substituents. In certain embodiments, thecarbocyclyl group is unsubstituted C₃₋₁₀ carbocyclyl. In certainembodiments, the carbocyclyl group is a substituted C₃₋₁₀ carbocyclyl.

In some embodiments, “carbocyclyl” is a monocyclic, saturatedcarbocyclyl group having from 3 to 14 ring carbon atoms (“C₃₋₁₄cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 10 ringcarbon atoms (“C₃₋₁₀ cycloalkyl”). In some embodiments, a cycloalkylgroup has 3 to 8 ring carbon atoms (“C₃₋₈ cycloalkyl”). In someembodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (“C₃₋₆cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 6 ringcarbon atoms (“C₅₋₆ cycloalkyl”). In some embodiments, a cycloalkylgroup has 5 to 10 ring carbon atoms (“C₅₋₁₀ cycloalkyl”). Examples ofC₅₋₆ cycloalkyl groups include cyclopentyl (C₅) and cyclohexyl (C₅).Examples of C₃₋₆ cycloalkyl groups include the aforementioned C₅₋₆cycloalkyl groups as well as cyclopropyl (C₃) and cyclobutyl (C₄).Examples of C₃₋₈ cycloalkyl groups include the aforementioned C₃₋₆cycloalkyl groups as well as cycloheptyl (C₇) and cyclooctyl (C₈). Incertain embodiments, each instance of a cycloalkyl group isindependently unsubstituted (an “unsubstituted cycloalkyl”) orsubstituted (a “substituted cycloalkyl”) with one or more substituents.In certain embodiments, the cycloalkyl group is unsubstituted C₃₋₁₀cycloalkyl. In certain embodiments, the cycloalkyl group is substitutedC₃₋₁₀ cycloalkyl.

“Heterocyclyl” or “heterocyclic” refers to a radical of a 3-14 memberednon-aromatic ring system having ring carbon atoms and 1 to 4 ringheteroatoms, wherein each heteroatom is independently selected fromnitrogen, oxygen, and sulfur (“3-14 membered heterocyclyl”). In someembodiments, a heterocyclyl group is a 3-10 membered non-aromatic ringsystem having ring carbon atoms and 1-4 ring heteroatoms, wherein eachheteroatom is independently selected from nitrogen, oxygen, and sulfur(“3-10 membered heterocyclyl”). In heterocyclyl groups that contain oneor more nitrogen atoms, the point of attachment can be a carbon ornitrogen atom, as valency permits. A heterocyclyl group can either bemonocyclic (“monocyclic heterocyclyl”) or a fused, bridged or spiro ringsystem such as a bicyclic system (“bicyclic heterocyclyl”) or tricyclicsystem (“tricyclic heterocyclyl”), and can be saturated or can bepartially unsaturated. Heterocyclyl bicyclic ring systems can includeone or more heteroatoms in one or both rings. “Heterocyclyl” alsoincludes ring systems wherein the heterocyclyl ring, as defined above,is fused with one or more carbocyclyl groups wherein the point ofattachment is either on the carbocyclyl or heterocyclyl ring, or ringsystems wherein the heterocyclyl ring, as defined above, is fused withone or more aryl or heteroaryl groups, wherein the point of attachmentis on the heterocyclyl ring, and in such instances, the number of ringmembers continue to designate the number of ring members in theheterocyclyl ring system. In certain embodiments, each instance ofheterocyclyl is independently optionally substituted, e.g.,unsubstituted (an “unsubstituted heterocyclyl”) or substituted (a“substituted heterocyclyl”) with one or more substituents. In certainembodiments, the heterocyclyl group is unsubstituted 3-10 memberedheterocyclyl. In certain embodiments, the heterocyclyl group issubstituted 3-10 membered heterocyclyl.

In some embodiments, a heterocyclyl group is a 5-10 memberednon-aromatic ring system having ring carbon atoms and 1-4 ringheteroatoms, wherein each heteroatom is independently selected fromnitrogen, oxygen, and sulfur (“5-10 membered heterocyclyl”). In someembodiments, a heterocyclyl group is a 5-8 membered non-aromatic ringsystem having ring carbon atoms and 1-4 ring heteroatoms, wherein eachheteroatom is independently selected from nitrogen, oxygen, and sulfur(“5-8 membered heterocyclyl”). In some embodiments, a heterocyclyl groupis a 5-6 membered non-aromatic ring system having ring carbon atoms and1-4 ring heteroatoms, wherein each heteroatom is independently selectedfrom nitrogen, oxygen, and sulfur (“5-6 membered heterocyclyl”). In someembodiments, the 5-6 membered heterocyclyl has 1-3 ring heteroatomsselected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen,oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclylhas one ring heteroatom selected from nitrogen, oxygen, and sulfur.

Exemplary 3-membered heterocyclyl groups containing one heteroatominclude, without limitation, azirdinyl, oxiranyl, and thiiranyl.Exemplary 4-membered heterocyclyl groups containing one heteroatominclude, without limitation, azetidinyl, oxetanyl, and thietanyl.Exemplary 5-membered heterocyclyl groups containing one heteroatominclude, without limitation, tetrahydrofuranyl, dihydrofuranyl,tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl,and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclyl groupscontaining two heteroatoms include, without limitation, dioxolanyl,oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-memberedheterocyclyl groups containing three heteroatoms include, withoutlimitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary6-membered heterocyclyl groups containing one heteroatom include,without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl,and thianyl. Exemplary 6-membered heterocyclyl groups containing twoheteroatoms include, without limitation, piperazinyl, morpholinyl,dithianyl, and dioxanyl. Exemplary 6-membered heterocyclyl groupscontaining three heteroatoms include, without limitation, triazinanyl.Exemplary 7-membered heterocyclyl groups containing one heteroatominclude, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary8-membered heterocyclyl groups containing one heteroatom include,without limitation, azocanyl, oxecanyl, and thiocanyl. Exemplary5-membered heterocyclyl groups fused to a C₆ aryl ring (also referred toherein as a 5,6-bicyclic heterocyclic ring) include, without limitation,indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl,benzoxazolinonyl, and the like. Exemplary 6-membered heterocyclyl groupsfused to an aryl ring (also referred to herein as a 6,6-bicyclicheterocyclic ring) include, without limitation, tetrahydroquinolinyl,tetrahydroisoquinolinyl, and the like.

“Aryl” refers to a radical of a monocyclic or polycyclic (e.g., bicyclicor tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 Telectrons shared in a cyclic array) having 6-14 ring carbon atoms andzero heteroatoms provided in the aromatic ring system (“C₆₋₁₄ aryl”). Insome embodiments, an aryl group has six ring carbon atoms (“C₆ aryl”;e.g., phenyl). In some embodiments, an aryl group has ten ring carbonatoms (“C₁₀ aryl”; e.g., naphthyl such as 1-naphthyl and 2-naphthyl). Insome embodiments, an aryl group has fourteen ring carbon atoms (“C₁₄aryl”; e.g., anthracyl). “Aryl” also includes ring systems wherein thearyl ring, as defined above, is fused with one or more carbocyclyl orheterocyclyl groups wherein the radical or point of attachment is on thearyl ring, and in such instances, the number of carbon atoms continue todesignate the number of carbon atoms in the aryl ring system. In certainembodiments, each instance of an aryl group is independently optionallysubstituted, e.g., unsubstituted (an “unsubstituted aryl”) orsubstituted (a “substituted aryl”) with one or more substituents. Incertain embodiments, the aryl group is unsubstituted C₆₋₁₄ aryl. Incertain embodiments, the aryl group is substituted C₆₋₁₄ aryl.

“Heteroaryl” refers to a radical of a 5-14 membered monocyclic orpolycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system(e.g., having 6 or 10 T electrons shared in a cyclic array) having ringcarbon atoms and 1-4 ring heteroatoms provided in the aromatic ringsystem, wherein each heteroatom is independently selected from nitrogen,oxygen and sulfur (“5-14 membered heteroaryl”). In some embodiments,heteroaryl refers to a radical of a 5-10 membered monocyclic or bicyclic4n+2 aromatic ring system (e.g., having 6 or 10 n electrons shared in acyclic array) having ring carbon atoms and 1-4 ring heteroatoms providedin the aromatic ring system, wherein each heteroatom is independentlyselected from nitrogen, oxygen and sulfur (“5-10 membered heteroaryl”).In heteroaryl groups that contain one or more nitrogen atoms, the pointof attachment can be a carbon or nitrogen atom, as valency permits.Heteroaryl bicyclic ring systems can include one or more heteroatoms inone or both rings. “Heteroaryl” includes ring systems wherein theheteroaryl ring, as defined above, is fused with one or more carbocyclylor heterocyclyl groups wherein the point of attachment is on theheteroaryl ring, and in such instances, the number of ring memberscontinue to designate the number of ring members in the heteroaryl ringsystem. “Heteroaryl” also includes ring systems wherein the heteroarylring, as defined above, is fused with one or more aryl groups whereinthe point of attachment is either on the aryl or heteroaryl ring, and insuch instances, the number of ring members designates the number of ringmembers in the fused (aryl/heteroaryl) ring system. Bicyclic heteroarylgroups wherein one ring does not contain a heteroatom (e.g., indolyl,quinolinyl, carbazolyl, and the like) the point of attachment can be oneither ring, e.g., either the ring bearing a heteroatom (e.g.,2-indolyl) or the ring that does not contain a heteroatom (e.g.,5-indolyl).

In some embodiments, a heteroaryl group is a 5-10 membered aromatic ringsystem having ring carbon atoms and 1-4 ring heteroatoms provided in thearomatic ring system, wherein each heteroatom is independently selectedfrom nitrogen, oxygen, and sulfur (“5-10 membered heteroaryl”). In someembodiments, a heteroaryl group is a 5-8 membered aromatic ring systemhaving ring carbon atoms and 1-4 ring heteroatoms provided in thearomatic ring system, wherein each heteroatom is independently selectedfrom nitrogen, oxygen, and sulfur (“5-8 membered heteroaryl”). In someembodiments, a heteroaryl group is a 5-6 membered aromatic ring systemhaving ring carbon atoms and 1-4 ring heteroatoms provided in thearomatic ring system, wherein each heteroatom is independently selectedfrom nitrogen, oxygen, and sulfur (“5-6 membered heteroaryl”). In someembodiments, the 5-6 membered heteroaryl has 1-3 ring heteroatomsselected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen,oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has1 ring heteroatom selected from nitrogen, oxygen, and sulfur. In certainembodiments, each instance of a heteroaryl group is independentlyoptionally substituted, e.g., unsubstituted (“unsubstituted heteroaryl”)or substituted (“substituted heteroaryl”) with one or more substituents.In certain embodiments, the heteroaryl group is unsubstituted 5-14membered heteroaryl. In certain embodiments, the heteroaryl group issubstituted 5-14 membered heteroaryl.

Exemplary 5-membered heteroaryl groups containing one heteroatominclude, without limitation, pyrrolyl, furanyl and thiophenyl. Exemplary5-membered heteroaryl groups containing two heteroatoms include, withoutlimitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, andisothiazolyl. Exemplary 5-membered heteroaryl groups containing threeheteroatoms include, without limitation, triazolyl, oxadiazolyl, andthiadiazolyl. Exemplary 5-membered heteroaryl groups containing fourheteroatoms include, without limitation, tetrazolyl. Exemplary6-membered heteroaryl groups containing one heteroatom include, withoutlimitation, pyridinyl. Exemplary 6-membered heteroaryl groups containingtwo heteroatoms include, without limitation, pyridazinyl, pyrimidinyl,and pyrazinyl. Exemplary 6-membered heteroaryl groups containing threeor four heteroatoms include, without limitation, triazinyl andtetrazinyl, respectively. Exemplary 7-membered heteroaryl groupscontaining one heteroatom include, without limitation, azepinyl,oxepinyl, and thiepinyl. Exemplary 5,6-bicyclic heteroaryl groupsinclude, without limitation, indolyl, isoindolyl, indazolyl,benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl,benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl,benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl,indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groupsinclude, without limitation, naphthyridinyl, pteridinyl, quinolinyl,isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.

“Fused” or “ortho-fused” are used interchangeably herein, and refer totwo rings that have two atoms and one bond in common, e.g.,

“Bridged” refers to a ring system containing (1) a bridgehead atom orgroup of atoms which connect two or more non-adjacent positions of thesame ring; or (2) a bridgehead atom or group of atoms which connect twoor more positions of different rings of a ring system and does notthereby form an ortho-fused ring, e.g.,

“Spiro” or “Spiro-fused” refers to a group of atoms which connect to thesame atom of a carbocyclic or heterocyclic ring system (geminalattachment), thereby forming a

Spiro-fusion at a bridgehead atom is also contemplated.

“Partially unsaturated” refers to a group that includes at least onedouble or triple bond. The term “partially unsaturated” is intended toencompass rings having multiple sites of unsaturation, but is notintended to include aromatic groups (e.g., aryl or heteroaryl groups) asherein defined. Likewise, “saturated” refers to a group that does notcontain a double or triple bond, i.e., contains all single bonds.

In some embodiments, alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl,aryl, and heteroaryl groups, as defined herein, are optionallysubstituted (e.g., “substituted” or “unsubstituted” alkyl, “substituted”or “unsubstituted” alkenyl, “substituted” or “unsubstituted” alkynyl,“substituted” or “unsubstituted” carbocyclyl, “substituted” or“unsubstituted” heterocyclyl, “substituted” or “unsubstituted” aryl or“substituted” or “unsubstituted” heteroaryl group). In general, the term“substituted”, whether preceded by the term “optionally” or not, meansthat at least one hydrogen present on a group (e.g., a carbon ornitrogen atom) is replaced with a permissible substituent, e.g., asubstituent which upon substitution results in a stable compound, e.g.,a compound which does not spontaneously undergo transformation such asby rearrangement, cyclization, elimination, or other reaction. Unlessotherwise indicated, a “substituted” group has a substituent at one ormore substitutable positions of the group, and when more than oneposition in any given structure is substituted, the substituent iseither the same or different at each position. The term “substituted” iscontemplated to include substitution with all permissible substituentsof organic compounds, including any of the substituents described hereinthat results in the formation of a stable compound. The presentdisclosure contemplates any and all such combinations in order to arriveat a stable compound. For purposes of this disclosure, heteroatoms suchas nitrogen may have hydrogen substituents and/or any suitablesubstituent as described herein which satisfy the valencies of theheteroatoms and results in the formation of a stable moiety.

Exemplary carbon atom substituents include, but are not limited to,halogen, —CN, —NO₂, —N₃, —SO₂H, —SO₃H, —OH, —OR^(aa), —ON(R^(bb))₂,—N(R^(bb))₂, —N(R^(bb))₃ ⁺X⁻, —N(OR^(cc))R^(bb), —SH, —SR^(aa)—,—SSR^(cc), —C(═O)R^(aa), —CO₂H, —CHO, —C(OR^(cc))₂, —CO₂R^(aa),—OC(═O)R^(aa), —OCO₂R^(aa), —C(═O)N(R^(bb))₂, —OC(═O)N(R^(bb))₂,—NR^(bb)C(═O)R^(aa), —NR^(bb)CO₂R^(aa), —NR^(bb)C(═O)N(R^(bb))₂,—C(═NR^(bb))R^(aa), —C(═NR^(bb))OR^(aa), —OC(═NR^(bb))R^(aa),—OC(═NR^(bb))OR^(aa), —C(═NR^(bb))N(R^(bb))₂, —OC(═NR^(bb))N(R^(bb))₂,—NR^(bb)C(═NR^(bb))N(R^(bb))₂, —C(═O)NR^(bb)SO₂R^(aa),—NR^(bb)SO₂R^(aa), —SO₂N(R^(bb))₂, —SO₂R^(aa), —SO₂OR^(aa), —OSO₂R^(aa),—S(═O)R^(aa), —OS(═O)R^(aa), —Si(R^(aa))₃,—OSi(R^(aa))₃—C(═S)N(R^(bb))₂, —C(═O)SR^(aa), —C(═S)SR^(aa),—SC(═S)SR^(aa), —SC(═O)SR^(aa), —OC(═O)SR^(aa), —SC(═O)OR^(aa),—SC(═O)R^(aa), —P(═O)₂R^(aa), —OP(═O)₂R^(aa), —P(═O)(R^(aa))₂,—OP(═O)(R^(aa))₂, —OP(═O)(OR^(cc))₂, —P(═O)₂N(R^(bb))₂,—OP(═O)₂N(R^(bb))₂, —P(═O)(NR^(bb))₂, —OP(═O)(NR^(bb))₂,—NR^(bb)P(═O)(OR^(cc))₂, —NR^(bb)P(═O)(NR^(bb))₂, —P(R^(cc))₂,—P(R^(cc))₃, —OP(R^(cc))₂, —OP(R^(cc))₃, —B(R^(aa))₂, —B(OR^(cc))₂,—BR′(OR^(cc)), C₁₋₁₀ alkyl, C₁₋₁₀ perhaloalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀alkynyl, C₃₋₁₀ carbocyclyl, 3-14 membered heterocyclyl, C₆₋₁₄ aryl, and5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl,carbocyclyl, heterocyclyl, aryl, and heteroaryl is independentlysubstituted with 0, 1, 2, 3, 4, or 5 R^(dd) groups;

or two geminal hydrogens on a carbon atom are replaced with the group═O, ═S, ═NN(R^(bb))₂, ═NNR^(bb)C(═O)R^(aa), ═NNR^(bb)C(═O)OR^(aa),═NNR^(bb)S(═O)₂R^(aa), ═NR^(bb), or ═NOR^(cc);

each instance of R^(aa) is, independently, selected from C₁₋₁₀ alkyl,C₁₋₁₀ perhaloalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₁₀ carbocyclyl,3-14 membered heterocyclyl, C₆₋₁₄ aryl, and 5-14 membered heteroaryl, ortwo R^(aa) groups are joined to form a 3-14 membered heterocyclyl or5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl,carbocyclyl, heterocyclyl, aryl, and heteroaryl is independentlysubstituted with 0, 1, 2, 3, 4, or 5 R^(dd) groups;

each instance of R^(bb) is, independently, selected from hydrogen, —OH,—OR^(aa), —N(R^(cc))₂, —CN, —C(═O)R^(aa), —C(═O)N(R^(cc))₂, —CO₂R^(aa),—SO₂R^(aa), —C(═NR^(cc))OR^(aa), —C(═NR^(cc))N(R^(cc))₂, —SO₂N(R^(cc))₂,—SO₂R^(cc), —SO₂OR^(cc), —SOR^(aa), —C(═S)N(R^(cc))₂, —C(═O)SR^(cc),—C(═S)SR^(cc), —P(═O)₂R^(aa), —P(═O)(R^(aa))₂, —P(═O)₂N(R^(cc))₂,—P(═O)(NR^(cc))₂, C₁₋₁₀ alkyl, C₁₋₁₀ perhaloalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀alkynyl, C₃₋₁₀ carbocyclyl, 3-14 membered heterocyclyl, C₆₋₁₄ aryl, and5-14 membered heteroaryl, or two R^(bb) groups are joined to form a 3-14membered heterocyclyl or 5-14 membered heteroaryl ring, wherein eachalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroarylis independently substituted with 0, 1, 2, 3, 4, or 5 R^(dd) groups;

each instance of R^(cc) is, independently, selected from hydrogen, C₁₋₁₀alkyl, C₁₋₁₀ perhaloalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₁₀carbocyclyl, 3-14 membered heterocyclyl, C₆₋₁₄ aryl, and 5-14 memberedheteroaryl, or two R^(cc) groups are joined to form a 3-14 memberedheterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl,alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl isindependently substituted with 0, 1, 2, 3, 4, or 5 R^(dd) groups;

each instance of R^(dd) is, independently, selected from halogen, —CN,—NO₂, —N₃, —SO₂H, —SO₃H, —OH, —OR^(ee), —ON(R^(ff))₂, —N(R^(ff))₂,—N(R^(ff))₃ ⁺X⁻, —N(OR^(ee))R^(ff), —SH, —SR^(ee), —SSR^(ee),—C(═O)R^(ee), —CO₂H, —CO₂R^(ee), —OC(═O)R^(ee), —OCO₂R^(ee),—C(═O)N(R^(ff))₂, —OC(═O)N(R^(ff))₂, —NR^(ff)C(═O)R^(ee),—NR^(ff)CO₂R^(ee), —NR^(ff)C(═O)N(R^(ff))₂, —C(═NR^(ff))OR^(ee),—OC(═NR^(ff))R^(ee), —OC(═NR^(ff))OR^(ee), —C(═NR^(ff))N(R^(ff))₂,—OC(═NR^(ff))N(R^(ff))₂, —NR^(ff)C(═NR^(ff))N(R^(ff))₂,—NR^(ff)SO₂R^(ee), —SO₂N(Re)₂, —SO₂R^(ee), —SO₂OR^(ee), —OSO₂R^(ee),—S(═O)R^(ee), —Si(R^(ee))₃, —OSi(R^(ee))₃, —C(═S)N(R^(ff))₂,—C(═O)SR^(ee), —C(═S)SR^(ee), —SC(═S)SR^(ee), —P(═O)₂R^(ee),—P(═O)(R^(ee))₂, —OP(═O)(R^(ee))₂, —OP(═O)(OR^(ee))₂, C₁₋₆ alkyl, C₁₋₆perhaloalkyl, C₂₋₆ alkenyl, C₂-6 alkynyl, C₃₋₁₀ carbocyclyl, 3-10membered heterocyclyl, C₆₋₁₀ aryl, 5-10 membered heteroaryl, whereineach alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, andheteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R^(gg)groups, or two geminal R^(dd) substituents can be joined to form ═O or═S;

each instance of R^(ee) is, independently, selected from C₁₋₆ alkyl,C₁₋₆ perhaloalkyl, C₂-6 alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ carbocyclyl, C₆₋₁₀aryl, 3-10 membered heterocyclyl, and 3-10 membered heteroaryl, whereineach alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, andheteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R^(gg)groups;

each instance of R^(ff) is, independently, selected from hydrogen, C₁₋₆alkyl, C₁₋₆ perhaloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ carbocyclyl,3-10 membered heterocyclyl, C₆₋₁₀ aryl and 5-10 membered heteroaryl, ortwo R^(ff) groups are joined to form a 3-14 membered heterocyclyl or5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl,carbocyclyl, heterocyclyl, aryl, and heteroaryl is independentlysubstituted with 0, 1, 2, 3, 4, or 5 R^(gg) groups; and

each instance of R^(gg) is, independently, halogen, —CN, —NO₂, —N₃,—SO₂H, —SO₃H, —OH, —OC₁₋₆ alkyl, —ON(C₁₋₆ alkyl)₂, —N(C₁₋₆ alkyl)₂,—N(C₁₋₆ alkyl)₃ ⁺X⁻, —NH(C₁₋₆ alkyl)₂ ⁺X⁻, —NH₂(C₁₋₆ alkyl)⁺X⁻, —NH₃⁺X⁻, —N(OC₁₋₆ alkyl)(C₁₋₆ alkyl), —N(OH)(C₁₋₆ alkyl), —NH(OH), —SH,—SC₁₋₆ alkyl, —SS(C₁₋₆ alkyl), —C(═O)(C₁₋₆ alkyl), —CO₂H, —CO₂(C₁₋₆alkyl), —OC(═O)(C₁₋₆ alkyl), —OCO₂(C₁₋₆ alkyl), —C(═O)NH₂, —C(═O)N(C₁₋₆alkyl)₂, —OC(═O)NH(C₁₋₆ alkyl), —NHC(═O)(C₁₋₆ alkyl), —N(C₁₋₆alkyl)C(═O)(C₁₋₆ alkyl), —NHCO₂(C₁₋₆ alkyl), —NHC(═O)N(C₁₋₆ alkyl)₂,—NHC(═O)NH(C₁₋₆ alkyl), —NHC(═O)NH₂, —C(═NH)O(C₁₋₆ alkyl), —OC(═NH)(C₁₋₆alkyl), —OC(═NH)OC₁₋₆ alkyl, —C(═NH)N(C₁₋₆ alkyl)₂, —C(═NH)NH(C₁₋₆alkyl), —C(═NH)NH₂, —OC(═NH)N(C₁₋₆ alkyl)₂, —OC(NH)NH(C₁₋₆ alkyl),—OC(NH)NH₂, —NHC(NH)N(C₁₋₆ alkyl)₂, —NHC(═NH)NH₂, —NHSO₂(C₁₋₆ alkyl),—SO₂N(C₁₋₆ alkyl)₂, —SO₂NH(C₁₋₆ alkyl), —SO₂NH₂, —SO₂C₁₋₆ alkyl,—SO₂OC₁₋₆ alkyl, —OSO₂C₁₋₆ alkyl, —SOC₁₋₆ alkyl, —Si(C₁₋₆ alkyl)₃,—OSi(C₁₋₆ alkyl)₃-C(═S)N(C₁₋₆ alkyl)₂, C(═S)NH(C₁₋₆ alkyl), C(═S)NH₂,—C(═O)S(C₁₋₆ alkyl), —C(═S)SC₁₋₆ alkyl, —SC(═S)SC₁₋₆ alkyl, —P(═O)₂(C₁₋₆alkyl), —P(═O)(C₁₋₆ alkyl)₂, —OP(═O)(C₁₋₆ alkyl)₂, —OP(═O)(OC₁₋₆alkyl)₂, C₁₋₆ alkyl, C₁₋₆ perhaloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₃₋₁₀ carbocyclyl, C₆₋₁₀ aryl, 3-10 membered heterocyclyl, 5-10 memberedheteroaryl; or two geminal R^(gg) substituents can be joined to form ═Oor ═S; wherein X⁻ is a counterion.

A “counterion” or “anionic counterion” is a negatively charged groupassociated with a cationic quaternary amino group in order to maintainelectronic neutrality. Exemplary counterions include halide ions (e.g.,F⁻, Cl⁻, Br⁻, I⁻), NO₃ ⁻, ClO₄ ⁻, OH⁻, H₂PO4⁻, HSO₄ ⁻, sulfonate ions(e.g., methansulfonate, trifluoromethanesulfonate, p-toluenesulfonate,benzenesulfonate, 10-camphor sulfonate, naphthalene-2-sulfonate,naphthalene-1-sulfonic acid-5-sulfonate, ethan-1-sulfonicacid-2-sulfonate, and the like), and carboxylate ions (e.g., acetate,ethanoate, propanoate, benzoate, glycerate, lactate, tartrate,glycolate, and the like).

“Halo” or “halogen” refers to fluorine (fluoro, —F), chlorine (chloro,—Cl), bromine (bromo, —Br), or iodine (iodo, —I).

“Hydroxyl” or “hydroxy” refers to the group —OH. “Substituted hydroxy”or “substituted hydroxyl,” by extension, refers to a hydroxyl groupwherein the oxygen atom directly attached to the parent molecule issubstituted with a group other than hydrogen, and includes groupsselected from —OR^(aa), —ON(R^(bb))₂, —OC(═O)SR^(aa), —OC(═O)R^(aa),—OCO₂R^(aa), —OC(═O)N(R^(bb))₂, —OC(═NR^(bb))R^(aa),—OC(═NR^(bb))OR^(aa), —OC(═NR^(bb))N(R^(bb))₂, —OS(═O)R^(aa),—OSO₂R^(aa), —OSi(R^(aa))₃, —OP(R^(cc))₂, —OP(R^(cc))₃, —OP(═O)₂R^(aa),—OP(═O)(R^(aa))₂, —OP(═O)(OR^(cc))₂, —OP(═O)₂N(R^(bb))₂, and—OP(═O)(NR^(bb))₂, wherein R^(aa), R^(bb), and R^(cc) are as definedherein.

“Thiol” or “thio” refers to the group —SH. “Substituted thiol” or“substituted thio,” by extension, refers to a thiol group wherein thesulfur atom directly attached to the parent molecule is substituted witha group other than hydrogen, and includes groups selected from —SR^(aa),—S═SR^(cc), —SC(═S)SR^(aa), —SC(═O)SR^(aa), —SC(═O)OR^(aa), and—SC(═O)R^(aa), wherein R^(aa) and R^(cc) are as defined herein.

“Amino” refers to the group —NH₂. “Substituted amino,” by extension,refers to a monosubstituted amino, a disubstituted amino, or atrisubstituted amino, as defined herein. In certain embodiments, the“substituted amino” is a monosubstituted amino or a disubstituted aminogroup.

“Monosubstituted amino” refers to an amino group wherein the nitrogenatom directly attached to the parent molecule is substituted with onehydrogen and one group other than hydrogen, and includes groups selectedfrom —NH(R^(bb)), —NHC(═O)R^(aa), —NHCO₂R^(aa), —NHC(═O)N(R^(bb))₂,—NHC(═NR^(bb))N(R^(bb))₂, —NHSO₂R^(aa), —NHP(═O)(OR^(cc))₂, and—NHP(═O)(NR^(bb))₂, wherein R^(aa), R^(bb) and R^(cc) are as definedherein, and wherein R^(bb) of the group —NH(R^(bb)) is not hydrogen.

“Disubstituted amino” refers to an amino group wherein the nitrogen atomdirectly attached to the parent molecule is substituted with two groupsother than hydrogen, and includes groups selected from —N(R^(bb))₂,—NR^(bb) C(═O)R^(aa), —NR^(bb)CO₂R^(aa), —NR^(bb)C(═O)N(R^(bb))₂,—NR^(bb)C(═NR^(bb))N(R^(bb))₂, —NR^(bb)SO₂R^(aa),—NR^(bb)P(═O)(OR^(cc))₂, and —NR^(bb)P(═O)(NR^(bb))₂, wherein R^(aa),R^(bb), and R^(cc) are as defined herein, with the proviso that thenitrogen atom directly attached to the parent molecule is notsubstituted with hydrogen.

“Trisubstituted amino” refers to an amino group wherein the nitrogenatom directly attached to the parent molecule is substituted with threegroups, and includes groups selected from —N(R^(bb))₃ and —N(R^(bb))₃⁺X⁻, wherein R^(bb) and X⁻ are as defined herein.

“Sulfonyl” refers to a group selected from —SO₂N(R^(bb))₂, —SO₂R^(aa),and —SO₂OR^(aa), wherein R^(aa) and R^(bb) are as defined herein.

“Sulfinyl” refers to the group —S(═O)R^(aa), wherein R^(aa) is asdefined herein.

“Carbonyl” refers a group wherein the carbon directly attached to theparent molecule is sp² hybridized, and is substituted with an oxygen,nitrogen or sulfur atom, e.g., a group selected from ketones(—C(═O)R^(aa)), carboxylic acids (—CO₂H), aldehydes (—CHO), esters(—CO₂R^(aa), —C(═O)SR^(aa), —C(═S)SR^(aa)), amides (—C(═O)N(R^(bb))₂,—C(═O)NR^(bb)SO₂R^(aa), —C(═S)N(R^(bb))₂), and imines(—C(═NR^(bb))R^(aa), —C(═NR^(bb))OR^(aa)), —C(═NR^(bb))N(R^(bb))₂),wherein R^(aa) and R^(bb) are as defined herein.

Nitrogen atoms can be substituted or unsubstituted as valency permits,and include primary, secondary, tertiary, and quarternary nitrogenatoms. Exemplary nitrogen atom substitutents include, but are notlimited to, hydrogen, —OH, —OR^(aa), —N(R^(cc))₂, —CN, —C(═O)R^(aa),—C(═O)N(R^(cc))₂, —CO₂R^(aa), —SO₂R^(aa), —C(═NR^(bb))R^(aa),—C(═NR^(cc))OR^(aa), —C(═NR^(cc))N(R^(cc))₂, —SO₂N(R^(cc))₂, —SO₂R^(cc),—SO₂OR^(cc), —SOR^(aa), —C(═S)N(R^(cc))₂, —C(═O)SR^(cc), —C(═S)SR^(cc),—P(═O)₂R^(aa), —P(═O)(R^(aa))₂, —P(═O)₂N(R^(cc))₂, —P(═O)(NR^(cc))₂,C₁₋₁₀ alkyl, C₁₋₁₀ perhaloalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₁₀carbocyclyl, 3-14 membered heterocyclyl, C₆₋₁₄ aryl, and 5-14 memberedheteroaryl, or two R^(cc) groups attached to a nitrogen atom are joinedto form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring,wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl,and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5R^(dd) groups, and wherein R^(aa), R^(bb), R^(cc) and R^(dd) are asdefined above.

In certain embodiments, the substituent present on a nitrogen atom is anitrogen protecting group (also referred to as an amino protectinggroup). Nitrogen protecting groups include, but are not limited to, —OH,—OR^(aa), —N(R^(cc))₂, —C(═O)R^(aa), —C(═O)N(R^(cc))₂, —CO₂R^(aa),—SO₂R^(aa), —C(═NR^(cc))R^(aa), —C(═NR^(cc))OR^(aa),—C(═NR^(cc))N(R^(cc))₂, —SO₂N(R^(cc))₂, —SO₂R^(cc), —SO₂OR^(cc),—SOR^(aa), —C(═S)N(R^(cc))₂, —C(═O)SR^(cc), —C(═S)SR^(cc), C₁₋₁₀ alkyl(e.g., aralkyl, heteroaralkyl), C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₁₀carbocyclyl, 3-14 membered heterocyclyl, C₆₋₁₄ aryl, and 5-14 memberedheteroaryl groups, wherein each alkyl, alkenyl, alkynyl, carbocyclyl,heterocyclyl, aralkyl, aryl, and heteroaryl is independently substitutedwith 0, 1, 2, 3, 4, or 5 R^(dd) groups, and wherein R^(aa), R^(bb),R^(cc), and R^(dd) are as defined herein. Nitrogen protecting groups arewell known in the art and include those described in detail inProtecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts,3^(rd) edition, John Wiley & Sons, 1999, incorporated herein byreference.

Amide nitrogen protecting groups (e.g., —C(═O)R^(aa)) include, but arenot limited to, formamide, acetamide, chloroacetamide,trichloroacetamide, trifluoroacetamide, phenylacetamide,3-phenylpropanamide, picolinamide, 3-pyridylcarboxamide,N-benzoylphenylalanyl derivative, benzamide, p-phenylbenzamide,o-nitophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide,(N′-dithiobenzyloxyacylamino)acetamide, 3-(p-hydroxyphenyl)propanamide,3-(o-nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide,2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide,3-methyl-3-nitrobutanamide, o-nitrocinnamide, N-acetylmethionine,o-nitrobenzamide, and o-(benzoyloxymethyl)benzamide.

Carbamate nitrogen protecting groups (e.g., —C(═O)OR^(aa)) include, butare not limited to, methyl carbamate, ethyl carbamante,9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethylcarbamate, 9-(2,7-dibromo)fluoroenylmethyl carbamate,2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methylcarbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc),2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate(Teoc), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1-methylethylcarbamate (Adpoc), 1,1-dimethyl-2-haloethyl carbamate,1,1-dimethyl-2,2-dibromoethyl carbamate (DB-t-BOC),1,1-dimethyl-2,2,2-trichloroethyl carbamate (TCBOC),1-methyl-1-(4-biphenylyl)ethyl carbamate (Bpoc),1-(3,5-di-t-butylphenyl)-1-methylethyl carbamate (t-Bumeoc), 2-(2′- and4′-pyridyl)ethyl carbamate (Pyoc), 2-(N,N-dicyclohexylcarboxamido)ethylcarbamate, t-butyl carbamate (BOC), 1-adamantyl carbamate (Adoc), vinylcarbamate (Voc), allyl carbamate (Alloc), 1-isopropylallyl carbamate(Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc),8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkyldithiocarbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz),p-nitobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzylcarbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzylcarbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate,2-methylthioethyl carbamate, 2-methylsulfonylethyl carbamate,2-(p-toluenesulfonyl)ethyl carbamate, [2-(1,3-dithianyl)]methylcarbamate (Dmoc), 4-methylthiophenyl carbamate (Mtpc),2,4-dimethylthiophenyl carbamate (Bmpc), 2-phosphonioethyl carbamate(Peoc), 2-triphenylphosphonioisopropyl carbamate (Ppoc),1,1-dimethyl-2-cyanoethyl carbamate, m-chloro-p-acyloxybenzyl carbamate,p-(dihydroxyboryl)benzyl carbamate, 5-benzisoxazolylmethyl carbamate,2-(trifluoromethyl)-6-chromonylmethyl carbamate (Tcroc), m-nitrophenylcarbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate,3,4-dimethoxy-6-nitrobenzyl carbamate, phenyl(o-nitrophenyl)methylcarbamate, t-amyl carbamate, S-benzyl thiocarbamate, p-cyanobenzylcarbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentylcarbamate, cyclopropylmethyl carbamate, p-decyloxybenzyl carbamate,2,2-dimethoxyacylvinyl carbamate, o-(N,N-dimethylcarboxamido)benzylcarbamate, 1,1-dimethyl-3-(N,N-dimethylcarboxamido)propyl carbamate,1,1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate,2-furanylmethyl carbamate, 2-iodoethyl carbamate, isoborynl carbamate,isobutyl carbamate, isonicotinyl carbamate,p-(p′-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl carbamate,1-methylcyclohexyl carbamate, 1-methyl-1-cyclopropylmethyl carbamate,1-methyl-1-(3,5-dimethoxyphenyl)ethyl carbamate,1-methyl-1-(p-phenylazophenyl)ethyl carbamate, 1-methyl-1-phenylethylcarbamate, 1-methyl-1-(4-pyridyl)ethyl carbamate, phenyl carbamate,p-(phenylazo)benzyl carbamate, 2,4,6-tri-t-butylphenyl carbamate,4-(trimethylammonium)benzyl carbamate, and 2,4,6-trimethylbenzylcarbamate.

Sulfonamide nitrogen protecting groups (e.g., —S(═O)₂R^(aa)) include,but are not limited to, p-toluenesulfonamide (Ts), benzenesulfonamide,2,3,6,-trimethyl-4-methoxybenzenesulfonamide (Mtr),2,4,6-trimethoxybenzenesulfonamide (Mtb),2,6-dimethyl-4-methoxybenzenesulfonamide (Pme),2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte),4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide(Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds),2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide(Ms), 3-trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide,4-(4′,8′-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS),benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide.

Other nitrogen protecting groups include, but are not limited to,phenothiazinyl-(10)-acyl derivative, N′-p-toluenesulfonylaminoacylderivative, N′-phenylaminothioacyl derivative, N-benzoylphenylalanylderivative, N-acetylmethionine derivative,4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts),N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole,N-1,1,4,4-tetramethyldisilylazacyclopentane adduct (STABASE),5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, 1-substituted3,5-dinitro-4-pyridone, N-methylamine, N-allylamine,N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine,N-(1-isopropyl-4-nitro-2-oxo-3-pyroolin-3-yl)amine, quaternary ammoniumsalts, N-benzylamine, N-di(4-methoxyphenyl)methylamine,N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr),N-[(4-methoxyphenyl)diphenylmethyl]amine (MMTr),N-9-phenylfluorenylamine (PhF),N-2,7-dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fcm),N-2-picolylamino N′-oxide, N-1,1-dimethylthiomethyleneamine,N-benzylideneamine, N-p-methoxybenzylideneamine,N-diphenylmethyleneamine, N-[(2-pyridyl)mesityl]methyleneamine,N—(N′,N′-dimethylaminomethylene)amine, N,N′-isopropylidenediamine,N-p-nitrobenzylideneamine, N-salicylideneamine,N-5-chlorosalicylideneamine,N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine,N-cyclohexylideneamine, N-(5,5-dimethyl-3-oxo-1-cyclohexenyl)amine,N-borane derivative, N-diphenylborinic acid derivative,N-[phenyl(pentaacylchromium- or tungsten)acyl]amine, N-copper chelate,N-zinc chelate, N-nitroamine, N-nitrosoamine, amine N-oxide,diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt),diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzylphosphoramidate, diphenyl phosphoramidate, benzenesulfenamide,o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide,pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide,triphenylmethylsulfenamide, and 3-nitropyridinesulfenamide (Npys).

In certain embodiments, the substituent present on an oxygen atom is anoxygen protecting group (also referred to as a hydroxyl protectinggroup). Oxygen protecting groups include, but are not limited to,—R^(aa), —N(R^(bb))₂, —C(═O)SR^(aa), —C(═O)R^(aa), —CO₂R^(aa),—C(═O)N(R^(bb))₂, —C(═NR^(bb))R^(aa), —C(═NR^(bb))OR^(aa),—C(═NR^(bb))N(R^(bb))₂, —S(═O)R^(aa), —SO₂R^(aa), —Si(R^(aa))₃,—P(R^(cc))₂, —P(R^(cc))₃, —P(═O)₂R^(aa), —P(═O)(R^(aa))₂,—P(═O)(OR^(cc))₂, —P(═O)₂N(R^(bb))₂, and —P(═O)(NR^(bb))₂, whereinR^(aa), R^(bb), and R^(cc) are as defined herein. Oxygen protectinggroups are well known in the art and include those described in detailin Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M.Wuts, 3^(rd) edition, John Wiley & Sons, 1999, incorporated herein byreference.

Exemplary oxygen protecting groups include, but are not limited to,methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl,(phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM),p-methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM),guaiacolmethyl (GUM), t-butoxymethyl, 4-pentenyloxymethyl (POM),siloxymethyl, 2-methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl,bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR),tetrahydropyranyl (THP), 3-bromotetrahydropyranyl,tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl(MTHP), 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranylS,S-dioxide, 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl(CTMP), 1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl,2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl,1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl,1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl,2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl,t-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl,benzyl (Bn), p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl,p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl,p-phenylbenzyl, 2-picolyl, 4-picolyl, 3-methyl-2-picolyl N-oxido,diphenylmethyl, p,p′-dinitrobenzhydryl, 5-dibenzosuberyl,triphenylmethyl, α-naphthyldiphenylmethyl,p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl,tri(p-methoxyphenyl)methyl, 4-(4′-bromophenacyloxyphenyl)diphenylmethyl,4,4′,4″-tris(4,5-dichlorophthalimidophenyl)methyl,4,4′,4″-tris(levulinoyloxyphenyl)methyl,4,4′,4″-tris(benzoyloxyphenyl)methyl,3-(imidazol-1-yl)bis(4′,4″-dimethoxyphenyl)methyl,1,1-bis(4-methoxyphenyl)-1′-pyrenylmethyl, 9-anthryl,9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl,1,3-benzodisulfuran-2-yl, benzisothiazolyl S,S-dioxido, trimethylsilyl(TMS), triethylsilyl (TES), triisopropylsilyl (TIPS),dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS),dimethylthexylsilyl, t-butyldimethylsilyl (TBDMS), t-butyldiphenylsilyl(TBDPS), tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl,diphenylmethylsilyl (DPMS), t-butylmethoxyphenylsilyl (TBMPS), formate,benzoylformate, acetate, chloroacetate, dichloroacetate,trichloroacetate, trifluoroacetate, methoxyacetate,triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate,3-phenylpropionate, 4-oxopentanoate (levulinate),4,4-(ethylenedithio)pentanoate (levulinoyldithioacetal), pivaloate,adamantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate,2,4,6-trimethylbenzoate (mesitoate), methyl carbonate, 9-fluorenylmethylcarbonate (Fmoc), ethyl carbonate, t-butyl carbonate (Boc),2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate(TMSEC), 2-(phenylsulfonyl) ethyl carbonate (Psec),2-(triphenylphosphonio) ethyl carbonate (Peoc), isobutyl carbonate,vinyl carbonate, allyl carbonate, p-nitrophenyl carbonate, benzylcarbonate, p-methoxybenzyl carbonate, 3,4-dimethoxybenzyl carbonate,o-nitrobenzyl carbonate, p-nitrobenzyl carbonate, S-benzylthiocarbonate, 4-ethoxy-1-napththyl carbonate, methyl dithiocarbonate,2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentanoate,o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate,2-(methylthiomethoxy)ethyl, 4-(methylthiomethoxy)butyrate,2-(methylthiomethoxymethyl)benzoate,2,6-dichloro-4-methylphenoxyacetate,2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate,2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate,isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate,o-(methoxyacyl)benzoate, α-naphthoate, nitrate, alkylN,N,N′,N′-tetramethylphosphorodiamidate, alkyl N-phenylcarbamate,borate, dimethylphosphinothioyl, alkyl 2,4-dinitrophenylsulfenate,sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate(Ts).

In certain embodiments, the substituent present on a sulfur atom is asulfur protecting group (also referred to as a thiol protecting group).Sulfur protecting groups include, but are not limited to, —R^(aa),—N(R^(bb))₂, —C(═O)SR^(aa), —C(═O)R^(aa), —CO₂R^(aa), —C(═O)N(R^(bb))₂,—C(═NR^(bb))R^(aa), —C(═NR^(bb))OR^(aa), —C(═NR^(bb))N(R^(bb))₂,—S(═O)R^(aa), —SO₂R^(aa), —Si(R^(aa))₃, —P(R^(cc))₂, —P(R^(cc))₃,—P(═O)₂R^(aa), —P(═O)(R^(aa))₂, —P(═O)(OR^(cc))₂, —P(═O)₂N(R^(bb))₂, and—P(═O)(NR^(bb))₂, wherein R^(aa), R^(bb), and R^(cc) are as definedherein. Sulfur protecting groups are well known in the art and includethose described in detail in Protecting Groups in Organic Synthesis, T.W. Greene and P. G. M. Wuts, 3^(rd) edition, John Wiley & Sons, 1999,incorporated herein by reference.

These and other exemplary substituents are described in more detail inthe Detailed Description, Examples, and claims. The present disclosureis not intended to be limited in any manner by the above exemplarylisting of substituents.

“Pharmaceutically acceptable salt” refers to those salts which are,within the scope of sound medical judgment, suitable for use in contactwith the tissues of humans and other animals without undue toxicity,irritation, allergic response, and the like, and are commensurate with areasonable benefit/risk ratio. Pharmaceutically acceptable salts arewell known in the art. For example, Berge et al. describepharmaceutically acceptable salts in detail in J. PharmaceuticalSciences (1977) 66:1-19. Pharmaceutically acceptable salts of thecompounds describe herein include those derived from suitable inorganicand organic acids and bases. Examples of pharmaceutically acceptable,nontoxic acid addition salts are salts of an amino group formed withinorganic acids such as hydrochloric acid, hydrobromic acid, phosphoricacid, sulfuric acid and perchloric acid or with organic acids such asacetic acid, oxalic acid, maleic acid, tartaric acid, citric acid,succinic acid, or malonic acid or by using other methods used in the artsuch as ion exchange. Other pharmaceutically acceptable salts includeadipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate,bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate,cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate,formate, fumarate, glucoheptonate, glycerophosphate, gluconate,hemisulfate, heptanoate, hexanoate, hydroiodide,2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, laurylsulfate, malate, maleate, malonate, methanesulfonate,2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate,pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate,pivalate, propionate, stearate, succinate, sulfate, tartrate,thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and thelike. Salts derived from appropriate bases include alkali metal,alkaline earth metal, ammonium and N⁺(C₁₋₄alkyl)₄ salts. Representativealkali or alkaline earth metal salts include sodium, lithium, potassium,calcium, magnesium, and the like. Further pharmaceutically acceptablesalts include, when appropriate, quaternary salts.

A “subject” to which administration is contemplated includes, but is notlimited to, humans (e.g., a male or female of any age group, e.g., apediatric subject (e.g, infant, child, adolescent) or adult subject(e.g., young adult, middle-aged adult or senior adult)) and/or othernon-human animals, for example, non-human mammals (e.g., primates (e.g.,cynomolgus monkeys, rhesus monkeys); commercially relevant mammals suchas cattle, pigs, horses, sheep, goats, cats, and/or dogs), birds (e.g.,commercially relevant birds such as chickens, ducks, geese, and/orturkeys), rodents (e.g., rats and/or mice), reptiles, amphibians, andfish. In certain embodiments, the non-human animal is a mammal. Thenon-human animal may be a male or female at any stage of development. Anon-human animal may be a transgenic animal.

“Condition,” “disease,” and “disorder” are used interchangeably herein.

“Treat,” “treating” and “treatment” encompasses an action that occurswhile a subject is suffering from a condition which reduces the severityof the condition or retards or slows the progression of the condition(“therapeutic treatment”). “Treat,” “treating” and “treatment” alsoencompasses an action that occurs before a subject begins to suffer fromthe condition and which inhibits or reduces the severity of thecondition (“prophylactic treatment”).

An “effective amount” of a compound refers to an amount sufficient toelicit the desired biological response, e.g., treat the condition. Aswill be appreciated by those of ordinary skill in this art, theeffective amount of a compound described herein may vary depending onsuch factors as the desired biological endpoint, the pharmacokinetics ofthe compound, the condition being treated, the mode of administration,and the age and health of the subject. An effective amount encompassestherapeutic and prophylactic treatment.

A “therapeutically effective amount” of a compound is an amountsufficient to provide a therapeutic benefit in the treatment of acondition or to delay or minimize one or more symptoms associated withthe condition. A therapeutically effective amount of a compound means anamount of therapeutic agent, alone or in combination with othertherapies, which provides a therapeutic benefit in the treatment of thecondition. The term “therapeutically effective amount” can encompass anamount that improves overall therapy, reduces or avoids symptoms orcauses of the condition, or enhances the therapeutic efficacy of anothertherapeutic agent.

A “prophylactically effective amount” of a compound is an amountsufficient to prevent a condition, or one or more symptoms associatedwith the condition or prevent its recurrence. A prophylacticallyeffective amount of a compound means an amount of a therapeutic agent,alone or in combination with other agents, which provides a prophylacticbenefit in the prevention of the condition. The term “prophylacticallyeffective amount” can encompass an amount that improves overallprophylaxis or enhances the prophylactic efficacy of anotherprophylactic agent.

As used herein, the term “methyltransferase” represents transferaseclass enzymes that are able to transfer a methyl group from a donormolecule to an acceptor molecule, e.g., an amino acid residue of aprotein or a nucleic base of a DNA molecule. Methytransferases typicallyuse a reactive methyl group bound to sulfur in S-adenosyl methionine(SAM) as the methyl donor. In some embodiments, a methyltransferasedescribed herein is a protein methyltransferase. In some embodiments, amethyltransferase described herein is a histone methyltransferase.Histone methyltransferases (HMT) are histone-modifying enzymes,(including histone-lysine N-methyltransferase and histone-arginineN-methyltransferase), that catalyze the transfer of one or more methylgroups to lysine and arginine residues of histone proteins. In certainembodiments, a methyltransferase described herein is a histone-arginineN-methyltransferase.

As generally described above, provided herein are compounds useful asCARM1 inhibitors. In some embodiments, the present disclosure provides acompound of Formula (I):

or a pharmaceutically acceptable salt thereof;wherein:

X is —O—, —S—, or —CH₂—;

R¹ and R^(1a) are each independently hydrogen or optionally substitutedC₁₋₄ aliphatic, or R¹ and R^(1a) may be joined to form a substituted orunsubstituted heterocyclic, or substituted or unsubstituted heteroarylring;

each of R^(2a), R^(2b), R^(2c), and R^(2d) is independently hydrogen,halogen, —CN, —NO₂, —C(═O)R^(A2), —C(═O)OR^(A2), —C(═O)N(R^(A2))₂,—OR^(A2), —SR^(A2), —N(R^(A2))₂, —S(═O)R^(A2), —S(═O)₂R^(A2), optionallysubstituted alkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted carbocyclyl, optionallysubstituted heterocyclyl, wherein each instance of R^(A2) isindependently hydrogen, optionally substituted alkyl, optionallysubstituted alkenyl, optionally substituted alkynyl, optionallysubstituted carbocyclyl, optionally substituted heterocyclyl, optionallysubstituted aryl, or optionally substituted heteroaryl, or two R^(A2)groups attached to the same nitrogen atom are joined to form anoptionally substituted heterocyclyl or optionally substituted heteroarylring;

Ring HET is a 6-membered monocylic heteroaryl ring system of theFormula:

wherein:

G₈ is C—R⁸ or N;

G₁₀ is C—R¹⁰ or N;

G₁₁ is C—R¹¹ or N;

G₁₂ is C—R¹² or N;

provided at least one instance of G₈, G₁₀, G₁₁, or G₁₂ is N;

each instance of R⁸, R¹⁰, R¹¹, and R¹² is independently selected fromthe group consisting of hydrogen, halo, —CN, —NO₂, —C(═O)R′, —C(═O)OR′,—C(═O)N(R′)₂, optionally substituted alkyl, optionally substitutedC₃₋₄cycloalkyl, and -L¹-R³;

each instance of R′ is independently hydrogen, optionally substitutedalkyl, optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted carbocyclyl, optionally substituted heterocyclyl,optionally substituted aryl, or optionally substituted heteroaryl, ortwo R′ groups attached to the same nitrogen are joined to form anoptionally substituted heterocyclyl ring or optionally substitutedheteroaryl ring;

each instance of L¹ and L² is independently a bond, —O—, —N(R^(L)), —S—,—C(O)—, —C(O)O—, —C(O)S—, —C(O)N(R^(L))—, —C(O)N(R^(L))N(R^(L))—,—OC(O)—, —OC(O)N(R^(L))—, —NR^(L)C(O)—, —NR^(L)C(O)N(R^(L))—,—NR^(L)C(O)N(R^(L))N(R^(L))—, —NR^(L)C(O)O—, —SC(O)—, —C(═NR^(L))—,—C(═NNR^(L))—, —C(═NOR^(L))—, —C(═NR^(L))N(R^(L))—, —NR^(L)C(═NR^(L)),—C(S)—, —C(S)N(R^(L))—, —NR^(L)C(S)—, —S(O)—, —OS(O)₂—, —S(O)₂O—, —SO₂—,—N(R^(L))SO₂—, —SO₂N(R^(L))—, —N(R^(L))SO₂N(R^(L))—, an optionallysubstituted C₁₋₁₀ saturated or unsaturated hydrocarbon chain, whereinone or more moieties selected from the group consisting of —O—,—N(R^(L))—, —S—, —C(O)—, —C(O)O—, —C(O)S—, —C(O)N(R^(L))—,—C(O)N(R^(L))N(R^(L))—, —OC(O)—, —OC(O)N(R^(L))—, —NR^(L)C(O)—,—NR^(L)C(O)N(R^(L))—, —NR^(L)C(O)N(R^(L))N(R^(L))—, —NR^(L)C(O)O—,—SC(O)—, —C(═NR^(L))—, —C(═NNR^(L))—, —C(═NOR^(L))—,—C(═NR^(L))N(R^(L))—, —NR^(L)C(═NR^(L))—, —C(S)—, —C(S)N(R^(L))—,—NR^(L)C(S)—, —S(O)—, —OS(O)₂—, —S(O)₂O—, —SO₂—, —N(R^(L))SO₂—,—SO₂N(R^(L))—, and —N(R^(L))SO₂N(R^(L))— is optionally and independentlypresent between two carbon atoms of the hydrocarbon chain, andoptionally and independently present at one or both ends of thehydrocarbon chain;

each R^(L) is independently hydrogen, optionally substituted alkyl, or anitrogen protecting group, or R^(L) and R³ taken together form anoptionally substituted heterocyclyl or optionally substituted heteroarylring, or R^(L) and R¹³ taken together form an optionally substitutedheterocyclyl or optionally substituted heteroaryl ring;

R³ is hydrogen, optionally substituted alkyl, optionally substitutedalkenyl, optionally substituted alkynyl, optionally substitutedcarbocyclyl, optionally substituted heterocyclyl, optionally substitutedaryl, or optionally substituted heteroaryl, provided when R³ ishydrogen, then L¹ is not a bond; and

R¹³ is optionally substituted carbocyclyl, optionally substitutedheterocyclyl, optionally substituted aryl, or optionally substitutedheteroaryl.

In certain embodiments of Formula (I), R^(1a) is hydrogen. In certainembodiments of Formula (I), R^(1a) is not hydrogen. In certainembodiments of Formula (I), R¹ is not hydrogen (e.g., —CH₃), and R^(1a)is hydrogen. In certain embodiments of Formula (I), each of R¹ andR^(1a) is not hydrogen (e.g., each is —CH₃). In certain embodiments ofFormula (I), each of R¹ and R^(1a) is hydrogen.

It is generally understood that compounds of Formula (I), as describedherein, comprises one or more asymmetric centers, and thus can exist invarious isomeric forms, e.g., enantiomeric and/or diastereomeric forms.In certain embodiments, the compound of Formula (I) has the followingstereochemistry (I-a) or (I-b):

In certain embodiments of Formula (I-a) or (I-b), R^(1a) is hydrogen. Incertain embodiments of Formula (I-a) or (I-b), R^(1a) is not hydrogen.In certain embodiments of Formula (I-a) or (I-b), R¹ is not hydrogen(e.g., —CH₃), and R^(1a) is hydrogen. In certain embodiments of Formula(I-a) or (I-b), each of R¹ and R^(1a) is not hydrogen (e.g., each is—CH₃). In certain embodiments of Formula (I-a) or (I-b), each of R¹ andR^(1a) is hydrogen.

For example, in certain embodiments, the hydroxyl group of the aminoalcohol moiety provided in any of the genera or compounds depictedherein has (S) stereochemistry. In certain embodiments the hydroxylgroup of the amino alcohol moiety provided in any of the genera orcompounds depicted herein has (R) stereochemistry.

As generally defined herein, X is —O—, —S—, or —CH₂—. In certainembodiments, X is —O—. In certain embodiments, X is —S—. In certainembodiments, X is —O—.

As generally defined herein, R¹ is hydrogen or optionally substitutedC₁₋₄ aliphatic. In certain embodiments, R¹ is hydrogen. In certainembodiments, R¹ is optionally substituted C₁₋₄ aliphatic, e.g.,optionally substituted C₁ aliphatic, optionally substituted C₂aliphatic, optionally substituted C₃ aliphatic, or optionallysubstituted C₄ aliphatic. It is understood that aliphatic, as usedherein, encompasses alkyl, alkenyl, alkynyl, and carbocyclic groups. Incertain embodiments, R¹ is optionally substituted C₁₋₄ alkyl, e.g.,optionally substituted C₁₋₂alkyl, optionally substituted C₂₋₃alkyl,optionally substituted C₃-4alkyl, optionally substituted C₁alkyl,optionally substituted C₂alkyl, optionally substituted C₃alkyl, oroptionally substituted C₄alkyl. In certain embodiments, R¹ isunsubstituted C₁₋₄ alkyl, e.g., unsubstituted C₁₋₂alkyl, unsubstitutedC₂₋₃alkyl, unsubstituted C₃₋₄alkyl, unsubstituted C₁alkyl, unsubstitutedC₂alkyl, unsubstituted C₃alkyl, or unsubstituted C₄alkyl. ExemplaryC₁₋₄alkyl groups include, but are not limited to, methyl (C₁), ethyl(C₂), n-propyl (C₃), isopropyl (C₃), n-butyl (C₄), tert-butyl (C₄),sec-butyl (C₄), or iso-butyl (C₄), each of which may be substituted orunsubstituted. In certain embodiments, R¹ is optionally substituted C₂₋₄alkenyl, e.g., optionally substituted C₂₋₃alkenyl, optionallysubstituted C₃₋₄alkenyl, optionally substituted C₂alkenyl, optionallysubstituted C₃alkenyl, or optionally substituted C₄alkenyl. In certainembodiments, R¹ is optionally substituted C₂₋₄ alkynyl, e.g., optionallysubstituted C₂₋₃alkynyl, optionally substituted C₃₋₄alkynyl, optionallysubstituted C₂alkynyl, optionally substituted C₃alkynyl, or optionallysubstituted C₄alkynyl. In certain embodiments, R¹ is optionallysubstituted C₃carbocylyl, e.g., optionally substituted cyclopropyl. Incertain embodiments, R¹ is hydrogen or an unsubstituted C₁₋₄ aliphaticgroup, e.g., for example, in certain embodiments, R¹ is hydrogen, methyl(—CH₃), ethyl (—CH₂CH₃), n-propyl (—CH₂CH₂CH₃), isopropyl (—CH(CH₃)₂),or cyclopropyl (—C₃H₅).

As generally defined herein, R^(1a) is hydrogen or optionallysubstituted C₁₋₄ aliphatic. In certain embodiments, R^(1a) is hydrogen.In certain embodiments, R^(1a) is not hydrogen. In certain embodiments,R^(1a) is optionally substituted C₁₋₄ aliphatic, e.g., optionallysubstituted C₁ aliphatic, optionally substituted C₂ aliphatic,optionally substituted C₃ aliphatic, or optionally substituted C₄aliphatic. It is understood that aliphatic, as used herein, encompassesalkyl, alkenyl, alkynyl, and carbocyclic groups. In certain embodiments,R^(1a) is optionally substituted C₁₋₄ alkyl, e.g., optionallysubstituted C₁₋₂alkyl, optionally substituted C₂₋₃alkyl, optionallysubstituted C₃₋₄alkyl, optionally substituted C₁alkyl, optionallysubstituted C₂alkyl, optionally substituted C₃alkyl, or optionallysubstituted C₄alkyl. In certain embodiments, R^(1a) is unsubstitutedC₁₋₄ alkyl, e.g., unsubstituted C₁₋₂alkyl, unsubstituted C₂₋₃alkyl,unsubstituted C₃₋₄alkyl, unsubstituted C₁alkyl, unsubstituted C₂alkyl,unsubstituted C₃alkyl, or unsubstituted C₄alkyl. Exemplary C₁₋₄alkylgroups include, but are not limited to, methyl (C₁), ethyl (C₂),n-propyl (C₃), isopropyl (C₃), n-butyl (C₄), tert-butyl (C₄), sec-butyl(C₄), or iso-butyl (C₄), each of which may be substituted orunsubstituted. In certain embodiments, R^(1a) is optionally substitutedC₂₋₄ alkenyl, e.g., optionally substituted C₂-3alkenyl, optionallysubstituted C₃₋₄alkenyl, optionally substituted C₂alkenyl, optionallysubstituted C₃alkenyl, or optionally substituted C₄alkenyl. In certainembodiments, R^(1a) is optionally substituted C₂₋₄ alkynyl, e.g.,optionally substituted C₂₋₃alkynyl, optionally substituted C₃₋₄alkynyl,optionally substituted C₂alkynyl, optionally substituted C₃alkynyl, oroptionally substituted C₄alkynyl. In certain embodiments, R^(1a) isoptionally substituted C₃carbocylyl, e.g., optionally substitutedcyclopropyl. In certain embodiments, R^(1a) is hydrogen or anunsubstituted C₁₋₄ aliphatic group, e.g., for example, in certainembodiments, R^(1a) is hydrogen, methyl (—CH₃), ethyl (—CH₂CH₃),n-propyl (—CH₂CH₂CH₃), isopropyl (—CH(CH₃)₂), or cyclopropyl (—C₃H₅).

In certain embodiments, R¹ is hydrogen, and R^(1a) is hydrogen.

In certain embodiments, R¹ is optionally substituted C₁₋₄ aliphatic,e.g., optionally substituted C₁ aliphatic, optionally substituted C₂aliphatic, optionally substituted C₃ aliphatic, or optionallysubstituted C₄ aliphatic; and R^(1a) is hydrogen. In certainembodiments, R¹ is optionally substituted C₁₋₄ alkyl, e.g., optionallysubstituted C₁₋₂alkyl, optionally substituted C₂₋₃alkyl, optionallysubstituted C₃₋₄alkyl, optionally substituted C₁alkyl, optionallysubstituted C₂alkyl, optionally substituted C₃alkyl, or optionallysubstituted C₄alkyl; and R^(1a) is hydrogen. In certain embodiments, R¹is optionally substituted C₂₋₄ alkenyl, e.g., optionally substitutedC₂₋₃alkenyl, optionally substituted C₃₋₄alkenyl, optionally substitutedC₂alkenyl, optionally substituted C₃alkenyl, or optionally substitutedC₄alkenyl; and R^(1a) is hydrogen. In certain embodiments, R¹ isoptionally substituted C₂₋₄ alkynyl, e.g., optionally substitutedC₂-3alkynyl, optionally substituted C₃₋₄alkynyl, optionally substitutedC₂alkynyl, optionally substituted C₃alkynyl, or optionally substitutedC₄alkynyl; and R^(1a) is hydrogen. In certain embodiments, R¹ isoptionally substituted C₃carbocylyl, e.g., optionally substitutedcyclopropyl; and R^(1a) is hydrogen. In certain embodiments, R¹ is anunsubstituted C₁₋₄ aliphatic group, e.g., for example, in certainembodiments, R¹ is methyl (—CH₃), ethyl (—CH₂CH₃), n-propyl(—CH₂CH₂CH₃), isopropyl (—CH(CH₃)₂), or cyclopropyl (—C₃H₅); and R^(1a)is hydrogen.

In certain embodiments, each of R¹ and R^(1a) is independently anon-hydrogen group.

In certain embodiments, R¹ is optionally substituted C₁₋₄ aliphatic,e.g., optionally substituted C₁ aliphatic, optionally substituted C₂aliphatic, optionally substituted C₃ aliphatic, or optionallysubstituted C₄ aliphatic; and R^(1a) is optionally substituted C₁₋₄aliphatic, e.g., optionally substituted C₁ aliphatic, optionallysubstituted C₂ aliphatic, optionally substituted C₃ aliphatic, oroptionally substituted C₄ aliphatic. In certain embodiments, R¹ isoptionally substituted C₁₋₄ alkyl, e.g., optionally substitutedC₁₋₂alkyl, optionally substituted C₂₋₃alkyl, optionally substitutedC₃₋₄alkyl, optionally substituted C₁alkyl, optionally substitutedC₂alkyl, optionally substituted C₃alkyl, or optionally substitutedC₄alkyl; and R^(1a) is optionally substituted C₁₋₄ alkyl, e.g.,optionally substituted C₁₋₂alkyl, optionally substituted C₂₋₃alkyl,optionally substituted C₃₋₄alkyl, optionally substituted C₁alkyl,optionally substituted C₂alkyl, optionally substituted C₃alkyl, oroptionally substituted C₄alkyl. In certain embodiments, R¹ is optionallysubstituted C₂₋₄ alkenyl, e.g., optionally substituted C₂₋₃alkenyl,optionally substituted C₃₋₄alkenyl, optionally substituted C₂alkenyl,optionally substituted C₃alkenyl, or optionally substituted C₄alkenyl;and R^(1a) is optionally substituted C₁₋₄ alkyl, e.g., optionallysubstituted C₁₋₂alkyl, optionally substituted C₂₋₃alkyl, optionallysubstituted C₃₋₄alkyl, optionally substituted C₁alkyl, optionallysubstituted C₂alkyl, optionally substituted C₃alkyl, or optionallysubstituted C₄alkyl. In certain embodiments, R¹ is optionallysubstituted C₂₋₄ alkynyl, e.g., optionally substituted C₂₋₃alkynyl,optionally substituted C₃₋₄alkynyl, optionally substituted C₂alkynyl,optionally substituted C₃alkynyl, or optionally substituted C₄alkynyl;and R^(1a) is optionally substituted C₁₋₄ alkyl, e.g., optionallysubstituted C₁₋₂alkyl, optionally substituted C₂₋₃alkyl, optionallysubstituted C₃₋₄alkyl, optionally substituted C₁alkyl, optionallysubstituted C₂alkyl, optionally substituted C₃alkyl, or optionallysubstituted C₄alkyl. In certain embodiments, R¹ is optionallysubstituted C₃carbocylyl, e.g., optionally substituted cyclopropyl; andR^(1a) is optionally substituted C₁₋₄ alkyl, e.g., optionallysubstituted C₁₋₂alkyl, optionally substituted C₂₋₃alkyl, optionallysubstituted C₃₋₄alkyl, optionally substituted C₁alkyl, optionallysubstituted C₂alkyl, optionally substituted C₃alkyl, or optionallysubstituted C₄alkyl. In certain embodiments, each of R¹ and R^(1a) isindependently an unsubstituted C₁₋₄ aliphatic group, e.g., for example,in certain embodiments, each of R¹ and R^(1a) is independently methyl(—CH₃), ethyl (—CH₂CH₃), n-propyl (—CH₂CH₂CH₃), isopropyl (—CH(CH₃)₂),or cyclopropyl (—C₃H₅). In certain embodiments, each of R¹ and R^(1a) ismethyl (—CH₃).

Alternatively, as generally defined herein, R¹ and R^(1a) may be joinedto form a substituted or unsubstituted heterocyclic, or substituted orunsubstituted heteroaryl ring. In certain embodiments, R¹ and R^(1a) arejoined to form a 3-6 membered substituted or unsubstituted heterocyclicring, e.g., 3-membered, 4-membered, 5-membered, or 6-membered,substituted or unsubstituted heterocyclic ring. In certain embodiments,R¹ and R^(1a) are joined to form a 5-6 membered substituted orunsubstituted heteroaryl ring, e.g., 5-membered or 6-membered,substituted or unsubstituted heteroaryl ring. In certain embodiments, R¹and R^(1a) may be joined to form a substituted or unsubstitutedazetidine. In certain embodiments, R¹ and R^(1a) may be joined to form asubstituted or unsubstituted pyrrolidine. In certain embodiments, R¹ andR^(1a) may be joined to form a substituted or unsubstituted piperidine.In certain embodiments, R¹ and R^(1a) may be joined to form asubstituted or unsubstituted piperazine. In certain embodiments, R¹ andR^(1a) may be joined to form a substituted or unsubstituted morpholine.In certain embodiments, R¹ and R^(1a) may be joined to form asubstituted or unsubstituted pyrrole. In certain embodiments, R¹ andR^(1a) may be joined to form a substituted or unsubstituted imidazole.In certain embodiments, R¹ and R^(1a) may be joined to form asubstituted or unsubstituted pyrazole. In certain embodiments, R¹ andR^(1a) may be joined to form a substituted or unsubstituted triazole. Incertain embodiments, R¹ and R^(1a) may be joined to form a substitutedor unsubstituted tetrazole.

However, in certain embodiments, R¹ and R^(1a) are not both methyl(—CH₃). In certain embodiments, R¹ and R^(1a) are not joined to form asubstituted or unsubstituted heterocyclic ring, e.g., a 3-membered,4-membered, 5-membered, or 6-membered substituted or unsubstitutedheterocyclic ring. In certain embodiments, R¹ and R^(1a) are not joinedto form a substituted or unsubstituted pyrrolidine ring. In certainembodiments, R¹ and R^(1a) are not joined to form a substituted orunsubstituted heteroaryl ring, e.g., 5-membered or 6-memberedsubstituted or unsubstituted heteroaryl ring.

As generally defined herein, each of R^(2a), R^(2b), R^(2c), and R^(2d)is independently hydrogen, halo, —CN, —NO₂, —C(═O)R^(A2), —C(═O)OR^(A2),—C(═O)N(R^(A2))₂, —OR^(A2), —SR^(A2), —N(R^(A2))₂, —S(═O)R^(A2),—S(═O)₂R^(A2), optionally substituted alkyl, optionally substitutedalkenyl, optionally substituted alkynyl, optionally substitutedcarbocyclyl, optionally substituted heterocyclyl, wherein each instanceof R^(A2) is independently hydrogen, optionally substituted alkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted carbocyclyl, optionally substituted heterocyclyl,optionally substituted aryl, or optionally substituted heteroaryl, ortwo R^(A2) groups attached to the same nitrogen atom are joined to forman optionally substituted heterocyclyl or optionally substitutedheteroaryl ring.

In certain embodiments, at least one of (e.g., one, two, three, each of)R^(2a), R^(2b), R^(2c), and R^(2d) is hydrogen. In certain embodiments,at least one of R^(2a), R^(2b), R^(2c), and R^(2d) is halo, e.g.,fluoro, chloro, bromo, or iodo. In certain embodiments, at least one ofR^(2a), R^(2b), R^(2c), and R^(2d) is chloro. However, in certainembodiments, neither of R^(2a), R^(2b), R^(2c), and R^(2d) are halo,e.g., fluoro, chloro, bromo, or iodo. In certain embodiments, R^(2a) isnot halo, e.g., fluoro, chloro, bromo, or iodo. In certain embodiments,R^(2a) is not chloro. In certain embodiments, R^(2d) is not halo, e.g.,fluoro, chloro, bromo, or iodo. In certain embodiments, R^(2d) is notfluoro. In certain embodiments, at least one of R^(2a), R^(2b), R^(2c),and R^(2d) is —CN. In certain embodiments, at least one of R^(2a),R^(2b), R^(2c), and R^(2d) is —NO₂. In certain embodiments, at least oneof R^(2a), R^(2b), R^(2c), and R^(2d) is —C(═O)R^(A2), e.g., whereinR^(A2) is hydrogen or optionally substituted alkyl (e.g., methyl). Incertain embodiments, at least one of R^(2a), R^(2b), R^(2c), and R^(2d)is —C(═O)OR^(A2), e.g., wherein R^(A2) is hydrogen or optionallysubstituted alkyl (e.g., methyl). In certain embodiments, at least oneof R^(2a), R^(2b), R^(2c), and R^(2d) is —C(═O)N(R^(A2))₂, e.g., whereineach instance of R^(A2) is hydrogen or optionally substituted alkyl(e.g., methyl), or two R^(A2) groups attached to the same nitrogen atomare joined to form an optionally substituted heterocyclyl or optionallysubstituted heteroaryl ring. In certain embodiments, at least one ofR^(2a), R^(2b), R^(2c), and R^(2d) is optionally substituted alkyl,e.g., optionally substituted C₁₋₄ alkyl, optionally substitutedC₁₋₂alkyl, optionally substituted C₂₋₃alkyl, optionally substitutedC₃-4alkyl, optionally substituted C₁alkyl, optionally substitutedC₂alkyl, optionally substituted C₃alkyl, or optionally substitutedC₄alkyl. Exemplary R^(2a), R^(2b), R^(2c), and R^(2d) C₁₋₄alkyl groupsinclude, but are not limited to, methyl (C₁), ethyl (C₂), n-propyl (C₃),isopropyl (C₃), n-butyl (C₄), tert-butyl (C₄), sec-butyl (C₄), andiso-butyl (C₄), each of which may be substituted or unsubstituted. Incertain embodiments, at least one of R^(2a), R^(2b), R^(2c), and R^(2d)is alkyl substituted with hydroxy or substituted hydroxy, e.g.,—(CH₂)_(a)OH or —(CH₂)_(a)OCH₃, wherein a is 1, 2, 3, 4, 5, or 6. Incertain embodiments, at least one of R^(2a), R^(2b), R^(2c), and R^(2d)is alkyl substituted with halogen (e.g., fluoro), e.g., at least one ofR^(2a), R^(2b), R^(2c), and R^(2d) is —CF₃. In certain embodiments, atleast one of R^(2a), R^(2b), R^(2c), and R^(2d) is optionallysubstituted alkenyl, e.g., optionally substituted C₂₋₄ alkenyl,optionally substituted C₂₋₃alkenyl, optionally substituted C₃₋₄alkenyl,optionally substituted C₂alkenyl, optionally substituted C₃alkenyl, oroptionally substituted C₄alkenyl. In certain embodiments, at least oneof R^(2a), R^(2b), R^(2c), and R^(2d) is optionally substitutedC₂alkenyl or optionally substituted C₃alkenyl, e.g., vinyl or allyl. Incertain embodiments, at least one of R^(2a), R^(2b), R^(2c), and R^(2d)is optionally substituted alkynyl, e.g., optionally substituted C₂₋₄alkynyl, optionally substituted C₂₋₃alkynyl, optionally substitutedC₃₋₄alkynyl, optionally substituted C₂alkynyl, optionally substitutedC₃alkynyl, or optionally substituted C₄alkynyl. In certain embodiments,at least one of R^(2a), R^(2b), R^(2c), and R^(2d) is optionallysubstituted C₂alkynyl, e.g., acetylene. In certain embodiments, at leastone of R^(2a), R^(2b), R^(2c), and R^(2d) is optionally substitutedcarbocyclyl, e.g., optionally substituted C₃₋₅carbocyclyl, optionallysubstituted C₃₋₄carbocyclyl, optionally substituted C₄₋₅ carbocyclyl,optionally substituted C₃carbocyclyl, optionally substitutedC₄carbocyclyl, or optionally substituted C₅carbocyclyl. In certainembodiments, at least one of R^(2a), R^(2b), R^(2c), and R^(2d) isoptionally substituted C₃carbocyclyl, e.g., cyclopropyl. In certainembodiments, at least one of R^(2a), R^(2b), R^(2c), and R^(2d) isoptionally substituted heterocyclyl, e.g., optionally substituted 3- to5-membered heterocyclyl, optionally substituted 3- to 4-memberedheterocyclyl, optionally substituted 4- to 5-membered heterocyclyl,optionally substituted 3-membered heterocyclyl, optionally substituted4-membered heterocyclyl, or optionally substituted 5-memberedheterocyclyl. In certain embodiments, at least one of R^(2a), R^(2b),R^(2c), and R^(2d) is —OR^(A2), —SR^(A2), or —N(R^(A2))₂, wherein R^(A2)is as defined herein. In certain embodiments, at least one of R^(2a),R^(2b), R^(2c), and R^(2d) is —S(═O)R^(A2) or —S(═O)₂R^(A2), whereinR^(A2) is as defined herein. In certain embodiments, at least one R^(A2)is hydrogen, e.g., for example, to provide at least one of R^(2a),R^(2b), R^(2c), and R^(2d) as —OH, —SH, —NH₂, or —NHR^(A2). In certainembodiments, at least one of R^(A2) is optionally substituted alkyl,e.g., optionally substituted C₁₋₄ alkyl, optionally substitutedC₁₋₂alkyl, optionally substituted C₂₋₃alkyl, optionally substitutedC₃₋₄alkyl, optionally substituted C₁alkyl, optionally substitutedC₂alkyl, optionally substituted C₃alkyl, or optionally substitutedC₄alkyl, e.g., for example, at least one of R^(A2) is methyl to providea group R^(2a), R^(2b), R^(2c), and R^(2d) of formula —OCH₃, —SCH₃,—NHCH₃, —N(CH₃)₂, or —NCH₃R^(A2). In certain embodiments, at least oneof R^(A2) is alkyl substituted with halogen (e.g., fluoro), e.g., toprovide a group R^(2a), R^(2b), R^(2c), and R^(2d) of formula —OCF₃,—SCF₃, —NHCF₃, —N(CF₃)₂, or —NCF₃R^(A2). In certain embodiments, atleast one of R^(A2) is a group of formula —CH₂CH(OH)CH₂NHR¹, wherein R¹is as defined herein, e.g., to provide a group R^(2a), R^(2b), R^(2c),and R^(2d) of formula —OCH₂CH(OH)CH₂NHR¹, —SCH₂CH(OH)CH₂NHR¹,—NHCH₂CH(OH)CH₂NHR¹, or —N(R^(A2))CH₂CH(OH)CH₂NHR¹. In certainembodiments, at least one of R^(A2) is alkyl substituted with anoptionally substituted aryl (e.g., optionally substituted phenyl) oroptionally substituted heteroaryl (e.g., optionally substitutedpyridinyl), e.g., to provide a group R^(2a), R^(2b), R^(2c), and R^(2d)of formula —O(CH₂)_(a)Ar, —S(CH₂)_(a)Ar, —NH(CH₂)_(a)Ar, or—N(R^(A2))(CH₂)_(a)Ar, wherein a is 1, 2, 3, 4, 5, or 6, and Ar isoptionally substituted aryl (e.g., optionally substituted phenyl) oroptionally substituted heteroaryl (e.g., optionally substitutedpyridinyl). In certain embodiments, at least one of R² is optionallysubstituted alkenyl, e.g., optionally substituted C₂₋₄ alkenyl,optionally substituted C₂-3alkenyl, optionally substituted C₃₋₄alkenyl,optionally substituted C₂alkenyl, optionally substituted C₃alkenyl, oroptionally substituted C₄alkenyl. In certain embodiments, at least oneof R^(A2) is optionally substituted alkynyl, e.g., optionallysubstituted C₂₋₄ alkynyl, optionally substituted C₂₋₃alkynyl, optionallysubstituted C₃₋₄alkynyl, optionally substituted C₂alkynyl, optionallysubstituted C₃alkynyl, or optionally substituted C₄alkynyl. In certainembodiments, at least one of R^(A2) is optionally substitutedcarbocyclyl, e.g., optionally substituted C₃₋₅carbocyclyl, optionallysubstituted C₃₋₄carbocyclyl, optionally substituted C₄₋₅ carbocyclyl,optionally substituted C₃carbocyclyl, optionally substitutedC₄carbocyclyl, or optionally substituted C₅carbocyclyl. In certainembodiments, at least one of R^(A2) is optionally substitutedheterocyclyl, e.g., optionally substituted 3- to 5-memberedheterocyclyl, optionally substituted 3- to 4-membered heterocyclyl,optionally substituted 4- to 5-membered heterocyclyl, optionallysubstituted 3-membered heterocyclyl, optionally substituted 4-memberedheterocyclyl, or optionally substituted 5-membered heterocyclyl. Incertain embodiments, at least one of R^(A2) is optionally substitutedaryl (e.g., optionally substituted phenyl) or optionally substitutedheteroaryl (e.g., optionally substituted pyridinyl). In certainembodiments, two R^(A2) groups, e.g., of —N(R^(A2))₂, are joined to forman optionally substituted heterocyclyl or optionally substitutedheteroaryl ring.

In certain embodiments, at least one of R^(2a), R^(2b), R^(2c), andR^(2d) is hydrogen. In certain embodiments, at least two of R^(2a),R^(2b), R^(2c), and R^(2d) is hydrogen. In certain embodiments, at leastthree of R^(2a), R^(2b), R^(2c), and R^(2d) are hydrogen. In certainembodiments, each of R^(2a), R^(2b), R^(2c), and R^(2d) is hydrogen,e.g., to provide a compound of Formula (I-c):

or a pharmaceutically acceptable salt thereof. In certain embodiments,R¹ is hydrogen or optionally substituted C₁₋₂ alkyl, e.g., methyl orethyl. In certain embodiments of Formula (I-c), R^(1a) is hydrogen. Incertain embodiments, R¹ is non-hydrogen (e.g., —CH₃), and R^(1a) ishydrogen. In certain embodiments, each of R¹ and R^(1a) is non-hydrogen(e.g., each is —CH₃). In certain embodiments, each of R¹ and R^(1a) ishydrogen. In certain embodiments, X is —O—.

However, in certain embodiments, at least one of R^(2a), R^(2b), R^(2c),and R^(2d) is a non-hydrogen group. For example, in certain embodiments,R^(2a) is a non-hydrogen group. In certain embodiments, R^(2a) is anon-hydrogen group, and each of R^(2b), R^(2c), and R^(2d) is hydrogen,e.g., to provide a compound of Formula (I-d):

or a pharmaceutically acceptable salt thereof. In certain embodiments,R^(2a) is a non-hydrogen group selected from the group consisting ofhalogen (e.g., chloro), —CN, —C(═O)R^(A2), —OR^(A2), —SR^(A2),—N(R^(A2))₂, optionally substituted cyclopropyl, optionally substitutedC₁₋₄alkyl, optionally substituted C₂₋₄alkenyl, and optionallysubstituted C₂₋₄alkynyl, wherein R² is hydrogen, optionally substitutedalkyl, or two R^(A2) groups, e.g., of —N(R^(A2))₂, are joined to form anoptionally substituted heterocyclyl or optionally substituted heteroarylring. In certain embodiments, R¹ is hydrogen or optionally substitutedC₁₋₂ alkyl, e.g., methyl or ethyl. In certain embodiments, R^(1a) ishydrogen. In certain embodiments, R¹ is non-hydrogen (e.g., —CH₃), andR^(1a) is hydrogen. In certain embodiments, each of R¹ and R^(1a) isnon-hydrogen (e.g., each is —CH₃). In certain embodiments, each of R¹and R^(1a) is hydrogen. In certain embodiments, X is —O—.

In certain embodiments, R^(2b) is a non-hydrogen group. In certainembodiments, R^(2b) is a non-hydrogen group, and each of R^(2a), R^(2c),and R^(2d) is hydrogen, e.g., to provide a compound of Formula (I-e):

or a pharmaceutically acceptable salt thereof. In certain embodiments,R^(2b) is a non-hydrogen group selected from the group consisting ofhalogen (e.g., chloro), —CN, —C(═O)R^(A2), —OR^(A2), —SR^(A2),—N(R^(A2))₂, optionally substituted cyclopropyl, optionally substitutedC₁₋₄alkyl, optionally substituted C₂₋₄alkenyl, and optionallysubstituted C₂₋₄alkynyl, wherein R^(A2) is hydrogen, optionallysubstituted alkyl, or two R^(A2) groups, e.g., of —N(R^(A2))₂, arejoined to form an optionally substituted heterocyclyl or optionallysubstituted heteroaryl ring. In certain embodiments, R¹ is hydrogen oroptionally substituted C₁₋₂ alkyl, e.g., methyl or ethyl. In certainembodiments, R^(1a) is hydrogen. In certain embodiments, R¹ isnon-hydrogen (e.g., —CH₃), and R^(1a) is hydrogen. In certainembodiments, each of R¹ and R^(1a) is non-hydrogen (e.g., each is —CH₃).In certain embodiments, each of R¹ and R^(1a) is hydrogen. In certainembodiments, X is —O—.

In certain embodiments, R^(2c) is a non-hydrogen group. In certainembodiments, R² is a non-hydrogen group, and each of R^(2a), R^(2b), andR^(2d) is hydrogen, e.g., to provide a compound of Formula (I-f):

or a pharmaceutically acceptable salt thereof. In certain embodiments,R^(2c) is a non-hydrogen group selected from the group consisting ofhalogen (e.g., chloro), —CN, —C(═O)R^(A2), —OR^(A2), —SR^(A2),—N(R^(A2))₂, optionally substituted cyclopropyl, optionally substitutedC₁₋₄alkyl, optionally substituted C₂₋₄alkenyl, and optionallysubstituted C₂₋₄alkynyl, wherein R^(A2) is hydrogen, optionallysubstituted alkyl, or two R^(A2)groups, e.g., of —N(R^(A2))₂, are joinedto form an optionally substituted heterocyclyl or optionally substitutedheteroaryl ring. In certain embodiments, R¹ is hydrogen or optionallysubstituted C₁₋₂ alkyl, e.g., methyl or ethyl. In certain embodiments,R^(1a) is hydrogen. In certain embodiments, R¹ is non-hydrogen (e.g.,—CH₃) and R^(1a) is hydrogen. In certain embodiments, each of R¹ andR^(1a) is non-hydrogen (e.g., each is —CH₃). In certain embodiments,each of R¹ and R^(1a) is hydrogen. In certain embodiments, X is —O—.

In certain embodiments, R^(2d) is a non-hydrogen group. In certainembodiments, R^(2d) is a non-hydrogen group, and each of R^(2a), R^(2b),and R^(2c) is hydrogen, e.g., to provide a compound of Formula (I-g):

or a pharmaceutically acceptable salt thereof. In certain embodiments,R^(2d) is a non-hydrogen group selected from the group consisting ofhalogen (e.g., chloro), —CN, —C(═O)R^(A2), —OR^(A2), —SR^(A2),—N(R^(A2))₂, optionally substituted cyclopropyl, optionally substitutedC₁₋₄alkyl, optionally substituted C₂₋₄alkenyl, and optionallysubstituted C₂₋₄alkynyl, wherein R^(A2) is hydrogen, optionallysubstituted alkyl, or two R^(A2) groups, e.g., of —N(R^(A2))₂, arejoined to form an optionally substituted heterocyclyl or optionallysubstituted heteroaryl ring. In certain embodiments, R^(2d) is nothalogen, e.g., fluoro. In certain embodiments, R¹ is hydrogen oroptionally substituted C₁₋₂ alkyl, e.g., methyl or ethyl. In certainembodiments, R^(1a) is hydrogen. In certain embodiments, R¹ isnon-hydrogen (e.g., —CH₃) and R^(1a) is hydrogen. In certainembodiments, each of R¹ and R^(1a) is non-hydrogen (e.g., each is —CH₃).In certain embodiments, each of R¹ and R^(1a) is hydrogen. In certainembodiments, X is —O—.

As generally understood from the present disclosure, Ring HET is a6-membered monocyclic heteroaryl ring system of Formula:

i.e., to provide a compound of Formula (I-h):

or pharmaceutically acceptable salt thereof, wherein at least oneinstance of G₈, G₁₀, G₁₁, or G₁₂ is N, e.g., at least one, two, or threeinstances of G₈, G₁₀, G₁₁, or G₁₂ are N. In certain embodiments, G₈ isN. In certain embodiments, G₁₀ is N. In certain embodiments, G₁₁ is N.In certain embodiments, G₁₂ is N. In certain embodiments, two instancesof G₈, G₁₀, G₁₁, or G₁₂ are N. In certain embodiments, G₈ and G₁₀ areboth N. In certain embodiments, G₈ and G₁₁ are both N. However, incertain embodiments, G₈ and G₁₁ are not both N. In certain embodiments,G₈ and G₁₂ are both N. In certain embodiments, G₁₀ and G₁₂ are both N.In certain embodiments, three instances of G₈, G₁₀, G₁₁, or G₁₂ are N.In certain embodiments, G₈, G₁₀, and G₁₂ are each N. In certainembodiments, R^(1a) is hydrogen. In certain embodiments, R¹ isnon-hydrogen (e.g., —CH₃), and R^(1a) is hydrogen. In certainembodiments, each of R¹ and R^(1a) is non-hydrogen (e.g., each is —CH₃).In certain embodiments, each of R and R^(1a) is hydrogen. In certainembodiments, X is —O—.

Exemplary Ring HET groups of the formula (i), (ii), or (iii), include,but are not limited to, any one of the following ring systems, whereinone, two, or three instances of G₈, G₁₀, G₁₁ and G₁₂ are N:

Furthermore, as generally defined above, each instance of R⁸, R¹⁰, R¹¹,and R¹² is independently selected from the group consisting of hydrogen,halo, —CN, —NO₂, —C(═O)R′, —C(═O)OR′, —C(═O)N(R′)₂, optionallysubstituted alkyl, optionally substituted C₃-4cycloalkyl, or -L¹-R³;wherein L¹, R³, and R′ are as defined herein.

In certain embodiments, one of R⁸, R¹⁰, R¹¹, and R¹² is -L¹-R³.Alternatively, neither R⁸, R¹⁰, R¹¹, and R¹² is -L¹-R³. In certainembodiments, R⁸ is -L¹-R³. In certain embodiments, R¹⁰ is -L¹-R³. Incertain embodiments, R¹¹ is -L¹-R³. In certain embodiments, R¹² is-L¹-R³. In certain embodiments, one instance of R⁸, R¹⁰, R¹¹, and R¹² isa -L¹-R³, and the other instances (i.e., one or two instances) arehydrogen or a non-hydrogen moiety selected from the group consisting ofhalo, —CN, —NO₂, —C(═O)R′, —C(═O)OR′, —C(═O)N(R′)₂, or optionallysubstituted alkyl. For example, in certain embodiments, at least oneinstance of R⁸, R¹⁰, R¹¹, and R¹² is halo, e.g., fluoro, chloro, bromo,or iodo. In certain embodiments, at least one instance of R⁸, R¹⁰, R¹¹,and R¹² is —CN. In certain embodiments, at least one instance of R⁸,R¹⁰, R¹¹, and R¹² is —NO₂. In certain embodiments, at least one instanceof R⁸, R¹⁰, R¹¹, and R¹² is —C(═O)R′, —C(═O)OR′, or —C(═O)N(R′)₂,wherein R′ is as defined herein. In certain embodiments, at least oneinstance of R⁸, R¹⁰, R¹¹, and R¹² is optionally substituted alkyl, e.g.,optionally substituted C₁₋₄ alkyl, optionally substituted C₁₋₂alkyl,optionally substituted C₂₋₃alkyl, optionally substituted C₃₋₄alkyl,optionally substituted C₁alkyl, optionally substituted C₂alkyl,optionally substituted C₃alkyl, or optionally substituted C₄alkyl. Incertain embodiments, at least one instance of R⁸, R¹⁰, R¹¹, and R¹² ishaloalkyl, e.g., alkyl substituted with 1 or more halogen atoms, e.g.,1, 2, 3, 4, 5, or 6 halogen atoms as valency permits. In certainembodiments, at least one instance of R⁸, R¹⁰, R¹¹, and R¹² is fluoroalkyl, in which the alkyl chain is substituted with one, two, or threefluoro groups. In certain embodiments, at least one instance of R⁸, R¹⁰,R¹¹, and R¹² is trifluoromethyl (—CF₃). In certain embodiments, at leastone instance of R⁸, R¹⁰, R¹¹, and R¹² is difluoromethyl (—CHF₂). Incertain embodiments, at least one instance of R⁸, R¹⁰, R¹¹, and R¹² isfluoromethyl (—CH₂F). In certain embodiments, at least one instance ofR⁸, R¹⁰, R¹¹, and R¹² is alkyl substituted by hydroxyl or substitutedhydroxyl, e.g., in certain embodiments, at least one instance of R⁸,R¹⁰, R¹¹, and R¹² is —CH₂OH. In certain embodiments, at least oneinstance of R⁸, R¹⁰, R¹¹, and R¹² is methyl. In certain embodiments, atleast one instance of R⁸, R¹⁰, R¹¹, and R¹² is optionally substitutedC₃₋₄cycloalkyl; e.g., optionally substituted cyclopropyl or optionallysubstituted cyclobutyl. In certain embodiments, each instance of R⁸,R¹⁰, R¹¹, and R¹² is hydrogen. In certain embodiments, at least oneinstance of R⁸, R¹⁰, R¹¹, and R¹² is hydrogen or methyl.

As understood from the present disclosure, Ring HET optionally comprisesa group -L¹-R³ attached thereto. In certain embodiments, Ring HET doesnot comprise a group of formula -L¹-R³ attached thereto, but in otherembodiments, Ring HET does comprise a group of formula -L¹-R³ attachedthereto. In certain embodiments, -L¹-R³ is meta to the point ofattachment of Ring HET to the parent moiety. In certain embodiments,-L¹-R³ is meta to -L²-R¹³. In certain embodiments, R³ is an acyclicmoiety selected from the group consisting of hydrogen, optionallysubstituted alkyl, optionally substituted alkenyl, or optionallysubstituted alkynyl. In certain embodiments, R³ is a cyclic moietyselected from the group consisting of optionally substitutedcarbocyclyl, optionally substituted heterocyclyl, optionally substitutedaryl, and optionally substituted heteroaryl. In certain embodiments, R³is directly attached to the Ring HET, i.e., wherein L is a bond,provided that R³ is not also hydrogen. In other embodiments, R³ isindirectly attached to Ring HET, i.e., wherein L¹ is a linking group.

As generally defined herein, L¹ is a bond, —O—, —N(R^(L))—, —S—, —C(O)—,—C(O)O—, —C(O)S—, —C(O)N(R^(L))—, —C(O)N(R^(L))N(R^(L))—, —OC(O)—,—OC(O)N(R^(L))—, —NR^(L)C(O)—, —NR^(L)C(O)N(R^(L))—,—NR^(L)C(O)N(R^(L))N(R^(L))—, —NR^(L)C(O)O—, —SC(O)—, —C(═NR^(L))—,—C(═NNR^(L))—, —C(═NOR^(L))—, —C(═NR^(L))N(R^(L))—, —NR^(L)C(═NR^(L))—,—C(S)—, —C(S)N(R^(L))—, —NR^(L)C(S)—, —S(O)—, —OS(O)₂—, —S(O)₂O—, —SO₂—,—N(R^(L))SO₂—, —SO₂N(R^(L))—, —N(R^(L))SO₂N(R^(L))—, or an optionallysubstituted C₁₋₁₀ saturated or unsaturated hydrocarbon chain, whereinone or more moieties selected from the group consisting of —O—,—N(R^(L))—, —S—, —C(O)—, —C(O)O—, —C(O)S—, —C(O)N(R^(L))—,—C(O)N(R^(L))N(R^(L))—, —OC(O)—, —OC(O)N(R^(L))—, —NR^(L)C(O)—,—NR^(L)C(O)N(R^(L))—, —NR^(L)C(O)N(R^(L))N(R^(L))—, —NR^(L)C(O)O—,—SC(O)—, —C(═NR^(L))—, —C(═NNR^(L))—, —C(═NOR^(L))—,—C(═NR^(L))N(R^(L))—, —NR^(L)C(═NR^(L))—, —C(S)—, —C(S)N(R^(L))—,—NR^(L)C(S)—, —S(O)—, —OS(O)₂—, —S(O)₂O—, —SO₂—, —N(R^(L))SO₂—,—SO₂N(R^(L))—, and —N(R^(L))SO₂N(R^(L))— is optionally and independentlypresent between two carbon atoms of the hydrocarbon chain, andoptionally and independently present at one or both ends of thehydrocarbon chain. It is understood that the linker joining R³ to RingHET may comprise one or more of the above recited moieties incombination to form the group L¹.

In certain embodiments, L¹ is a bond. In certain embodiments, L¹ is abond, and R³ is optionally substituted alkyl, optionally substitutedalkenyl, or optionally substituted alkynyl. In certain embodiments, L¹is a bond, and R³ is optionally substituted carbocyclyl, optionallysubstituted heterocyclyl, optionally substituted aryl, and optionallysubstituted heteroaryl. However, in certain embodiments, when L¹ is abond, R³ is not optionally substituted phenyl.

In certain embodiments, L¹ is —O—. In certain embodiments, L is—N(R^(L))—. However, in certain embodiments, L¹ is not —N(R^(L))—wherein R^(L) and R³ are each hydrogen. In certain embodiments, L¹ is-5-. In certain embodiments, L¹ is —C(O)—. In certain embodiments, L¹ is—C(O)O—. In certain embodiments, L¹ is —C(O)S—. In certain embodiments,L¹ is —C(O)N(R^(L))—. In certain embodiments, L is—C(O)N(R^(L))N(R^(L))—. In certain embodiments, L¹ is —OC(O)—. Incertain embodiments, L is —OC(O)N(R^(L))—. In certain embodiments, L¹ is—NR^(L)C(O)—. In certain embodiments, L¹ is —NR^(L)C(O)N(R^(L))—. Incertain embodiments, L¹ is —NR^(L)C(O)N(R^(L))N(R^(L))—. In certainembodiments, L¹ is —NR^(L)C(O)O—. In certain embodiments, L¹ is —SC(O)—.In certain embodiments, L¹ is —C(═NR^(L))—. In certain embodiments, L¹is —C(═NNR^(L))—. In certain embodiments, L¹ is —C(═NOR^(L))—. Incertain embodiments, L¹ is —C(═NR^(L))N(R^(L))—. In certain embodiments,L¹ is —NR^(L)C(═NR^(L))—. In certain embodiments, L¹ is —C(S)—. Incertain embodiments, L¹ is —C(S)N(R^(L))—. In certain embodiments, L¹ is—NR^(L)C(S)—. In certain embodiments, L¹ is —S(O)—. In certainembodiments, L¹ is —OS(O)₂—. In certain embodiments, L¹ is —S(O)₂O—. Incertain embodiments, L¹ is —SO₂—. In certain embodiments, L¹ is—N(R^(L))SO₂—. In certain embodiments, L¹ is —SO₂N(R^(L))—. In certainembodiments, L¹ is —N(R^(L))SO₂N(R^(L))—.

In certain embodiments, L¹ is an optionally substituted C₁₋₁₀ saturatedor unsaturated hydrocarbon chain, e.g., in certain embodiments, L¹ is anoptionally substituted C₁₋₁₀ alkyl chain, L¹ is an optionallysubstituted C₂₋₁₀ alkenyl chain, or L¹ is an optionally substitutedC₂₋₁₀ alkynyl chain. In certain embodiments, L¹ is an optionallysubstituted C₁₋₁₀ alkyl chain, e.g., an optionally substituted C₁₋₈alkyl chain, optionally substituted C₁₋₆ alkyl chain, optionallysubstituted C₁₋₄ alkyl chain, optionally substituted C₁₋₃ alkyl chain,or optionally substituted C₁₋₂ alkyl chain. In certain embodiments, L¹is an unsubstituted C₁₋₁₀ n-alkyl chain of the formula —(CH₂)_(x)—,wherein x is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In certain embodiments,L¹ is an optionally substituted C₂₋₁₀ alkenyl chain, e.g., an optionallysubstituted C₂₋₈ alkenyl chain, optionally substituted C₂₋₆ alkenylchain, optionally substituted C₂₋₄ alkenyl chain, optionally substitutedC₂₋₃ alkenyl chain, or optionally substituted C₂ alkenyl chain. Incertain embodiments, L¹ is an optionally substituted C₂₋₁₀ alkynylchain, e.g., an optionally substituted C₂₋₈ alkynyl chain, optionallysubstituted C₂₋₆ alkynyl chain, optionally substituted C₂₋₄ alkynylchain, optionally substituted C₂₋₃ alkynyl chain, or optionallysubstituted C₂ alkynyl chain.

In certain embodiments, L¹ is an optionally substituted C₁₋₁₀ saturatedor unsaturated hydrocarbon chain, wherein one or more moieties selectedfrom the group consisting of —O—, —N(R^(L))—, —S—, —C(O)—, —C(O)O—,—C(O)S—, —C(O)N(R^(L))—, —C(O)N(R^(L))N(R^(L))—, —OC(O)—,—OC(O)N(R^(L))—, —NR^(L)C(O)—, —NR^(L)C(O)N(R^(L))—,—NR^(L)C(O)N(R^(L))N(R^(L))—, —NR^(L)C(O)O—, —SC(O)—, —C(═NR^(L))—,—C(═NNR^(L))—, —C(═NOR^(L))—, —C(═NR^(L))N(R^(L))—, —NR^(L)C(═NR^(L))—,—C(S)—, —C(S)N(R^(L))—, —NR^(L)C(S)—, —S(O)—, —OS(O)₂—, —S(O)₂O—, —SO₂—,—N(R^(L))SO₂—, —SO₂N(R^(L))—, or —N(R^(L))SO₂N(R^(L))— independentlypresent between two carbon atoms of the hydrocarbon chain, or present atone or both ends of the hydrocarbon chain. In this instance, in certainembodiments, L¹ is a chain of at least 2 atoms, e.g., L¹ is a chaincomprising 1 to 10 carbon atoms (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10carbon atoms), and 1 or more of the above recited moieties (e.g., 1, 2,3, or more), to provide a chain of between 2 and 20 atoms, inclusive,e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or20 chain atoms. In certain embodiments, a moiety is present between twocarbon atoms of the hydrocarbon chain. In certain embodiments, a moietyis present at one end of the hydrocarbon chain. In certain embodiments,a moiety is independently present at each end of the hydrocarbon chain.In certain embodiments, L¹ is an optionally substituted C₁₋₁₀ alkylchain, L¹ is an optionally substituted C₂₋₁₀ alkenyl chain, or L¹ is anoptionally substituted C₂₋₁₀ alkynyl chain comprising one or more of theabove recited moieties independently present between two carbon atoms ofthe hydrocarbon chain, or present at one or both ends of the hydrocarbonchain. In certain embodiments, L¹ is an optionally substituted C₁₋₁₀alkyl chain, e.g., an optionally substituted C₁₋₈ alkyl chain,optionally substituted C₁₋₆ alkyl chain, optionally substituted C₁₋₄alkyl chain, optionally substituted C₁₋₃ alkyl chain, or optionallysubstituted C₁₋₂ alkyl chain, comprising one or more of the aboverecited moieties independently present between two carbon atoms of thehydrocarbon chain, or present at one or both ends of the hydrocarbonchain. In certain embodiments, L¹ is an unsubstituted C₁₋₁₀ n-alkylchain of the formula —(CH₂)_(x)—, wherein x is 1, 2, 3, 4, 5, 6, 7, 8,9, or 10, comprising one or more of the above recited moietiesindependently present between two carbon atoms of the hydrocarbon chain,or present at one or both ends of the hydrocarbon chain. In certainembodiments, L¹ is an optionally substituted C₂₋₁₀ alkenyl chain, e.g.,an optionally substituted C₂₋₈ alkenyl chain, optionally substitutedC₂₋₆ alkenyl chain, optionally substituted C₂₋₄ alkenyl chain,optionally substituted C₂₋₃ alkenyl chain, or optionally substituted C₂alkenyl chain, comprising one or more of the above recited moietiesindependently present between two carbon atoms of the hydrocarbon chain,or present at one or both ends of the hydrocarbon chain. In certainembodiments, L¹ is an optionally substituted C₂₋₁₀ alkynyl chain, e.g.,an optionally substituted C₂₋₈ alkynyl chain, optionally substitutedC₂₋₆ alkynyl chain, optionally substituted C₂₋₄ alkynyl chain,optionally substituted C₂₋₃ alkynyl chain, or optionally substituted C₂alkynyl chain, comprising one or more of the above recited moietiesindependently present between two carbon atoms of the hydrocarbon chain,or present at one or both ends of the hydrocarbon chain.

As described above, in certain embodiments, L¹ is an unsubstituted C₁₋₁₀n-alkyl chain of the formula —(CH₂)_(x)—, wherein x is 1, 2, 3, 4, 5, 6,7, 8, 9, or 10, comprising one or more of the above recited moietiesindependently present between two carbon atoms of the hydrocarbon chain,or present at one or both ends of the hydrocarbon chain. In certainembodiments, L¹ is —O—(CH₂)_(x)—, —(CH₂)_(x)—O—, or —O—(CH₂)_(x)—O—. Incertain embodiments, L¹ is —N(R^(L))—(CH₂)_(x)—, —(CH₂)_(x)—N(R^(L))—,—N(R^(L))—(CH₂)_(x)—N(R^(L))—, —O—(CH₂)_(x)—N(R^(L))—,—N(R^(L))—(CH₂)_(x)—O—, —NR^(L)—(CH₂)_(x)—C(O)O—, or—OC(O)—(CH₂)_(x)—N(R^(L))—. In certain embodiments, L¹ is —S—(CH₂)_(x)—or —(CH₂)_(x)—S—. In certain embodiments, L¹ is —C(O)—(CH₂)_(x)— or—(CH₂)_(x)—C(O)—. In certain embodiments, L¹ is —C(O)O—(CH₂)_(x)— or—(CH₂)_(x) C(O)O—. In certain embodiments, L¹ is —C(O)S—(CH₂)_(x)— or—(CH₂)_(x)—C(O)S—. In certain embodiments, L¹ is —C(O)N(R^(L))—(CH₂)_(x)or —(CH₂)_(x)—C(O)N(R^(L))—. In certain embodiments, L¹ is—C(O)N(R^(L))N(R^(L))—(CH₂)_(x) or —(CH₂)_(x)—C(O)N(R^(L))N(R^(L))—. Incertain embodiments, L¹ is —OC(O)—(CH₂)_(x)— or —(CH₂)_(x)—OC(O)—. Incertain embodiments, L¹ is —OC(O)N(R^(L))—(CH₂)_(x)— or—(CH₂)_(x)—OC(O)N(R^(L))—. In certain embodiments, L¹ is—NR^(L)C(O)—(CH₂)_(x) or —(CH₂)_(x)—NR^(L)C(O)—. In certain embodiments,L¹ is —NR^(L)C(O)N(R^(L))—(CH₂)_(x) or —(CH₂)_(x)—NR^(L)C(O)N(R^(L))—.In certain embodiments, L¹ is —NR^(L)C(O)N(R^(L))N(R^(L))—(CH₂)_(x) or—(CH₂)_(x)—NR^(L)C(O)N(R^(L))N(R^(L))—. In certain embodiments, L¹ is—NR^(L)C(O)O—(CH₂)_(x) or —(CH₂)_(x)—NR^(L)C(O)O—. In certainembodiments, L¹ is —SC(O)—(CH₂)_(x)— or —(CH₂)_(x)—SC(O)—. In certainembodiments, L¹ is —C(═NR^(L))—(CH₂)_(x) or —(CH₂)_(x)—C(═NR^(L))—. Incertain embodiments, L¹ is —C(═NNR^(L))—(CH₂)_(x)— or—(CH₂)_(x)—C(═NNR^(L))—. In certain embodiments, L¹ is—C(═NOR^(L))—(CH₂)_(x) or —(CH₂)_(x)—C(═NOR^(L))—. In certainembodiments, L¹ is —C(═NR^(L))N(R^(L))—(CH₂)_(x) or—(CH₂)_(x)—C(═NR^(L))N(R^(L))—. In certain embodiments, L¹ is—NR^(L)C(═NR^(L))—(CH₂)_(x) or —(CH₂)_(x)—NR^(L)C(═NR^(L))—. In certainembodiments, L¹ is —C(S)—(CH₂)_(x)— or —(CH₂)_(x)—C(S)—. In certainembodiments, L¹ is —C(S)N(R^(L))—(CH₂)_(x) or —(CH₂)_(x) C(S)N(R^(L))—.In certain embodiments, L¹ is —NR^(L)C(S)—(CH₂)_(x) or—(CH₂)_(x)—NR^(L)C(S)—. In certain embodiments, L¹ is —S(O)—(CH₂)_(x)—or —(CH₂)_(x)—S(O)—. In certain embodiments, L¹ is —OS(O)₂—(CH₂)_(x) or—(CH₂)_(x)—OS(O)₂—. In certain embodiments, L¹ is —S(O)₂O—(CH₂)_(x)— or—(CH₂)_(x)—S(O)₂—. In certain embodiments, L¹ is —SO₂—(CH₂)_(x)— or—(CH₂)_(x)—SO₂—. In certain embodiments, L¹ is —N(R^(L))SO₂—(CH₂)_(x) or—(CH₂)_(x)—N(R^(L))SO₂—. In certain embodiments, L¹ is—SO₂N(R^(L))—(CH₂)_(x) or —(CH₂)_(x)—SO₂N(R^(L))—. In certainembodiments, L¹ is —N(R^(L))SO₂N(R^(L))—(CH₂)_(x)— or—(CH₂)_(x)—N(R^(L))SO₂N(R^(L))—. In certain embodiments, L is a bond,—N(R^(L))—, —NR^(L)C(O)O—, —NR^(L)C(O)N(R^(L))—, —N(R^(L))—,—N(R^(L))SO₂N(R^(L))—, —NR^(L)—(CH₂)_(x)—C(O)O—, —NR^(L)—(CH₂)_(x)—O—,—NR^(L)C(O)N(R^(L))—, —NR^(L)—(CH₂)_(x)—,—(CH₂)_(x)—NR^(L)—NR^(L)C(O)O(CH₂)_(x)—, —NR^(L)C(O)NR^(L)(CH₂)_(x)—, or—NR^(L)(CH₂)_(x)NR^(L)C(O)—.

In certain embodiments, R³ is an acyclic moiety selected from the groupconsisting of hydrogen, optionally substituted alkyl, optionallysubstituted alkenyl, and optionally substituted alkynyl. In certainembodiments, R³ is hydrogen, e.g., for example, when L¹ is —N(R^(L))— or—NR^(L)—(CH₂)_(x)—NR^(L)—. In certain embodiments, R³ is optionallysubstituted alkyl, e.g., for example, when L¹ is —NR^(L)C(O)O—,—NR^(L)C(O)N(R^(L))—, —N(R^(L))—, —N(R^(L))SO₂N(R^(L))—,—NR^(L)—(CH₂)_(x)—C(O)O—, or —NR^(L)—(CH₂)_(x)—O—. In certainembodiments, R³ is optionally substituted C₁₋₆ alkyl, e.g., optionallysubstituted C₁₋₅alkyl, optionally substituted C₁₋₄alkyl, optionallysubstituted C₁₋₂alkyl, optionally substituted C₂₋₃alkyl, optionallysubstituted C₃₋₄alkyl, optionally substituted C₁alkyl, optionallysubstituted C₂alkyl, optionally substituted C₃alkyl, optionallysubstituted C₄alkyl, optionally substituted C₅alkyl, or optionallysubstituted C₆alkyl. Exemplary R³ C₁₋₆alkyl groups include, but are notlimited to, methyl (C₁), ethyl (C₂), n-propyl (C₃), isopropyl (C₃),n-butyl (C₄), tert-butyl (C₄), sec-butyl (C₄), iso-butyl (C₄), n-pentyl(C₅), 3-pentanyl (C₅), amyl (C₅), neopentyl (C₅), 3-methyl-2-butanyl(C₅), tertiary amyl (C₅), and n-hexyl (C₆). In certain embodiments, R³is alkyl substituted with —CN, e.g., —(CH₂)_(y)CN, wherein y is 1, 2, 3,4, 5, or 6. In certain embodiments, R³ is alkyl substituted with hydroxyor substituted hydroxy, e.g., —(CH₂)_(y)OCH₃, wherein y is 1, 2, 3, 4,5, or 6. In certain embodiments, R³ is alkyl substituted with amino orsubstituted substituted amino, e.g., —(CH₂)_(y)NH₂, wherein y is 1, 2,3, 4, 5, or 6. In certain embodiments, R³ is optionally substitutedalkenyl, e.g., for example, when L¹ is a bond. In certain embodiments,R³ is optionally substituted C₂₋₄ alkenyl, e.g., optionally substitutedC₂₋₃alkenyl, optionally substituted C₃₋₄alkenyl, optionally substitutedC₂alkenyl, optionally substituted C₃alkenyl, or optionally substitutedC₄alkenyl. In certain embodiments, R³ is optionally substitutedC₂alkenyl or C₃alkenyl, e.g., optionally substituted vinyl or optionallysubstituted allyl. In certain embodiments, R³ is optionally substitutedalkynyl, e.g., for example, when L¹ is a bond. In certain embodiments,R³ is optionally substituted C₂₋₄ alkynyl, e.g., optionally substitutedC₂₋₃alkynyl, optionally substituted C₃₋₄alkynyl, optionally substitutedC₂alkynyl, optionally substituted C₃alkynyl, or optionally substitutedC₄alkynyl. In certain embodiments, R³ is optionally substitutedC₂alkynyl, e.g., optionally substituted acetylene.

Alternatively, in certain embodiments, R³ is a cyclic moiety selectedfrom the group consisting of optionally substituted carbocyclyl,optionally substituted heterocyclyl, optionally substituted aryl, andoptionally substituted heteroaryl. It is understood that the R³ cyclicmoiety may be monocyclic or polycyclic (e.g., bicyclic or tricyclic). Incertain embodiments, R³ is a monocylic optionally substitutedcarbocyclyl, monocylic optionally substituted heterocyclyl, monocylicoptionally substituted aryl, or monocylic optionally substitutedheteroaryl. In certain embodiments, R³ is a bicyclic optionallysubstituted carbocyclyl, bicyclic optionally substituted heterocyclyl,bicyclic optionally substituted aryl, or bicyclic optionally substitutedheteroaryl.

In certain embodiments, R³ is an optionally substituted monocyclic orbicyclic carbocyclyl, e.g., an optionally substituted C₃₋₁₀ carbocyclyl,optionally substituted C₃₋₉ carbocyclyl, optionally substituted C₃₋₈carbocyclyl, optionally substituted C₃₋₇ carbocyclyl, optionallysubstituted C₃₋₆ carbocyclyl, optionally substituted C₃₋₄carbocyclyl,optionally substituted C₅₋₁₀ carbocyclyl, optionally substituted C₃carbocyclyl, optionally substituted C₄ carbocyclyl, optionallysubstituted C₅ carbocyclyl, optionally substituted C₆ carbocyclyl,optionally substituted C₇ carbocyclyl, optionally substituted C₈carbocyclyl, optionally substituted C₉ carbocyclyl, or optionallysubstituted C₁₀ carbocyclyl. In certain embodiments, R³ is an optionallysubstituted cyclopropyl (C₃), cyclopropenyl (C₃), cyclobutyl (C₄),cyclobutenyl (C₄), cyclopentyl (C₅), cyclopentenyl (C₅), cyclohexyl(C₆), cyclohexenyl (C₆), cyclohexadienyl (C₆), cycloheptyl (C₇),cycloheptenyl (C₇), cycloheptadienyl (C₇), cycloheptatrienyl (C₇),cyclooctyl (C₈), cyclooctenyl (C₈), bicyclo[2.2.1]heptanyl (C₇),bicyclo[2.2.2]octanyl (C₈), cyclononyl (C₉), cyclononenyl (C₉),cyclodecyl (C₁₀), cyclodecenyl (C₁₀), octahydro-1H-indenyl (C₉),decahydronaphthalenyl (C₁₀), or spiro[4.5]decanyl (C₁₀) ring.

In certain embodiments, R³ is an optionally substituted monocyclic orbicyclic heterocyclyl, e.g., an optionally substituted 3- to 10-memberedheterocyclyl, 3- to 8-membered heterocyclyl, 3- to 6-memberedheterocyclyl, 3- to 5-membered heterocyclyl, 3- to 4-memberedheterocyclyl, 3-membered heterocyclyl, 4-membered heterocyclyl,5-membered heterocyclyl, 6-membered heterocyclyl, 7-memberedheterocyclyl, 8-membered heterocyclyl, 9-membered heterocyclyl, or10-membered heterocyclyl. In certain embodiments, R³ is an optionallysubstituted azirdinyl, oxiranyl, thiorenyl, azetidinyl, oxetanyl,thietanyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl,dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, pyrrolidin-2-one,pyrrolyl-2,5-dione, dioxolanyl, oxasulfuranyl, disulfuranyl,oxazolidin-2-one, triazolinyl, oxadiazolinyl, thiadiazolinyl,piperidinyl, tetrahydropyranyl, dihydropyridinyl, thianyl, piperazinyl,morpholinyl, dithianyl, dioxanyl, triazinanyl, azepanyl, oxepanyl,thiepanyl, azocanyl, oxecanyl, thiocanyl, indolinyl, isoindolinyl,dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl,tetrahydroquinolinyl, tetrahydroisoquinolinyl, furo[2,3-b]furanyl,2,3-dihydro-1,4-dioxinyl, 3-oxa-8-azabicyclo[3.2.1]octanyl, or8-oxa-3-azabicyclo[3.2.1]octanyl ring.

In certain embodiments, R³ is an optionally substituted monocyclic orbicyclic aryl, e.g., an optionally substituted phenyl, or optionallysubstituted naphthyl ring.

In certain embodiments, R³ is an optionally substituted monocyclic orbicyclic heteroaryl, e.g., an optionally substituted 5- to 10-memberedheteroaryl, optionally substituted 5- to 8-membered heteroaryl,optionally substituted 5- to 6-membered heteroaryl, optionallysubstituted 5-membered heteroaryl, or optionally substituted 6-memberedheteroaryl. In certain embodiments, R³ is an optionally substitutedpyrrolyl, furanyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl,isoxazolyl, thiazolyl, isothiazolyl, tetrazolyl, pyridinyl, pyridazinyl,pyrimidinyl, pyrazinyl, triazinyl, tetrazinyl, azepinyl, oxepinyl,thiepinyl, indolyl, isoindolyl, indazolyl, benzotriazolyl,benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl,benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl,benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, purinyl,naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl,quinoxalinyl, phthalazinyl, or quinazolinyl ring.

In certain embodiments, R³ is an optionally substituted spiro-fusedheterocyclic ring system, e.g., comprising an optionally substitutedheterocyclic ring spiro fused to an optionally substituted carbocyclicor optionally substituted heterocyclic ring, wherein the point ofattachment is either on the heterocylic or carbocyclic ring. In certainembodiments, R³ is an optionally substituted 3,4-spiro-fusedheterocyclic ring system, e.g., wherein the point of attachment iseither on the 3- or 4-membered ring. In certain embodiments, R³ is anoptionally substituted 3,5-spiro-fused heterocyclic ring system, e.g.,wherein the point of attachment is either on the 3- or 5-membered ring.In certain embodiments, R³ is an optionally substituted 3,6-spiro-fusedheterocyclic ring system, e.g., wherein the point of attachment iseither on the 3- or 6-membered ring. In certain embodiments, R³ is anoptionally substituted 4,4-spiro-fused heterocyclic ring system. Incertain embodiments, R³ is an optionally substituted 4,5-spiro-fusedheterocyclic ring system, e.g., wherein the point of attachment iseither on the 4- or 5-membered ring. In certain embodiments, R³ is anoptionally substituted 4,6-spiro-fused heterocyclic ring system, e.g.,wherein the point of attachment is either on the 4- or 6-membered ring.In certain embodiments, R³ is an optionally substituted 5,5-spiro-fusedheterocyclic ring system. In certain embodiments, R³ is an optionallysubstituted 5,6-spiro-fused heterocyclic ring system, e.g., wherein thepoint of attachment is either on the 5- or 6-membered ring. In certainembodiments, R³ is an optionally substituted 6,6-spiro-fusedheterocyclic ring system. In any of the above embodiments, R³ is anN-linked, optionally substituted spiro-fused heterocyclic ring system,i.e., wherein the point of attachment is on a nitrogen atom.Alternatively, in any of the above embodiments, R³ is an C-linked,optionally substituted spiro-fused heterocyclic ring system, i.e.,wherein the point of attachment is on a carbon atom.

In certain embodiments, R³ is an optionally substituted ortho-fusedheterocyclic ring system, e.g., comprising an optionally substitutedheterocyclic ring ortho fused to an optionally substituted carbocyclicor optionally substituted heterocyclic ring wherein the point ofattachment is either on the heterocylic or carbocyclic ring orcomprising an optionally substituted heterocyclic ring ortho fused to anoptionally substituted aryl or optionally substituted heteroaryl ring,wherein the point of attachment is on the heterocylic ring. In certainembodiments, R³ is an optionally substituted 3,4-ortho-fusedheterocyclic ring system, e.g., wherein the point of attachment iseither on the 3- or 4-membered ring. In certain embodiments, R³ is anoptionally substituted 3,5-ortho-fused heterocyclic ring system, e.g.,wherein the point of attachment is either on the 3- or 5-membered ring.In certain embodiments, R³ is an optionally substituted 3,6-ortho-fusedheterocyclic ring system, e.g., wherein the point of attachment iseither on the 3- or 6-membered ring. In certain embodiments, R³ is anoptionally substituted 4,4-ortho-fused heterocyclic ring system. Incertain embodiments, R³ is an optionally substituted 4,5-ortho-fusedheterocyclic ring system, e.g., wherein the point of attachment iseither on the 4- or 5-membered ring. In certain embodiments, R³ is anoptionally substituted 4,6-ortho-fused heterocyclic ring system, e.g.,wherein the point of attachment is either on the 4- or 6-membered ring.In certain embodiments, R³ is an optionally substituted 5,5-ortho-fusedheterocyclic ring system. In certain embodiments, R³ is an optionallysubstituted 5,6-ortho-fused heterocyclic ring system, e.g., wherein thepoint of attachment is either on the 5- or 6-membered ring. In certainembodiments, R³ is an optionally substituted 6,6-ortho-fusedheterocyclic ring system. In any of the above embodiments, R³ is anN-linked, optionally substituted ortho-fused heterocyclic ring system,i.e., wherein the point of attachment is on a nitrogen atom.Alternatively, in any of the above embodiments, R³ is an C-linked,optionally substituted ortho-fused heterocyclic ring system, i.e.,wherein the point of attachment is on a carbon atom.

In certain embodiments, R³ is an optionally substituted ortho-fusedheteroaryl ring system, e.g., comprising an optionally substitutedheteroaryl ring ortho fused to an optionally substituted carbocyclic oroptionally substituted heterocyclic ring wherein the point of attachmentis on the heteroaryl ring or comprising an optionally substitutedheteroaryl ring ortho fused to an optionally substituted aryl oroptionally substituted heteroaryl ring, wherein the point of attachmentis either on the aryl ring or heteroaryl ring. In certain embodiments,the R³ heteroaryl ring ortho fused to an optionally substitutedcarbocyclic or optionally substituted heterocyclic ring is a 5-memberedheteroaryl ring, e.g., to provide a 3,5-, 4,5-, 5,5-, or 6,5-ortho fusedring system. In certain embodiments, the R³ heteroaryl ring ortho fusedto an optionally substituted carbocyclic or optionally substitutedheterocyclic ring is a 6-membered heteroaryl ring, e.g., to provide a3,6-, 4,6-, 5,6-, or 6,6-ortho fused ring system. In certainembodiments, the R³ optionally substituted heteroaryl ring ortho fusedto an optionally substituted aryl ring is a 5-membered heteroaryl ring,e.g., to provide a 5,6-ortho fused ring system. In certain embodiments,the R³ optionally substituted heteroaryl ring ortho fused to anoptionally substituted aryl ring is a 6-membered heteroaryl ring, e.g.,to provide a 6,6-fused ring system. In certain embodiments, the R³optionally substituted heteroaryl ring ortho fused to an optionallyheteroaryl ring is a 5-membered heteroaryl ring, e.g., to provide a 6,5-or 5,5-fused ring system. In certain embodiments, the R³ optionallysubstituted heteroaryl ring ortho fused to an optionally heteroaryl ringis a 6-membered heteroaryl ring, e.g., to provide a 6,5- or 5,5-fusedring system. In any of the above embodiments, R³ is an N-linked,optionally substituted ortho-fused heteroaryl ring system, i.e., whereinthe point of attachment is on a nitrogen atom. Alternatively, in any ofthe above embodiments, R³ is an C-linked, optionally substitutedortho-fused heteroaryl ring system, i.e., wherein the point ofattachment is on a carbon atom.

In certain embodiments, R³ is an optionally substituted ortho-fused arylring system, e.g., comprising an optionally substituted 6-membered arylring ortho fused to an optionally substituted carbocyclic or optionallysubstituted heterocyclic ring wherein the point of attachment is on thearyl ring, e.g., to provide a 3,6-, 4,6-, 5,6-, or 6,6-ortho fused ringsystem. In certain embodiments, R³ is an optionally substitutedortho-fused aryl ring system, e.g., comprising an optionally substituted6-membered aryl ring ortho fused to an optionally substituted 6-memberedaryl ring.

In certain embodiments, R³ is a cyclic moiety selected from the groupconsisting of

wherein:

each instance of

independently represents a single or double bond;

n is 0, 1, 2, or 3;

x is 0 or 1;

Y is O, S, N, or NR^(3B) and each instance of Q and W is independentlyCH, CR^(3A), N, or NR^(3B), as valency permits;

each instance of R^(3A) is independently hydroxyl, substituted hydroxyl,thiol, substituted thiol, amino, substituted amino, carbonyl, sulfonyl,sulfinyl, —CN, —NO₂, halogen, optionally substituted alkyl, optionallysubstituted alkenyl, optionally substituted alkynyl, optionallysubstituted carbocyclic, optionally substituted heterocyclic, optionallysubstituted aryl, or optionally substituted heteroaryl, or two R^(3A)groups are joined to form an optionally substituted carbocyclic,optionally substituted heterocyclic, optionally substituted aryl,optionally substituted heteroaryl, or oxo (═O) group, or R^(3A) andR^(3B) groups are joined to form an optionally substituted carbocyclic,optionally substituted heterocyclic, optionally substituted aryl, oroptionally substituted heteroaryl ring; and

R^(3B) is hydrogen, optionally substituted alkyl, hydroxyl, substitutedhydroxyl, amino, substituted amino, carbonyl, sulfonyl, optionallysubstituted carbocyclic, optionally substituted heterocyclic, optionallysubstituted aryl, optionally substituted heteroaryl, or a nitrogenprotecting group.

In certain embodiments, n is 0. In certain embodiments, n is 1. Incertain embodiments, n is 2. In certain embodiments, n is 3. In certainembodiments, each instance of R^(3A) is independently hydroxyl, —OCH₃,optionally substituted C₁₋₄alkyl (e.g., methyl, trifluoromethyl, ethyl,propyl, isopropyl, butyl, isobutyl, secbutyl, tertbutyl), —CN, orsulfonyl (e.g., —S(O)₂CH₃).

As generally defined herein, L² is a bond, —O—, —N(R^(L))—, —S—, —C(O)—,—C(O)O—, —C(O)S—, —C(O)N(R^(L))—, —C(O)N(R^(L))N(R^(L))—, —OC(O)—,—OC(O)N(R^(L))—, —NR^(L)C(O)—, —NR^(L)C(O)N(R^(L))—,—NR^(L)C(O)N(R^(L))N(R^(L))—, —NR^(L)C(O)O—, —SC(O)—, —C(═NR^(L))—,—C(═NNR^(L))—, —C(═NOR^(L))—, —C(═NR^(L))N(R^(L))—, —NR^(L)C(═NR^(L))—,—C(S)—, —C(S)N(R^(L))—, —NR LC(S)—, —S(O)—, —OS(O)₂—, —S(O)₂O—, —SO₂—,—N(R^(L))SO₂—, —SO₂N(R^(L))—, —N(R^(L))SO₂N(R^(L))—, or an optionallysubstituted C₁₋₁₀ saturated or unsaturated hydrocarbon chain, whereinone or more moieties selected from the group consisting of —O—,—N(R^(L))—, —S—, —C(O)—, —C(O)O—, —C(O)S—, —C(O)N(R^(L))—,—C(O)N(R^(L))N(R^(L))—, —OC(O)—, —OC(O)N(R^(L))—, —NR^(L)C(O)—,—NR^(L)C(O)N(R^(L))—, —NR^(L)C(O)N(R^(L))N(R^(L))—, —NR^(L)C(O)O—,—SC(O)—, —C(═NR^(L))—, —C(═NNR^(L))—, —C(═NOR^(L))—,—C(═NR^(L))N(R^(L))—, —NR^(L)C(═NR^(L))—, —C(S)—, —C(S)N(R^(L))—,—NR^(L)C(S)—, —S(O)—, —OS(O)₂—, —S(O)₂O—, —SO₂—, —N(R^(L))SO₂—,—SO₂N(R^(L))—, and —N(R^(L))SO₂N(R^(L))— is optionally and independentlypresent between two carbon atoms of the hydrocarbon chain, andoptionally and independently present at one or both ends of thehydrocarbon chain. It is understood that the linker joining R¹³ to RingHET may comprise one or more of the above recited moieties incombination to form the group L².

In certain embodiments, L² is a bond. In certain embodiments, L² is —O—.In certain embodiments, L² is —N(R^(L))—. In certain embodiments, L² is-5-. In certain embodiments, L² is —C(O)—. In certain embodiments, L² is—C(O)O—. In certain embodiments, L² is —C(O)S—. In certain embodiments,L² is —C(O)N(R^(L))—. However, in certain embodiments, L² is not—C(O)N(R^(L))— wherein R¹³ is optionally substituted carbocyclyl, e.g.,optionally substituted adamantanyl. In certain embodiments, L²is-C(O)N(R^(L))N(R^(L))—. In certain embodiments, L² is —OC(O)—. Incertain embodiments, L² is —OC(O)N(R^(L))—. In certain embodiments, L²is —NR^(L)C(O)—. In certain embodiments, L² is —NR^(L)C(O)N(R^(L))—. Incertain embodiments, L² is —NR^(L)C(O)N(R^(L))N(R^(L))—. In certainembodiments, L² is —NR^(L)C(O)O—. In certain embodiments, L² is —SC(O)—.In certain embodiments, L² is —C(═NR^(L))—. In certain embodiments, L²is —C(═NNR^(L))—. In certain embodiments, L² is —C(═NOR^(L))—. Incertain embodiments, L² is —C(═NR^(L))N(R^(L))—. In certain embodiments,L² is —NR^(L)C(═NR^(L))—. In certain embodiments, L² is —C(S)—. Incertain embodiments, L² is —C(S)N(R^(L))—. In certain embodiments, L² is—NR^(L)C(S)—. In certain embodiments, L² is —S(O)—. In certainembodiments, L² is —OS(O)₂—. In certain embodiments, L² is —S(O)₂O—. Incertain embodiments, L² is —SO₂—. In certain embodiments, L² is—N(R^(L))SO₂—. In certain embodiments, L² is —SO₂N(R^(L))—. In certainembodiments, L² is —N(R^(L))SO₂N(R^(L))—.

In certain embodiments, L² is an optionally substituted C₁₋₁₀ saturatedor unsaturated hydrocarbon chain, e.g., in certain embodiments, L² is anoptionally substituted C₁₋₁₀ alkyl chain, L² is an optionallysubstituted C₂₋₁₀ alkenyl chain, or L² is an optionally substitutedC₂₋₁₀ alkynyl chain. In certain embodiments, L² is an optionallysubstituted C₁₋₁₀ alkyl chain, e.g., an optionally substituted C₁₋₈alkyl chain, optionally substituted C₁₋₆ alkyl chain, optionallysubstituted C₁₋₄ alkyl chain, optionally substituted C₁₋₃ alkyl chain,or optionally substituted C₁₋₂ alkyl chain. In certain embodiments, L²is an unsubstituted C₁₋₁₀ n-alkyl chain of the formula —(CH₂)_(x)—,wherein x is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In certain embodiments,L² is an optionally substituted C₂₋₁₀ alkenyl chain, e.g., an optionallysubstituted C₂₋₈ alkenyl chain, optionally substituted C₂₋₆ alkenylchain, optionally substituted C₂₋₄ alkenyl chain, optionally substitutedC₂₋₃ alkenyl chain, or optionally substituted C₂ alkenyl chain. Incertain embodiments, L² is an optionally substituted C₂₋₁₀ alkynylchain, e.g., an optionally substituted C₂₋₈ alkynyl chain, optionallysubstituted C₂₋₆ alkynyl chain, optionally substituted C₂₋₄ alkynylchain, optionally substituted C₂₋₃ alkynyl chain, or optionallysubstituted C₂ alkynyl chain.

In certain embodiments, L² is an optionally substituted C₁₋₁₀ saturatedor unsaturated hydrocarbon chain, wherein one or more moieties selectedfrom the group consisting of —O—, —N(R^(L))—, —S—, —C(O)—, —C(O)O—,—C(O)S—, —C(O)N(R^(L))—, —C(O)N(R^(L))N(R^(L))—, —OC(O)—,—OC(O)N(R^(L))—, —NR^(L)C(O)—, —NR^(L)C(O)N(R^(L))—,—NR^(L)C(O)N(R^(L))N(R^(L))—, —NR^(L)C(O)O—, —SC(O)—, —C(═NR^(L))—,—C(═NNR^(L))—, —C(═NOR^(L))—, —C(═NR^(L))N(R^(L))—, —NR^(L)C(═NR^(L))—,—C(S)—, —C(S)N(R^(L))—, —NR^(L)C(S)—, —S(O)—, —OS(O)₂—, —S(O)₂O—, —SO₂—,—N(R^(L))SO₂—, —SO₂N(R^(L))—, or —N(R^(L))SO₂N(R^(L))— independentlypresent between two carbon atoms of the hydrocarbon chain, or present atone or both ends of the hydrocarbon chain. In this instance, in certainembodiments, L² is a chain of at least 2 atoms, e.g., L² is a chaincomprising 1 to 10 carbon atoms (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10carbon atoms), and 1 or more of the above recited moieties (e.g., 1, 2,3, or more), to provide a chain of between 2 and 20 atoms, inclusive,e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or20 chain atoms. In certain embodiments, a moiety is present between twocarbon atoms of the hydrocarbon chain. In certain embodiments, a moietyis present at one end of the hydrocarbon chain. In certain embodiments,a moiety is independently present at each end of the hydrocarbon chain.In certain embodiments, L² is an optionally substituted C₁₋₁₀ alkylchain, L² is an optionally substituted C₂₋₁₀ alkenyl chain, or L² is anoptionally substituted C₂₋₁₀ alkynyl chain comprising one or more of theabove recited moieties independently present between two carbon atoms ofthe hydrocarbon chain, or present at one or both ends of the hydrocarbonchain. In certain embodiments, L² is an optionally substituted C₁₋₁₀alkyl chain, e.g., an optionally substituted C₁₋₈ alkyl chain,optionally substituted C₁₋₆ alkyl chain, optionally substituted C₁₋₄alkyl chain, optionally substituted C₁₋₃ alkyl chain, or optionallysubstituted C₁₋₂ alkyl chain, comprising one or more of the aboverecited moieties independently present between two carbon atoms of thehydrocarbon chain, or present at one or both ends of the hydrocarbonchain. In certain embodiments, L² is an unsubstituted C₁₋₁₀ n-alkylchain of the formula —(CH₂)_(x)—, wherein x is 1, 2, 3, 4, 5, 6, 7, 8,9, or 10, comprising one or more of the above recited moietiesindependently present between two carbon atoms of the hydrocarbon chain,or present at one or both ends of the hydrocarbon chain. In certainembodiments, L² is an optionally substituted C₂₋₁₀ alkenyl chain, e.g.,an optionally substituted C₂₋₈ alkenyl chain, optionally substitutedC₂₋₆ alkenyl chain, optionally substituted C₂₋₄ alkenyl chain,optionally substituted C₂₋₃ alkenyl chain, or optionally substituted C₂alkenyl chain, comprising one or more of the above recited moietiesindependently present between two carbon atoms of the hydrocarbon chain,or present at one or both ends of the hydrocarbon chain. In certainembodiments, L² is an optionally substituted C₂₋₁₀ alkynyl chain, e.g.,an optionally substituted C₂₋₈ alkynyl chain, optionally substitutedC₂₋₆ alkynyl chain, optionally substituted C₂₋₄ alkynyl chain,optionally substituted C₂₋₃ alkynyl chain, or optionally substituted C₂alkynyl chain, comprising one or more of the above recited moietiesindependently present between two carbon atoms of the hydrocarbon chain,or present at one or both ends of the hydrocarbon chain.

As described above, in certain embodiments, L² is an unsubstituted C₁₋₁₀n-alkyl chain of the formula —(CH₂)_(x)—, wherein x is 1, 2, 3, 4, 5, 6,7, 8, 9, or 10, comprising one or more of the above recited moietiesindependently present between two carbon atoms of the hydrocarbon chain,or present at one or both ends of the hydrocarbon chain. In certainembodiments, L² is —O—(CH₂)_(x)—, —(CH₂)_(x)—O—, or —O—(CH₂)_(x)—O—. Incertain embodiments, L² is —N(R^(L))—(CH₂)_(x)—, —(CH₂)_(x)—N(R^(L))—,—N(R^(L))—(CH₂)_(x)—N(R^(L))—, —O—(CH₂)_(x)—N(R^(L))—,—N(R^(L))—(CH₂)_(x)—O—, —NR^(L)—(CH₂)_(x)—C(O)O—, or—OC(O)—(CH₂)_(x)—N(R^(L))—. In certain embodiments, L² is —S—(CH₂)_(x)—or —(CH₂)_(x)—S—. In certain embodiments, L² is —C(O)—(CH₂)_(x)— or—(CH₂)_(x)—C(O)—. In certain embodiments, L² is —C(O)O—(CH₂)_(x)— or—(CH₂)_(x) C(O)O—. In certain embodiments, L² is —C(O)S—(CH₂)_(x)— or—(CH₂)_(x)—C(O)S—. In certain embodiments, L² is —C(O)N(R^(L))—(CH₂)_(x)or —(CH₂)_(x)—C(O)N(R^(L))—. In certain embodiments, L² is—C(O)N(R^(L))N(R^(L))—(CH₂)_(x) or —(CH₂)_(x)—C(O)N(R^(L))N(R^(L))—. Incertain embodiments, L² is —OC(O)—(CH₂)_(x)— or —(CH₂)_(x)—OC(O)—. Incertain embodiments, L² is —OC(O)N(R^(L))—(CH₂)_(x)— or—(CH₂)_(x)—OC(O)N(R^(L))—. In certain embodiments, L² is—NR^(L)C(O)—(CH₂)_(x) or —(CH₂)_(x)—NR^(L)C(O)—. In certain embodiments,L² is —NR^(L)C(O)N(R^(L))—(CH₂)_(x) or —(CH₂)_(x)—NR^(L)C(O)N(R^(L))—.In certain embodiments, L² is —NR^(L)C(O)N(R^(L))N(R^(L))—(CH₂)_(x) or—(CH₂)_(x)—NR^(L)C(O)N(R^(L))N(R^(L))—. In certain embodiments, L² is—NR^(L)C(O)O—(CH₂)_(x) or —(CH₂)_(x)—NR^(L)C(O)O—. In certainembodiments, L² is —SC(O)—(CH₂)_(x)— or —(CH₂)_(x)—SC(O)—. In certainembodiments, L² is —C(═NR^(L))—(CH₂)_(x) or —(CH₂)_(x)—C(═NR^(L))—. Incertain embodiments, L² is —C(═NNR^(L))—(CH₂)_(x)— or—(CH₂)_(x)—C(═NNR^(L))—. In certain embodiments, L² is—C(═NOR^(L))—(CH₂)_(x) or —(CH₂)_(x)—C(═NOR^(L))—. In certainembodiments, L² is —C(═NR^(L))N(R^(L))—(CH₂)_(x) or—(CH₂)_(x)—C(═NR^(L))N(R^(L))—. In certain embodiments, L²is-NR^(L)C(═NR^(L))—(CH₂)_(x) or —(CH₂)_(x)—NR^(L)C(═NR^(L))—. Incertain embodiments, L² is —C(S)—(CH₂)_(x)— or —(CH₂)_(x)—C(S)—. Incertain embodiments, L² is —C(S)N(R^(L))—(CH₂)_(x) or —(CH₂)_(x)C(S)N(R^(L))—. In certain embodiments, L² is —NR^(L)C(S)—(CH₂)_(x) or—(CH₂)_(x)—NR^(L)C(S)—. In certain embodiments, L² is —S(O)—(CH₂)_(x)—or —(CH₂)_(x)—S(O)—. In certain embodiments, L² is —OS(O)₂—(CH₂)_(x) or—(CH₂)_(x)—OS(O)₂—. In certain embodiments, L² is —S(O)₂O—(CH₂)_(x)— or—(CH₂)_(x)—S(O)₂—. In certain embodiments, L² is —SO₂—(CH₂)_(x)— or—(CH₂)_(x)—SO₂—. In certain embodiments, L² is —N(R^(L))SO₂—(CH₂)_(x) or—(CH₂)_(x)—N(R^(L))SO₂—. In certain embodiments, L² is—SO₂N(R^(L))—(CH₂)_(x) or —(CH₂)_(x)—SO₂N(R^(L))—. In certainembodiments, L² is —N(R^(L))SO₂N(R^(L))—(CH₂)_(x) or—(CH₂)_(x)—N(R^(L))SO₂N(R^(L))—. In certain embodiments, L² is a bond,—N(R^(L))—, —NR^(L)C(O)O—, —NR^(L)C(O)N(R^(L))—, —N(R^(L))—,—N(R^(L))SO₂N(R^(L))—, —NR^(L)—(CH₂)_(x)—C(O)O—, —NR^(L)—(CH₂)_(x)—O—,—NR^(L)C(O)N(R^(L))—, —NR^(L)—(CH₂)_(x)—,—(CH₂)_(x)—NR^(L)—NR^(L)C(O)O(CH₂)_(x)—, —NR^(L)C(O)NR^(L)(CH₂)_(x)—, or—NR^(L)(CH₂)_(x)NR^(L)C(O)—.

As generally defined herein, R¹³ attached directly (wherein L² is abond) or indirectly (wherein L² is a linking group) to Ring HET is acyclic moiety selected from the group consisting of optionallysubstituted carbocyclyl, optionally substituted heterocyclyl, optionallysubstituted aryl, and optionally substituted heteroaryl. It isunderstood that the R¹³ cyclic moiety may be monocyclic or polycyclic(e.g., bicyclic or tricyclic). In certain embodiments, R¹³ is amonocylic optionally substituted carbocyclyl, monocylic optionallysubstituted heterocyclyl, monocylic optionally substituted aryl, ormonocylic optionally substituted heteroaryl. In certain embodiments, R¹³is a bicyclic optionally substituted carbocyclyl, bicyclic optionallysubstituted heterocyclyl, bicyclic optionally substituted aryl, orbicyclic optionally substituted heteroaryl.

In certain embodiments, R¹³ is an optionally substituted monocyclic orbicyclic carbocyclyl, e.g., an optionally substituted C₃₋₁₀ carbocyclyl,optionally substituted C₃₋₉ carbocyclyl, optionally substituted C₃₋₈carbocyclyl, optionally substituted C₃₋₇ carbocyclyl, optionallysubstituted C₃₋₆ carbocyclyl, optionally substituted C₃₋₄carbocyclyl,optionally substituted C₅₋₁₀ carbocyclyl, optionally substituted C₃carbocyclyl, optionally substituted C₄ carbocyclyl, optionallysubstituted C₅ carbocyclyl, optionally substituted C₆ carbocyclyl,optionally substituted C₇ carbocyclyl, optionally substituted C₈carbocyclyl, optionally substituted C₉ carbocyclyl, or optionallysubstituted C₁₀ carbocyclyl. In certain embodiments, R¹³ is anoptionally substituted cyclopropyl (C₃), cyclopropenyl (C₃), cyclobutyl(C₄), cyclobutenyl (C₄), cyclopentyl (C₅), cyclopentenyl (C₅),cyclohexyl (C₆), cyclohexenyl (C₆), cyclohexadienyl (C₆), cycloheptyl(C₇), cycloheptenyl (C₇), cycloheptadienyl (C₇), cycloheptatrienyl (C₇),cyclooctyl (C₈), cyclooctenyl (C₈), bicyclo[2.2.1]heptanyl (C₇),bicyclo[2.2.2]octanyl (C₈), cyclononyl (C₉), cyclononenyl (C₉),cyclodecyl (C₁₀), cyclodecenyl (C₁₀), octahydro-1H-indenyl (C₉),decahydronaphthalenyl (C₁₀), or spiro[4.5]decanyl (C₁₀) ring.

In certain embodiments, R¹³ is an optionally substituted monocyclic orbicyclic heterocyclyl, e.g., an optionally substituted 3- to 10-memberedheterocyclyl, 3- to 8-membered heterocyclyl, 3- to 6-memberedheterocyclyl, 3- to 5-membered heterocyclyl, 3- to 4-memberedheterocyclyl, 3-membered heterocyclyl, 4-membered heterocyclyl,5-membered heterocyclyl, 6-membered heterocyclyl, 7-memberedheterocyclyl, 8-membered heterocyclyl, 9-membered heterocyclyl, or10-membered heterocyclyl. In certain embodiments, R³ is an optionallysubstituted azirdinyl, oxiranyl, thiorenyl, azetidinyl, oxetanyl,thietanyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl,dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, pyrrolidin-2-one,pyrrolyl-2,5-dione, dioxolanyl, oxasulfuranyl, disulfuranyl,oxazolidin-2-one, triazolinyl, oxadiazolinyl, thiadiazolinyl,piperidinyl, tetrahydropyranyl, dihydropyridinyl, thianyl, piperazinyl,morpholinyl, dithianyl, dioxanyl, triazinanyl, azepanyl, oxepanyl,thiepanyl, azocanyl, oxecanyl, thiocanyl, indolinyl, isoindolinyl,dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl,tetrahydroquinolinyl, tetrahydroisoquinolinyl, furo[2,3-b]furanyl,2,3-dihydro-1,4-dioxinyl, 3-oxa-8-azabicyclo[3.2.1]octanyl, or8-oxa-3-azabicyclo[3.2.1]octanyl ring.

In certain embodiments, R¹³ is an optionally substituted spiro-fusedheterocyclic ring system, e.g., comprising an optionally substitutedheterocyclic ring spiro fused to an optionally substituted carbocyclicor optionally substituted heterocyclic ring, wherein the point ofattachment is either on the heterocylic or carbocyclic ring. In certainembodiments, R¹³ is an optionally substituted 3,4-spiro-fusedheterocyclic ring system, e.g., wherein the point of attachment iseither on the 3- or 4-membered ring. In certain embodiments, R¹³ is anoptionally substituted 3,5-spiro-fused heterocyclic ring system, e.g.,wherein the point of attachment is either on the 3- or 5-membered ring.In certain embodiments, R¹³ is an optionally substituted 3,6-spiro-fusedheterocyclic ring system, e.g., wherein the point of attachment iseither on the 3- or 6-membered ring. In certain embodiments, R¹³ is anoptionally substituted 4,4-spiro-fused heterocyclic ring system. Incertain embodiments, R¹³ is an optionally substituted 4,5-spiro-fusedheterocyclic ring system, e.g., wherein the point of attachment iseither on the 4- or 5-membered ring. In certain embodiments, R¹³ is anoptionally substituted 4,6-spiro-fused heterocyclic ring system, e.g.,wherein the point of attachment is either on the 4- or 6-membered ring.In certain embodiments, R¹³ is an optionally substituted 5,5-spiro-fusedheterocyclic ring system. In certain embodiments, R¹³ is an optionallysubstituted 5,6-spiro-fused heterocyclic ring system, e.g., wherein thepoint of attachment is either on the 5- or 6-membered ring. In certainembodiments, R¹³ is an optionally substituted 6,6-spiro-fusedheterocyclic ring system. In any of the above embodiments, R¹³ is anN-linked, optionally substituted spiro-fused heterocyclic ring system,i.e., wherein the point of attachment is on a nitrogen atom.Alternatively, in any of the above embodiments, R¹³ is an C-linked,optionally substituted spiro-fused heterocyclic ring system, i.e.,wherein the point of attachment is on a carbon atom.

In certain embodiments, R¹³ is an optionally substituted ortho-fusedheterocyclic ring system, e.g., comprising an optionally substitutedheterocyclic ring ortho fused to an optionally substituted carbocyclicor optionally substituted heterocyclic ring wherein the point ofattachment is either on the heterocylic or carbocyclic ring orcomprising an optionally substituted heterocyclic ring ortho fused to anoptionally substituted aryl or optionally substituted heteroaryl ring,wherein the point of attachment is on the heterocylic ring. In certainembodiments, R¹³ is an optionally substituted 3,4-ortho-fusedheterocyclic ring system, e.g., wherein the point of attachment iseither on the 3- or 4-membered ring. In certain embodiments, R¹³ is anoptionally substituted 3,5-ortho-fused heterocyclic ring system, e.g.,wherein the point of attachment is either on the 3- or 5-membered ring.In certain embodiments, R¹³ is an optionally substituted 3,6-ortho-fusedheterocyclic ring system, e.g., wherein the point of attachment iseither on the 3- or 6-membered ring. In certain embodiments, R¹³ is anoptionally substituted 4,4-ortho-fused heterocyclic ring system. Incertain embodiments, R¹³ is an optionally substituted 4,5-ortho-fusedheterocyclic ring system, e.g., wherein the point of attachment iseither on the 4- or 5-membered ring. In certain embodiments, R¹³ is anoptionally substituted 4,6-ortho-fused heterocyclic ring system, e.g.,wherein the point of attachment is either on the 4- or 6-membered ring.In certain embodiments, R¹³ is an optionally substituted 5,5-ortho-fusedheterocyclic ring system. In certain embodiments, R¹³ is an optionallysubstituted 5,6-ortho-fused heterocyclic ring system, e.g., wherein thepoint of attachment is either on the 5- or 6-membered ring. In certainembodiments, R¹³ is an optionally substituted 6,6-ortho-fusedheterocyclic ring system. In any of the above embodiments, R¹³ is anN-linked, optionally substituted ortho-fused heterocyclic ring system,i.e., wherein the point of attachment is on a nitrogen atom.Alternatively, in any of the above embodiments, R¹³ is an C-linked,optionally substituted ortho-fused heterocyclic ring system, i.e.,wherein the point of attachment is on a carbon atom.

In certain embodiments, R¹³ is an optionally substituted ortho-fusedheteroaryl ring system, e.g., comprising an optionally substitutedheteroaryl ring ortho fused to an optionally substituted carbocyclic oroptionally substituted heterocyclic ring wherein the point of attachmentis on the heteroaryl ring or comprising an optionally substitutedheteroaryl ring ortho fused to an optionally substituted aryl oroptionally substituted heteroaryl ring, wherein the point of attachmentis either on the aryl ring or heteroaryl ring. In certain embodiments,the heteroaryl ring ortho fused to an optionally substituted carbocyclicor optionally substituted heterocyclic ring is a 5-membered heteroarylring, e.g., to provide a 3,5-, 4,5-, 5,5-, or 6,5-ortho fused ringsystem. In certain embodiments, the heteroaryl ring ortho fused to anoptionally substituted carbocyclic or optionally substitutedheterocyclic ring is a 6-membered heteroaryl ring, e.g., to provide a3,6-, 4,6-, 5,6-, or 6,6-ortho fused ring system. In certainembodiments, the optionally substituted heteroaryl ring ortho fused toan optionally substituted aryl ring is a 5-membered heteroaryl ring,e.g., to provide a 5,6-ortho fused ring system. In certain embodiments,the optionally substituted heteroaryl ring ortho fused to an optionallysubstituted aryl ring is a 6-membered heteroaryl ring, e.g., to providea 6,6-fused ring system. In certain embodiments, the optionallysubstituted heteroaryl ring ortho fused to an optionally heteroaryl ringis a 5-membered heteroaryl ring, e.g., to provide a 6,5- or 5,5-fusedring system. In certain embodiments, the optionally substitutedheteroaryl ring ortho fused to an optionally heteroaryl ring is a6-membered heteroaryl ring, e.g., to provide a 6,5- or 5,5-fused ringsystem. In any of the above embodiments, R¹³ is an N-linked, optionallysubstituted ortho-fused heteroaryl ring system, i.e., wherein the pointof attachment is on a nitrogen atom. Alternatively, in any of the aboveembodiments, R¹³ is an C-linked, optionally substituted ortho-fusedheteroaryl ring system, i.e., wherein the point of attachment is on acarbon atom.

In certain embodiments, R¹³ is an optionally substituted monocyclic orbicyclic aryl, e.g., an optionally substituted phenyl, or optionallysubstituted naphthyl ring. However, in certain embodiments, R¹³ is notoptionally substituted monocyclic or bicyclic aryl. In certainembodiments, R¹³ is not optionally substituted phenyl. In certainembodiments, R¹³ is not substituted phenyl.

In certain embodiments, R¹³ is an optionally substituted ortho-fusedaryl ring system, e.g., comprising an optionally substituted 6-memberedaryl ring ortho fused to an optionally substituted carbocyclic or anoptionally substituted heterocyclic ring wherein the point of attachmentis on the aryl ring, e.g., to provide a 3,6-, 4,6-, 5,6-, or 6,6-orthofused ring system. In certain embodiments, R¹³ is an optionallysubstituted ortho-fused aryl ring system, e.g., comprising an optionallysubstituted 6-membered aryl ring ortho fused to an optionallysubstituted 6-membered aryl ring.

In certain embodiments, R¹³ is an optionally substituted monocyclic orbicyclic heteroaryl, e.g., an optionally substituted 5- to 10-memberedheteroaryl, optionally substituted 5- to 8-membered heteroaryl,optionally substituted 5- to 6-membered heteroaryl, optionallysubstituted 5-membered heteroaryl, or optionally substituted 6-memberedheteroaryl. In certain embodiments, R¹³ is an optionally substitutedpyrrolyl, furanyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl,isoxazolyl, thiazolyl, isothiazolyl, tetrazolyl, pyridinyl, pyridazinyl,pyrimidinyl, pyrazinyl, triazinyl, tetrazinyl, azepinyl, oxepinyl,thiepinyl, indolyl, isoindolyl, indazolyl, benzotriazolyl,benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl,benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl,benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, purinyl,naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl,quinoxalinyl, phthalazinyl, or quinazolinyl ring.

In certain embodiments, R¹³ is a cyclic moiety selected from the groupconsisting of:

wherein:

each instance of

independently represents a single or double bond;

x is 0 or 1;

m is 0, 1, 2, or 3;

Y is O, S, N, or NR^(13B) and each instance of Q and W is independentlyCH, CR^(13A), N, or NR^(13B), as valency permits;

each instance of R^(13A) is independently hydroxyl, substitutedhydroxyl, thiol, substituted thiol, amino, substituted amino, carbonyl,sulfonyl, sulfinyl, —CN, —NO₂, halogen, optionally substituted alkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted carbocyclic, optionally substituted heterocyclic,optionally substituted aryl, or optionally substituted heteroaryl, ortwo R^(13A) groups are joined to form an optionally substitutedcarbocyclic, optionally substituted heterocyclic, optionally substitutedaryl, optionally substituted heteroaryl, or oxo (═O) group, or R^(13A)and R^(13B) groups are joined to form an optionally substitutedcarbocyclic, optionally substituted heterocyclic, optionally substitutedaryl, or optionally substituted heteroaryl ring; and

R^(13B) is hydrogen, optionally substituted alkyl, hydroxyl, substitutedhydroxyl, amino, substituted amino, carbonyl, sulfonyl, optionallysubstituted carbocyclic, optionally substituted heterocyclic, optionallysubstituted aryl, optionally substituted heteroaryl, or a nitrogenprotecting group.

In certain embodiments, m is 0. In certain embodiments, m is 1. Incertain embodiments, m is 2. In certain embodiments, m is 3. In certainembodiments, each instance of R^(13A) is independently hydroxyl, —OCH₃,optionally substituted C₁₋₄alkyl (e.g., methyl, trifluoromethyl, ethyl,propyl, isopropyl, butyl, isobutyl, secbutyl, tertbutyl), —CN, orsulfonyl (e.g., —S(O)₂CH₃).

As generally defined herein, each R^(L) provided in L¹ and L² isindependently hydrogen, optionally substituted alkyl, or a nitrogenprotecting group, or R^(L) and R³ taken together form an optionallysubstituted heterocyclyl or optionally substituted heteroaryl ring, orR^(L) and R¹³ taken together form an optionally substituted heterocyclylor optionally substituted heteroaryl ring. In certain embodiments, atleast one instance of R^(L) is hydrogen. In certain embodiments, eachinstance of R^(L) is hydrogen. In certain embodiments, at least oneinstance of R^(L) is optionally substituted alkyl, e.g., optionallysubstituted C₁₋₆ alkyl, optionally substituted C₁₋₅alkyl, optionallysubstituted C₁₋₄alkyl, optionally substituted C₁₋₂alkyl, optionallysubstituted C₂₋₃alkyl, optionally substituted C₃₋₄alkyl, optionallysubstituted C₁alkyl, optionally substituted C₂alkyl, optionallysubstituted C₃alkyl, optionally substituted C₄alkyl, optionallysubstituted C₅alkyl, or optionally substituted C₆alkyl. ExemplaryR^(L)C₁₋₆alkyl groups include, but are not limited to, methyl (C₁),ethyl (C₂), n-propyl (C₃), isopropyl (C₃), n-butyl (C₄), tert-butyl(C₄), sec-butyl (C₄), iso-butyl (C₄), n-pentyl (C₅), 3-pentanyl (C₅),amyl (C₅), neopentyl (C₅), 3-methyl-2-butanyl (C₅), tertiary amyl (C₅),and n-hexyl (C₆). In certain embodiments, R^(L) is alkyl substitutedwith —CN, e.g., —(CH₂)zCN, wherein z is 1, 2, 3, 4, 5, or 6. In certainembodiments, R^(L) is alkyl substituted with hydroxy or substitutedhydroxy, e.g., —(CH₂)_(z)OCH₃, wherein z is 1, 2, 3, 4, 5, or 6. Incertain embodiments, R^(L) is alkyl substituted with amino orsubstituted substituted amino, e.g., —(CH₂)_(z)NH₂, wherein z is 1, 2,3, 4, 5, or 6. In certain embodiments, at least one instance of R^(L) isa nitrogen protecting group. In certain embodiments, R^(L) and R³ takentogether form an optionally substituted heterocyclyl ring, e.g., anoptionally substituted 3- to 10-membered heterocyclyl, 3- to 8-memberedheterocyclyl, 3- to 6-membered heterocyclyl, 3- to 5-memberedheterocyclyl, 3- to 4-membered heterocyclyl, 3-membered heterocyclyl,4-membered heterocyclyl, 5-membered heterocyclyl, 6-memberedheterocyclyl, 7-membered heterocyclyl, 8-membered heterocyclyl,9-membered heterocyclyl, or 10-membered heterocyclyl ring. In certainembodiments, R^(L) and R³ taken together form an optionally substitutedheteroaryl ring, e.g., an optionally substituted 5- to 10-memberedheteroaryl, optionally substituted 5- to 8-membered heteroaryl,optionally substituted 5- to 6-membered heteroaryl, optionallysubstituted 5-membered heteroaryl, or optionally substituted 6-memberedheteroaryl. In certain embodiments, R^(L) and R¹³ taken together form anoptionally substituted heterocyclyl ring, e.g., an optionallysubstituted 3- to 10-membered heterocyclyl, 3- to 8-memberedheterocyclyl, 3- to 6-membered heterocyclyl, 3- to 5-memberedheterocyclyl, 3- to 4-membered heterocyclyl, 3-membered heterocyclyl,4-membered heterocyclyl, 5-membered heterocyclyl, 6-memberedheterocyclyl, 7-membered heterocyclyl, 8-membered heterocyclyl,9-membered heterocyclyl, or 10-membered heterocyclyl ring. However, incertain embodiments, when L² is —N(R^(L))—, R^(L) and R¹³ taken togetherdo not form an optionally substituted heterocyclyl ring, e.g., a6-membered heterocyclyl, e.g., an optionally substituted piperidinylring. In certain embodiments, R^(L) and R¹³ taken together form anoptionally substituted heteroaryl ring, e.g., an optionally substituted5- to 10-membered heteroaryl, optionally substituted 5- to 8-memberedheteroaryl, optionally substituted 5- to 6-membered heteroaryl,optionally substituted 5-membered heteroaryl, or optionally substituted6-membered heteroaryl.

In certain embodiments, compounds wherein R^(2d) is hydrogen or fluoro,each of R^(2b), R^(2c), and R^(2a) is hydrogen, L² is a bond and R¹³ issubstituted phenyl, or L² is —N(R^(L))— and R^(L) and R¹³ taken togetherdo not form an optionally substituted piperidinyl ring, G₈ and G₁₁ areboth N, G₁₀ is L¹-R³, wherein L¹ is —N(R^(L))— and R^(L) and R³ are eachhydrogen, and G₁₂ is not N, are specifically excluded. In certainembodiments, the following compounds are specifically excluded:

In certain embodiments, compounds wherein R¹ and R^(1a) are each methyl,R^(2a) is chloro, each of R^(2b), R^(2c), and R^(2d) is hydrogen, G₈ isN and G₁₀ and G₁₁ are not N, G¹² is L-R³, wherein L¹ is a bond and R³ isoptionally substituted phenyl, L² is —C(O)N(R^(L))—, and R¹³ isoptionally substituted adamantanyl, is specifically excluded. In certainembodiments, the following compounds are specifically excluded:

Various combination of the above described embodiments are furthercontemplated herein. For example, in certain embodiments of Formula(I-h), wherein G₈ and G₁₂ are both N, provided is a compound of Formula(I-i):

or a pharmaceutically acceptable salt thereof. In certain embodiments, Xis —O—. In certain embodiments, R¹ is hydrogen, methyl, ethyl, n-propyl,isopropyl, or cyclopropyl. In certain embodiments, R^(1a) is hydrogen.In certain embodiments, R¹ is non-hydrogen (e.g., —CH₃), and R^(1a) ishydrogen. In certain embodiments, each of R¹ and R^(1a) is non-hydrogen(e.g., each is —CH₃). In certain embodiments, each of R¹ and R^(1a) ishydrogen. In certain embodiments, R^(2a), R^(2c), and R^(2d) arehydrogen. In certain embodiments, R^(2b) is halogen (e.g., chloro), —CN,—C(═O)R^(A2), —OR^(A2), —SR^(A2), —N(R^(A2))₂, optionally substitutedcyclopropyl, optionally substituted C₁₋₄alkyl, optionally substitutedC₂₋₄alkenyl, optionally substituted C₂₋₄alkynyl, wherein R^(A2) isoptionally substituted alkyl. In certain embodiments, L² is a bond,—N(R^(L))—, —NR^(L)C(O)O—, —NR^(L)C(O)N(R^(L))—, —N(R^(L))—,—N(R^(L))SO₂N(R^(L))—, —NR^(L)—(CH₂)_(x)—C(O)O—, —NR^(L)—(CH₂)_(x)—O—,—NR^(L)C(O)N(R^(L))—, —NR^(L)—(CH₂)_(x)—, —(CH₂)_(x)—NR^(L)—,—NR^(L)C(O)O(CH₂)_(x)—, —NR^(L)C(O)NR^(L)(CH₂)_(x)—, or—NR^(L)(CH₂)_(x)NR^(L)C(O)—. In certain embodiments, R¹³ is optionallysubstituted heterocylyl or optionally substituted heteroaryl.

In certain embodiments of Formula (I-h), wherein G₈ and G₁₂ are both N,and G₁₁ is a group of formula C—R¹¹, provided is a compound of Formula(I-j):

or a pharmaceutically acceptable salt thereof. In certain embodiments, Xis —O—. In certain embodiments, R¹ is hydrogen, methyl, ethyl, n-propyl,isopropyl, or cyclopropyl. In certain embodiments, R^(1a) is hydrogen.In certain embodiments, R¹ is non-hydrogen (e.g., —CH₃), and R^(1a) ishydrogen. In certain embodiments, each of R¹ and R^(1a) is non-hydrogen(e.g., each is —CH₃). In certain embodiments, each of R¹ and R^(1a) ishydrogen. In certain embodiments, R^(2a), R^(2c), and R^(2d) arehydrogen. In certain embodiments, R^(2b) is halogen (e.g., chloro), —CN,—C(═O)R^(A2), —OR^(A2), —SR^(A2), —N(R^(A2))₂, optionally substitutedcyclopropyl, optionally substituted C₁₋₄alkyl, optionally substitutedC₂₋₄alkenyl, optionally substituted C₂₋₄alkynyl, wherein R^(A2) isoptionally substituted alkyl. In certain embodiments, L² is a bond,—N(R^(L))—, —NR^(L)C(O)O—, —NR^(L)C(O)N(R^(L))—, —N(R^(L))—,—N(R^(L))SO₂N(R^(L))—, —NR^(L)—(CH₂)_(x)—C(O)O—, —NR^(L)—(CH₂)_(x)—O—,—NR^(L)C(O)N(R^(L))—, —NR^(L)—(CH₂)_(x)—, —(CH₂)_(x)—NR^(L)—,—NR^(L)C(O)O(CH₂)_(x)—, —NR^(L)C(O)NR^(L)(CH₂)_(x)—, or—NR^(L)(CH₂)_(x)NR^(L)C(O)—. In certain embodiments, R¹³ is optionallysubstituted heterocylyl or optionally substituted heteroaryl. In certainembodiments, R¹¹ is hydrogen or a group -L¹-R³.

In certain embodiments of Formula (I-h), wherein G₈ and G₁₂ are both N,G₁₁ is C—R¹¹, and G₁₀ is C—R¹⁰, provided is a compound of Formula (I-k):

or a pharmaceutically acceptable salt thereof. In certain embodiments, Xis —O—. In certain embodiments, R¹ is hydrogen, methyl, or ethyl. Incertain embodiments, R^(1a) is hydrogen. In certain embodiments, R¹ isnon-hydrogen (e.g., —CH₃), and R^(1a) is hydrogen. In certainembodiments, each of R¹ and R^(1a) is non-hydrogen (e.g., each is —CH₃).In certain embodiments, each of R¹ and R^(1a) is hydrogen. In certainembodiments, R^(2a), R^(2c), and R^(2d) are hydrogen. In certainembodiments, R^(2b) is halogen (e.g., chloro), —CN, —C(═O)R^(A2),—OR^(A2), —SR^(A2), —N(R^(A2))₂, optionally substituted cyclopropyl,optionally substituted C₁₋₄alkyl, optionally substituted C₂₋₄alkenyl,optionally substituted C₂₋₄alkynyl, wherein R^(A2) is optionallysubstituted alkyl. In certain embodiments, L² is a bond, —N(R^(L))—,—NR^(L)C(O)O—, —NR^(L)C(O)N(R^(L))—, —N(R^(L))—, —N(R^(L))SO₂N(R^(L))—,—NR^(L)—(CH₂)_(x)—C(O)O—, —NR^(L)—(CH₂)_(x)—O—, —NR^(L)C(O)N(R^(L))—,—NR^(L)—(CH₂)_(x)—, —(CH₂)_(x)—NR^(L)—, —NR^(L)C(O)O(CH₂)_(x)—,—NR^(L)C(O)NR^(L)(CH₂)_(x)—, or —NR^(L)(CH₂)_(x)NR^(L)C(O)—. In certainembodiments, R¹³ is optionally substituted heterocylyl or optionallysubstituted heteroaryl. In certain embodiments, R¹¹ is hydrogen or agroup -L¹-R³. In certain embodiments, R¹⁰ is hydrogen, optionallysubstituted alkyl (e.g., methyl, ethyl, —CH₂OH, CHF₂), optionallysubstituted C₃₋₄cycloalkyl (e.g., cyclopropyl, cyclobutyl), or halo(e.g., fluoro, chloro, bromo, iodo). In certain embodiments, R¹⁰ ishydrogen, methyl, or halogen (e.g., chloro).

In certain embodiments of Formula (I-h), wherein G₈ and G₁₂ are both N,G₁₁ is C—R¹¹, R¹¹ is -L¹-R³, and G₁₀ is C—R¹⁰, provided is a compound ofFormula (I-1):

or a pharmaceutically acceptable salt thereof. In certain embodiments, Xis —O—. In certain embodiments, R¹ is hydrogen, methyl, ethyl, n-propyl,isopropyl, or cyclopropyl. In certain embodiments, R^(1a) is hydrogen.In certain embodiments, R¹ is non-hydrogen (e.g., —CH₃), and R^(1a) ishydrogen. In certain embodiments, each of R¹ and R^(1a) is non-hydrogen(e.g., each is —CH₃). In certain embodiments, each of R¹ and R^(1a) ishydrogen. In certain embodiments, R^(2a), R^(2c), and R^(2d) arehydrogen. In certain embodiments, R^(2b) is halogen (e.g., chloro), —CN,—C(═O)R^(A2), —OR^(A2), —SR^(A2), —N(R^(A2))₂, optionally substitutedcyclopropyl, optionally substituted C₁₋₄alkyl, optionally substitutedC₂₋₄alkenyl, optionally substituted C₂₋₄alkynyl, wherein R^(A2) isoptionally substituted alkyl. In certain embodiments, L² is a bond,—N(R^(L))—, —NR^(L)C(O)O—, —NR^(L)C(O)N(R^(L))—, —N(R^(L))—,—N(R^(L))SO₂N(R^(L))—, —NR^(L)—(CH₂)_(x)—C(O)O—, —NR^(L)—(CH₂)_(x)—O—,—NR^(L)C(O)N(R^(L))—, —NR^(L)—(CH₂)_(x)—, —(CH₂)_(x)—NR^(L)—,—NR^(L)C(O)O(CH₂)_(x)—, —NR^(L)C(O)NR^(L)(CH₂)_(x)—, or—NR^(L)(CH₂)_(x)NR^(L)C(O)—. In certain embodiments, R¹³ is optionallysubstituted heterocylyl or optionally substituted heteroaryl. In certainembodiments, L¹ is a bond, —N(R^(L))—, —NR^(L)C(O)O—,—NR^(L)C(O)N(R^(L))—, —N(R^(L))—, —N(R^(L))SO₂N(R^(L))—,—NR^(L)—(CH₂)_(x)—C(O)O—, —NR^(L)—(CH₂)_(x)—O—, —NR^(L)C(O)N(R^(L))—,—NR^(L)—(CH₂)_(x)—, —(CH₂)_(x)—NR^(L)—, —NR^(L)C(O)O(CH₂)_(x)—,—NR^(L)C(O)NR^(L)(CH₂)_(x)—, or —NR^(L)(CH₂)_(x)NR^(L)C(O)—. In certainembodiments, R³ is an acyclic moiety. In certain embodiments, R³ is acyclic moiety. In certain embodiments, R¹⁰ is hydrogen, optionallysubstituted alkyl (e.g., methyl, ethyl, —CH₂OH, CHF₂), optionallysubstituted C₃₋₄cycloalkyl (e.g., cyclopropyl, cyclobutyl), or halo(e.g., fluoro, chloro, bromo, iodo). In certain embodiments, R¹⁰ ishydrogen, methyl, or halogen (e.g., chloro).

In other embodiments of Formula (I-h), wherein G₈ and G₁₀ are both N,provided is a compound of Formula (I-m):

or a pharmaceutically acceptable salt thereof. In certain embodiments, Xis —O—. In certain embodiments, R¹ is hydrogen, methyl, ethyl, n-propyl,isopropyl, or cyclopropyl. In certain embodiments, R^(1a) is hydrogen.In certain embodiments, R¹ is non-hydrogen (e.g., —CH₃) and R^(1a) ishydrogen. In certain embodiments, each of R¹ and R^(1a) is non-hydrogen(e.g., each is —CH₃). In certain embodiments, each of R¹ and R^(1a) ishydrogen. In certain embodiments, R^(2a), R^(2c), and R^(2d) arehydrogen. In certain embodiments, R^(2b) is halogen (e.g., chloro), —CN,—C(═O)R^(A2), —OR^(A2), —SR^(A2), —N(R^(A2))₂, optionally substitutedcyclopropyl, optionally substituted C₁₋₄alkyl, optionally substitutedC₂₋₄alkenyl, optionally substituted C₂₋₄alkynyl, wherein R^(A2) isoptionally substituted alkyl. In certain embodiments, L² is a bond,—N(R^(L))—, —NR^(L)C(O)O—, —NR^(L)C(O)N(R^(L))—, —N(R^(L))—,—N(R^(L))SO₂N(R^(L))—, —NR^(L)—(CH₂)_(x)—C(O)O—, —NR^(L)—(CH₂)_(x)—O—,—NR^(L)C(O)N(R^(L))—, —NR^(L)—(CH₂)_(x)—, —(CH₂)_(x)—NR^(L)—,—NR^(L)C(O)O(CH₂)_(x)—, —NR^(L)C(O)NR^(L)(CH₂)_(x)—, or—NR^(L)(CH₂)_(x)NR^(L)C(O)—. In certain embodiments, R¹³ is optionallysubstituted heterocylyl or optionally substituted heteroaryl.

In certain embodiments of Formula (I-h), wherein G₈ and G₁₂ are both N,and G₁₁ is C—R¹¹, provided is a compound of Formula (I-n):

or a pharmaceutically acceptable salt thereof. In certain embodiments, Xis —O—. In certain embodiments, R¹ is hydrogen, methyl, ethyl, n-propyl,isopropyl, or cyclopropyl. In certain embodiments, R^(1a) is hydrogen.In certain embodiments, R¹ is non-hydrogen (e.g., —CH₃) and R^(1a) ishydrogen. In certain embodiments, each of R¹ and R^(1a) is non-hydrogen(e.g., each is —CH₃). In certain embodiments, each of R¹ and R^(1a) ishydrogen. In certain embodiments, R^(2a), R^(2c), and R^(2d) arehydrogen. In certain embodiments, R^(2b) is halogen (e.g., chloro), —CN,—C(═O)R^(A2), —OR^(A2), —SR^(A2), —N(R^(A2))₂, optionally substitutedcyclopropyl, optionally substituted C₁₋₄alkyl, optionally substitutedC₂₋₄alkenyl, optionally substituted C₂₋₄alkynyl, wherein R^(A2) isoptionally substituted alkyl. In certain embodiments, L² is a bond,—N(R^(L))—, —NR^(L)C(O)O—, —NR^(L)C(O)N(R^(L))—, —N(R^(L))—,—N(R^(L))SO₂N(R^(L))—, —NR^(L)—(CH₂)_(x)—C(O)O—, —NR^(L)—(CH₂)_(x)—O—,—NR^(L)C(O)N(R^(L))—, —NR^(L)—(CH₂)_(x)—, —(CH₂)_(x)—NR^(L)—,—NR^(L)C(O)O(CH₂)_(x)—, —NR^(L)C(O)NR^(L)(CH₂)_(x)—, or—NR^(L)(CH₂)_(x)NR^(L)C(O)—. In certain embodiments, R¹³ is optionallysubstituted heterocylyl or optionally substituted heteroaryl. In certainembodiments, R¹¹ is hydrogen or a group -L¹-R³.

In certain embodiments of Formula (I-h), wherein G₈ and G₁₂ are both N,G₁₁ is C—R¹¹, and G₁₂ is C—R¹², provided is a compound of Formula (I-o):

or a pharmaceutically acceptable salt thereof. In certain embodiments, Xis —O—. In certain embodiments, R¹ is hydrogen, methyl, ethyl, n-propyl,isopropyl, or cyclopropyl. In certain embodiments, R^(1a) is hydrogen.In certain embodiments, R¹ is non-hydrogen (e.g., —CH₃), and R^(1a) ishydrogen. In certain embodiments, each of R¹ and R^(1a) is non-hydrogen(e.g., each is —CH₃). In certain embodiments, each of R¹ and R^(1a) ishydrogen. In certain embodiments, R^(2a), R^(2c), and R^(2d) arehydrogen. In certain embodiments, R^(2b) is halogen (e.g., chloro), —CN,—C(═O)R^(A2), —OR^(A2), —SR^(A2), —N(R^(A2))₂, optionally substitutedcyclopropyl, optionally substituted C₁₋₄alkyl, optionally substitutedC₂₋₄alkenyl, optionally substituted C₂₋₄alkynyl, wherein R^(A2) isoptionally substituted alkyl. In certain embodiments, L² is a bond,—N(R^(L))—, —NR^(L)C(O)O—, —NR^(L)C(O)N(R^(L))—, —N(R^(L))—,—N(R^(L))SO₂N(R^(L))—, —NR^(L)—(CH₂)_(x)—C(O)O—, —NR^(L)—(CH₂)_(x)—O—,—NR^(L)C(O)N(R^(L))—, —NR^(L)—(CH₂)_(x)—, —(CH₂)_(x)—NR^(L)—,—NR^(L)C(O)O(CH₂)_(x)—, —NR^(L)C(O)NR^(L)(CH₂)_(x)—, or—NR^(L)(CH₂)_(x)NR^(L)C(O)—. In certain embodiments, R¹³ is optionallysubstituted heterocylyl or optionally substituted heteroaryl. In certainembodiments, R¹¹ is hydrogen or a group -L¹-R³. In certain embodiments,R¹² is hydrogen or methyl.

In certain embodiments of Formula (I-h), wherein G₈ and G₁₂ are both N,G₁₁ is C—R¹¹, R¹¹ is a group of formula -L¹-R³, and G₁₂ is C—R¹²,provided is a compound of Formula (I-p):

or a pharmaceutically acceptable salt thereof. In certain embodiments, Xis —O—. In certain embodiments, R¹ is hydrogen, methyl, ethyl, n-propyl,isopropyl, or cyclopropyl. In certain embodiments, R^(1a) is hydrogen.In certain embodiments, R¹ is non-hydrogen (e.g., —CH₃), and R^(1a) ishydrogen. In certain embodiments, each of R¹ and R^(1a) is non-hydrogen(e.g., each is —CH₃). In certain embodiments, each of R¹ and R^(1a) ishydrogen. In certain embodiments, R^(2a), R^(2c), and R^(2d) arehydrogen. In certain embodiments, R^(2b) is halogen (e.g., chloro), —CN,—C(═O)R^(A2), —OR^(A2), —SR^(A2), —N(R^(A2))₂, optionally substitutedcyclopropyl, optionally substituted C₁₋₄alkyl, optionally substitutedC₂₋₄alkenyl, optionally substituted C₂₋₄alkynyl, wherein R^(A2) isoptionally substituted alkyl. In certain embodiments, L² is a bond,—N(R^(L))—, —NR^(L)C(O)O—, —NR^(L)C(O)N(R^(L))—, —N(R^(L))—,—N(R^(L))SO₂N(R^(L))—, —NR^(L)—(CH₂)_(x)—C(O)O—, —NR^(L)—(CH₂)_(x)—O—,—NR^(L)C(O)N(R^(L))—, —NR^(L)—(CH₂)_(x)—, —(CH₂)_(x)—NR^(L)—,—NR^(L)C(O)O(CH₂)_(x)—, —NR^(L)C(O)NR^(L)(CH₂)_(x)—, or—NR^(L)(CH₂)_(x)NR^(L)C(O)—. In certain embodiments, R¹³ is optionallysubstituted heterocylyl or optionally substituted heteroaryl. In certainembodiments, L¹ is a bond, —N(R^(L))—, —NR^(L)C(O)O—,—NR^(L)C(O)N(R^(L))—, —N(R^(L))—, —N(R^(L))SO₂N(R^(L))—,—NR^(L)—(CH₂)_(x)—C(O)O—, —NR^(L)—(CH₂)_(x)—O—, —NR^(L)C(O)N(R^(L))—,—NR^(L)—(CH₂)_(x)—, —(CH₂)_(x)—NR^(L)—, —NR^(L)C(O)O(CH₂)_(x)—,—NR^(L)C(O)NR^(L)(CH₂)_(x)—, or —NR^(L)(CH₂)_(x)NR^(L)C(O)—. In certainembodiments, R³ is an acyclic moiety. In certain embodiments, R³ is acyclic moiety. In certain embodiments, R¹² is hydrogen or methyl.

In any of the above embodiments, as recited herein, in certainembodiments, R¹³ is an optionally substituted heteroaryl, e.g., anoptionally substituted 5-membered heteroaryl. For example, in any of theabove embodiments, as recited herein, R¹³ is a group of Formula:

wherein Y is O, S, N, or NR^(13B) and each instance of Q and W isindependently CH, CR^(13A), N, or NR^(13B), as valency permits, m is 0or 1, and R^(13A) and R^(13B) are as defined herein. In certainembodiments, Y is O. In certain embodiments, Y is S. In certainembodiments, Y is NR^(13B). In certain embodiments, Q is N, Y is 0, andW is CH or CR^(13A). In certain embodiments, Q is N, Y is S, and W is CHor CR^(13A). In certain embodiments, Q is N, Y is NR^(13B), and W is CHor CR^(13A). In certain embodiments, Q is N, Y is 0, and W is N. Incertain embodiments, Q is N, Y is S, and W is N. In certain embodiments,Q is N, Y is NR^(13B), and W is N. In certain embodiments, Q is N, Y isN, and W is NR^(13B). In certain embodiments, if Q is NR^(13A), thenneither Y nor W is O. In certain embodiments, if Q is NR^(13A), thenneither Y nor W is S. In certain embodiments, if Y is NR^(13A), thenneither Q nor W is O. In certain embodiments, if Y is NR^(13A), thenneither Q nor W is S. In certain embodiments, if W is NR^(13A), thenneither Y nor Q is O. In certain embodiments, if W is NR^(13A), thenneither Y nor Q is S. In certain embodiments, only one of Q, Y, and W isNR^(13A). In any of these instances, in certain embodiments, L² is abond.

For example, in certain embodiments of Formula (I-1), provided is acompound of Formula (I-1-A) or (I-1-A′):

or a pharmaceutically acceptable salt thereof. In certain embodiments, Xis —O—. In certain embodiments, R¹ is hydrogen, methyl, ethyl, n-propyl,isopropyl, or cyclopropyl. In certain embodiments, R^(1a) is hydrogen.In certain embodiments, R¹ is non-hydrogen (e.g., —CH₃), and R^(1a) ishydrogen. In certain embodiments, each of R¹ and R^(1a) is non-hydrogen(e.g., each is —CH₃). In certain embodiments, each of R¹ and R^(1a) ishydrogen. In certain embodiments, R^(2a), R^(2c), and R^(2d) arehydrogen. In certain embodiments, R^(2b) is halogen (e.g., chloro), —CN,—C(═O)R^(A2), —OR^(A2), —SR^(A2), —N(R^(A2))₂, optionally substitutedcyclopropyl, optionally substituted C₁₋₄alkyl, optionally substitutedC₂₋₄alkenyl, optionally substituted C₂₋₄alkynyl, wherein R^(A2) isoptionally substituted alkyl. In certain embodiments, R^(2b) is hydrogenor halogen (e.g., chloro, fluoro), and R^(2a), R^(2c), and R^(2d) ishydrogen. In certain embodiments, R^(2a), R^(2b), and R^(2d) arehydrogen. In certain embodiments, R^(2c) is halogen (e.g., chloro), —CN,—C(═O)R^(A2), —OR^(A2), —SR^(A2), —N(R^(A2))₂, optionally substitutedcyclopropyl, optionally substituted C₁₋₄alkyl, optionally substitutedC₂₋₄alkenyl, optionally substituted C₂₋₄alkynyl, wherein R^(A2) isoptionally substituted alkyl. In certain embodiments, R^(2c) is hydrogenor halogen (e.g., chloro, fluoro), and R^(2a), R^(2b), and R^(2d) ishydrogen. In certain embodiments, L¹ is a bond, —N(R^(L))—,—NR^(L)C(O)O—, —NR^(L)C(O)N(R^(L))—, —N(R^(L))—, —N(R^(L))SO₂N(R^(L))—,—NR^(L)—(CH₂)_(x)—C(O)O—, —NR^(L)—(CH₂)_(x)—O—, —NR^(L)C(O)N(R^(L))—,—NR^(L)—(CH₂)_(x)—, —(CH₂)_(x)—NR^(L)—, —NR^(L)C(O)O(CH₂)_(x)—,—NR^(L)C(O)NR^(L)(CH₂)_(x)—, or —NR^(L)(CH₂)_(x)NR^(L)C(O)—. In certainembodiments, R³ is an acyclic moiety. In certain embodiments, R³ is acyclic moiety. In certain embodiments, R¹⁰ is hydrogen, optionallysubstituted alkyl (e.g., methyl, ethyl, —CH₂OH, CHF₂), optionallysubstituted C₃₋₄cycloalkyl (e.g., cyclopropyl, cyclobutyl), or halo(e.g., fluoro, chloro, bromo, iodo). In certain embodiments, R¹⁰ ishydrogen, methyl, or halogen (e.g., chloro). In certain embodiments, Yis O. In certain embodiments, Y is S. In certain embodiments, Y isNR^(13B). In certain embodiments, Q is N, Y is O, and W is CH orCR^(13A). In certain embodiments, Q is N, Y is S, and W is CH orCR^(13A). In certain embodiments, Q is N, Y is NR^(13B), and W is CH orCR^(13A). In certain embodiments, Q is N, Y is 0, and W is N. In certainembodiments, Q is N, Y is S, and W is N. In certain embodiments, Q is N,Y is NR^(13B), and W is N. In certain embodiments, Q is N, Y is N, and Wis NR^(13B). In certain embodiments, m is 0. In certain embodiments, mis 1, and R^(13A) is optionally substituted alkyl (e.g., methyl)

In certain embodiments of Formula (I-1-A) or (I-1-A′), wherein Q is N,provided is a compound of Formula (I-1-Aa) or (I-1-Aa′):

or a pharmaceutically acceptable salt thereof. In certain embodiments, Xis —O—. In certain embodiments, R¹ is hydrogen or methyl. In certainembodiments, R^(1a) is hydrogen. In certain embodiments, R¹ isnon-hydrogen (e.g., —CH₃), and R^(1a) is hydrogen. In certainembodiments, each of R¹ and R^(1a) is non-hydrogen (e.g., each is —CH₃).In certain embodiments, each of R¹ and R^(1a) is hydrogen. In certainembodiments, R^(2a), R^(2b), and R^(2d) are hydrogen. In certainembodiments, R^(2c) is hydrogen, chloro, or fluoro, and R^(2a), R^(2b),and R^(2d) is hydrogen. In certain embodiments, L¹ is a bond or—N(R^(L))—. In certain embodiments, R³ is a cyclic moiety. In certainembodiments, R¹⁰ is hydrogen, methyl, or chloro. In certain embodiments,W is CH or CR^(13A). In certain embodiments, W is N. In certainembodiments, m is 0. In certain embodiments, m is 1, and R^(13A) isoptionally substituted alkyl (e.g., methyl).

In certain embodiments of Formula (I-1-Aa) or (I-1-Aa′), wherein L¹ is—N(R^(L))—, provided is a compound of Formula (I-1-Aa1) or (I-1-Aa1′):

or a pharmaceutically acceptable salt thereof. In certain embodiments, Xis —O—. In certain embodiments, R¹ is hydrogen or methyl. In certainembodiments, R^(1a) is hydrogen. In certain embodiments, R¹ isnon-hydrogen (e.g., —CH₃), and R^(1a) is hydrogen. In certainembodiments, each of R¹ and R^(1a) is non-hydrogen (e.g., each is —CH₃).In certain embodiments, each of R¹ and R^(1a) is hydrogen. In certainembodiments, R^(2a), R^(2b), and R^(2d) are hydrogen. In certainembodiments, R^(2c) is hydrogen, chloro, or fluoro, and R^(2a), R^(2b),and R^(2d) is hydrogen. In certain embodiments, R^(L) is hydrogen. Incertain embodiments, R³ is a cyclic moiety. In certain embodiments, R¹⁰is hydrogen, methyl, or chloro. In certain embodiments, W is CH orCR^(13A). In certain embodiments, W is N. In certain embodiments, m is0. In certain embodiments, m is 1, and R^(13A) is optionally substitutedalkyl (e.g., methyl). In certain embodiments, R^(L) and R³ are takentogether to form an optionally substituted heterocyclic ring. In certainembodiments, R^(L) and R³ are taken together to form an optionallysubstituted heterocyclic ring which is fused to an optionallysubstituted aromatic ring. In certain embodiments, R^(L) and R³ aretaken together to form an optionally substituted heterocyclic ring whichis fused to an optionally substituted heteroaromatic ring. In certainembodiments, R^(L) and R³ are taken together to form an optionallysubstituted bicyclic heterocyclic ring system. In certain embodiments,R^(L) and R³ are taken together to form an optionally substitutedortho-fused heterocyclic ring system. In certain embodiments, R^(L) andR³ are taken together to form an optionally substituted spiro-fusedheterocyclic ring system. In certain embodiments, R^(L) and R³ are takentogether to form an optionally substituted bridged heterocyclic ringsystem.

In certain embodiments of Formula (I-1-Aa) or (I-1-Aa′), wherein L¹ is—N(R^(L))—, provided is a compound of Formula (I-1-Aa2) or (I-1-Aa2′):

or a pharmaceutically acceptable salt thereof. In certain embodiments, Xis —O—. In certain embodiments, R¹ is hydrogen or methyl. In certainembodiments, R^(1a) is hydrogen. In certain embodiments, R¹ isnon-hydrogen (e.g., —CH₃), and R^(1a) is hydrogen. In certainembodiments, each of R¹ and R^(1a) is non-hydrogen (e.g., each is —CH₃).In certain embodiments, each of R¹ and R^(1a) is hydrogen. In certainembodiments, R^(2a), R^(2b), and R^(2d) are hydrogen. In certainembodiments, R^(2c) is hydrogen, chloro, or fluoro, and R^(2a), R^(2b),and R^(2d) is hydrogen. In certain embodiments, R^(L) is hydrogen. Incertain embodiments, R^(3B) is —CO₂R^(aa). In certain embodiments,R^(aa) is C₁₋₁₀ alkyl. In certain embodiments, R^(3B) is —CO₂Me. Incertain embodiments, R^(3B) is —CO₂Et. In certain embodiments, R^(3B) isa nitrogen protecting group. In certain embodiments, R¹⁰ is hydrogen,methyl, or chloro. In certain embodiments, W is CH or CR^(13A). Incertain embodiments, W is N. In certain embodiments, m is 0. In certainembodiments, m is 1, and R^(13A) is optionally substituted alkyl (e.g.,methyl). In certain embodiments, n is 0. In certain embodiments, n is 1.In certain embodiments, R^(3A) is a optionally substituted C₁₋₆ alkyl.In certain embodiments, R^(3A) is methyl.

In certain embodiments of Formula (I-1-Aa) or (I-1-Aa′), wherein L¹ is—N(R^(L))—, provided is a compound of Formula (I-1-Aa3) or (I-1-Aa3′):

or a pharmaceutically acceptable salt thereof. In certain embodiments, Xis —O—. In certain embodiments, R¹ is hydrogen or methyl. In certainembodiments, R^(1a) is hydrogen. In certain embodiments, R¹ isnon-hydrogen (e.g., —CH₃) and R^(1a) is hydrogen. In certainembodiments, each of R¹ and R^(1a) is non-hydrogen (e.g., each is —CH₃).In certain embodiments, each of R¹ and R^(1a) is hydrogen. In certainembodiments, R^(2a), R^(2b), and R^(2d) are hydrogen. In certainembodiments, R^(2c) is hydrogen, chloro, or fluoro, and R^(2a), R^(2b),and R^(2d) is hydrogen. In certain embodiments, R^(L) is hydrogen. Incertain embodiments, R^(3B) is —CO₂R. In certain embodiments, R^(aa) isC₁₋₁₀ alkyl. In certain embodiments, R^(3B) is —CO₂Me. In certainembodiments, R^(3B) is —CO₂Et. In certain embodiments, R^(3B) is anitrogen protecting group. In certain embodiments, R¹⁰ is hydrogen,methyl, or chloro. In certain embodiments, W is CH or CR^(13A). Incertain embodiments, W is N. In certain embodiments, m is 0. In certainembodiments, m is 1, and R^(13A) is optionally substituted alkyl (e.g.,methyl). In certain embodiments, n is 0. In certain embodiments, n is 1.In certain embodiments, R^(3A) is a optionally substituted C₁₋₆ alkyl.In certain embodiments, R^(3A) is methyl.

In certain embodiments of Formula (I-1-Aa) or (I-1-Aa′), wherein L¹ is—N(R^(L))—, provided is a compound of Formula (I-1-Aa4) or (I-1-Aa4′):

or a pharmaceutically acceptable salt thereof. In certain embodiments, Xis —O—. In certain embodiments, R¹ is hydrogen or methyl. In certainembodiments, R^(1a) is hydrogen. In certain embodiments, R¹ isnon-hydrogen (e.g., —CH₃) and R^(1a) is hydrogen. In certainembodiments, each of R¹ and R^(1a) is non-hydrogen (e.g., each is —CH₃).In certain embodiments, each of R¹ and R^(1a) is hydrogen. In certainembodiments, R^(2a), R^(2b), and R^(2d) are hydrogen. In certainembodiments, R^(2e) is hydrogen, chloro, or fluoro, and R^(2a), R^(2b),and R^(2d) is hydrogen. In certain embodiments, R^(L) is hydrogen. Incertain embodiments, R^(3B) is —CO₂R. In certain embodiments, R^(aa) isC₁₋₁₀ alkyl. In certain embodiments, R^(3B) is —CO₂Me. In certainembodiments, R^(3B) is —CO₂Et. In certain embodiments, R^(3B) is anitrogen protecting group. In certain embodiments, R¹⁰ is hydrogen,methyl, or chloro. In certain embodiments, W is CH or CR^(13A). Incertain embodiments, W is N. In certain embodiments, m is 0. In certainembodiments, m is 1, and R^(13A) is optionally substituted alkyl (e.g.,methyl). In certain embodiments, n is 0. In certain embodiments, n is 1.In certain embodiments, R^(3A) is a optionally substituted C₁₋₆ alkyl.In certain embodiments, R^(3A) is methyl.

In certain embodiments of Formula (I-1-Aa) or (I-1-Aa′), wherein L¹ is—N(R^(L))—, provided is a compound of Formula (I-1-Aa5) or (I-1-Aa5′):

or a pharmaceutically acceptable salt thereof. In certain embodiments, Xis —O—. In certain embodiments, R¹ is hydrogen or methyl. In certainembodiments, R^(1a) is hydrogen. In certain embodiments, R¹ isnon-hydrogen (e.g., —CH₃) and R^(1a) is hydrogen. In certainembodiments, each of R¹ and R^(1a) is non-hydrogen (e.g., each is —CH₃).In certain embodiments, each of R¹ and R^(1a) is hydrogen. In certainembodiments, R^(2a), R^(2b), and R^(2d) are hydrogen. In certainembodiments, R^(2c) is hydrogen, chloro, or fluoro, and R^(2a), R^(2b),and R^(2d) is hydrogen. In certain embodiments, R^(L) is hydrogen. Incertain embodiments, R^(3B) is —CO₂R. In certain embodiments, R^(aa) isC₁₋₁₀ alkyl. In certain embodiments, R^(3B) is —CO₂Me. In certainembodiments, R^(3B) is —CO₂Et. In certain embodiments, R^(3B) is anitrogen protecting group. In certain embodiments, R¹⁰ is hydrogen,methyl, or chloro. In certain embodiments, W is CH or CR^(13A). Incertain embodiments, W is N. In certain embodiments, m is 0. In certainembodiments, m is 1, and R^(13A) is optionally substituted alkyl (e.g.,methyl). In certain embodiments, n is 0. In certain embodiments, n is 1.In certain embodiments, R^(3A) is a optionally substituted C₁₋₆ alkyl.In certain embodiments, R^(3A) is methyl. In certain embodiments, thestereochemistry at the morpholine sidechain is

In certain embodiments, the stereochemistry at the morpholine sidechainis

In certain embodiments of Formula (I-1-Aa) or (I-1-Aa′), wherein L¹ is abond, provided is a compound of Formula (I-1-Aa6) or (I-1-Aa6′):

or a pharmaceutically acceptable salt thereof. In certain embodiments, Xis —O—. In certain embodiments, R¹ is hydrogen or methyl. In certainembodiments, R^(1a) is hydrogen. In certain embodiments, R¹ isnon-hydrogen (e.g., —CH₃) and R^(1a) is hydrogen. In certainembodiments, each of R¹ and R^(1a) is non-hydrogen (e.g., each is —CH₃).In certain embodiments, each of R¹ and R^(1a) is hydrogen. In certainembodiments, R^(2a), R^(2b), and R^(2d) are hydrogen. In certainembodiments, R^(2c) is hydrogen, chloro, or fluoro, and R^(2a), R^(2b),and R^(2d) is hydrogen. In certain embodiments, R^(3B) is —CO₂R. Incertain embodiments, R^(aa) is C₁₋₁₀ alkyl. In certain embodiments,R^(3B) is —CO₂Me. In certain embodiments, R^(3B) is —CO₂Et. In certainembodiments, R^(3B) is a nitrogen protecting group. In certainembodiments, R¹⁰ is hydrogen, methyl, or chloro. In certain embodiments,W is CH or CR^(13A). In certain embodiments, W is N. In certainembodiments, m is 0. In certain embodiments, m is 1, and R^(13A) isoptionally substituted alkyl (e.g., methyl). In certain embodiments, nis 0. In certain embodiments, n is 1. In certain embodiments, R^(3A) isa optionally substituted C₁₋₆ alkyl. In certain embodiments, R^(3A) ismethyl.

In certain embodiments of Formula (I-1-Aa) or (I-1-Aa′), wherein L¹ is abond, provided is a compound of Formula (I-1-Aa7) or (I-1-Aa7′):

or a pharmaceutically acceptable salt thereof. In certain embodiments, Xis —O—. In certain embodiments, R¹ is hydrogen or methyl. In certainembodiments, R^(1a) is hydrogen. In certain embodiments, R¹ isnon-hydrogen (e.g., —CH₃) and R^(1a) is hydrogen. In certainembodiments, each of R¹ and R^(1a) is non-hydrogen (e.g., each is —CH₃).In certain embodiments, each of R¹ and R^(1a) is hydrogen. In certainembodiments, R^(2a), R^(2b), and R^(2d) are hydrogen. In certainembodiments, R^(2C) is hydrogen, chloro, or fluoro, and R^(2a), R^(2b),and R^(2d) is hydrogen. In certain embodiments, R¹⁰ is hydrogen, methyl,or chloro. In certain embodiments, W is CH or CR^(13A). In certainembodiments, W is N. In certain embodiments, m is 0. In certainembodiments, m is 1, and R^(13A) is optionally substituted alkyl (e.g.,methyl). In certain embodiments, n is 0. In certain embodiments, n is 1.In certain embodiments, R^(3A) is a optionally substituted C₁₋₆ alkyl.In certain embodiments, R^(3A) is methyl. In certain embodiments ofFormula (I-1-Aa) or (I-1-Aa′), wherein Y is 0 and W is CR^(13A),provided is a compound of Formula (I-1-Ab) or (I-1-Ab′):

or a pharmaceutically acceptable salt thereof. In certain embodiments, Xis —O—. In certain embodiments, R¹ is hydrogen or methyl. In certainembodiments, R^(1a) is hydrogen or methyl. In certain embodiments,R^(1a) is hydrogen. In certain embodiments, both R¹ and R^(1a) arehydrogen or methyl. In certain embodiments, both R¹ and R^(1a) aremethyl. In certain embodiments, R¹ is methyl; and R^(1a) is hydrogen. Incertain embodiments, R^(2a), R^(2b), and R^(2d)are hydrogen. In certainembodiments, R^(2c) is hydrogen, chloro, or fluoro, and R^(2a), R^(2b),and R^(2d) is hydrogen. In certain embodiments, L¹ is a bond or—N(R^(L))—. In certain embodiments, R³ is a cyclic moiety. In certainembodiments, R¹⁰ is hydrogen, methyl, or chloro. In certain embodiments,m is 0. In certain embodiments, m is 1, and R^(13A) is optionallysubstituted alkyl (e.g., methyl).

In certain embodiments of Formula (I-1-A) or (I-1-A′), wherein Q is N, Yis N, and W is NR^(13B), provided is a compound of Formula (I-1-Ac) or(I-1-Ac′):

or a pharmaceutically acceptable salt thereof. In certain embodiments, Xis —O—. In certain embodiments, R¹ is hydrogen or methyl. In certainembodiments, R^(1a) is hydrogen or methyl. In certain embodiments,R^(1a) is hydrogen. In certain embodiments, R^(1a) is hydrogen. Incertain embodiments, both R¹ and R^(1a) are hydrogen or methyl. Incertain embodiments, both R¹ and R^(1a) are methyl. In certainembodiments, R¹ is methyl; and R^(1a) is hydrogen. In certainembodiments, R^(2a), R^(2b), and R^(2d) are hydrogen. In certainembodiments, R^(2c) is hydrogen, chloro, or fluoro, and R^(2a), R^(2b),and R^(2d) is hydrogen. In certain embodiments, L¹ is a bond or—N(R^(L))—. In certain embodiments, R³ is a cyclic moiety. In certainembodiments, R¹⁰ is hydrogen, methyl, or chloro. In certain embodiments,m is 0. In certain embodiments, m is 1, and R^(13A) is optionallysubstituted alkyl (e.g., methyl).

In any of the above embodiments, as recited herein, in certainembodiments R¹³ is an optionally substituted heterocyclyl, e.g., anoptionally substituted 5- to 6-membered heterocylyl. For example, in anyof the above embodiments, as recited herein, in certain embodiments R¹³is a group of formula:

wherein x is 0 or 1, m is 0, 1, 2, or 3, and R is as defined herein. Inthis instance, in certain embodiments, L² is —N(R^(L))—.

For example, in certain embodiments of Formula (I-1), provided is acompound of Formula (I-1-B) or (I-1-B′):

or a pharmaceutically acceptable salt thereof. In certain embodiments, Xis —O—. In certain embodiments, R¹ is hydrogen, methyl, ethyl, n-propyl,isopropyl, or cyclopropyl. In certain embodiments, R^(1a) is hydrogen,methyl, ethyl, n-propyl, isopropyl, or cyclopropyl. In certainembodiments, R^(1a) is hydrogen. In certain embodiments, both R¹ andR^(1a) are hydrogen, methyl, ethyl, n-propyl, isopropyl, or cyclopropyl.In certain embodiments, both R¹ and R^(1a) are methyl. In certainembodiments, R¹ is methyl; and R^(1a) is hydrogen. In certainembodiments, R^(2a), R^(2c), and R^(2d) are hydrogen. In certainembodiments, R^(2b) is halogen (e.g., chloro), —CN, —C(═O)R^(A2),—OR^(A2), —SR^(A2), —N(R^(A2))₂, optionally substituted cyclopropyl,optionally substituted C₁₋₄alkyl, optionally substituted C₂₋₄alkenyl,optionally substituted C₂-4alkynyl, wherein R^(A2) is optionallysubstituted alkyl. In certain embodiments, R^(2b) is hydrogen or halogen(e.g., chloro, fluoro), and R^(2a), R^(2c), and R^(2d) is hydrogen. Incertain embodiments, R^(2a), R^(2b), and R^(2d) are hydrogen. In certainembodiments, R^(2c) is halogen (e.g., chloro), —CN, —C(═O)R^(A2),—OR^(A2), —SR^(A2), —N(R^(A2))₂, optionally substituted cyclopropyl,optionally substituted C₁₋₄alkyl, optionally substituted C₂₋₄alkenyl,optionally substituted C₂-4alkynyl, wherein R^(A2) is optionallysubstituted alkyl. In certain embodiments, R² is hydrogen or halogen(e.g., chloro, fluoro), and R^(2a), R^(2b), and R^(2d) is hydrogen. Incertain embodiments, L¹ is a bond, —N(R^(L))—, —NR^(L)C(O)O—,—NR^(L)C(O)N(R^(L))—, —N(R^(L))—, —N(R^(L))SO₂N(R^(L))—,—NR^(L)—(CH₂)_(x)—C(O)O—, —NR^(L)—(CH₂)_(x)—O—, —NR^(L)C(O)N(R^(L))—,—NR^(L)—(CH₂)_(x)—, —(CH₂)_(x)—NR^(L)—, —NR^(L)C(O)O(CH₂)_(x)—,—NR^(L)C(O)NR^(L)(CH₂)_(x)—, or —NR^(L)(CH₂)_(x)NR^(L)C(O)—. In certainembodiments, R³ is an acyclic moiety. In certain embodiments, R³ is acyclic moiety. In certain embodiments, R¹⁰ is hydrogen, optionallysubstituted alkyl (e.g., methyl, ethyl, —CH₂OH, CHF₂), optionallysubstituted C₃₋₄cycloalkyl (e.g., cyclopropyl, cyclobutyl), or halo(e.g., fluoro, chloro, bromo, iodo). In certain embodiments, R¹⁰ ishydrogen, methyl, or halogen (e.g., chloro). In certain embodiments, R¹⁰is methyl. In certain embodiments, x is 0. In certain embodiments, xis 1. In certain embodiments, m is 0 or 1. In certain embodiments, R^(L)is hydrdogen or optionally substituted alkyl (e.g., methyl).

In certain embodiments of Formula (I-1-B) or (I-1-B′), wherein x is 0 or1, provided is a compound of Formula (I-1-Ba) or (I-1-Ba′) or Formula(I-1-Bb) or (I-1-Bb′):

or a pharmaceutically acceptable salt thereof. In certain embodiments, Xis —O—. In certain embodiments, R¹ is hydrogen or methyl. In certainembodiments, R^(1a) is hydrogen or methyl. In certain embodiments,R^(1a) is hydrogen. In certain embodiments, both R¹ and R^(1a) arehydrogen or methyl. In certain embodiments, both R¹ and R^(1a) aremethyl. In certain embodiments, R¹ is methyl; and R^(1a) is hydrogen. Incertain embodiments, R^(2a), R^(2b), and R^(2d)are hydrogen. In certainembodiments, R^(2c) is hydrogen, chloro, or fluoro, and R^(2a), R^(2b),and R^(2d) is hydrogen. In certain embodiments, L¹ is a bond or—N(R^(L))—. In certain embodiments, R³ is a cyclic moiety. In certainembodiments, R¹⁰ is hydrogen, methyl, or chloro. In certain embodiments,m is 0 or 1. In certain embodiments, R^(L) is hydrogen or methyl.

In certain embodiments, a compound of Formula (I) is selected from anyone of the compounds provided in Tables 1A, 1B, 1C, and 2, andpharmaceutically acceptable salts thereof.

TABLE 1A Exemplary Compounds # Structure LC-MS m/z (M + H)  1-1

450.3  3-1

444.3  4-1

359.2  5-1

383.2  6-1

387.2  7-1

397.2  8-1

403.3  9-1

408.1 10-1

413.3 11-1

413.3 12-1

414.2 13-1

415.3 14-1

416.3 15-1

416.3 16-1

416.3 17-1

419.2 18-1

420.1 19-1

427.2 20-1

428.3 21-1

429.3 22-1

430.3 23-1

434.2 24-1

443.2 25-1

443.3 26-1

444.3 27-1

444.4 28-1

447.3 29-1

449.2 30-1

449.2 31-1

449.2 32-1

450.2 33-1

454.3 34-1

455.3 35-1

458.2 36-1

458.4 37-1

458.3 38-1

460.2 39-1

460.2 40-1

464.3 41-1

464.2 42-1

466.1 43-1

469.0 44-1

469.2 45-1

470.3 46-1

475.2 47-1

475.2 48-1

476.0 49-1

478.2 50-1

478.1 51-1

481.3 52-1

486.3 53-1

486.2 54-1

487.1 55-1

489.3 56-1

496.3 57-1

498.1 58-1

498.2 59-1

507.1 60-1

507.2 61-1

509.2 62-1

525.0 63-1

526.2 64-1

527.2 65-1

532.2 66-1

534.2 67-1

536.3 68-1

536.3 69-1

537.3 70-1

538.3 71-1

545.2 72-1

545.2 73-1

554.2 74-1

559.2 75-1

561.0

TABLE 1B Exemplary Compounds # Structure LC-MS m/z (M + H)   1-1a

468.2   2-1a

355.2   3-1a

450.2   4-1a

484.2   5-1a

437.1   6-1a

468.3   7-1a

488.2   8-1a

433.1   9-1a

482.1  10-1a

474.3  11-1a

440.2  12-1a

474.2  13-1a

440.2  14-1a

495.1  15-1a

440.2  16-1a

440.2  17-1a

454.2  18-1a

454.2  19-1a

452.9  20-1a

467.3  21-1a

448.3  22-1a

426.2  23-1a

454.3  24-1a

454.3  25-1a

463.3  26-1a

463.3  27-1a

384.2  28-1a

511.0  29-1a

482.9  30-1a

479.2  31-1a

440.0  32-1a

467.9  33-1a

467.9  34-1a

482.3  35-1a

453.0  36-1a

467.0  37-1a

486.2  38-1a

495.0  39-1a

495.3  40-1a

452.9  41-1a

440.2  42-1a

521.9  43-1a

440.2  44-1a

454.0  45-1a

481.9  46-1a

510.2  47-1a

502.3  48-1a

465.3  49-1a

462.3  50-1a

462.3  51-1a

492.3  52-1a

482.2  53-1a

415.3  54-1a

454.3  55-1a

468.3  56-1a

468.3  57-1a

502.2  58-1a

530.2  59-1a

516.2  60-1a

502.1  61-1a

476.1  62-1a

496.3  63-1a

426.2  64-1a

426.2  65-1a

496.3  66-1a

454.2  67-1a

454.0  68-1a

485.0  69-1a

502.0  70-1a

507.0  71-1a

509.3  72-1a

478.2  73-1a

385.2  74-1a

483.2  75-1a

498.3  76-1a

484.2  77-1a

525.0  78-1a

468.2  79-1a

503.0  80-1a

529.2  81-1a

497.0  82-1a

507.0  83-1a

399.2  84-1a

479.3  85-1a

468.0  86-1a

496.3  87-1a

482.3  88-1a

482.3  89-1a

539.0  90-1a

525.0  91-1a

524.3  92-1a

531.2  93-1a

467.3  94-1a

509.0  95-1a

493.0  96-1a

472.0  97-1a

515.0  98-1a

512.0  99-1a

523.2 100-1a

529.0 101-1a

482.0 102-1a

511.0 103-1a

499.2 104-1a

535.3 105-1a

509.1 106-1a

524.2 107-1a

531.1 108-1a

565.2 109-1a

451.0 110-1a

509.1 111-1a

516.2 112-1a

472.0 113-1a

511.3 114-1a

498.2 115-1a

496.2 116-1a

493.3 117-1a

493.0 118-1a

525.0 119-1a

517.3 120-1a

510.0 121-1a

543.2 122-1a

478.1 123-1a

484.2 124-1a

497.3 125-1a

484.2 126-1a

575.2 127-1a

555.3 128-1a

568.3 129-1a

497.3 130-1a

463.3 131-1a

506.9 132-1a

521.0 133-1a

507.0 134-1a

555.3 135-1a

468.1 136-1a

497.3 137-1a

536.2 139-1a

497.0 140-1a

525.3 141-1a

510.3 142-1a

502.2 143-1a

486.3 144-1a

535.3 145-1a

499.3 146-1a

524.3 147-1a

531.2 148-1a

511.4 149-1a

555.3 150-1a

575.3 151-1a

511.3 152-1a

573.3 153-1a

559.3 154-1a

573.3 155-1a

559.2 156-1a

563.8 157-1a

496.4 158-1a

482.3 159-1a

486.3 160-1a

495.3 161-1a

561.3 162-1a

509.0 163-1a

468.3 164-1a

482.0 165-1a

534.0 166-1a

523.0 167-1a

573.3 168-1a

559.2 169-1a

525.3 170-1a

525.3 171-1a

497.0 172-1a

539.3 173-1a

575.0 174-1a

517.3 175-1a

467.3 176-1a

568.3 177-1a

481.4 178-1a

521.4 179-1a

571.3 180-1a

539.3 181-1a

469.0 182-1a

483.0 183-1a

482.3 184-1a

539.3 185-1a

507.3 186-1a

511.3 187-1a

579.2 188-1a

531.0 189-1a

539.3 190-1a

539.3 191-1a

553.3 192-1a

573.3 193-1a

545.3 194-1a

553.3 195-1a

517.3 196-1a

525.3 197-1a

545.3 198-1a

545.3 199-1a

482.0 200-1a

482.0 201-1a

525.3 202-1a

544.8 203-1a

531.3 204-1a

559.3 205-1a

545.3 206-1a

555.4 207-1a

485.3 208-1a

585.4 209-1a

468.0 210-1a

464.3 211-1a

468.0 212-1a

466.0 213-1a

484.0 214-1a

504.0 215-1a

468.2 216-1a

538.3 217-1a

508.1 218-1a

468.0 219-1a

468.0 220-1a

498.0 221-1a

496.2 222-1a

482.3 223-1a

482.1 224-1a

485.3 225-1a

543.3 226-1a

557.3 227-1a

585.3 228-1a

543.3 229-1a

557.2 230-1a

575.3 231-1a

496.3 232-1a

496.3 233-1a

465.2 234-1a

482.4 235-1a

593.9 236-1a

494.3 237-1a

503.2 238-1a

511.3 239-1a

482.0 240-1a

509.3 241-1a

452.0 242-1a

551.3 243-1a

521.3 244-1a

538.3 245-1a

535.3 246-1a

523.3 247-1a

535.3 248-1a

552.3 249-1a

549.3 250-1a

468.0 251-1a

551.3 252-1a

564.4 253-1a

585.3 254-1a

454.0 255-1a

468.0 256-1a

454.0 257-1a

488.9 258-1a

554.3 259-1a

615.9 260-1a

525.3 261-1a

525.3 262-1a

537.3 263-1a

523.3 264-1a

507.3 265-1a

551.0 266-1a

551.0 267-1a

467.9 268-1a

468.0 269-1a

482.0 270-1a

558.9 271-1a

486.2 273-1a

531.2 274-1a

547.3 275-1a

497.2 276-1a

482.3 277-1a

555.3 278-1a

555.3 279-1a

486.3 280-1a

484.2 281-1a

468.0 282-1a

523.3 283-1a

521.3 284-1a

540.0 285-1a

553.0 286-1a

559.9 287-1a

524.0 288-1a

546.0 289-1a

482.3 290-1a

496.0 291-1a

468.0 292-1a

438.3 293-1a

424.2 294-1a

533.3 295-1a

565.2 296-1a

585.2 297-1a

564.3 298-1a

554.3 299-1a

523.3 300-1a

512.3 301-1a

537.3 302-1a

573.3 303-1a

522.0 304-1a

579.2 305-1a

579.2 306-1a

541.3 307-1a

453.0 308-1a

412.3 309-1a

536.3 310-1a

552.4 311-1a

559.3 312-1a

552.4 313-1a

565.0 314-1a

517.2 315-1a

521.3 316-1a

553.3 317-1a

488.0 318-1a

515.9 319-1a

498.2 320-1a

559.3 321-1a

474.0 322-1a

565.0 323-1a

468.0 324-1a

468.0 325-1a

541.3 326-1a

557.3 327-1a

539.3 328-1a

523.3 329-1a

493.2 330-1a

505.3 331-1a

470.7 332-1a

436.3 333-1a

436.3 334-1a

484.3 335-1a

440.2 336-1a

534.3 337-1a

438.9 338-1a

425.2 339-1a

450.3 340-1a

494.1 341-1a

461.2 346-1a

500.4 347-1a

443.3 348-1a

454.1 349-1a

424.9 350-1a

437.1 351-1a

457.0 352-1a

457.0 353-1a

547.8 354-1a

466.9 355-1a

475.1 356-1a

467.1 357-1a

453.1 358-1a

457.9 359-1a

479.8 360-1a

470.4 361-1a

458.3 364-1a

514.2 365-1a

548.8 366-1a

450.2 367-1a

527.2 368-1a

471.3 369-1a

457.9 370-1a

472.1 371-1a

451.7 372-1a

484.3 373-1a

472.3 374-1a

486.3 375-1a

472.4 376-1a

464.3 377-1a

413.9 378-1a

572.8 379-1a

485.2 380-1a

456.9 382-1a

453.3 383-1a

486.3 384-1a

416.3 385-1a

472.3 386-1a

516.3 387-1a

430.4 388-1a

465.2 389-1a

479.2 390-1a

538.3 391-1a

527.9 392-1a

471.3 393-1a

478.9 394-1a

476.8 395-1a

471.9 396-1a

499.3 397-1a

499.2 398-1a

544.9 399-1a

502.0 400-1a

484.0 401-1a

512.0 402-1a

500.4 403-1a

472.3 404-1a

458.4 405-1a

502.8 406-1a

509.8 407-1a

490.9 408-1a

466.1 409-1a

452.2 410-1a

513.3 412-1a

470.3 413-1a

470.0 414-1a

506.8 415-1a

495.9 416-1a

451.2 418-1a

480.9 419-1a

511.0 420-1a

498.3 421-1a

499.3 422-1a

443.3 423-1a

511.0 424-1a

511.3 425-1a

492.2 426-1a

466.7 427-1a

477.8 428-1a

511.2 429-1a

511.3 430-1a

499.3 431-1a

506.2 432-1a

529.3 433-1a

448.1 434-1a

521.0 435-1a

470.8 436-1a

482.8 437-1a

443.8 438-1a

511.1 439-1a

513.3 440-1a

469.2 441-1a

519.8 442-1a

491.3 443-1a

469.3 445-1a

476.0 446-1a

489.3 447-1a

529.3 448-1a

563.3 449-1a

525.3 450-1a

485.2 451-1a

436.7 452-1a

455.3 453-1a

554.2 454-1a

499.3 455-1a

485.4 456-1a

515.2 457-1a

535.3 458-1a

507.3 459-1a

437.1 460-1a

465.3 461-1a

505.3 462-1a

498.3 463-1a

471.2 464-1a

535.3 465-1a

497.2 466-1a

497.2 467-1a

505.4 468-1a

522.3 469-1a

547.2 470-1a

529.1 471-1a

521.3 472-1a

510.3 475-1a

533.2 478-1a

541.3 479-1a

533.3 480-1a

483.3 481-1a

541.2 482-1a

548.3 483-1a

568.3 484-1a

583.3 485-1a

504.1 486-1a

490.0 487-1a

480.3 488-1a

582.0 489-1a

490.3 490-1a

490.3 491-1a

467.4 492-1a

520.3 493-1a

470.0 494-1a

526.0 495-1a

470.0 496-1a

509.3 497-1a

563.3 498-1a

475.3 499-1a

527.2 500-1a

476.0 501-1a

453.3 502-1a

485.3 503-1a

508.3 504-1a

490.2 505-1a

485.4 506-1a

514.2 507-1a

490.4 508-1a

548.2 509-1a

542.3 510-1a

507.3 511-1a

567.9 512-1a

536.4 513-1a

480.4 514-1a

561.0 515-1a

527.4 516-1a

495.2 517-1a

467.3 518-1a

521.2 519-1a

467.4 520-1a

549.3 521-1a

453.3 522-1a

524.3 523-1a

525.0 524-1a

487.0 525-1a

451.1 526-1a

504.3 527-1a

534.3 528-1a

481.4 529-1a

467.4 530-1a

500.4 531-1a

471.4 532-1a

510.3 533-1a

514.3 534-1a

467.4 535-1a

521.3 536-1a

491.1 537-1a

464.3 538-1a

472.4 539-1a

539.3 540-1a

486.4 541-1a

480.2 542-1a

439.2 543-1a

483.0 544-1a

429.3 545-1a

445.3 546-1a

498.4 547-1a

513.3 548-1a

514.3 549-1a

485.4 550-1a

439.3 551-1a

496.3 552-1a

525.2 553-1a

498.0 554-1a

430.3 555-1a

496.3 556-1a

479.1 557-1a

478.3 559-1a

559.0 560-1a

471.3 561-1a

537.3 562-1a

469.4 563-1a

494.3 564-1a

490.3 565-1a

541.9 566-1a

484.4 567-1a

485.3 568-1a

467.0 569-1a

483.9 570-1a

488.8 571-1a

490.2 572-1a

483.3 573-1a

419.2 574-1a

524.3 575-1a

471.3 576-1a

513.3 577-1a

562.3 578-1a

517.3 579-1a

498.4 580-1a

453.4 581-1a

529.3 582-1a

512.0 583-1a

453.3 584-1a

535.0 585-1a

515.4 586-1a

539.2 587-1a

548.2 588-1a

494.2 589-1a

439.3 590-1a

458.3 591-1a

516.4 592-1a

528.4 593-1a

444.3 594-1a

553.3 595-1a

535.3 596-1a

504.3 597-1a

483.4 598-1a

518.9 599-1a

458.3 600-1a

472.4 601-1a

484.4 602-1a

514.3 603-1a

453.3 604-1a

486.3 605-1a

498.5 606-1a

500.4 607-1a

512.4 608-1a

451.3 609-1a

527.3 610-1a

487.3 611-1a

564.2 612-1a

548.8 613-1a

518.2 614-1a

541.3 615-1a

456.4 616-1a

499.9 617-1a

487.3 618-1a

486.9 619-1a

447.2 620-1a

490.2 621-1a

439.2 622-1a

473.9 623-1a

465.1 624-1a

470.0 625-1a

536.3 626-1a

435.1 627-1a

511.0 628-1a

467.3 629-1a

491.9 630-1a

469.3 631-1a

512.9 632-1a

456.3 635-1a

522.2 636-1a

477.9 637-1a

486.9 638-1a

440.0 639-1a

518.9 640-1a

506.8 641-1a

485.4 642-1a

429.4 643-1a

499.4 644-1a

499.4 645-1a

471.4 646-1a

399.3 647-1a

501.2 648-1a

527.2 649-1a

515.8 650-1a

458.9 651-1a

456.9 652-1a

470.4 653-1a

466.0 654-1a

503.9 655-1a

437.0 656-1a

512.9 657-1a

492.9 658-1a

494.9 659-1a

410.9 660-1a

535.3 661-1a

467.4 662-1a

449.0 663-1a

497.4 664-1a

485.4 665-1a

469.3 666-1a

435.4 667-1a

398.9 668-1a

549.3 669-1a

449.0 670-1a

453.4 671-1a

491.0 672-1a

472.3 673-1a

486.3 674-1a

463.0 675-1a

467.4 676-1a

416.4 677-1a

528.2 678-1a

481.0 679-1a

458.0 680-1a

499.4 681-1a

555.4 682-1a

430.3 683-1a

442.3 684-1a

458.3 685-1a

513.3 686-1a

567.8 687-1a

458.3

TABLE 1C Exemplary Compounds # Structure LC-MS m/z (M + H)  1-3

439.00  2-3

573.20  3-3

456.00  4-3

577.00  5-3

454.20  6-3

502.20  7-3

502.20  8-3

492.30  9-3

516.30  10-3

482.00  11-3

547.2  12-3

497.20  13-3

510.20  14-3

495.10  15-3

539.30  16-3

557.30  17-3

560.90  18-3

464.30  19-3

482.30  20-3

496.30  21-3

565.30  22-3

541.30  23-3

589.30  24-3

589.20  25-3

589.30  26-3

543.20  27-3

587.30  28-3

587.30  29-3

502.20  30-3

502.20  31-3

516.30  32-3

539.30  33-3

539.30  34-3

490.00  35-3

487.00  36-3

574.20  37-3

599.00  38-3

556.00  39-3

516.30  40-3

543.30  41-3

518.00  42-3

589.20  43-3

559.20  44-3

559.20  45-3

571.00  46-3

586.90  47-3

503.00  48-3

529.00  49-3

573.00  50-3

459.20  51-3

500.30  52-3

486.20  53-3

502.00  54-3

502.00  55-3

567.30  56-3

609.20  57-3

530.20  58-3

575.00  59-3

573.30  60-3

573.30  61-3

573.30  62-3

573.30  63-3

561.00  64-3

561.00  65-3

576.90  66-3

573.00  67-3

593.20  68-3

545.00  69-3

553.30  70-3

575.2  71-3

591.2  72-3

486.20  73-3

500.30  74-3

550.90  75-3

605.20  76-3

589.30  77-3

529.20  78-3

481.90  79-3

502.20  80-3

516.20  81-3

482.00  82-3

518.00  83-3

502.00  84-3

569.30  85-3

585.30  86-3

539.20  87-3

555.20  88-3

573.20  89-3

559.20  90-3

521.00  91-3

505.30  92-3

521.20  93-3

605.2  94-3

488.30  95-3

530.00  96-3

518.20  97-3

518.2  98-3

543.3  99-3

543.3 100-3

488 101-3

573.2 102-3

573.2 103-3

573.2 104-3

558.9 105-3

573.3 106-3

569.3 107-3

558.8 108-3

567.3 109-3

585.3 110-3

516.2 111-3

487.8 112-3

559.2 113-3

521.20 114-3

504.9 115-3

585.3 116-3

503.3 117-3

503.3 118-3

528.3 119-3

528.2 120-3

514.3 121-3

514.2 122-3

538 123-3

482.3 124-3

496.4 125-3

539.3 126-3

503.3 127-3

502.2 128-3

515.8 129-3

579.2 130-3

502.2 131-3

502.2 132-3

515.8 133-3

574.2 134-3

603.3 135-3

573.3 136-3

586.8 137- 3

586.9 138-3

567.3 139-3

555 140-3

524.2 141-3

555.2 142-3

522.2 143-3

501.9 144-3

501.9 145-3

484.2 146-3

571.3 147-3

533.2 148-3

522.2 149-3

535.7 150-3

559.2 151-3

579.2 152-3

501.9 153-3

606.7 154-3

586.8 155-3

535.7 156-3

556.9 157-3

539.2 158-3

567.3 159-3

520.9 160-3

587.3 161-3

589.7 162-3

502.2 163-3

518.2 164-3

523.2 165-3

550.3 166-3

493.3 167-3

559.2 168-3

541.2 169-3

573.3 170-3

554.8 171-3

568.9 172-3

529.8 173-3

549.8 174-3

520.8 175-3

571.2 176-3

553.3 177-3

571.2 178-3

553.3 179-3

502.2 180-3

522.2 181-3

522.2 182-3

529.8 183-3

549.8 184-3

494.2 185-3

539.2 186-3

513.9 187-3

487.7 188-3

490.2 189-3

508.2 190-3

521.9 191-3

514.3 192-3

540.8 193-3

587.3 194-3

533.2 195-3

579.2 196-3

516.30 197-3

535.7 198-3

502 199-3

521 200-3

536.2 201-3

522.2 202-3

563.2 203-3

545.3 204-3

593.3 205-3

443.2 206-3

475.8 207-3

472.3 208-3

553.2 209-3

504.2 210-3

553.2 211-3

579.2 212-3

516.3 213-3

530.2 214-3

541.1 215-3

521.7 216-3

521.8 217-3

521.8 218-3

498.2 219-3

515.8 220-3

529.9 221-3

587.8 222-3

530.3 223-3

508.2 224-3

524.3 225-3

542.2 226-3

506.2 227-3

512.3 228-3

501.8 229-3

548.2 230-3

486.2 231-3

510.20 232-3

551.10 233-3

501.90 234-3

498.30 235-3

484.20 236-3

538.30 237-3

538.20 238-3

458.30 239-3

483.00 240-3

530.20 241-3

558.30 242-3

530.20 243-3

560.80 244-3

534.90 245-3

536.20 246-3

498.00 247-3

556.30 248-3

601.10 249-3

514.20 250-3

510.20 251-3

508.20 252-3

538.20 253-3

530.20 254-3

558.30 255-3

558.30 256-3

484.20 257-3

516.30 258-3

550.80 259-3

561.70 260-3

506.30 261-3

532.20 262-3

457.20 263-3

590.20 264-3

564.20 265-3

592.20 266-3

521.80 267-3

537.70 268-3

487.20 269-3

512.30 270-3

550.20 271-3

550.20 272-3

552.20 273-3

518.20 274-3

492.20 275-3

494.20 276-3

528.20 277-3

498.20 278-3

511.2 279-3

554.00 280-3

575.20 281-3

597.40 282-3

583.30 283-3

591.20 284-3

613.30 285-3

599.20 286-3

599.30 287-3

585.30 288-3

527.80 289-3

528.00 290-3

528.20 291-3

564.70 292-3

576.70 293-3

588.20 294-3

532.30 295-3

526.20 296-3

535.20 297-3

526.30

TABLE 2 Exemplary Compounds # Structure LC-MS m/z (M + H)  1-2

387.2  2-2

401.3  3-2

402.2  4-2

413.2  5-2

413.3  6-2

415.3  7-2

416.3  8-2

416.3  9-2

416.3 10-2

429.3 11-2

436.3 12-2

444.3 13-2

444.2 14-2

450.2 15-2

458.2 16-2

489.2  2-1

450.3

In certain embodiments, a provided compound inhibits CARM1. In certainembodiments, a provided compound inhibits wild-type CARM1. In certainembodiments, a provided compound inhibits a mutant CARM1. In certainembodiments, a provided compound inhibits CARM1, e.g., as measured in anassay described herein. In certain embodiments, the CARM1 is from ahuman. In certain embodiments, a provided compound inhibits CARM1 at anIC₅₀ less than or equal to 10 μM. In certain embodiments, a providedcompound inhibits CARM1 at an IC₅₀ less than or equal to 1 μM. Incertain embodiments, a provided compound inhibits CARM1 at an IC₅₀ lessthan or equal to 0.1 μM. In certain embodiments, a provided compoundinhibits CARM1 in a cell at an EC₅₀ less than or equal to 10 μM. Incertain embodiments, a provided compound inhibits CARM1 in a cell at anEC₅₀ less than or equal to 1 μM. In certain embodiments, a providedcompound inhibits CARM1 in a cell at an EC₅₀ less than or equal to 0.1μM. In certain embodiments, a provided compound inhibits cellproliferation at an EC₅₀ less than or equal to 10 μM. In certainembodiments, a provided compound inhibits cell proliferation at an EC₅₀less than or equal to 1 μM. In certain embodiments, a provided compoundinhibits cell proliferation at an EC₅₀ less than or equal to 0.1 μM. Insome embodiments, a provided compound is selective for CARM1 over othermethyltransferases. In certain embodiments, a provided compound is atleast about 10-fold selective, at least about 20-fold selective, atleast about 30-fold selective, at least about 40-fold selective, atleast about 50-fold selective, at least about 60-fold selective, atleast about 70-fold selective, at least about 80-fold selective, atleast about 90-fold selective, or at least about 100-fold selective forPRMT1 relative to one or more other methyltransferases.

It will be understood by one of ordinary skill in the art that the CARM1can be wild-type CARM1, or any mutant or variant of CARM1.

The present disclosure provides pharmaceutical compositions comprising acompound described herein, e.g., a compound of Formula (I), or apharmaceutically acceptable salt thereof, as described herein, andoptionally a pharmaceutically acceptable excipient. It will beunderstood by one of ordinary skill in the art that the compoundsdescribed herein, or salts thereof, may be present in various forms,such as amorphous, hydrates, solvates, or polymorphs. In certainembodiments, a provided composition comprises two or more compoundsdescribed herein. In certain embodiments, a compound described herein,or a pharmaceutically acceptable salt thereof, is provided in aneffective amount in the pharmaceutical composition. In certainembodiments, the effective amount is a therapeutically effective amount.In certain embodiments, the effective amount is an amount effective forinhibiting CARM1. In certain embodiments, the effective amount is anamount effective for treating a CARM1-mediated disorder. In certainembodiments, the effective amount is a prophylactically effectiveamount. In certain embodiments, the effective amount is an amounteffective to prevent a CARM1-mediated disorder.

Pharmaceutically acceptable excipients include any and all solvents,diluents, or other liquid vehicles, dispersions, suspension aids,surface active agents, isotonic agents, thickening or emulsifyingagents, preservatives, solid binders, lubricants, and the like, assuited to the particular dosage form desired. General considerations informulation and/or manufacture of pharmaceutical compositions agents canbe found, for example, in Remington's Pharmaceutical Sciences, SixteenthEdition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980), andRemington: The Science and Practice of Pharmacy, 21st Edition(Lippincott Williams & Wilkins, 2005).

Pharmaceutical compositions described herein can be prepared by anymethod known in the art of pharmacology. In general, such preparatorymethods include the steps of bringing a compound described herein (the“active ingredient”) into association with a carrier and/or one or moreother accessory ingredients, and then, if necessary and/or desirable,shaping and/or packaging the product into a desired single- ormulti-dose unit.

Pharmaceutical compositions can be prepared, packaged, and/or sold inbulk, as a single unit dose, and/or as a plurality of single unit doses.As used herein, a “unit dose” is discrete amount of the pharmaceuticalcomposition comprising a predetermined amount of the active ingredient.The amount of the active ingredient is generally equal to the dosage ofthe active ingredient which would be administered to a subject and/or aconvenient fraction of such a dosage such as, for example, one-half orone-third of such a dosage.

Relative amounts of the active ingredient, the pharmaceuticallyacceptable excipient, and/or any additional ingredients in apharmaceutical composition of the present disclosure will vary,depending upon the identity, size, and/or condition of the subjecttreated and further depending upon the route by which the composition isto be administered. By way of example, the composition may comprisebetween 0.1% and 100% (w/w) active ingredient.

Pharmaceutically acceptable excipients used in the manufacture ofprovided pharmaceutical compositions include inert diluents, dispersingand/or granulating agents, surface active agents and/or emulsifiers,disintegrating agents, binding agents, preservatives, buffering agents,lubricating agents, and/or oils. Excipients such as cocoa butter andsuppository waxes, coloring agents, coating agents, sweetening,flavoring, and perfuming agents may also be present in the composition.

Exemplary diluents include calcium carbonate, sodium carbonate, calciumphosphate, dicalcium phosphate, calcium sulfate, calcium hydrogenphosphate, sodium phosphate lactose, sucrose, cellulose,microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodiumchloride, dry starch, cornstarch, powdered sugar, and mixtures thereof.

Exemplary granulating and/or dispersing agents include potato starch,corn starch, tapioca starch, sodium starch glycolate, clays, alginicacid, guar gum, citrus pulp, agar, bentonite, cellulose and woodproducts, natural sponge, cation-exchange resins, calcium carbonate,silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone)(crospovidone), sodium carboxymethyl starch (sodium starch glycolate),carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose(croscarmellose), methylcellulose, pregelatinized starch (starch 1500),microcrystalline starch, water insoluble starch, calcium carboxymethylcellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate,quaternary ammonium compounds, and mixtures thereof.

Exemplary surface active agents and/or emulsifiers include naturalemulsifiers (e.g., acacia, agar, alginic acid, sodium alginate,tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk,casein, wool fat, cholesterol, wax, and lecithin), colloidal clays(e.g., bentonite (aluminum silicate) and Veegum (magnesium aluminumsilicate)), long chain amino acid derivatives, high molecular weightalcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetinmonostearate, ethylene glycol distearate, glyceryl monostearate, andpropylene glycol monostearate, polyvinyl alcohol), carbomers (e.g.,carboxy polymethylene, polyacrylic acid, acrylic acid polymer, andcarboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g.,carboxymethylcellulose sodium, powdered cellulose, hydroxymethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose,methylcellulose), sorbitan fatty acid esters (e.g., polyoxyethylenesorbitan monolaurate (Tween 20), polyoxyethylene sorbitan (Tween 60),polyoxyethylene sorbitan monooleate (Tween 80), sorbitan monopalmitate(Span 40), sorbitan monostearate (Span 60], sorbitan tristearate (Span65), glyceryl monooleate, sorbitan monooleate (Span 80)),polyoxyethylene esters (e.g., polyoxyethylene monostearate (Myrj 45),polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil,polyoxymethylene stearate, and Solutol), sucrose fatty acid esters,polyethylene glycol fatty acid esters (e.g., Cremophor™),polyoxyethylene ethers, (e.g., polyoxyethylene lauryl ether (Brij 30)),poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamineoleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyllaurate, sodium lauryl sulfate, Pluronic F68, Poloxamer 188, cetrimoniumbromide, cetylpyridinium chloride, benzalkonium chloride, docusatesodium, and/or mixtures thereof.

Exemplary binding agents include starch (e.g., cornstarch and starchpaste), gelatin, sugars (e.g., sucrose, glucose, dextrose, dextrin,molasses, lactose, lactitol, mannitol, etc.), natural and synthetic gums(e.g., acacia, sodium alginate, extract of Irish moss, panwar gum,ghatti gum, mucilage of isapol husks, carboxymethylcellulose,methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, microcrystalline cellulose,cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate(Veegum), and larch arabogalactan), alginates, polyethylene oxide,polyethylene glycol, inorganic calcium salts, silicic acid,polymethacrylates, waxes, water, alcohol, and/or mixtures thereof.

Exemplary preservatives include antioxidants, chelating agents,antimicrobial preservatives, antifungal preservatives, alcoholpreservatives, acidic preservatives, and other preservatives.

Exemplary antioxidants include alpha tocopherol, ascorbic acid, acorbylpalmitate, butylated hydroxyanisole, butylated hydroxytoluene,monothioglycerol, potassium metabisulfite, propionic acid, propylgallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, andsodium sulfite.

Exemplary chelating agents include ethylenediaminetetraacetic acid(EDTA) and salts and hydrates thereof (e.g., sodium edetate, disodiumedetate, trisodium edetate, calcium disodium edetate, dipotassiumedetate, and the like), citric acid and salts and hydrates thereof(e.g., citric acid monohydrate), fumaric acid and salts and hydratesthereof, malic acid and salts and hydrates thereof, phosphoric acid andsalts and hydrates thereof, and tartaric acid and salts and hydratesthereof. Exemplary antimicrobial preservatives include benzalkoniumchloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide,cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol,chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea,phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate,propylene glycol, and thimerosal.

Exemplary antifungal preservatives include butyl paraben, methylparaben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoicacid, potassium benzoate, potassium sorbate, sodium benzoate, sodiumpropionate, and sorbic acid.

Exemplary alcohol preservatives include ethanol, polyethylene glycol,phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate,and phenylethyl alcohol. Exemplary acidic preservatives include vitaminA, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid,dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.

Other preservatives include tocopherol, tocopherol acetate, deteroximemesylate, cetrimide, butylated hydroxyanisol (BHA), butylatedhydroxytoluened (BHT), ethylenediamine, sodium lauryl sulfate (SLS),sodium lauryl ether sulfate (SLES), sodium bisulfite, sodiummetabisulfite, potassium sulfite, potassium metabisulfite, Glydant Plus,Phenonip, methylparaben, Germall 115, Germaben II, Neolone, Kathon, andEuxyl. In certain embodiments, the preservative is an anti-oxidant. Inother embodiments, the preservative is a chelating agent.

Exemplary buffering agents include citrate buffer solutions, acetatebuffer solutions, phosphate buffer solutions, ammonium chloride, calciumcarbonate, calcium chloride, calcium citrate, calcium glubionate,calcium gluceptate, calcium gluconate, D-gluconic acid, calciumglycerophosphate, calcium lactate, propanoic acid, calcium levulinate,pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasiccalcium phosphate, calcium hydroxide phosphate, potassium acetate,potassium chloride, potassium gluconate, potassium mixtures, dibasicpotassium phosphate, monobasic potassium phosphate, potassium phosphatemixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodiumcitrate, sodium lactate, dibasic sodium phosphate, monobasic sodiumphosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide,aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline,Ringer's solution, ethyl alcohol, and mixtures thereof.

Exemplary lubricating agents include magnesium stearate, calciumstearate, stearic acid, silica, talc, malt, glyceryl behanate,hydrogenated vegetable oils, polyethylene glycol, sodium benzoate,sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate,sodium lauryl sulfate, and mixtures thereof.

Exemplary natural oils include almond, apricot kernel, avocado, babassu,bergamot, black current seed, borage, cade, camomile, canola, caraway,carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee,corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed,geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate,jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademianut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange,orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed,pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood,sasquana, savoury, sea buckthorn, sesame, shea butter, silicone,soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, andwheat germ oils. Exemplary synthetic oils include, but are not limitedto, butyl stearate, caprylic triglyceride, capric triglyceride,cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate,mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and mixturesthereof.

Liquid dosage forms for oral and parenteral administration includepharmaceutically acceptable emulsions, microemulsions, solutions,suspensions, syrups and elixirs. In addition to the active ingredients,the liquid dosage forms may comprise inert diluents commonly used in theart such as, for example, water or other solvents, solubilizing agentsand emulsifiers such as ethyl alcohol, isopropyl alcohol, ethylcarbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butylene glycol, dimethylformamide, oils (e.g., cottonseed,groundnut, corn, germ, olive, castor, and sesame oils), glycerol,tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid estersof sorbitan, and mixtures thereof. Besides inert diluents, the oralcompositions can include adjuvants such as wetting agents, emulsifyingand suspending agents, sweetening, flavoring, and perfuming agents. Incertain embodiments for parenteral administration, the compoundsdescribed herein are mixed with solubilizing agents such as Cremophor™,alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins,polymers, and mixtures thereof.

Injectable preparations, for example, sterile injectable aqueous oroleaginous suspensions can be formulated according to the known artusing suitable dispersing or wetting agents and suspending agents. Thesterile injectable preparation can be a sterile injectable solution,suspension or emulsion in a nontoxic parenterally acceptable diluent orsolvent, for example, as a solution in 1,3-butanediol. Among theacceptable vehicles and solvents that can be employed are water,Ringer's solution, U.S.P. and isotonic sodium chloride solution. Inaddition, sterile, fixed oils are conventionally employed as a solventor suspending medium. For this purpose any bland fixed oil can beemployed including synthetic mono- or diglycerides. In addition, fattyacids such as oleic acid are used in the preparation of injectables.

The injectable formulations can be sterilized, for example, byfiltration through a bacterial-retaining filter, or by incorporatingsterilizing agents in the form of sterile solid compositions which canbe dissolved or dispersed in sterile water or other sterile injectablemedium prior to use.

In order to prolong the effect of a drug, it is often desirable to slowthe absorption of the drug from subcutaneous or intramuscular injection.This can be accomplished by the use of a liquid suspension ofcrystalline or amorphous material with poor water solubility. The rateof absorption of the drug then depends upon its rate of dissolutionwhich, in turn, may depend upon crystal size and crystalline form.Alternatively, delayed absorption of a parenterally administered drugform is accomplished by dissolving or suspending the drug in an oilvehicle.

Compositions for rectal or vaginal administration are typicallysuppositories which can be prepared by mixing the compounds describedherein with suitable non-irritating excipients or carriers such as cocoabutter, polyethylene glycol or a suppository wax which are solid atambient temperature but liquid at body temperature and therefore melt inthe rectum or vaginal cavity and release the active ingredient.

Solid dosage forms for oral administration include capsules, tablets,pills, powders, and granules. In such solid dosage forms, the activeingredient is mixed with at least one inert, pharmaceutically acceptableexcipient or carrier such as sodium citrate or dicalcium phosphateand/or a) fillers or extenders such as starches, lactose, sucrose,glucose, mannitol, and silicic acid, b) binders such as, for example,carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone,sucrose, and acacia, c) humectants such as glycerol, d) disintegratingagents such as agar, calcium carbonate, potato or tapioca starch,alginic acid, certain silicates, and sodium carbonate, e) solutionretarding agents such as paraffin, f) absorption accelerators such asquaternary ammonium compounds, g) wetting agents such as, for example,cetyl alcohol and glycerol monostearate, h) absorbents such as kaolinand bentonite clay, and i) lubricants such as talc, calcium stearate,magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate,and mixtures thereof. In the case of capsules, tablets and pills, thedosage form may comprise buffering agents.

Solid compositions of a similar type can be employed as fillers in softand hard-filled gelatin capsules using such excipients as lactose ormilk sugar as well as high molecular weight polyethylene glycols and thelike. The solid dosage forms of tablets, dragees, capsules, pills, andgranules can be prepared with coatings and shells such as entericcoatings and other coatings well known in the pharmaceutical formulatingart. They may optionally comprise opacifying agents and can be of acomposition that they release the active ingredient(s) only, orpreferentially, in a certain part of the intestinal tract, optionally,in a delayed manner. Examples of embedding compositions which can beused include polymeric substances and waxes. Solid compositions of asimilar type can be employed as fillers in soft and hard-filled gelatincapsules using such excipients as lactose or milk sugar as well as highmolecular weight polyethylene glycols and the like.

The active ingredient can be in micro-encapsulated form with one or moreexcipients as noted above. The solid dosage forms of tablets, dragees,capsules, pills, and granules can be prepared with coatings and shellssuch as enteric coatings, release controlling coatings and othercoatings well known in the pharmaceutical formulating art. In such soliddosage forms the active ingredient can be admixed with at least oneinert diluent such as sucrose, lactose, or starch. Such dosage forms maycomprise, as is normal practice, additional substances other than inertdiluents, e.g., tableting lubricants and other tableting aids such amagnesium stearate and microcrystalline cellulose. In the case ofcapsules, tablets, and pills, the dosage forms may comprise bufferingagents. They may optionally comprise opacifying agents and can be of acomposition that they release the active ingredient(s) only, orpreferentially, in a certain part of the intestinal tract, optionally,in a delayed manner. Examples of embedding compositions which can beused include polymeric substances and waxes.

Dosage forms for topical and/or transdermal administration of a providedcompound may include ointments, pastes, creams, lotions, gels, powders,solutions, sprays, inhalants and/or patches. Generally, the activeingredient is admixed under sterile conditions with a pharmaceuticallyacceptable carrier and/or any desired preservatives and/or buffers ascan be required. Additionally, the present disclosure encompasses theuse of transdermal patches, which often have the added advantage ofproviding controlled delivery of an active ingredient to the body. Suchdosage forms can be prepared, for example, by dissolving and/ordispensing the active ingredient in the proper medium. Alternatively oradditionally, the rate can be controlled by either providing a ratecontrolling membrane and/or by dispersing the active ingredient in apolymer matrix and/or gel.

Formulations suitable for topical administration include, but are notlimited to, liquid and/or semi liquid preparations such as liniments,lotions, oil in water and/or water in oil emulsions such as creams,ointments and/or pastes, and/or solutions and/or suspensions.Topically-administrable formulations may, for example, comprise fromabout 1% to about 10% (w/w) active ingredient, although theconcentration of the active ingredient can be as high as the solubilitylimit of the active ingredient in the solvent. Formulations for topicaladministration may further comprise one or more of the additionalingredients described herein.

A provided pharmaceutical composition can be prepared, packaged, and/orsold in a formulation suitable for pulmonary administration via thebuccal cavity. Such a formulation may comprise dry particles whichcomprise the active ingredient and which have a diameter in the rangefrom about 0.5 to about 7 nanometers or from about 1 to about 6nanometers. Such compositions are conveniently in the form of drypowders for administration using a device comprising a dry powderreservoir to which a stream of propellant can be directed to dispersethe powder and/or using a self-propelling solvent/powder dispensingcontainer such as a device comprising the active ingredient dissolvedand/or suspended in a low-boiling propellant in a sealed container. Suchpowders comprise particles wherein at least 98% of the particles byweight have a diameter greater than 0.5 nanometers and at least 95% ofthe particles by number have a diameter less than 7 nanometers.Alternatively, at least 95% of the particles by weight have a diametergreater than 1 nanometer and at least 90% of the particles by numberhave a diameter less than 6 nanometers. Dry powder compositions mayinclude a solid fine powder diluent such as sugar and are convenientlyprovided in a unit dose form.

Low boiling propellants generally include liquid propellants having aboiling point of below 65° F. at atmospheric pressure. Generally thepropellant may constitute 50 to 99.9% (w/w) of the composition, and theactive ingredient may constitute 0.1 to 20% (w/w) of the composition.The propellant may further comprise additional ingredients such as aliquid non-ionic and/or solid anionic surfactant and/or a solid diluent(which may have a particle size of the same order as particlescomprising the active ingredient).

Pharmaceutical compositions formulated for pulmonary delivery mayprovide the active ingredient in the form of droplets of a solutionand/or suspension. Such formulations can be prepared, packaged, and/orsold as aqueous and/or dilute alcoholic solutions and/or suspensions,optionally sterile, comprising the active ingredient, and mayconveniently be administered using any nebulization and/or atomizationdevice. Such formulations may further comprise one or more additionalingredients including, but not limited to, a flavoring agent such assaccharin sodium, a volatile oil, a buffering agent, a surface activeagent, and/or a preservative such as methylhydroxybenzoate. The dropletsprovided by this route of administration may have an average diameter inthe range from about 0.1 to about 200 nanometers.

Formulations described herein as being useful for pulmonary delivery areuseful for intranasal delivery of a pharmaceutical composition. Anotherformulation suitable for intranasal administration is a coarse powdercomprising the active ingredient and having an average particle fromabout 0.2 to 500 micrometers. Such a formulation is administered byrapid inhalation through the nasal passage from a container of thepowder held close to the nares.

Formulations for nasal administration may, for example, comprise fromabout as little as 0.1% (w/w) and as much as 100% (w/w) of the activeingredient, and may comprise one or more of the additional ingredientsdescribed herein. A provided pharmaceutical composition can be prepared,packaged, and/or sold in a formulation for buccal administration. Suchformulations may, for example, be in the form of tablets and/or lozengesmade using conventional methods, and may contain, for example, 0.1 to20% (w/w) active ingredient, the balance comprising an orallydissolvable and/or degradable composition and, optionally, one or moreof the additional ingredients described herein. Alternately,formulations for buccal administration may comprise a powder and/or anaerosolized and/or atomized solution and/or suspension comprising theactive ingredient. Such powdered, aerosolized, and/or aerosolizedformulations, when dispersed, may have an average particle and/ordroplet size in the range from about 0.1 to about 200 nanometers, andmay further comprise one or more of the additional ingredients describedherein.

A provided pharmaceutical composition can be prepared, packaged, and/orsold in a formulation for ophthalmic administration. Such formulationsmay, for example, be in the form of eye drops including, for example, a0.1/1.0% (w/w) solution and/or suspension of the active ingredient in anaqueous or oily liquid carrier. Such drops may further comprisebuffering agents, salts, and/or one or more other of the additionalingredients described herein. Other opthalmically-administrableformulations which are useful include those which comprise the activeingredient in microcrystalline form and/or in a liposomal preparation.Ear drops and/or eye drops are contemplated as being within the scope ofthis disclosure.

Although the descriptions of pharmaceutical compositions provided hereinare principally directed to pharmaceutical compositions which aresuitable for administration to humans, it will be understood by theskilled artisan that such compositions are generally suitable foradministration to animals of all sorts. Modification of pharmaceuticalcompositions suitable for administration to humans in order to renderthe compositions suitable for administration to various animals is wellunderstood, and the ordinarily skilled veterinary pharmacologist candesign and/or perform such modification with ordinary experimentation.

Compounds provided herein are typically formulated in dosage unit formfor ease of administration and uniformity of dosage. It will beunderstood, however, that the total daily usage of provided compositionswill be decided by the attending physician within the scope of soundmedical judgment. The specific therapeutically effective dose level forany particular subject or organism will depend upon a variety of factorsincluding the disease, disorder, or condition being treated and theseverity of the disorder; the activity of the specific active ingredientemployed; the specific composition employed; the age, body weight,general health, sex and diet of the subject; the time of administration,route of administration, and rate of excretion of the specific activeingredient employed; the duration of the treatment; drugs used incombination or coincidental with the specific active ingredientemployed; and like factors well known in the medical arts.

The compounds and compositions provided herein can be administered byany route, including enteral (e.g., oral), parenteral, intravenous,intramuscular, intra-arterial, intramedullary, intrathecal,subcutaneous, intraventricular, transdermal, interdermal, rectal,intravaginal, intraperitoneal, topical (as by powders, ointments,creams, and/or drops), mucosal, nasal, bucal, sublingual; byintratracheal instillation, bronchial instillation, and/or inhalation;and/or as an oral spray, nasal spray, and/or aerosol. Specificallycontemplated routes are oral administration, intravenous administration(e.g., systemic intravenous injection), regional administration viablood and/or lymph supply, and/or direct administration to an affectedsite. In general the most appropriate route of administration willdepend upon a variety of factors including the nature of the agent(e.g., its stability in the environment of the gastrointestinal tract),and/or the condition of the subject (e.g., whether the subject is ableto tolerate oral administration).

The exact amount of a compound required to achieve an effective amountwill vary from subject to subject, depending, for example, on species,age, and general condition of a subject, severity of the side effects ordisorder, identity of the particular compound(s), mode ofadministration, and the like. The desired dosage can be delivered threetimes a day, two times a day, once a day, every other day, every thirdday, every week, every two weeks, every three weeks, or every fourweeks. In certain embodiments, the desired dosage can be delivered usingmultiple administrations (e.g., two, three, four, five, six, seven,eight, nine, ten, eleven, twelve, thirteen, fourteen, or moreadministrations).

In certain embodiments, an effective amount of a compound foradministration one or more times a day to a 70 kg adult human maycomprise about 0.0001 mg to about 3000 mg, about 0.0001 mg to about 2000mg, about 0.0001 mg to about 1000 mg, about 0.001 mg to about 1000 mg,about 0.01 mg to about 1000 mg, about 0.1 mg to about 1000 mg, about 1mg to about 1000 mg, about 1 mg to about 100 mg, about 10 mg to about1000 mg, or about 100 mg to about 1000 mg, of a compound per unit dosageform.

In certain embodiments, a compound described herein may be administeredat dosage levels sufficient to deliver from about 0.001 mg/kg to about1000 mg/kg, from about 0.01 mg/kg to about mg/kg, from about 0.1 mg/kgto about 40 mg/kg, from about 0.5 mg/kg to about 30 mg/kg, from about0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, orfrom about 1 mg/kg to about 25 mg/kg, of subject body weight per day,one or more times a day, to obtain the desired therapeutic effect.

In some embodiments, a compound described herein is administered one ormore times per day, for multiple days. In some embodiments, the dosingregimen is continued for days, weeks, months, or years.

It will be appreciated that dose ranges as described herein provideguidance for the administration of provided pharmaceutical compositionsto an adult. The amount to be administered to, for example, a child oran adolescent can be determined by a medical practitioner or personskilled in the art and can be lower or the same as that administered toan adult.

It will be also appreciated that a compound or composition, as describedherein, can be administered in combination with one or more additionaltherapeutically active agents. In certain embodiments, a compound orcomposition provided herein is administered in combination with one ormore additional therapeutically active agents that improve itsbioavailability, reduce and/or modify its metabolism, inhibit itsexcretion, and/or modify its distribution within the body. It will alsobe appreciated that the therapy employed may achieve a desired effectfor the same disorder, and/or it may achieve different effects.

The compound or composition can be administered concurrently with, priorto, or subsequent to, one or more additional therapeutically activeagents. In certain embodiments, the additional therapeutically activeagent is a compound of Formula (I). In certain embodiments, theadditional therapeutically active agent is not a compound of Formula(I). In general, each agent will be administered at a dose and/or on atime schedule determined for that agent. In will further be appreciatedthat the additional therapeutically active agent utilized in thiscombination can be administered together in a single composition oradministered separately in different compositions. The particularcombination to employ in a regimen will take into account compatibilityof a provided compound with the additional therapeutically active agentand/or the desired therapeutic effect to be achieved. In general, it isexpected that additional therapeutically active agents utilized incombination be utilized at levels that do not exceed the levels at whichthey are utilized individually. In some embodiments, the levels utilizedin combination will be lower than those utilized individually.

Exemplary additional therapeutically active agents include, but are notlimited to, small organic molecules such as drug compounds (e.g.,compounds approved by the U.S. Food and Drug Administration as providedin the Code of Federal Regulations (CFR)), peptides, proteins,carbohydrates, monosaccharides, oligosaccharides, polysaccharides,nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides orproteins, small molecules linked to proteins, glycoproteins, steroids,nucleic acids, DNAs, RNAs, nucleotides, nucleosides, oligonucleotides,antisense oligonucleotides, lipids, hormones, vitamins, and cells.

Also encompassed by the present discosure are kits (e.g., pharmaceuticalpacks). The kits provided may comprise a provided pharmaceuticalcomposition or compound and a container (e.g., a vial, ampule, bottle,syringe, and/or dispenser package, or other suitable container). In someembodiments, provided kits may optionally further include a secondcontainer comprising a pharmaceutical excipient for dilution orsuspension of a provided pharmaceutical composition or compound. In someembodiments, a provided pharmaceutical composition or compound providedin the container and the second container are combined to form one unitdosage form. In some embodiments, a provided kits further includesinstructions for use.

Compounds and compositions described herein are generally useful for theinhibition of CARM1. In some embodiments, the CARM1 is human CARM1. Insome embodiments, methods of treating CARM1-mediated disorder in asubject are provided which comprise administering an effective amount ofa compound described herein (e.g., a compound of Formula (I), or apharmaceutically acceptable salt thereof), to a subject in need oftreatment. In certain embodiments, the effective amount is atherapeutically effective amount. In certain embodiments, the effectiveamount is a prophylactically effective amount. In certain embodiments,the subject is suffering from a CARM1-mediated disorder. In certainembodiments, the subject is susceptible to a CARM1-mediated disorder.

As used herein, the term “CARM1-mediated disorder” means any disease,disorder, or other pathological condition in which CARM1 is known toplay a role. Accordingly, in some embodiments, the present disclosurerelates to treating or lessening the severity of one or more diseases inwhich CARM1 is known to play a role.

In some embodiments, the present disclosure provides a method ofinhibiting CARM1 comprising contacting CARM1 with an effective amount ofa compound described herein, e.g., a compound of Formula (I), or apharmaceutically acceptable salt thereof. The CARM1 may be purified orcrude, and may be present in a cell, tissue, or subject. Thus, suchmethods encompass both inhibition of in vitro and in vivo CARM1activity. In certain embodiments, the method is an in vitro method,e.g., such as an assay method. It will be understood by one of ordinaryskill in the art that inhibition of CARM1 does not necessarily requirethat all of the CARM1 be occupied by an inhibitor at once. Exemplarylevels of inhibition of CARM1 include at least 10% inhibition, about 10%to about 25% inhibition, about 25% to about 50% inhibition, about 50% toabout 75% inhibition, at least 50% inhibition, at least 75% inhibition,about 80% inhibition, about 90% inhibition, and greater than 90%inhibition.

In some embodiments, provided is a method of inhibiting CARM1 activityin a subject in need thereof comprising administering to the subject aneffective amount of a compound described herein (e.g., a compound ofFormula (I), or a pharmaceutically acceptable salt thereof, or apharmaceutical composition thereof.

In certain embodiments, provided is a method of modulating geneexpression or activity in a cell which comprises contacting a cell withan effective amount of a compound of Formula (I), or a pharmaceuticallyacceptable salt thereof. In certain embodiments, the cell in culture invitro. In certain embodiments, the cell is in an animal, e.g., a human.In certain embodiments, the cell is in a subject in need of treatment.

In certain embodiments, provided is a method of modulating transcriptionin a cell which comprises contacting a cell with an effective amount ofa compound of Formula (I), or a pharmaceutically acceptable saltthereof. In certain embodiments, the cell in culture in vitro. Incertain embodiments, the cell is in an animal, e.g., a human. In certainembodiments, the cell is in a subject in need of treatment.

In certain embodiments, a method is provided of selecting a therapy fora subject having a disease associated with CARM1-mediated disorder ormutation comprising the steps of determining the presence ofCARM1-mediated disorder or gene mutation in the CARM1 gene or andselecting, based on the presence of CARM1-mediated disorder a genemutation in the CARM1 gene a therapy that includes the administration ofa provided compound. In certain embodiments, the disease is cancer.

In certain embodiments, a method of treatment is provided for a subjectin need thereof comprising the steps of determining the presence ofCARM1-mediated disorder or a gene mutation in the CARM1 gene andtreating the subject in need thereof, based on the presence of aCARM1-mediated disorder or gene mutation in the CARM1 gene with atherapy that includes the administration of a provided compound. Incertain embodiments, the subject is a cancer patient.

In some embodiments, a compound provided herein is useful in treating aproliferative disorder, such as cancer. For example, while not beingbound to any particular mechanism, protein arginine methylation by CARM1is a modification that has been implicated in signal transduction, genetranscription, DNA repair and mRNA splicing, among others; andoverexpression of CARM1 within these pathways is often associated withvarious cancers. Thus, compounds which inhibit the action of PRMTs, andspecifically CARM1, as provided herein, are effective in the treatmentof cancer.

In some embodiments, compounds provided herein are effective in treatingcancer through the inhibition of CARM1. For example, CARM1 levels havebeen shown to be elevated in castration-resistant prostate cancer (CRPC)(e.g., see Di Lorenzo et al., Drugs (2010) 70:983-1000), as well as inaggressive breast tumors (Hong et al., Cancer 2004 101, 83-89; ElMessaoudi et al., Proc. Natl. Acad. Sci. U.S.A 2006, 103, 13351-13356;Majumder et al., Prostate 2006 66, 1292-1301). Thus, in someembodiments, inhibitors of CARM1, as described herein, are useful intreating cancers associated with aberrant CARM1 activity, e.g., CARM1overexpression or aberrant protein methylation. For example, aberrantCARM1 activity has been found in prostate cancer (e.g., see Hong et al.,Cancer (2004), 101:83-89); plays a coactivator role in the dysragulationof beta-catenin activity in colorectal cancer (e.g., see Ou et al., Mol.Cancer Res. (2011) 9:660); and has been linked to estrogen signaling andestrogen related cancers such as breast cancer (see, e.g., Teyssiewr etal., Trends in Endocrinology and Metabolism (2010) 21:181-189). CARM1has also been shown to affect estrogen receptor alpha (ER-alpha)dependent breast cancer cell differentiation and proliferation(Al-Dhaheri et al., Cancer Res. 2011 71, 2118-2128), thus in someaspects CARM1 inhibitors, as described herein, are useful in treatingERα-dependent breast cancer by inhibiting cell differentiation andproliferation. In another example, CARM1 has been shown to be recruitedto the promoter of E2F1 (which encodes a cell cycle regulator) as atranscriptional co-activator (Frietze et al., Cancer Res. 2008 68,301-306). Thus, CARM1-mediated upregulation of E2F1 expression maycontribute to cancer progression and chemoresistance as increasedabundance of E2F1 triggers invasion and metastasis by activating growthreceptor signaling pathways, which in turn promote an antiapoptotictumor environment (Engelmann and Pützer, Cancer Res 2012 72; 571).Accordingly, in some embodiments, the inhibition of CARM1, e.g., bycompounds provided herein, is useful in treating cancers associated withE2F1 upregulation, e.g., such as lung cancer (see, e.g., Eymin et al.,Oncogene (2001) 20:1678-1687), and breast cancer (see, e.g., Brietz etal., Cancer Res. (2008) 68:301-306). Thus, without being bound by anyparticular mechanism, the inhibition of CARM1, e.g., by compoundsdescribed herein, is beneficial in the treatment of cancer. CARM1overexpression has also been demonstrated to be elevated in 75% ofcolorectal cancers (Kim et al., BMC Cancer, 10, 197). It has beenadditionally been determined that depletion of CARM1 in WNT/β-catenindysregulated colorectal cancer suppressed anchorage independent growth(Ou et al., Mol. Cancer. Res., 20119, 660-670). This, in someembodiments, the inhibition of CARM1, e.g. by compounds provided herein,is useful in colorectal cancer associated with elevated CARM1 expressionor dysregulated WNT/β-catenin signaling.

In some embodiments, compounds described herein are useful for treatinga cancer including, but not limited to, acoustic neuroma,adenocarcinoma, adrenal gland cancer, anal cancer, angiosarcoma (e.g.,lymphangiosarcoma, lymphangioendotheliosarcoma, hemangiosarcoma),appendix cancer, benign monoclonal gammopathy, biliary cancer (e.g.,cholangiocarcinoma), bladder cancer, breast cancer (e.g., adenocarcinomaof the breast, papillary carcinoma of the breast, mammary cancer,medullary carcinoma of the breast), brain cancer (e.g., meningioma;glioma, e.g., astrocytoma, oligodendroglioma; medulloblastoma), bronchuscancer, carcinoid tumor, cervical cancer (e.g., cervicaladenocarcinoma), choriocarcinoma, chordoma, craniopharyngioma,colorectal cancer (e.g., colon cancer, rectal cancer, colorectaladenocarcinoma), epithelial carcinoma, ependymoma, endotheliosarcoma(e.g., Kaposi's sarcoma, multiple idiopathic hemorrhagic sarcoma),endometrial cancer (e.g., uterine cancer, uterine sarcoma), esophagealcancer (e.g., adenocarcinoma of the esophagus, Barrett's adenocarinoma),Ewing sarcoma, eye cancer (e.g., intraocular melanoma, retinoblastoma),familiar hypereosinophilia, gall bladder cancer, gastric cancer (e.g.,stomach adenocarcinoma), gastrointestinal stromal tumor (GIST), head andneck cancer (e.g., head and neck squamous cell carcinoma, oral cancer(e.g., oral squamous cell carcinoma (OSCC), throat cancer (e.g.,laryngeal cancer, pharyngeal cancer, nasopharyngeal cancer,oropharyngeal cancer)), hematopoietic cancers (e.g., leukemia such asacute lymphocytic leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acutemyelocytic leukemia (AML) (e.g., B-cell AML, T-cell AML), chronicmyelocytic leukemia (CML) (e.g., B-cell CML, T-cell CML), and chroniclymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL); lymphoma suchas Hodgkin lymphoma (HL) (e.g., B-cell HL, T-cell HL) and non-Hodgkinlymphoma (NHL) (e.g., B-cell NHL such as diffuse large cell lymphoma(DLCL) (e.g., diffuse large B-cell lymphoma (DLBCL)), follicularlymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma(CLL/SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphomas(e.g., mucosa-associated lymphoid tissue (MALT) lymphomas, nodalmarginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma),primary mediastinal B-cell lymphoma, Burkitt lymphoma, lymphoplasmacyticlymphoma (i.e., “Waldenström's macroglobulinemia”), hairy cell leukemia(HCL), immunoblastic large cell lymphoma, precursor B-lymphoblasticlymphoma and primary central nervous system (CNS) lymphoma; and T-cellNHL such as precursor T-lymphoblastic lymphoma/leukemia, peripheralT-cell lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g.,mycosis fungiodes, Sezary syndrome), angioimmunoblastic T-cell lymphoma,extranodal natural killer T-cell lymphoma, enteropathy type T-celllymphoma, subcutaneous panniculitis-like T-cell lymphoma, anaplasticlarge cell lymphoma); a mixture of one or more leukemia/lymphoma asdescribed above; and multiple myeloma (MM)), heavy chain disease (e.g.,alpha chain disease, gamma chain disease, mu chain disease),hemangioblastoma, inflammatory myofibroblastic tumors, immunocyticamyloidosis, kidney cancer (e.g., nephroblastoma a.k.a. Wilms' tumor,renal cell carcinoma), liver cancer (e.g., hepatocellular cancer (HCC),malignant hepatoma), lung cancer (e.g., bronchogenic carcinoma, smallcell lung cancer (SCLC), non-small cell lung cancer (NSCLC),adenocarcinoma of the lung), leiomyosarcoma (LMS), mastocytosis (e.g.,systemic mastocytosis), myelodysplastic syndrome (MDS), mesothelioma,myeloproliferative disorder (MPD) (e.g., polycythemia Vera (PV),essential thrombocytosis (ET), agnogenic myeloid metaplasia (AMM) a.k.a.myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myelocyticleukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilicsyndrome (HES)), neuroblastoma, neurofibroma (e.g., neurofibromatosis(NF) type 1 or type 2, schwannomatosis), neuroendocrine cancer (e.g.,gastroenteropancreatic neuroendoctrine tumor (GEP-NET), carcinoidtumor), osteosarcoma, ovarian cancer (e.g., cystadenocarcinoma, ovarianembryonal carcinoma, ovarian adenocarcinoma), papillary adenocarcinoma,pancreatic cancer (e.g., pancreatic andenocarcinoma, intraductalpapillary mucinous neoplasm (IPMN), Islet cell tumors), penile cancer(e.g., Paget's disease of the penis and scrotum), pinealoma, primitiveneuroectodermal tumor (PNT), prostate cancer (e.g., prostateadenocarcinoma), rectal cancer, rhabdomyosarcoma, salivary gland cancer,skin cancer (e.g., squamous cell carcinoma (SCC), keratoacanthoma (KA),melanoma, basal cell carcinoma (BCC)), small bowel cancer (e.g.,appendix cancer), soft tissue sarcoma (e.g., malignant fibroushistiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor(MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma), sebaceous glandcarcinoma, sweat gland carcinoma, synovioma, testicular cancer (e.g.,seminoma, testicular embryonal carcinoma), thyroid cancer (e.g.,papillary carcinoma of the thyroid, papillary thyroid carcinoma (PTC),medullary thyroid cancer), urethral cancer, vaginal cancer, and vulvarcancer (e.g., Paget's disease of the vulva).

In certain embodiments, the cancer is a solid cancer. In certainembodiments, the cancer is a liquid cancer.

In certain embodiments, the cancer is breast cancer, prostate cancer,colorectal cancer, or a hematopoietic cancer (e.g., multiple myeloma).

CARM1 is also the most abundant PRMT expressed in skeletal muscle cells,and has been found to selectively control the pathways modulatingglycogen metabolism, and associated AMPK (AMP-activated protein kinase)and p38 MAPK (mitogen-activated protein kinase) expression. See, e.g.,Wang et al., Biochem (2012) 444:323-331. Thus, in some embodiments,inhibitors of CARM1, as described herein, are useful in treatingmetabolic disorders, e.g., for example skeletal muscle metabolicdisorders, e.g., glycogen and glucose metabolic disorders. Exemplaryskeletal muscle metabolic disorders include, but are not limited to,Acid Maltase Deficiency (Glycogenosis type 2; Pompe disease), Debrancherdeficiency (Glycogenosis type 3), Phosphorylase deficiency (McArdle's;GSD 5), X-linked syndrome (GSD9D), Autosomal recessive syndrome (GSD9B),Tarui's disease (Glycogen storage disease VII; GSD 7), PhosphoglycerateMutase deficiency (Glycogen storage disease X; GSDX; GSD 10), Lactatedehydrogenase A deficiency (GSD 11), Branching enzyme deficiency (GSD4), Aldolase A (muscle) deficiency, β-Enolase deficiency,Triosephosphate isomerase (TIM) deficiency, Lafora's disease(Progressive myoclonic epilepsy 2), Glycogen storage disease (Muscle,Type 0, Phosphoglucomutase 1 Deficiency (GSD 14)), and GlycogeninDeficiency (GSD 15).

Other Aspects of the Invention

Aspect 1 provides a compound of Formula (I):

or a pharmaceutically acceptable salt thereof;wherein:

X is —O—, —S—, or —CH₂—;

R¹ is hydrogen or optionally substituted C₁₋₄ aliphatic;

R^(1a) is hydrogen or optionally substituted C₁₋₄ aliphatic;

each of R^(2a), R^(2b), R^(2c), and R^(2d) is independently hydrogen,halogen, —CN, —NO₂, —C(═O)R^(A2), —C(═O)OR^(A2), —C(═O)N(R^(A2))₂,—OR^(A2), —SR^(A2), —N(R^(A2))₂, —S(═O)R^(A2), —S(═O)₂R^(A2), optionallysubstituted alkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted carbocyclyl, optionallysubstituted heterocyclyl, wherein each instance of R^(A2) isindependently hydrogen, optionally substituted alkyl, optionallysubstituted alkenyl, optionally substituted alkynyl, optionallysubstituted carbocyclyl, optionally substituted heterocyclyl, optionallysubstituted aryl, or optionally substituted heteroaryl, or two R^(A2)groups attached to the same nitrogen atom are joined to form anoptionally substituted heterocyclyl or optionally substituted heteroarylring; Ring HET is a 6-membered monocylic heteroaryl ring system of theFormula:

wherein:

G₈ is C—R⁸ or N;

G₁₀ is C—R¹⁰ or N;

G₁₁ is C—R¹¹ or N;

G₁₂ is C—R¹² or N;

provided at least one instance of G₈, G₁₀, G₁₁, or G₁₂ is N;

each instance of R⁸, R¹⁰, R¹¹, and R¹² is independently selected fromthe group consisting of hydrogen, halo, —CN, —NO₂, —C(═O)R′, —C(═O)OR′,—C(═O)N(R′)₂, optionally substituted alkyl, and -L¹-R³;

each instance of R′ is independently hydrogen, optionally substitutedalkyl, optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted carbocyclyl, optionally substituted heterocyclyl,optionally substituted aryl, or optionally substituted heteroaryl, ortwo R′ groups attached to the same nitrogen are joined to form anoptionally substituted heterocyclyl ring or optionally substitutedheteroaryl ring;

each instance of L¹ and L² is independently a bond, —O—, —N(R^(L)), —S—,—C(O)—, —C(O)O—, —C(O)S—, —C(O)N(R^(L))—, —C(O)N(R^(L))N(R^(L))—,—OC(O)—, —OC(O)N(R^(L))—, —NR^(L)C(O)—, —NR^(L)C(O)N(R^(L))—,—NR^(L)C(O)N(R^(L))N(R^(L))—, —NR^(L)C(O)O—, —SC(O)—, —C(═NR^(L))—,—C(═NNR^(L))—, —C(═NOR^(L))—, —C(═NR^(L))N(R^(L))—, —NR^(L)C(═NR^(L))—,—C(S)—, —C(S)N(R^(L))—, —NR^(L)C(S)—, —S(O)—, —OS(O)₂—, —S(O)₂O—, —SO₂—,—N(R^(L))SO₂—, —SO₂N(R^(L))—, —N(R^(L))SO₂N(R^(L))—, an optionallysubstituted C₁₋₁₀ saturated or unsaturated hydrocarbon chain, whereinone or more moieties selected from the group consisting of —O—,—N(R^(L))—, —S—, —C(O)—, —C(O)O—, —C(O)S—, —C(O)N(R^(L))—,—C(O)N(R^(L))N(R^(L))—, —OC(O)—, —OC(O)N(R^(L))—, —NR^(L)C(O)—,—NR^(L)C(O)N(R^(L))—, —NR^(L)C(O)N(R^(L))N(R^(L))—, —NR^(L)C(O)—,—SC(O)—, —C(═NR^(L))—, —C(═NNR^(L))—, —C(═NOR^(L))—,—C(═NR^(L))N(R^(L))—, —NR^(L)C(═NR^(L))—, —C(S)—, —C(S)N(R^(L))—,—NR^(L)C(S)—, —S(O)—, —OS(O)₂—, —S(O)₂O—, —SO₂—, —N(R^(L))SO₂—,—SO₂N(R^(L))—, and —N(R^(L))SO₂N(R^(L))— is optionally and independentlypresent between two carbon atoms of the hydrocarbon chain, andoptionally and independently present at one or both ends of thehydrocarbon chain;

each R^(L) is independently hydrogen, optionally substituted alkyl, or anitrogen protecting group, or R^(L) and R³ taken together form anoptionally substituted heterocyclyl or optionally substituted heteroarylring, or R^(L) and R¹³ taken together form an optionally substitutedheterocyclyl or optionally substituted heteroaryl ring;

R³ is hydrogen, optionally substituted alkyl, optionally substitutedalkenyl, optionally substituted alkynyl, optionally substitutedcarbocyclyl, optionally substituted heterocyclyl, optionally substitutedaryl, or optionally substituted heteroaryl, provided when R³ ishydrogen, then L¹ is not a bond; and

R¹³ is optionally substituted carbocyclyl, optionally substitutedheterocyclyl, optionally substituted aryl, or optionally substitutedheteroaryl,

Aspect 2 provides a compound of Formula (I-1-Aa2) or (I-1-Aa2′):

or a pharmaceutically acceptable salt thereof;wherein:

R¹ is hydrogen or optionally substituted C₁₋₄ aliphatic;

R^(1a) is hydrogen or optionally substituted C₁₋₄ aliphatic;

each of R^(2a), R^(2b), R^(2c), and R^(2d) is independently hydrogen,halogen, —CN, —NO₂, —C(═O)R^(A2), —C(═O)OR^(A2), —C(═O)N(R^(A2))₂,—OR^(A2), —SR^(A2), —N(R^(A2))₂, —S(═O)R^(A2), —S(═O)₂R^(A2), optionallysubstituted alkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted carbocyclyl, optionallysubstituted heterocyclyl, wherein each instance of R^(A2) isindependently hydrogen, optionally substituted alkyl, optionallysubstituted alkenyl, optionally substituted alkynyl, optionallysubstituted carbocyclyl, optionally substituted heterocyclyl, optionallysubstituted aryl, or optionally substituted heteroaryl, or two R^(A2)groups attached to the same nitrogen atom are joined to form anoptionally substituted heterocyclyl or optionally substituted heteroarylring;

R¹⁰ is independently selected from the group consisting of hydrogen,halo, —CN, —NO₂, —C(═O)R′, —C(═O)OR′, —C(═O)N(R′)₂, optionallysubstituted alkyl, and -L¹-R³;

each instance of R′ is independently hydrogen, optionally substitutedalkyl, optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted carbocyclyl, optionally substituted heterocyclyl,optionally substituted aryl, or optionally substituted heteroaryl, ortwo R′ groups attached to the same nitrogen are joined to form anoptionally substituted heterocyclyl ring or optionally substitutedheteroaryl ring;

each R^(L) is independently hydrogen, optionally substituted alkyl, or anitrogen protecting group, or R^(L) and R³ taken together form anoptionally substituted heterocyclyl or optionally substituted heteroarylring, or R^(L) and R¹³ taken together form an optionally substitutedheterocyclyl or optionally substituted heteroaryl ring;

R¹³ is optionally substituted carbocyclyl, optionally substitutedheterocyclyl, optionally substituted aryl, or optionally substitutedheteroaryl;

R^(3A) is independently hydroxyl, substituted hydroxyl, thiol,substituted thiol, amino, substituted amino, carbonyl, sulfonyl,sulfinyl, —CN, —NO₂, halogen, optionally substituted alkyl, or twoR^(3A) groups are joined to form an optionally substituted carbocyclic,optionally substituted heterocyclic, optionally substituted aryl, oroptionally substituted heteroaryl ring, or R^(3A) and R^(3B) groups arejoined to form an optionally substituted carbocyclic, optionallysubstituted heterocyclic, optionally substituted aryl, or optionallysubstituted heteroaryl ring;

R^(3B) is hydrogen, optionally substituted alkyl, or a nitrogenprotecting group;

R^(13A) each instance of R^(13A) is independently hydroxyl, substitutedhydroxyl, thiol, substituted thiol, amino, substituted amino, carbonyl,sulfonyl, sulfinyl, —CN, —NO₂, halogen, optionally substituted alkyl, ortwo R^(13A) groups are joined to form an optionally substitutedcarbocyclic, optionally substituted heterocyclic, optionally substitutedaryl, or optionally substituted heteroaryl ring, or R^(13A) and R^(13B)group are joined to form an optionally substituted carbocyclic,optionally substituted heterocyclic, optionally substituted aryl, oroptionally substituted heteroaryl ring;

R^(13B) is hydrogen, optionally substituted alkyl, or a nitrogenprotecting group;

Y is O, S, N, or NR^(13B);

W is CH, CR^(13A), N, or NR^(13B), as valency permits;

m is 0, 1, 2, or 3; and

n is 0, 1, 2, or 3.

Aspect 3 provides a compound of Formula (I-1-Aa3) or (I-1-Aa3′):

or a pharmaceutically acceptable salt thereof;wherein:

R¹ is hydrogen or optionally substituted C₁₋₄ aliphatic;

R^(1a) is hydrogen or optionally substituted C₁₋₄ aliphatic;

each of R^(2a), R^(2b), R^(2c), and R^(2d) is independently hydrogen,halogen, —CN, —NO₂, —C(═O)R^(A2), —C(═O)OR^(A2), —C(═O)N(R^(A2))₂,—OR^(A2), —SR^(A2), —N(R^(A2))₂, —S(═O)R^(A2), —S(═O)₂R^(A2), optionallysubstituted alkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted carbocyclyl, optionallysubstituted heterocyclyl, wherein each instance of R^(A2) isindependently hydrogen, optionally substituted alkyl, optionallysubstituted alkenyl, optionally substituted alkynyl, optionallysubstituted carbocyclyl, optionally substituted heterocyclyl, optionallysubstituted aryl, or optionally substituted heteroaryl, or two R^(A2)groups attached to the same nitrogen atom are joined to form anoptionally substituted heterocyclyl or optionally substituted heteroarylring;

R¹⁰ is independently selected from the group consisting of hydrogen,halo, —CN, —NO₂, —C(═O)R′, —C(═O)OR′, —C(═O)N(R′)₂, optionallysubstituted alkyl, and -L¹-R³;

each instance of R′ is independently hydrogen, optionally substitutedalkyl, optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted carbocyclyl, optionally substituted heterocyclyl,optionally substituted aryl, or optionally substituted heteroaryl, ortwo R′ groups attached to the same nitrogen are joined to form anoptionally substituted heterocyclyl ring or optionally substitutedheteroaryl ring;

each R^(L) is independently hydrogen, optionally substituted alkyl, or anitrogen protecting group, or R^(L) and R³ taken together form anoptionally substituted heterocyclyl or optionally substituted heteroarylring, or R^(L) and R¹³ taken together form an optionally substitutedheterocyclyl or optionally substituted heteroaryl ring;

R¹³ is optionally substituted carbocyclyl, optionally substitutedheterocyclyl, optionally substituted aryl, or optionally substitutedheteroaryl;

R^(3A) is independently hydroxyl, substituted hydroxyl, thiol,substituted thiol, amino, substituted amino, carbonyl, sulfonyl,sulfinyl, —CN, —NO₂, halogen, optionally substituted alkyl, or twoR^(3A) groups are joined to form an optionally substituted carbocyclic,optionally substituted heterocyclic, optionally substituted aryl, oroptionally substituted heteroaryl ring, or R^(3A) and R^(3B) groups arejoined to form an optionally substituted carbocyclic, optionallysubstituted heterocyclic, optionally substituted aryl, or optionallysubstituted heteroaryl ring;

R^(3B) is hydrogen, optionally substituted alkyl, or a nitrogenprotecting group;

R^(13A) each instance of R^(13A) is independently hydroxyl, substitutedhydroxyl, thiol, substituted thiol, amino, substituted amino, carbonyl,sulfonyl, sulfinyl, —CN, —NO₂, halogen, optionally substituted alkyl, ortwo R^(13A) groups are joined to form an optionally substitutedcarbocyclic, optionally substituted heterocyclic, optionally substitutedaryl, or optionally substituted heteroaryl ring, or R^(13A) and R^(13B)group are joined to form an optionally substituted carbocyclic,optionally substituted heterocyclic, optionally substituted aryl, oroptionally substituted heteroaryl ring;

R^(13B) is hydrogen, optionally substituted alkyl, or a nitrogenprotecting group;

Y is O, S, N, or NR^(13B);

W is CH, CR^(13A), N, or NR^(13B), as valency permits;

m is 0, 1, 2, or 3; and

n is 0, 1, 2, or 3.

Aspect 4 provides a compound of Formula (I-1-Aa4) or (I-1-Aa4′):

or a pharmaceutically acceptable salt thereof;wherein:

R¹ is hydrogen or optionally substituted C₁₋₄ aliphatic;

R^(1a) is hydrogen or optionally substituted C₁₋₄ aliphatic;

each of R^(2a), R^(2b), R^(2c), and R^(2d) is independently hydrogen,halogen, —CN, —NO₂, —C(═O)R^(A2), —C(═O)OR^(A2), —C(═O)N(R^(A2))₂,—OR^(A2), —SR^(A2), —N(R^(A2))₂, —S(═O)R^(A2), —S(═O)₂R^(A2), optionallysubstituted alkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted carbocyclyl, optionallysubstituted heterocyclyl, wherein each instance of R^(A2) isindependently hydrogen, optionally substituted alkyl, optionallysubstituted alkenyl, optionally substituted alkynyl, optionallysubstituted carbocyclyl, optionally substituted heterocyclyl, optionallysubstituted aryl, or optionally substituted heteroaryl, or two R^(A2)groups attached to the same nitrogen atom are joined to form anoptionally substituted heterocyclyl or optionally substituted heteroarylring;

R¹⁰ is independently selected from the group consisting of hydrogen,halo, —CN, —NO₂, —C(═O)R′, —C(═O)OR′, —C(═O)N(R′)₂, optionallysubstituted alkyl, and -L¹-R³;

each instance of R′ is independently hydrogen, optionally substitutedalkyl, optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted carbocyclyl, optionally substituted heterocyclyl,optionally substituted aryl, or optionally substituted heteroaryl, ortwo R′ groups attached to the same nitrogen are joined to form anoptionally substituted heterocyclyl ring or optionally substitutedheteroaryl ring;

each R^(L) is independently hydrogen, optionally substituted alkyl, or anitrogen protecting group, or R^(L) and R³ taken together form anoptionally substituted heterocyclyl or optionally substituted heteroarylring, or R^(L) and R¹³ taken together form an optionally substitutedheterocyclyl or optionally substituted heteroaryl ring;

R¹³ is optionally substituted carbocyclyl, optionally substitutedheterocyclyl, optionally substituted aryl, or optionally substitutedheteroaryl;

R^(3A) is independently hydroxyl, substituted hydroxyl, thiol,substituted thiol, amino, substituted amino, carbonyl, sulfonyl,sulfinyl, —CN, —NO₂, halogen, optionally substituted alkyl, or twoR^(3A) groups are joined to form an optionally substituted carbocyclic,optionally substituted heterocyclic, optionally substituted aryl, oroptionally substituted heteroaryl ring, or R^(3A) and R^(3B) groups arejoined to form an optionally substituted carbocyclic, optionallysubstituted heterocyclic, optionally substituted aryl, or optionallysubstituted heteroaryl ring;

R^(3B) is hydrogen, optionally substituted alkyl, or a nitrogenprotecting group;

R^(13A) each instance of R^(13A) is independently hydroxyl, substitutedhydroxyl, thiol, substituted thiol, amino, substituted amino, carbonyl,sulfonyl, sulfinyl, —CN, —NO₂, halogen, optionally substituted alkyl, ortwo R^(13A) groups are joined to form an optionally substitutedcarbocyclic, optionally substituted heterocyclic, optionally substitutedaryl, or optionally substituted heteroaryl ring, or R^(13A) and R^(13B)group are joined to form an optionally substituted carbocyclic,optionally substituted heterocyclic, optionally substituted aryl, oroptionally substituted heteroaryl ring;

R^(13B) is hydrogen, optionally substituted alkyl, or a nitrogenprotecting group;

Y is O, S, N, or NR^(13B);

W is CH, CR^(13A), N, or NR^(13B), as valency permits;

m is 0, 1, 2, or 3; and

n is 0, 1, 2, or 3.

Aspect 5 provides a compound of Formula (I-1-Aa5) or (I-1-Aa5′):

or a pharmaceutically acceptable salt thereof;wherein:

R¹ is hydrogen or optionally substituted C₁₋₄ aliphatic;

R^(1a) is hydrogen or optionally substituted C₁₋₄ aliphatic;

each of R^(2a), R^(2b), R^(2c), and R^(2d) is independently hydrogen,halogen, —CN, —NO₂, —C(═O)R^(A2), —C(═O)OR^(A2), —C(═O)N(R^(A2))₂,—OR^(A2), —SR^(A2), —N(R^(A2))₂, —S(═O)R^(A2), —S(═O)₂R^(A2), optionallysubstituted alkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted carbocyclyl, optionallysubstituted heterocyclyl, wherein each instance of R^(A2) isindependently hydrogen, optionally substituted alkyl, optionallysubstituted alkenyl, optionally substituted alkynyl, optionallysubstituted carbocyclyl, optionally substituted heterocyclyl, optionallysubstituted aryl, or optionally substituted heteroaryl, or two R^(A2)groups attached to the same nitrogen atom are joined to form anoptionally substituted heterocyclyl or optionally substituted heteroarylring;

R¹⁰ is independently selected from the group consisting of hydrogen,halo, —CN, —NO₂, —C(═O)R′, —C(═O)OR′, —C(═O)N(R′)₂, optionallysubstituted alkyl, and -L¹-R³;

each instance of R′ is independently hydrogen, optionally substitutedalkyl, optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted carbocyclyl, optionally substituted heterocyclyl,optionally substituted aryl, or optionally substituted heteroaryl, ortwo R′ groups attached to the same nitrogen are joined to form anoptionally substituted heterocyclyl ring or optionally substitutedheteroaryl ring;

each R^(L) is independently hydrogen, optionally substituted alkyl, or anitrogen protecting group, or R^(L) and R³ taken together form anoptionally substituted heterocyclyl or optionally substituted heteroarylring, or R^(L) and R¹³ taken together form an optionally substitutedheterocyclyl or optionally substituted heteroaryl ring;

R¹³ is optionally substituted carbocyclyl, optionally substitutedheterocyclyl, optionally substituted aryl, or optionally substitutedheteroaryl;

R^(3A) is independently hydroxyl, substituted hydroxyl, thiol,substituted thiol, amino, substituted amino, carbonyl, sulfonyl,sulfinyl, —CN, —NO₂, halogen, optionally substituted alkyl, or twoR^(3A) groups are joined to form an optionally substituted carbocyclic,optionally substituted heterocyclic, optionally substituted aryl, oroptionally substituted heteroaryl ring, or R^(3A) and R^(3B) groups arejoined to form an optionally substituted carbocyclic, optionallysubstituted heterocyclic, optionally substituted aryl, or optionallysubstituted heteroaryl ring;

R^(3B) is hydrogen, optionally substituted alkyl, or a nitrogenprotecting group;

R^(13A) each instance of R^(13A) is independently hydroxyl, substitutedhydroxyl, thiol, substituted thiol, amino, substituted amino, carbonyl,sulfonyl, sulfinyl, —CN, —NO₂, halogen, optionally substituted alkyl, ortwo R^(13A) groups are joined to form an optionally substitutedcarbocyclic, optionally substituted heterocyclic, optionally substitutedaryl, or optionally substituted heteroaryl ring, or R^(13A) and R^(13B)group are joined to form an optionally substituted carbocyclic,optionally substituted heterocyclic, optionally substituted aryl, oroptionally substituted heteroaryl ring;

R^(13B) is hydrogen, optionally substituted alkyl, or a nitrogenprotecting group;

Y is O, S, N, or NR^(13B);

W is CH, CR^(13A), N, or NR^(13B), as valency permits;

m is 0, 1, 2, or 3; and

n is 0, 1, 2, or 3.

Aspect 6 provides a compound of Formula (I-1-Aa6) or (I-1-Aa6′):

or a pharmaceutically acceptable salt thereof;wherein:

R¹ is hydrogen or optionally substituted C₁₋₄ aliphatic;

R^(1a) is hydrogen or optionally substituted C₁₋₄ aliphatic;

each of R^(2a), R^(2b), R^(2c), and R^(2d) is independently hydrogen,halogen, —CN, —NO₂, —C(═O)R^(A2), —C(═O)OR^(A2), —C(═O)N(R^(A2))₂,—OR^(A2), —SR^(A2), —N(R^(A2))₂, —S(═O)R^(A2), —S(═O)₂R^(A2), optionallysubstituted alkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted carbocyclyl, optionallysubstituted heterocyclyl, wherein each instance of R^(A2) isindependently hydrogen, optionally substituted alkyl, optionallysubstituted alkenyl, optionally substituted alkynyl, optionallysubstituted carbocyclyl, optionally substituted heterocyclyl, optionallysubstituted aryl, or optionally substituted heteroaryl, or two R^(A2)groups attached to the same nitrogen atom are joined to form anoptionally substituted heterocyclyl or optionally substituted heteroarylring;

R¹⁰ is independently selected from the group consisting of hydrogen,halo, —CN, —NO₂, —C(═O)R′, —C(═O)OR′, —C(═O)N(R′)₂, optionallysubstituted alkyl, and -L¹-R³;

each instance of R′ is independently hydrogen, optionally substitutedalkyl, optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted carbocyclyl, optionally substituted heterocyclyl,optionally substituted aryl, or optionally substituted heteroaryl, ortwo R′ groups attached to the same nitrogen are joined to form anoptionally substituted heterocyclyl ring or optionally substitutedheteroaryl ring;

each R^(L) is independently hydrogen, optionally substituted alkyl, or anitrogen protecting group, or R^(L) and R³ taken together form anoptionally substituted heterocyclyl or optionally substituted heteroarylring, or R^(L) and R¹³ taken together form an optionally substitutedheterocyclyl or optionally substituted heteroaryl ring;

R¹³ is optionally substituted carbocyclyl, optionally substitutedheterocyclyl, optionally substituted aryl, or optionally substitutedheteroaryl;

R^(3A) is independently hydroxyl, substituted hydroxyl, thiol,substituted thiol, amino, substituted amino, carbonyl, sulfonyl,sulfinyl, —CN, —NO₂, halogen, optionally substituted alkyl, or twoR^(3A) groups are joined to form an optionally substituted carbocyclic,optionally substituted heterocyclic, optionally substituted aryl, oroptionally substituted heteroaryl ring, or R^(3A) and R^(3B) groups arejoined to form an optionally substituted carbocyclic, optionallysubstituted heterocyclic, optionally substituted aryl, or optionallysubstituted heteroaryl ring;

R^(3B) is hydrogen, optionally substituted alkyl, or a nitrogenprotecting group;

R^(13A) each instance of R^(13A) is independently hydroxyl, substitutedhydroxyl, thiol, substituted thiol, amino, substituted amino, carbonyl,sulfonyl, sulfinyl, —CN, —NO₂, halogen, optionally substituted alkyl, ortwo R^(13A) groups are joined to form an optionally substitutedcarbocyclic, optionally substituted heterocyclic, optionally substitutedaryl, or optionally substituted heteroaryl ring, or R^(13A) and R^(13B)group are joined to form an optionally substituted carbocyclic,optionally substituted heterocyclic, optionally substituted aryl, oroptionally substituted heteroaryl ring;

R^(13B) is hydrogen, optionally substituted alkyl, or a nitrogenprotecting group;

Y is O, S, N, or NR^(13B);

W is CH, CR^(13A), N, or NR^(13B), as valency permits;

m is 0, 1, 2, or 3; and

n is 0, 1, 2, or 3.

Aspect 7 provides a compound of Formula (I-1-Aa7) or (I-1-Aa7′):

or a pharmaceutically acceptable salt thereof;wherein:

R¹ is hydrogen or optionally substituted C₁₋₄ aliphatic;

R^(1a) is hydrogen or optionally substituted C₁₋₄ aliphatic;

each of R^(2a), R^(2b), R^(2c), and R^(2d) is independently hydrogen,halogen, —CN, —NO₂, —C(═O)R^(A2), —C(═O)OR^(A2), —C(═O)N(R^(A2))₂,—OR^(A2), —SR^(A2), —N(R^(A2))₂, —S(═O)R^(A2), —S(═O)₂R^(A2), optionallysubstituted alkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted carbocyclyl, optionallysubstituted heterocyclyl, wherein each instance of R^(A2) isindependently hydrogen, optionally substituted alkyl, optionallysubstituted alkenyl, optionally substituted alkynyl, optionallysubstituted carbocyclyl, optionally substituted heterocyclyl, optionallysubstituted aryl, or optionally substituted heteroaryl, or two R^(A2)groups attached to the same nitrogen atom are joined to form anoptionally substituted heterocyclyl or optionally substituted heteroarylring;

R¹⁰ is independently selected from the group consisting of hydrogen,halo, —CN, —NO₂, —C(═O)R′, —C(═O)OR′, —C(═O)N(R′)₂, optionallysubstituted alkyl, and -L¹-R³;

each instance of R′ is independently hydrogen, optionally substitutedalkyl, optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted carbocyclyl, optionally substituted heterocyclyl,optionally substituted aryl, or optionally substituted heteroaryl, ortwo R′ groups attached to the same nitrogen are joined to form anoptionally substituted heterocyclyl ring or optionally substitutedheteroaryl ring;

each R^(L) is independently hydrogen, optionally substituted alkyl, or anitrogen protecting group, or R^(L) and R³ taken together form anoptionally substituted heterocyclyl or optionally substituted heteroarylring, or R^(L) and R¹³ taken together form an optionally substitutedheterocyclyl or optionally substituted heteroaryl ring;

R¹³ is optionally substituted carbocyclyl, optionally substitutedheterocyclyl, optionally substituted aryl, or optionally substitutedheteroaryl;

R^(3A) is independently hydroxyl, substituted hydroxyl, thiol,substituted thiol, amino, substituted amino, carbonyl, sulfonyl,sulfinyl, —CN, —NO₂, halogen, optionally substituted alkyl, or twoR^(3A) groups are joined to form an optionally substituted carbocyclic,optionally substituted heterocyclic, optionally substituted aryl, oroptionally substituted heteroaryl ring, or R^(3A) and R^(3B) groups arejoined to form an optionally substituted carbocyclic, optionallysubstituted heterocyclic, optionally substituted aryl, or optionallysubstituted heteroaryl ring;

R^(3B) is hydrogen, optionally substituted alkyl, or a nitrogenprotecting group;

R^(13A) each instance of R^(13A) is independently hydroxyl, substitutedhydroxyl, thiol, substituted thiol, amino, substituted amino, carbonyl,sulfonyl, sulfinyl, —CN, —NO₂, halogen, optionally substituted alkyl, ortwo R^(13A) groups are joined to form an optionally substitutedcarbocyclic, optionally substituted heterocyclic, optionally substitutedaryl, or optionally substituted heteroaryl ring, or R^(13A) and R^(13B)group are joined to form an optionally substituted carbocyclic,optionally substituted heterocyclic, optionally substituted aryl, oroptionally substituted heteroaryl ring;

R^(13B) is hydrogen, optionally substituted alkyl, or a nitrogenprotecting group;

Y is O, S, N, or NR^(13B);

W is CH, CR^(13A), N, or NR^(13B), as valency permits;

m is 0, 1, 2, or 3; and

n is 0, 1, 2, or 3.

Aspect 8 provides a compound of Aspect 1, wherein the compound ofFormula (I) is of Formula (I-a):

or a pharmaceutically acceptable salt thereof.

Aspect 9 provides a compound of Aspect 1, wherein the compound ofFormula (I) is of Formula (I-b):

or a pharmaceutically acceptable salt thereof.

Aspect 10 provides a compound of any of Aspects 1, 8, and 9, wherein Xis —O—.

Aspect 11 provides a compound of any of Aspects 1, 8, and 9, wherein Xis —S—.

Aspect 12 provides a compound of any of Aspects 1, 8, and 9, wherein Xis —CH₂-Aspect 13 provides a compound of any of Aspects 1, and 8-12,wherein Ring HET is:

Aspect 14 provides a compound of any of Aspects 1, and 8-12, whereinRing HET is:

Aspect 15 provides a compound of any of Aspects 1, and 8-12, whereinRing HET is:

Aspect 16 provides a compound of any of Aspects 1, and 8-12, whereinRing HET is:

Aspect 17 provides a compound of any of Aspects 1, and 8-12, whereinRing HET is:

Aspect 18 provides a compound of any of Aspects 1, and 8-12, whereinRing HET is:

Aspect 19 provides a compound of any of Aspects 1, and 8-12, whereinRing HET is:

Aspect 20 provides a compound of any of Aspects 1, and 8-12, whereinRing HET is:

Aspect 21 provides a compound of Aspects 1, and 8-12, wherein Ring HETis selected from the group consisting of:

Aspect 22 provides a compound of any of Aspects 1-21 wherein, R¹ ishydrogen, methyl, ethyl, n-propyl, isopropyl, or cyclopropyl.

Aspect 23 provides a compound of any of Aspects 1-22, wherein R^(2a),R^(2c), and R^(2d)are hydrogen.

Aspect 24 provides a provides a compound of any of Aspects 1-23, whereinR^(2b) is halogen or —OR^(A2).

Aspect 25 provides a provides a compound of any of Aspects 1, 8-20, and22-24, wherein L² is a bond, —N(R^(L))—, —NR^(L)C(O)O—,—NR^(L)C(O)N(R^(L))—, —N(R^(L))—, —N(R^(L))SO₂N(R^(L))—,—NR^(L)—(CH₂)_(x)—C(O)O—, —NR^(L)—(CH₂)_(x)—O—, —NR^(L)C(O)N(R^(L))—,—NR^(L)—(CH₂)_(x)—, —(CH₂)_(x)—NR^(L)—, —NR^(L)C(O)O(CH₂)_(x)—,—NR^(L)C(O)NR^(L)(CH₂)_(x)—, or —NR^(L)(CH₂)_(x)NR^(L)C(O)—.

Aspect 26 provides a compound of any of Aspects 1, 8-20, and 22-24,wherein Ring HET comprises a group -L¹-R³ is attached thereto.

Aspect 27 provides a compound of any of Aspects 1, 8-20, and 22-24,wherein L¹ is a bond, —N(R^(L))—, —NR^(L)C(O)O—, —NR^(L)C(O)N(R^(L))—,—N(R^(L))—, —N(R^(L))SO₂N(R^(L))—, —NR^(L)—(CH₂)_(x)—C(O)O—,—NR^(L)—(CH₂)_(x)—O—, —NR^(L)C(O)N(R^(L))—, —NR^(L)—(CH₂)_(x)—,—(CH₂)_(x)—NR^(L)—, —NR^(L)C(O)O(CH₂)_(x)—, —NR^(L)C(O)NR^(L)(CH₂)_(x)—,or —NR^(L)(CH₂)_(x)NR^(L)C(O)—.

Aspect 28 provides a compound of any of Aspects 1-27, wherein R^(1a) ishydrogen, methyl, ethyl, n-propyl, isopropyl, or cyclopropyl.

Aspect 29 provides a compound of any of Aspects 1, 8-20, and 22-28,wherein an R¹³ group is present and is selected from the groupconsisting of:

wherein:

each instance of

independently represents a single or double bond;

x is 0 or 1;

m is 0, 1, 2, or 3;

Y is O, S, N, or NR^(13B) and each instance of Q and W is independentlyCH, CR^(13A), N, or NR^(13B), as valency permits;

each instance of R^(13A) is independently hydroxyl, substitutedhydroxyl, thiol, substituted thiol, amino, substituted amino, carbonyl,sulfonyl, sulfinyl, —CN, —NO₂, halogen, optionally substituted alkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted carbocyclic, optionally substituted heterocyclic,optionally substituted aryl, or optionally substituted heteroaryl, ortwo R^(13A) groups are joined to form an optionally substitutedcarbocyclic, optionally substituted heterocyclic, optionally substitutedaryl, optionally substituted heteroaryl, or oxo (═O) group, or R^(13A)and R^(13B) groups are joined to form an optionally substitutedcarbocyclic, optionally substituted heterocyclic, optionally substitutedaryl, or optionally substituted heteroaryl ring; and

R^(13B) is hydrogen, optionally substituted alkyl, hydroxyl, substitutedhydroxyl, amino, substituted amino, carbonyl, sulfonyl, optionallysubstituted carbocyclic, optionally substituted heterocyclic, optionallysubstituted aryl, optionally substituted heteroaryl, or a nitrogenprotecting group.

Aspect 30 provides a compound of any of Aspects 1, 8-20, and 22-28,wherein an R³ group is present and is selected from the group consistingof:

wherein:

each instance

independently represents a single or double bond;

n is 0, 1, 2, or 3;

x is 0 or 1;

Y is O, S, N, or NR^(3B) and each instance of Q and W is independentlyCH, CR^(3A), N, or NR^(13B), as valency permits;

each instance of R^(3A) is independently hydroxyl, substituted hydroxyl,thiol, substituted thiol, amino, substituted amino, carbonyl, sulfonyl,sulfinyl, —CN, —NO₂, halogen, optionally substituted alkyl, optionallysubstituted alkenyl, optionally substituted alkynyl, optionallysubstituted carbocyclic, optionally substituted heterocyclic, optionallysubstituted aryl, or optionally substituted heteroaryl, or two R^(3A)groups are joined to form an optionally substituted carbocyclic,optionally substituted heterocyclic, optionally substituted aryl,optionally substituted heteroaryl, or oxo (═O) group, or R^(3A) andR^(3B) groups are joined to form an optionally substituted carbocyclic,optionally substituted heterocyclic, optionally substituted aryl, oroptionally substituted heteroaryl ring; and

R^(3B) is hydrogen, optionally substituted alkyl, hydroxyl, substitutedhydroxyl, amino, substituted amino, carbonyl, sulfonyl, optionallysubstituted carbocyclic, optionally substituted heterocyclic, optionallysubstituted aryl, optionally substituted heteroaryl, or a nitrogenprotecting group.

Aspect 31 provides a compound selected from the group consisting ofcompounds depicted in Tables 1A, 1B, 1C, and 2, or a pharmaceuticallyacceptable salt thereof.

Aspect 32 provides a compound selected from the following list: 77-1a,304-1a, 102-1a, 187-1a, 226-1a, 257-1a, 277-1a, 278-1a, 304-1a, 305-1a,2-3, 4-3, 23-3, 17-3, 22-3, 24-3, 25-3, 26-3, 27-3, 28-3, 32-3, 33-3,35-3, 36-3, 37-3, 40-3, 42-3, 55-3, 56-3, 58-3, 59-3, 60-3, 61-3, 62-3,63-3, 64-3, 65-3, 66-3, 69-3, 84-3, 85-3, 86-3, 87-3, 88-3, 89-3, 90-3,91-3, 92-3, 93-3, 101-3, 102-3, 103-3, 104-3, 105-3, 107-3, 108-3,109-3, 113-3, 114-3, 115-3, 125-3, 134-3, 135-3, 153-3, 154-3, 158-3,159-3, 161-3, 165-3, 204-3, 278-3, 282-3, and 285-3.

Aspect 33 provides a pharmaceutical composition comprising a compound ofany one of Aspects 1-32 or a pharmaceutically acceptable salt thereof,and a pharmaceutically acceptable excipient.

Aspect 34 provides a kit or packaged pharmaceutical comprising acompound of any one of Aspects 1-32 or a pharmaceutically acceptablesalt thereof, and instructions for use thereof.

Aspect 35 provides a method of treating a CARM1-mediated disorder,comprising administering to a subject in need thereof an effectiveamount of a compound of any one of claims Aspects 1-32, or apharmaceutically acceptable salt thereof, or a pharmaceuticalcomposition of claim 33.

Aspect 36 provides the method of Aspect 35, wherein the disorder is aproliferative disorder.

Aspect 37 provides the method of Aspect 36, wherein the disorder iscancer.

Aspect 38 provides the method of Aspect 37, wherein the cancer isassociated with E2F1 upregulation.

Aspect 39 provides the method of Aspect 36 or 37, wherein the cancer isassociated with aberrant CARM1 activity.

Aspect 40 provides the method of any one of Aspects 37-39, wherein thecancer is breast cancer, prostate cancer, or colorectal cancer.

Aspect 41 provides the method of any one of Aspects 37-39, wherein thecancer is ERα-dependent breast cancer.

Aspect 42 provides the method of any one of Aspects 37-39, wherein thecancer is castration-resistant prostate cancer.

Aspect 43 provides the method of any one of Aspects 37-39, wherein thecancer is colorectal cancer associated with dysregulated WNT/β-cateninsignaling.

Aspect 44 provides the method of any one of Aspects 37-39, wherein thecancer is multiple myeloma.

Aspect 45 provides the method of Aspect 35, wherein the disorder is ametabolic disorder.

Compound Synthesis

Scheme 1 shows a general synthesis route to compounds of Formula I-(ii)wherein R^(3′) is the same as R³ as defined above or is a suitableprecursor that may be converted to R³. This method is based on Suzukicoupling reactions of heteroaryl chloride intermediates of generalFormula XI-(ii) with pinacol borane intermediates of general Formula X.In a first step, Suzuki coupling reaction of these intermediates istypically conducted in the presence of a palladium catalyst (e.g.PdCl₂(dppf)) and a base (e.g. potassium carbonate) in an organic solvent(e.g. toluene) at elevated temperature. In a second optional set ofsteps the R^(3′) group as well as other groups in the molecule may beconverted to the defined final substituents in Formula I-(ii). In afinal deprotection step the N-Boc protecting is removed by for exampleusing an acid (e.g. HCl) in a suitable organic solvent (e.g. ethanol) togive certain corresponding embodiments of compounds of Formula I-(ii).

Compounds of general Formula XI-(ii) can be prepared from heteroaryldichlorides of general Formula XX-(ii) as depicted in Scheme 2. Incertain embodiments when L is —N(R^(L))—, —C(O)N(R^(L))—, or—OC(O)N(R^(L))—, —NR^(L)C(O)N(R^(L))—, Buchwald coupling of XX-(ii)respectively with active amines R^(3′)N(R^(L))H, amidesR^(3′)C(O)N(R^(L))H, carbamates —OC(O)N(R^(L))H, or ureas—NR^(L)C(O)N(R^(L))H, may be implemented in the first step.

In certain embodiments when L¹ is a bond, and the monocyclic heterocyclecore structure is directly attached to R^(3′) by a carbon-carbon bond,Suzuki coupling of XXI-(i) with boronic acids or ester intermediatesR^(3′)B(OH)₂ may be implemented to yield the corresponding certainembodiments of XI-(ii). In certain embodiments the formation ofcompounds of Formula XI-(ii) using the methods described above can beaccompanied by formation of the regioisomeric intermediate compounds ofFormula XI-(ii)-a. In certain embodiments when a mixture of XI-(ii) andXI-(ii)-regioisomers is formed they may be separated by chromatography.Intermediates of Formula XI-(ii)-a may in turn be implemented to preparecompounds of the invention using the same general method described inScheme 1.

In certain embodiments wherein X in general Formulas I-(ii) is 0,pinacol borane intermediates of general Formula X can be prepared usingstandard methods as depicted in Scheme 3. Thus, in a first step3-bromophenols of general structure XXX are treated with epibromohydrinto give epoxides XXXI. Opening of the epoxide group of intermediatesXXXI in with amines of Formula R¹NH₂ in an organic solvent with heatingas necessary followed by protection of the resulting amine withBoc-anhydride gives intermediates XXXII. TBS protection of the alcoholgroup in the next step using t-butyldimethylsilyltriflate givesintermediate bromides XXXIII. In a final step the Br group is convertedto the pinacol borane function to give intermediates XX under standardSuzuki-Miyura conditions.

Certain heteroaryl dichlorides of general Formula XX-(ii) arecommercially available. Certain embodiments of general structure XX-(ii)may be prepared by known methods. For example embodiments ofintermediates of general structure XX-(ii)-x may be prepared fromtrichloropyrimidine intermediates L-(ii)-x as depicted in Scheme 4. Incertain embodiments Suzuki coupling of L-(ii)-x with aryl or heteroarylboronates gives intermediate compounds of Formula L-(ii)-x a wherein R¹¹is aryl or heteroaryl. In certain embodiments Buchwald coupling ofL-(ii)-x with primary or secondary cyclic (e.g. morpholine) or acyclicamines gives intermediate compounds of Formula L-(ii)-x a wherein R¹¹ isan acyclic or cyclic amino group.

EXAMPLES

In order that the invention described herein may be more fullyunderstood, the following examples are set forth. It should beunderstood that these examples are for illustrative purposes only andare not to be construed as limiting this invention in any manner.

Synthetic Methods

The synthesis of an exemplary set of compounds of Formula (I) isprovided below. These compounds are also listed in Tables 1A, 1B, 1C,and 2, infra. Compounds provided in Tables 1A, 1B, 1C, and 2 have beenprepared following Examples 1-3.

Example 1. Preparation of1-(3-(4-(methyl(tetrahydro-2H-pyran-4-yl)amino)-6-(pyridine-4-yl)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

Step 1: Synthesis of(2,6-dichloro-pyrimidin-4-yl)-methyl-(tetrahydro-pyran-4-yl)-amine

To a solution of 2,4,6-trichloro-pyrimidine (9.2 g, 50 mmol) andtriethylamine (10.1 g, 100 mmol) in EtOH (100 mL) was addedN-methyltetrahydro-2H-pyran-4-amine (5.17 g, 45 mmol) dropwise at −40°C. The mixture was warmed up to room temperature then stirred for 14 h.,quenched with H₂O (25 mL), concentrated and the residue was extractedwith EtOAc (100 mL×3). The combined organic layers were dried overNa₂SO₄, filtered and concentrated. The residue was purified bychromatographic column on silica gel (petroleum ether/EtOAc=30/1 to 2/1)to give(2,6-dichloro-pyrimidin-4-yl)-methyl-(tetrahydro-pyran-4-yl)amine aswhite solid (7.8 g, 60% yield). ESI-LCMS (m/z): 263.14 [M+1]⁺;

Step 2: Synthesis of[2-(tert-Butyl-dimethyl-silanyloxy)-3-(3-{4-chloro-6-[methyl-(tetrahydro-pyran-4-yl)-amino]-pyrimidin-2-yl}-phenoxy)-propyl]-methyl-carbamicacid tert-butyl ester and[2-(tert-Butyl-dimethyl-silanyloxy)-3-(3-{2-chloro-6-[methyl-(tetrahydro-pyran-4-yl)-amino]-pyrimidin-4-yl}-phenoxy)-propyl]-methyl-carbamicacid tert-butyl ester

To a solution of(2,6-dichloro-pyrimidin-4-yl)-methyl-(tetrahydro-pyran-4-yl)amine (0.4g, 1.5 mmol) in degassed dioxane and H₂O (4/1, 25 mL) was added Na₂CO₃(315 mg, 3.0 mmol); Pd(PPh₃)₄ (86 mg, 0.075 mmol) and{2-(tert-Butyl-dimethyl-silanyloxy)-3-[3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenoxy]-propyl}-methyl-carbamicacid tert-butyl ester (703 mg, 1.35 mmol). The system was purged with N₂stream and the mixture was stirred at 100° C. for 2 h., cooled to roomtemperature, diluted with water (50 mL) and extracted with EtOAc (50mL×2). The organic layers were combined, dried over Na₂SO₄, filtered andconcentrated. The residue was purified by preparative HPLC to give[2-(tert-Butyl-dimethyl-silanyloxy)-3-(3-{4-chloro-6-[methyl-(tetrahydro-pyran-4-yl)-amino]-pyrimidin-2-yl}-phenoxy)-propyl]-methyl-carbamicacid tert-butyl ester (373 mg, 40% yield) as major product. ESI-LCMS(m/z): 411.2 [M+1]⁺ along with the minor product[2-(tert-Butyl-dimethyl-silanyloxy)-3-(3-{2-chloro-6-[methyl-(tetrahydro-pyran-4-yl)-amino]-pyrimidin-4-yl}-phenoxy)-propyl]-methyl-carbamicacid tert-butyl ester (140 mg, 15% yield). ESI-LCMS (m/z): 411.2 [M+1]⁺.

Step 3: Synthesis of[2-(tert-Butyl-dimethyl-silanyloxy)-3-(3-{4-[methyl-(tetrahydro-pyran-4-yl)-amino]-6-pyridin-4-yl-pyrimidin-2-yl}-phenoxy)-propyl]-methyl-carbamicacid tert-butyl ester

To a solution of[2-(tert-Butyl-dimethyl-silanyloxy)-3-(3-{4-chloro-6-[methyl-(tetrahydro-pyran-4-yl)-amino]-pyrimidin-2-yl}-phenoxy)-propyl]-methyl-carbamicacid tert-butyl ester (160 mg, 0.26 mmol) in degassed dioxane and H₂O(4/1, 25 mL) was added Na₂CO₃ (83 mg, 0.78 mmol); Pd(PPh₃)₄ (30 mg,0.026 mmol) and pyridin-4-ylboronic acid (64 mg, 0.52 mmol). The systemwas purged with N₂ stream and the mixture was stirred 100° C. for 2 h.,cooled down to room temperature, diluted with water (25 mL) andextracted with EtOAc (25 mL×2). The organic layers were combined, driedover Na₂SO₄, filtered and concentrated. The residue was purified bychromatographic column on silica gel (petroleum ether/EtOAc=10/1 to 1/1)to give[2-(tert-Butyl-dimethyl-silanyloxy)-3-(3-{4-[methyl-(tetrahydro-pyran-4-yl)-amino]-6-pyridin-4-yl-pyrimidin-2-yl}-phenoxy)-propyl]-methyl-carbamicacid tert-butyl ester (128 mg, 75% yield). ESI-LCMS (m/z): 664.4 [M+1]⁺.

Step 4: Synthesis of1-methylamino-3-(3-{4-[methyl-(tetrahydro-pyran-4-yl)-amino]-6-pyridin-4-yl-pyrimidin-2-yl}-phenoxy)-propan-2-ol

A solution of[2-(tert-Butyl-dimethyl-silanyloxy)-3-(3-{4-[methyl-(tetrahydro-pyran-4-yl)-amino]-6-pyridin-4-yl-pyrimidin-2-yl}-phenoxy)-propyl]-methyl-carbamicacid tert-butyl ester (135 mg, 0.20 mmol) was treated with a 2.5 N HClsolution in methanol (10 mL) and the mixture was stirred at roomtemperature for 4 h., concentrated under vacuum and the residue waspurified by preparative HPLC to give1-methylamino-3-(3-{4-[methyl-(tetrahydro-pyran-4-yl)-amino]-6-pyridin-4-yl-pyrimidin-2-yl}-phenoxy)-propan-2-olas white solid (49 mg, 56% yield). ¹HNMR (500 MHz, CD₃OD) δ ppm:8.72-8.70 (m, 2H), 8.23 (brs, 2H), 8.14-8.10 (m, 2H), 7.43 (t, J=8.5 Hz,1H), 7.16-7.10 (m, 2H), 4.24-4.18 (m, 1H), 4.15-4.08 (m, 4H), 3.72-3.65(m, 2H), 3.14 (s, 3H), 3.00-2.85 (m, 2H), 2.56 (s, 3H), 2.09-1.98 (m,2H), 1.79-1.72 (m, 2H). ESI-LCMS: 450.5 (M+1)+.

Example 2. Preparation of1-Methylamino-3-(3-{6-[methyl-(tetrahydro-pyran-4-yl)-amino]-2-pyridin-4-yl-pyrimidin-4-yl}-phenoxy)-propan-2-ol

Step 5: Synthesis of[2-(tert-Butyl-dimethyl-silanyloxy)-3-(3-{4-[methyl-(tetrahydro-pyran-4-yl)-amino]-6-pyridin-4-yl-pyrimidin-2-yl}-phenoxy)-propyl]-methyl-carbamicacid tert-butyl ester

To a solution of[2-(tert-Butyl-dimethyl-silanyloxy)-3-(3-{2-chloro-6-[methyl-(tetrahydro-pyran-4-yl)-amino]-pyrimidin-4-yl}-phenoxy)-propyl]-methyl-carbamicacid tert-butyl ester (160 mg, 0.26 mmol) in degassed dioxane and H₂O(4/1, 25 mL) was added Na₂CO₃ (83 mg, 0.78 mmol); Pd(PPh₃)₄ (30 mg,0.026 mmol) and pyridin-4-ylboronic acid (64 mg, 0.52 mmol). The systempurged with N₂ stream and the mixture was stirred to 100° C. for 2 h.,cooled down to room temperature, diluted with water (25 mL) andextracted with EtOAc (25 mL×2). The organic layers were combined, driedover Na₂SO₄, filtered and concentrated. The residue was purified bychromatographic column on silica gel (petroleum ether/EtOAc=10/1 to 2/3)to give[2-(tert-Butyl-dimethyl-silanyloxy)-3-(3-{4-[methyl-(tetrahydro-pyran-4-yl)-amino]-6-pyridin-4-yl-pyrimidin-2-yl}-phenoxy)-propyl]-methyl-carbamicacid tert-butyl ester (135 mg, 79% yield). ESI-LCMS (m/z): 664.4 [M+1]⁺.

Step 6: Synthesis of1-Methylamino-3-(3-{6-[methyl-(tetrahydro-pyran-4-yl)-amino]-2-pyridin-4-yl-pyrimidin-4-yl}-phenoxy)-propan-2-ol

A solution of[2-(tert-Butyl-dimethyl-silanyloxy)-3-(3-{4-[methyl-(tetrahydro-pyran-4-yl)-amino]-6-pyridin-4-yl-pyrimidin-2-yl}-phenoxy)-propyl]-methyl-carbamicacid tert-butyl ester (128 mg, 0.19 mmol) was treated with a 2.5 N HClsolution in methanol, (10 mL), and the mixture was stirred at roomtemperature for 4 h., concentrated under vacuum and the residue waspurified by preparative HPLC to give1-methylamino-3-(3-{6-[methyl-(tetrahydro-pyran-4-yl)-amino]-2-pyridin-4-yl-pyrimidin-4-yl}-phenoxy)-propan-2-olas white solid (52 mg, 57% yield). ¹HNMR (500 MHz, CD₃OD) δ ppm: 8.71(d, J=5.5 Hz, 2H), 8.47 (d, J=5.0 Hz, 2H), 7.84 (s, 1H), 7.79 (d, J=8.0Hz, 1H), 7.47-7.43 (m, 1H), 7.13 (d, J=8.0 Hz, 1H), 7.09 (s, 1H),4.22-4.17 (m, 1H), 4.15-4.09 (m, 4H), 3.74-3.66 (m, 2H), 3.15 (s, 3H),2.96-2.82 (m, 2H), 2.53 (s, 3H), 2.07-1.97 (m, 2H), 1.78-1.73 (m, 2H);LCMS: 450.3 (M+H)+;

Example 3. Preparation of1-(3-(5-methyl-4-morpholino-6-((R)-tetrahydrofuran-3-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

Step 1: Synthesis of (R)-2,6-dichloro-5-methyl-N-(tetrahydrofuran-3-yl)pyrimidin-4-amine

A mixture of 2,4,6-trichloro-5-methylpyrimidine (2 g, 10.2 mmol),(R)-tetrahydro-furan-3-amine hydrochloride (1.12 g, 9.2 mmol) and Et₃N(2.1 g, 20.3 mmol) in EtOH (20 mL) was stirred at room temperature for14 h., concentrated under vacuum and the residue was purified bychromatographic column on silica gel (EtOAc/petroleum ether, gradientelution, from 1/10 to 2/1) to give the(R)-2,6-dichloro-5-methyl-N-(tetrahydrofuran-3-yl)pyrimidin-4-amine(1.25 g, 53% yield) as a white solid. ESI-LCMS (m/z): 248.1 [M+1]⁺.

Step 2: Synthesis of(R)-3-(4-chloro-5-methyl-6-(tetrahydrofuran-3-ylamino)pyrimidin-2-yl)phenol

To a solution of of(R)-2,6-dichloro-5-methyl-N-(tetrahydrofuran-3-yl)pyrimidin-4-amine (1.8g, 7.3 mmol) in degassed dioxane and H₂O (4/1, 21 mL) was added Na₂CO₃(1.5 g, 14.5 mmol); Pd(PPh₃)₄ (296 mg, 0.36 mmol) and3-hydroxy-phenylboronic acid (1.21 g, 8.8 mmol). The system was purgedwith nitrogen stream and then stirred at 100° C. for 14 h., cooled downto room temperature, diluted with water (30 mL) and the resultingmixture extracted with EtOAc (30 mL×2). The combined organic layer weredried over Na₂SO₄, filtered and concentrated. The residue was purifiedby chromatographic column on silica gel (EtOAc/petroleum ether, gradientelution, from 1/10 to 2:1) to give(R)-3-(4-chloro-5-methyl-6-(tetrahydrofuran-3-ylamino)pyrimidin-2-yl)phenol (2.4 g, 33%) as a white solid. ESI-LCMS (m/z): 306.1 [M+1]⁺.

Step 3: Synthesis of(R)-3-(5-methyl-4-morpholino-6-(tetrahydrofuran-3-ylamino)pyrimidin-2-yl)phenol

A mixture of(R)-3-(4-chloro-5-methyl-6-(tetrahydrofuran-3-ylamino)pyrimidin-2-yl)phenol (800 mg, 2.6 mmol); neat morpholine (274 mg, 3.1 mmol) and Na₂CO₃(556 mg, 5.2 mmol) in EtOH (12 mL) was stirred at 80° C. in a sealedvial for 14 h. The mixture was filtered and the filtrate wasconcentrated. The residue was purified by chromatographic column onsilica gel (EtOAc/petroleum ether, gradient elution, from 1/2 to 2/1) togive the(R)-3-(5-methyl-4-morpholino-6-(tetrahydrofuran-3-ylamino)pyrimidin-2-yl)phenol(120 mg, 13% yield) as a light yellow solid. ESI-LCMS (m/z): 357.1[M+1]⁺.

Step 4: Synthesis of5-methyl-6-morpholino-2-(3-(oxiran-2-ylmethoxy)phenyl)-N—((R)-tetrahydrofuran-3-yl)pyrimidin-4-amine

A mixture of(R)-3-(5-methyl-4-morpholino-6-(tetrahydrofuran-3-ylamino)pyrimidin-2-yl)phenol(50 mg, 0.14 mmol); 2-(chloromethyl)oxirane (16 mg, 0.17 mmol) and K₂CO₃(39 mg, 0.28 mmol) in MeCN (10 mL) was heated at 80° C. in a sealed vialfor 14 h. The mixture was filtered and the filtrate was concentrated.The residue was purified by chromatographic column on silica gel(EtOAc/petroleum ether, gradient elution, from 1/5 to 4:1) to give the5-methyl-6-morpholino-2-(3-(oxiran-2-ylmethoxy)phenyl)-N—((R)-tetrahydrofuran-3-yl)pyrimidin-4-amine (20 mg, 34% yield)as a light yellow solid. ESI-LCMS (m/z): 413.2 [M+1]⁺.

Step 5: Synthesis of1-(3-(5-methyl-4-morpholino-6-((R)-tetrahydrofuran-3-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

5-Methyl-6-morpholino-2-(3-(oxiran-2-ylmethoxy)phenyl)-N—((R)-tetra-hydrofuran-3-yl)pyrimidin-4-amine(20 mg, 0.05 mmol) was dissolved in a 2N MeNH₂ solution in methanol, (10mL) and the mixture was stirred at room temperature for 14 h.,concentrated under vacuum and the residue was purified by preparativeHPLC to obtain the1-(3-(5-methyl-4-morpholino-6-((R)-tetrahydrofuran-3-ylamino)pyrimidin-2-yl)phenoxy)-3-(methyl-amino)propan-2-ol(8 mg, 37% yield) as a white solid. ¹H NMR (500 MHz, CD₃OD) δ ppm:8.02-7.96 (m, 2H), 7.34 (t, J=8.0 Hz, 1H), 7.05-7.00 (m, 1H), 4.85-4.80(m, 1H), 4.20-4.14 (m, 2H), 4.07-4.01 (m, 3H), 3.93-3.84 (m, 5H),3.78-3.74 (m, 1H), 2.96-2.92 (m, 1H), 2.88-2.82 (m, 1H), 2.53 (s, 3H),2.42-2.35 (m, 1H), 2.11-2.04 (m, 4H); ESI-LCMS (m/z): 444.3 [M+1]⁺.

Example 4. Preparation of methyl4-(6-(3,5-dimethylisoxazol-4-yl)-2-(3-((S)-2-hydroxy-3-(methylamino)propoxy)phenyl)-5-methylpyrimidin-4-ylamino)piperidine-1-carboxylateformate

Step 1: Synthesis of (S)-2-((3-bromophenoxy)methyl)oxirane

To a suspension of 3-bromophenol (or any other substituted orunsubstituted phenol, 0.29 mol) and K₂CO₃ (120.35 g, 0.87 mol) in MeCN(600 mL) was treated with (S)-2-(chloromethyl)oxirane (applies also tothe corresponding R-enantiomer or any other .substituted oxirane, 0.58mol) with slow addition at room temperature, then the reaction mixturewas heated at 80° C. and stirred at the same temperature for 12 h. Afterbeing cooled to room temperature, the mixture was filtered and thefiltrate was concentrated. The residue was purified by chromatographiccolumn on silica gel (petroleum ether/EtOAc=80/1 to 60/1) to give(S)-2-((3-bromophenoxy)methyl) oxirane (36 g, 54% yield) as colorlessoil. ESI-LCMS (m/z): 228.7 [M+1]⁺.

Step 2: Synthesis of (S)-1-(3-bromophenoxy)-3-(methylamino)propan-2-ol

A 33% solution of MeNH₂ (or any other substituted amine or ammonia) inMeOH (50 mL) was slowly added to a solution of(S)-2-((3-bromophenoxy)methyl)oxirane (36 g, 0.157 mol) in MeOH (100 mL)kept at 0° C., after the addition was completed the cooling bath wasremoved and the reaction mixture further stirred at room temperature for12 h; and finally concentrated and stored under vacuum to give(S)-1-(3-bromophenoxy)-3-(methylamino)propan-2-ol in quantitative yield.The title product was used directly in the next step without furtherpurification. ESI-LCMS (m/z): 260.1 [M+1]⁺.

Step 3: Synthesis of (S)-tert-butyl3-(3-bromophenoxy)-2-hydroxypropyl(methyl) carbamate

Neat Boc₂O (42.44 g, 0.18 mol) was added portionwise into a solution of(S)-1-(3-bromophenoxy)-3-(methylamino)propan-2-ol (or any other primaryor secondary amine; 0.157 mol) and triethylamine (31.89 g, 0.31 mol) inDCM (600 mL) while stirring at 0° C.; after completing addition, themixture was stirred at room temperature for 3 h. The reaction mixturewas consecutively washed with water (300 mL×2), saturated NH₄Cl aqueoussolution (200 mL×2) and brine (300 mL). The organic phase was dried overNa₂SO₄, filtered and concentrated to render (S)-tert-butyl3-(3-bromophenoxy)-2-hydroxypropyl (methyl)carbamate as a pale a yellowoil in quantitative yield. This material was submitted to the next stepwithout further purification. ESI-LCMS (m/z): 382.0 [M+23]⁺.

Step 4: Synthesis of (S)-tert-butyl3-(3-bromophenoxy)-2-(tert-butyldimethyl-silyloxy)propyl(methyl)carbamate

A solution of (S)-tert-butyl 3-(3-bromophenoxy)-2-hydroxypropyl(methyl)carbamate (or any other alcohol; 0.157 mol) and imidazole (23.47 g, 0.34mol) in DCM (500 mL) was treated with neat TBSCl (47.37 g, 0.31 mol)added slowly at 0° C. The reaction mixture was then stirred at 35° C.for 2 h followed by washing with water (300 mL×2) and brine (300 mL).The organic layer was dried over Na₂SO₄, filtered and concentrated andthe resulting residue was purified by chromatographic column on silicagel (petroleum ether/EtOAc=80/1 to 60/1) to give (S)-tert-butyl3-(3-bromo-phenoxy)-2-(tert-butyldimethylsilyloxy)propyl(methyl)carbamate as a pale yellow oil (66 g, 88% yield for 3 steps). ESI-LCMS:496.1 [M+23]⁺.

Step 5: Synthesis of (S)-tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4,6-di-chloro-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

To a solution of (S)-tert-butyl3-(3-bromophenoxy)-2-(tert-butyldimethylsilyloxy) propyl(methyl)carbamate (105 mmol) (or any other conveniently substitutedtert-butyl 3-(3-bromophenoxy)-2-(tert-butyldimethyl silyloxy) propyl(methyl)carbamate) in dry THF (210 mL) stirred at −78° C. under N₂atmosphere, was treated with 2.5 M n-butyl lithium in hexane (44.3 mL,1.05 eq.) added over 20 min., the mixture was then stirred for another10 min. at −78° C. before a solution of 4,6-dichloro-5-methylpyrimidine(or any other substituted or unsubstituted pyrimidine, 126 mmol) in THF(20 mL) was added slowly over 10 min. The resulting mixture was stirredat same temperature for 30 min., then quenched with water (10 mL) andslowly warmed to 0° C. DDQ (33 g, 147 mmol) was then added portionwiseand the mixture further stirred at for 0° C. 30 min.; diluted withCH₂Cl₂ (300 mL), successively washed with 10% NaOH (100 mL) and brine(100 mL) and finally dried over Na₂SO₄, filtered and concentrated. Theresidue was purified by cromatographic column on silicagel eluted withpetroleum ether/EtOAc=80/1 to afford (S)-tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4,6-di-chloro-5-methyl-pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (30 g, 52% yield) as a white solid. ESI-LCMS (m/z): 577.8[M+23]⁺.

For other examples disclosed elsewhere in this document, (S)-tert-butyl3-(3-bromophenoxy)-2-(tert-butyldimethylsilyloxy)propyl(methyl)carbamate can be replaced for its corresponding(R)-enantiomer, its racemic mixture or any other convenientlysubstituted derivative of any of these coupling partners.

Step 6: Synthesis of tert-butyl(S)-2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

To a solution of (S)-tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4,6-dichloro-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (or any other heteroarylor aryl substituted with a leaving group, e.g., halo (e.g., chloro,bromo, iodo) and sulfonyl substituted hydroxyl groups (e.g., tosyl,mesyl, besyl); 2.5 g, 4.5 mmol) in degassed 10:1 dioxane:H₂O mixture (50mL), was added 3,5-dimethylisoxazol-4-ylboronic acid (or any otherboronic acid or ester; 635 mg, 4.5 mmol), Pd(PPh₃)₄ (260 mg, 0.22 mmol)and Na₂CO₃ (1.43 g, 13.52 mmol). The system was purged with N₂ streamand heated at 100° C. for 12 h. After cooling down to room temperature,the mixture was diluted with water (25 mL) and extracted with EtOAc (25mL×2). The organic layers were combined, dried over Na₂SO₄, filtered andconcentrated; the resulting residue was purified by chromatographiccolumn on silicagel (eluted with petroleum ether/EtOAc=60/1 to 30/1) togive tert-butyl(S)-2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methyl-pyrimidin-2-yl)phenoxy)propyl(methyl)carbamateas a white solid (1.6 g, 58% yield). ESI-LCMS: 616.8 [M+1]⁺.

Step 7: Synthesis of methyl4-(2-(3-((S)-3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyldimethylsilyloxy)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-ylamino)piperidine-1-carboxylate

A pressure vessel containing a solution of tert-butyl(S)-2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-di-methylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (or any other heteroaryl or aryl substituted with a leavinggroup, e.g., halo (e.g., chloro, bromo, iodo) and sulfonyl substitutedhydroxyl groups (e.g., tosyl, mesyl, besyl), 0.56 mmol), methyl4-aminopiperidine-1-carboxylate hydrochloride (or any other primary orsecondary amine, 2.84 mmol), triethylamine (287 mg, 2.84 mmol) and KI(47 mg, 0.28 mmol) in DMSO (7 mL) was placed in a microwave reactor andthe mixture irradiated for 60 min. at external temperature of 145° C.After cooling down to room temperature, the mixture was diluted withEtOAc (30 mL), washed with water (10 mL×2) followed by brine (10 mL);the organic layer was dried over Na₂SO₄, filtered and concentrated. Theresidue was purified by preparative TLC (petroleum ether/EtOAc=1.5/1) toobtain methyl 4-(2-(3-((S)-3-(tert-butoxycarbonyl (methyl)amino)-2-(tert-butyldimethylsilyloxy) propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methyl-pyrimidin-4-ylamino)piperidine-1-carboxylate(290 mg, 71% yield) as a white solid. ESI-LCMS: 739.0 [M+1]⁺.

Step 8: Synthesis of methyl 4-(6-(3,5-dimethylisoxazol-4-yl)-2-(3-((S)-2-hydroxy-3-(methylamino)propoxy)phenyl)-5-methylpyrimidin-4-ylamino)piperidine-1-carboxylate

Methyl 4-(2-(3-((S)-3-(tert-butoxycarbonyl (methyl)amino)-2-(tert-butyl-dimethylsilyloxy)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-ylamino)piperidine-1-carboxylate (or any other aminoalcohol bearing a silylprotecting group; 0.393 mmol) was dissolved in 90% TFA aqueous solution(5 mL), and the mixture was stirred at 35° C. for 2 h. After removingthe solvent under vacuum, the residue was dissolved in MeOH (5 mL) andthe solution pH adjusted to 9 with saturated aqueous K₂CO₃. The mixturewas filtered, the filtrate was concentrated and the resulting residuewas purified by preparative HPLC to give methyl4-(6-(3,5-dimethylisoxazol-4-yl)-2-(3-((S)-2-hydroxy-3-(methylamino)propoxy)phenyl)-5-methylpyrimidin-4-ylamino)piperidine-1-carboxylateas a formic acid salt (white solid, 116 mg, 51% yield). ¹HNMR (500 MHz,CD₃OD) δ ppm: 8.56 (brs, 1H), 7.93 (d, J=7.5 Hz, 1H), 7.89 (s, 1H), 7.37(t, J=8.0 Hz, 1H), 7.06 (d, J=7.5 Hz, 1H), 4.50-4.42 (m, 1H), 4.30-4.20(m, 3H), 4.15-4.06 (m, 2H), 3.71 (s, 3H), 3.26-3.20 (m, 1H), 3.18-3.05(m, 3H), 2.72 (s, 3H), 2.35 (s, 3H), 2.24 (s, 3H), 2.16-2.10 (m, 2H),2.00 (s, 3H), 1.66-1.56 (m, 2H); ESI-LCMS:525.3 [M+1]⁺.

Example 5. Preparation of1-(3-chloro-5-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

Step 1: Synthesis of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-chloro-5-(4-chloro-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

To a solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-chloro-5-(4,6-dichloro-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(1 g, 1.7 mmol) in DMSO (30 ml), tetrahydro-2H-pyran-4-amine (or anyother suitable amine, 2.5 mmol) and triethylamine (344 mg, 3.4 mmol) wasadded at room temperature. The mixture was then placed in a heating bathpreheated at 120° C. and stirred at the same temperature for 3 h; themixture was then cooled down to room temperature, diluted with EtOAc(150 mL) and washed with water (80 mL×3). The aqueous layer wasextracted with EtOAc (50 ml) and the combined organic layers dried overNa₂SO₄, filtered and the filtrate concentrated in vacuo. The cruderesidue was purified by preparative TLC (petroleum ether/EtOAc=2:1) toobtain tert-butyl 2-(tert-butyldimethylsilyloxy)-3-(3-chloro-5-(4-chloro-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl (methyl)carbamate (740 mg, 67% yield) as a white solid.ESI-LCMS (m/z): 654.7 [M+1]⁺.

Step 2: Synthesis of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-chloro-5-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

To a solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-chloro-5-(4-chloro-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (120 mg, 0.18 mmol) in degassed dioxane:H₂O 3:1 mixture (4 mL)was added Na₂CO₃ (57 mg, 0.54 mmol), Pd(PPh₃)₄ (30 mg, 0.026 mmol) and3,5-dimethylisoxazol-4-ylboronic acid (or any other suitable boronicacid; 0.36 mmol). The system was purged with N₂ stream and the mixturewas stirred 100° C. for 12 h. After being cooled down to roomtemperature, the reaction mixture was diluted with EtOAc (25 mL) andwashed with water (10 mL) and brine (10 mL). The organic layer was driedover Na₂SO₄, filtered and concentrated. The residue was purified bychromatographic column on silicagel (petroleum ether/EtOAc=10/1 to 1/1)to give tert-butyl2-(tert-butyldimethyl-silyloxy)-3-(3-chloro-5-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (30 mg, 23% yield).ESI-LCMS (m/z): 716.7 [M+1]⁺.

Step 3: Synthesis of1-(3-chloro-5-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-yl-amino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

The tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-chloro-5-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (30 mg, 0.04 mmol) was treated with 2.5N HCl solutionin methanol (10 mL) and the mixture was stirred at room temperature for2 h. After concentrated under vacuum, the residue was purified bypreparative HPLC to give1-(3-chloro-5-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-yl-amino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-olas a white solid (10 mg, 48% yield). ¹HNMR (500 MHz, CD₃OD) δ ppm: 7.91(d, J=2.0 Hz, 1H), 7.86 (d, J=2.5 Hz, 1H), 7.10 (t, J=2.0 Hz, 1H),4.53-4.48 (m, 1H), 4.16-4.12 (m, 1H), 4.09-4.02 (m, 4H), 3.68-3.63 (m,2H), 2.91-2.79 (m, 2H), 2.51 (s, 3H), 2.39 (s, 3H), 2.26 (s, 3H),2.11-2.08 (m, 2H), 2.03 (s, 3H), 1.83-1.75 (m, 2H); ESI-LCMS: 502.7[M+1]⁺.

Example 6. Preparation of (3S)-ethyl 3-((6-(3,5-dimethylisoxazol-4-yl)-2-(3-(2-hydroxy-3-(methylamino)propoxy)phenyl)-5-methylpyrimidin-4-ylamino)methyl)morpholine-4-carboxylate

Step 1: Synthesis of (S)-ethyl 3-((tert-butoxycarbonylamino)methyl)morpholine-4-carboxylate

To a solution of (S)-tert-butyl morpholin-3-ylmethylcarbamate (or anyother suitable amine, 2.3 mmol) and triethylamine (350 mg, 3.4 mmol) inDCM (20 mL) stirred at 0° C. under N₂ atmosphere, was added ethylchloroformate* (325 mg, 3.0 mmol). The mixture was warmed to roomtemperature and stirred for 2 h. Water (30 mL) was added and the mixturewas extracted with DCM (30 mL×2). The combined organic layers were driedover Na₂SO₄, filtered and concentrated to give the crude (S)-ethyl3-((tert-butoxycarbonylamino) methyl) morpholine-4-carboxylate, whichwas used directly without further purification. Quantitative yield.

*Alternatively, other alkylating, acylating, carbamoylating, orsulfonylating agents can be employed is similar manner.

Step 2: Synthesis of (S)-ethyl 3-(aminomethyl)morpholine-4-carboxylatehydrochloride

To a solution of ((S)-ethyl3-((tert-butoxycarbonylamino)methyl)morpholine-4-carboxylate (3.4 mmol)in MeOH (5 mL) was added 4 mL of 4N HCl in dioxane and the mixture wasstirred at room temperature for 1 h. Then the solution was concentratedand titurated with EtOAc (15 mL) to give the (S)-ethyl 3-(aminomethyl)morpholine-4-carboxylate hydrochloride as a white solid, (750 mg, 3.3mmol, 98% yield).

Step 3: Synthesis of (3S)-ethyl 3-((2-(3-(3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyldimethylsilyloxy)propoxy)phenyl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methylpyrimidin-4-ylamino)methyl)morpholine-4-carboxylate

To a solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-di-methylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(400 mg, 0.64 mmol) in toluene (5 mL) was added (S)-ethyl3-(aminomethyl) morpholine-4-carboxylate hydrochloride (or any othersuitable substituted primary amine, 0.89 mmol), Pd(t-Bu₃P)₂ (40 mg,0.008 mmol) and t-BuONa (180 mg, 1.87 mmol). The system was purged withN₂ stream, sealed and heated at 100° C. for 12 h. After being cooleddown to room temperature, water (30 mL) was added and the mixture wasextracted with EtOAc (30 mL×2). The combined organic layers were driedover Na₂SO₄, filtered and concentrated. The residue was purified bypreparative TLC (petroleum ether/EtOAc=1/2) to obtain (3S)-ethyl3-((2-(3-(3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyldimethylsilyloxy)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-ylamino)methyl)morpholine-4-carboxylate(200 mg, 40% yield). ESI-LCMS (m/z): 769 [M+1]⁺.

Step 4: Synthesis of (3S)-ethyl 3-((6-(3,5-dimethylisoxazol-4-yl)-2-(3-(2-hydroxy-3-(methylamino)propoxy)phenyl)-5-methylpyrimidin-4-ylamino)methyl)morpholine-4-carboxylate

A solution of (3S)-ethyl3-((2-(3-(3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyldimethylsilyloxy)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-ylamino)methyl)morpholine-4-carboxylate(200 mg) in MeOH (5 mL) stirred at room temperature, was treated with 4NHCl solution in dioxane (4 mL). The reaction mixture was then stirred atsame temperature for 1 h; concentrated under vaccum, the residue wasdissolved in MeOH (5 mL) and treated with aqueous ammonium hydroxidetill pH=8. The mixture was concentrated and the residue was purified bypreparative HPLC to give (3S)-ethyl 3-((6-(3,5-dimethylisoxazol-4-yl)-2-(3-(2-hydroxy-3-(methylamino)propoxy)phenyl)-5-methylpyrimidin-4-ylamino)methyl)morpholine-4-carboxylate (100 mg, 69% yield) as white solid. ¹HNMR (500MHz, CD₃OD) δ ppm: 7.94 (brs, 2H), 7.37 (t, J=8.5 Hz, 1H), 7.07 (dd,J=2.0 and 8.0 Hz, 1H), 4.70-4.30 (m, 2H), 4.18-4.11 (m, 1H), 4.06 (d,J=5.0 Hz, 1H), 4.02-3.90 (m, 4H), 3.89-3.68 (m, 4H), 3.58-3.45 (m, 2H),2.90-2.85 (m, 1H), 2.82-2.76 (m, 1H), 2.49 (s, 3H), 2.37 (s, 3H), 2.26(s, 3H), 1.99 (s, 3H), 1.20-0.80 (m, 3H); ESI-LCMS (m/z): 555.4 [M+1]⁺.

Example 7. Preparation of1-(3-(4-(5-cyclopropyl-1,3,4-thiadiazol-2-ylamino)-6-(3,5-di-methylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

Step 1: Synthesis of [tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(5-cyclopropyl-1,3,4-thiadiazol-2-ylamino)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

To a solution of [tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(100 mg, 0.16 mmol) in toluene (4 mL) was added Cs₂CO₃ (105 mg, 0.32mmol); (t-Bu₃P)₂Pd (20 mg, 0.016 mmol) and5-cyclopropyl-1,3,4-thiadiazol-2-amine (or any other aromatic amine,0.32 mmol). The system was purged with N₂ stream, sealed and heated at110° C. for 12 h. After being cooled down to room temperature, thereaction mixture was diluted with water (25 mL) and extracted with EtOAc(25 mL×2). The organic layers were combined, dried over Na₂SO₄, filteredand concentrated. The residue was purified by chromatographic column onsilicagel (petroleum ether/EtOAc=10/1 to 2/3) to give tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(5-cyclopropyl-1,3,4-thiadiazol-2-ylamino)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (100 mg, 85% yield). ESI-LCMS (m/z): 721.9 [M+1]⁺.

Step 2: Synthesis of1-(3-(4-(5-cyclopropyl-1,3,4-thiadiazol-2-ylamino)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

tert-Butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(5-cyclopropyl-1,3,4-thiadiazol-2-ylamino)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (100 mg, 0.14 mmol) was dissolved in 4N HCl solutionin dioxane (5 mL) at room temperature and the mixture was stirred at thesame temperature for 1 h; concentrated in vacuo and the residue waspurified by preparative HPLC to give1-(3-(4-(5-cyclopropyl-1,3,4-thiadiazol-2-ylamino)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-olas formic acid salt (white solid, 14 mg, 19% yield). ¹HNMR (500 MHz,CD₃OD) δ ppm: 8.56 (s, 1H), 8.12 (d, J=8.0 Hz, 1H), 8.07 (d, J=1.5 Hz,1H), 7.49 (t, J=8.0 Hz, 1H), 7.18 (dd, J=8.0 and 1.5 Hz, 1H), 4.33-4.29(m, 1H), 4.20-4.15 (m, 2H), 3.32-3.26 (m, 1H), 3.23-3.16 (m, 1H), 2.76(s, 3H), 2.50-2.40 (m, 4H), 2.30 (s, 3H), 2.29 (s, 3H), 1.31-1.26 (m,2H), 1.16-1.13 (m, 2H); LCMS: 508.1 [M+H]⁺.

Example 8. Preparation of1-(3-(4-(4-(2,2-difluoroethyl)piperazin-1-yl)-5-methyl-6-((R)-tetrahydrofuran-3-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

Step 1: Synthesis of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-5-methyl-6-((R)-tetrahydrofuran-3-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

To a solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4,6-dichloro-5-methyl-pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(2.0 g, 3.6 mmol) in DMF (35 mL) was added triethylamine (1.46 g, 14.4mmol), (R)-tetrahydrofuran-3-amine (or any other suitable amine, 5.4mmol) at room temperature, and the mixture was placed in a preheatedbath at 110° C. and stirred for 12 h. After being cooled down to roomtemperature, the reaction mixture was diluted with water (50 mL) andextracted with EtOAc (40 mL×2). The combined organic phase was washedwith saturated aqueous ammonium chloride solution (40 mL×2) and brine(40 mL×1), dried over Na₂SO₄, filtered and concentrated. The residue waspurified by chromatographic column on silica gel (petroleumether/EtOAc=50/1 to 1/1) to give tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-5-methyl-6-((R)-tetrahydrofuran-3-yl-amino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (1.3 g, 59% yield). ESI-LCMS (m/z): 606.8 [M+1]⁺.

Step 2: Synthesis of [tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(5-methyl-4-(piperazin-1-yl)-6-((R)-tetrahydrofuran-3-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

To a solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-5-methyl-6-((R)-tetrahydrofuran-3-yl-amino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(700 mg, 1.2 mmol) in degassed toulene (15 mL) was added Cs₂CO₃ (750 mg,2.3 mmol), piperazine (or any other appropriate diamine, 2.3 mmol) and(t-Bu₃P)₂Pd (70 mg, 0.2 mmol). The system was purged with N₂ stream, thereaction vessel was sealed and heated at 110° C. for 12 h. After beingcooled down to room temperature, the reaction mixture was diluted withEtOAc (50 mL), washed with water (30 mL×2), the organic layer was driedover Na₂SO₄, filtered and concentrated. The residue was purified bypreparative TLC (petroleum ether/EtOAc=1/2) to give tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(5-methyl-4-(piperazin-1-yl)-6-((R)-tetrahydrofuran-3-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (373 mg, 49% yield).ESI-LCMS (m/z): 657.0 [M+1]⁺.

Step 3: Synthesis of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(4-(2,2-di-fluoroethyl)piperazin-1-yl)-5-methyl-6-((R)-tetrahydrofuran-3-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

To a solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(5-methyl-4-(piperazin-1-yl)-6-((R)-tetrahydrofuran-3-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (120 mg, 0.18 mmol) in CH₃CN (5 mL) was added potassium iodide(50 mg, 0.36 mmol), 2-bromo-1,1-difluoroethane (or any other suitablealkylating reagent, 1.7 mmol) and Cs₂CO₃ (120 mg, 0.36 mmol) at roomtemperature; the reaction vessel was sealed and heated at 110° C. for 12h. After being cooled down to room temperature, the mixture was dilutedwith EtOAc (50 mL) and washed with water (35 mL×2). The organic layerwas dried over Na₂SO₄, filtered and concentrated. The residue waspurified by preparative TLC (petroleum ether/EtOAc=1/1) to give[tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(4-(2,2-difluoroethyl)piperazin-1-yl)-5-methyl-6-((R)-tetrahydrofuran-3-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(90 mg, 68% yield). ESI-LCMS (m/z): 721.4 [M+1]⁺.

Step 4: Synthesis of1-(3-(4-(4-(2,2-difluoroethyl)piperazin-1-yl)-5-methyl-6-((R)-tetrahydrofuran-3-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

The tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(4-(2,2-difluoroethyl)piperazin-1-yl)-5-methyl-6-((R)-tetrahydrofuran-3-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (90 mg, 0.12 mmol) was treated with 2.5N HCl solutionin dioxane (5 mL) and the mixture was stirred at room temperature for 1h; concentrated under vacuum and the residue submitted to purificationby preparative HPLC to give 1-(3-(4-(4-(2,2-difluoroethyl)piperazin-1-yl)-5-methyl-6-((R)-tetrahydrofuran-3-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino) propan-2-ol as a yellow solid (33 mg, 52% yield). ¹HNMR (500 MHz,CDCl₃) δ ppm: 8.01 (d, J=8.9 Hz, 1H), 7.97 (d, J=2.5 Hz, 1H), 7.32 (t,J=8.0 Hz, 1H), 6.96 (dd, J=2.5 and 8.5 Hz, 1H), 5.93 (tt, J=4.5 and 56.0Hz, 1H), 4.90-4.84 (m, 1H), 4.48 (d, J=6.5 Hz, 1H), 4.17-4.11 (m, 1H),4.10-3.98 (m, 4H), 3.90-3.84 (m, 1H), 3.81-3.76 (m, 1H), 3.36-3.30 (s,4H), 2.90-2.75 (m, 4H), 2.74-2.70 (m, 4H), 2.50 (s, 3H), 2.45-2.37 (m,1H), 2.26 (brs, 2H), 1.98 (s, 3H), 1.95-1.89 (m, 1H); ESI-LCMS (m/z):507.3 [M+H]⁺.

Example 9. Preparation of1-(3-(4-(methyl(tetrahydro-2H-pyran-4-yl)amino)-6-(7-(methyl-sulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)pyrimidin-2-yl)phenoxy)-3-(methyl-amino)propan-2-ol

Step 1: Synthesis of5-bromo-7-(methylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine

To a solution of 5-bromo-7H-pyrrolo[2,3-d]pyrimidine (or any othersuitable aromatic halide, 1 mmol) in DMF (5 mL) was added NaH (43 mg,60%, 1.1 mmol) at 0° C., After 5 min., MsCl* (114 mg, 1.0 mmol) wasadded and the mixture was stirred at 0° C. for 1 h. The mixture wasdiluted with EtOAc (20 mL), successively washed with water (20 mL) andbrine (20 mL). The organic layer was dried over Na₂SO₄, filtered andconcentrated. The residue was purified by chromatographic column onsilicagel to give 5-bromo-7-(methylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine(265 mg, 95% yield). ESI-LCMS (m/z): 275.9 [M+1]⁺.

*Alternatively, other alkylating, acylating, carbamoylating, orsulfonylating agents can be employed is similar manner.

Step 2: Synthesis of(2,6-dichloro-pyrimidin-4-yl)-methyl-(tetrahydro-pyran-4-yl)-amine

To a solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4,6-dichloro-pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(5.4 g, 10 mmol) and triethylamine (2.0 g, 20 mmol) in DMF (25 mL) wasadded N-methyltetrahydro-2H-pyran-4-amine (or any other substituted orunsubstituted amine, 15 mmol) and the mixture was stirred at 100° C. for14 h. After cooling down to room temperature, the mixture was dilutedwith EtOAc (50 mL) and washed with H₂O (20 mL×2), saturated NH₄Claqueous solution (20 mL×2) and brine (20 mL). The organic layer wasdried over Na₂SO₄, filtered and concentrated. The residue was purifiedby chromatographic column on silicagel (petroleum ether/EtOAc=10/1 to3/1) to give[2-(tert-butyl-dimethyl-silanyloxy)-3-(3-{4-chloro-6-[methyl-(tetrahydro-pyran-4-yl)-amino]pyrimidin-2-yl}phenoxy)propyl]methyl-carbamicacid tert-butyl ester as a white solid (5.3 g, 85% yield). ESI-LCMS(m/z): 621.3 [M+1]⁺.

Step 3: Synthesis of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(methyl(tetra-hydro-2H-pyran-4-yl)amino)-6-(7-(methylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

To a solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(methyl(tetrahydro-2H-pyran-4-yl)amino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(150 mg, 0.24 mmol) in dioxane (3 mL) was added5-bromo-7-(methylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine (134 mg, 0.48mmol), Pd(PPh₃)₄ (28 mg, 0.024 mmol) and triethylamine (48 mg, 0.48mmol). The system was purged with N₂ stream, sealed and stirred at 120°C. for 12 h. After being cooled down to room temperature, the mixturewas filtered through celite, the filtrate was concentrated and theresidue was purified by preparative TLC to give tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(methyl(tetra-hydro-2H-pyran-4-yl)amino)-6-(7-(methylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(65 mg, 34% yield). ESI-LCMS (m/z): 781.8 [M+1]⁺.

Step 3: Synthesis of1-(3-(4-(methyl(tetrahydro-2H-pyran-4-yl)amino)-6-(7-(methylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

A solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(methyl(tetrahydro-2H-pyran-4-yl)amino)-6-(7-(methylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (65 mg, 0.08 mmol) in 4N HCl in dioxane(1 mL) was stirred at room temperature for 1 h, concentrated undervacuum and the residure was purified by preparative HPLC to give1-(3-(4-(methyl(tetrahydro-2H-pyran-4-yl)amino)-6-(7-(methylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol as a formic acid salt (35 mg, 68% yield). ¹HNMR (500 MHz,CD₃OD) δ ppm: 10.06 (s, 1H), 9.07 (s, 1H), 8.66 (s, 1H), 8.55 (s, 1H),8.12-8.08 (m, 2H), 7.45 (t, J=8.5 Hz, 1H), 7.15-7.11 (m, 2H), 4.37-4.32(m, 1H), 4.24-4.19 (m, 1H), 4.18-4.10 (m, 3H), 3.78 (s, 3H), 3.72-3.65(m, 2H), 3.39-3.36 (m, 1H), 3.28-3.24 (m, 2H), 3.14 (s, 3H), 2.82 (s,3H), 2.10-2.00 (m, 2H), 1.79-1.75 (m, 2H). ESI-LCMS (m/z): 568.3 [M+1]⁺.

Example 10. Preparation of1-(3-(6-(3,5-dimethylisoxazol-4-yl)-4,5′-bipyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

Step 1: Synthesis of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

To a solution of tert-butyl2-(tert-butyldi-methylsilyloxy)-3-(3-(4,6-di-chloro-pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(or any other bis-halide, 14.7 mmol) in degassed dioxane and H₂O (3/1,150 mL) was added 3,5-dimethylisoxazol-4-ylboronic acid (or any othersuitable boron specie, 14.7 mmol), Pd(PPh₃)₄ (853 mg, 0.74 mmol) andNa₂CO₃ (4.7 g, 44.3 mmol). The system was purged with N₂ stream andheated at 100° C. for 12 h. After being cooled down to room temperature,the mixture was diluted with water (100 mL) and extracted with EtOAc (50mL×2). The organic layers were combined, dried over Na₂SO₄, filtered andconcentrated. The residue was purified by chromatographic column onsilicagel (petroleum ether/EtOAc=60/1 to 30/1) to give the tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methyl-pyrimidin-2-yl)phenoxy)propyl(methyl)carbamateas a white solid (4.2 g, 46% yield). ESI-LCMS (m/z): 624.9 [M+23]⁺.

Step 2: Synthesis of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(6-(3,5-di-methylisoxazol-4-yl)-4,5′-bipyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

To a solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(300 mg, 0.5 mmol) in degassed dioxane and H₂O (10/1, 10 mL) was addedpyrimidin-5-yl boronic acid (or any other boronic acid, 0.75 mmol),Pd(dppf)Cl₂ (40 mg, 0.05 mmol) and Cs₂CO₃ (490 mg, 1.5 mmol). The systemwas purged with N₂ stream and heated at 90° C. for 3 h. After beingcooled down to room temperature, the mixture was filtered and thefiltrate was concentrated. The residue was purified by chromatographiccolumn on silicagel (petroleum ether/EtOAc=6/1 to 3/1) to give thetert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(6-(3,5-dimethylisoxazol-4-yl)-4,5′-bipyrimidin-2-yl)phenoxy)propyl(methyl)carbamate as a white solid (100 mg, 31% yield). ESI-LCMS (m/z): 646.8[M+H]⁺.

Step 3:1-(3-(6-(3,5-dimethylisoxazol-4-yl)-4,5′-bipyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

The tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(6-(3,5-dimethylisoxazol-4-yl)-4,5′-bipyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(80 mg, 0.12 mmol) was treated with a 4N HCl in dioxane (5 mL), and themixture was stirred at room temperature for 1 h. After concentratedunder vacuum, the residue was purified by preparative HPLC to give1-(3-(6-(3,5-dimethylisoxazol-4-yl)-4,5′-bipyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-olas a formic acid salt (white solid, 30 mg, 51% yield). ¹HNMR (500 MHz,CD₃OD) δ ppm: 9.62 (s, 2H), 9.34 (s, 1H), 8.54 (brs, 1H), 8.19 (d, J=8.0Hz, 1H), 8.14 (s, 1H), 7.98 (s, 1H), 7.48 (t, J=8.0 Hz, 1H), 7.16 (dd,J=2.5 and 8.5 Hz, 1H), 4.36-4.32 (m, 1H), 4.20-4.10 (m, 2H), 3.62 (s,3H), 3.37-3.33 (m, 1H), 3.28-3.23 (m, 1H), 2.82 (s, 3H), 2.63 (s, 3H);ESI-LCMS (m/z): 433.1 [M+H]⁺.

Example 11. Preparation of1-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-fluoro-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

Step 1: Synthesis of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-di-methylisoxazol-4-yl)-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

A mixture of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-di-methylisoxazol-4-yl)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(602 mg, 1.0 mmol), (tetrahydro-2H-pyran-4-yl)methanamine (345 mg, 3.0mmol) and KI (166 mg, 1.0 mmol) in n-BuOH (5 mL) was places in amicrowave reactor and irradiated for 70 min at external temperature of140° C. After being cooled down to room temperature, the mixture wasdiluted with EtOAc (30 mL), and washed with water (30 mL×2). The organicphase was dried over Na₂SO₄, filtered and concentrated. The residue waspurified by chromatographic column on silicagel (petroleumether/EtOAc=30/1 to 2/1) to give tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-dimethylisoxazol-4-yl)-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamateas a white solid (560 mg, 82% yield). ESI-LCMS (m/z): 682.4 [M+1]⁺.

Step 2: Synthesis of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-di-methylisoxazol-4-yl)-5-fluoro-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

A solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-di-methyl-isoxazol-4-yl)-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (136 mg, 0.2 mmol) in MeCN (5 mL), stirred underN₂ atmosphere at room temperature was treated with neat SelectFluor (105mg, 0.3 mmol) added slowly. The reaction mixture was further stirred atthe same temperature for 12 h, diluted with EtOAc (50 mL) and washedwith water (50 mL×2). The organic layer was dried over Na₂SO₄, filteredand concentrated. The residue was purified by chromatographic column onsilica gel (petroleum ether/EtOAc=30/1 to 2/1) to give tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-fluoro-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate as a white solid (100 mg,71% yield). ESI-LCMS (m/z): 700.4 [M+1]⁺.

Step 3: Synthesis of(4-(3,5-dimethylisoxazol-4-yl)-5-fluoro-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

tert-Butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-fluoro-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (100 mg, 0.14 mmol) was dissolved in 4N HCl solutionin dioxane (4 mL) and the mixture stirred at room temperature for 2 h,concentrated under vacuum and the residue was purified by preparativeHPLC to give1-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-fluoro-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol as aformic acid salt (white solid, 36 mg, 48% yield). ¹HNMR (500 MHz, CD₃OD)δ ppm: 8.55 (brs, 1H), 7.97 (d, J=8.0 Hz, 1H), 7.94 (s, 1H), 7.40 (t,J=8.5 Hz 1H), 7.09 (dd, J=2.0 and 8.0 Hz, 1H), 4.34-4.27 (m, 1H),4.15-4.06 (m, 2H), 4.03-3.97 (m, 2H), 3.57 (d, J=6.5 Hz, 2H), 3.50-3.42(m, 2H), 3.32-3.28 (m, 1H), 3.22-3.17 (m, 1H), 2.78 (s, 3H), 2.52 (s,3H), 2.41 (s, 3H), 2.12-2.02 (m, 1H), 1.82-1.75 (d, 2H), 1.48-1.40 (m,2H). ESI-LCMS: 486.3 [M+1]⁺.

Example 12. Preparation of1-(3-(5-chloro-4-(3,5-dimethylisoxazol-4-yl)-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

Step 1: tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(5-chloro-4-(3,5-dimethyl-isoxazol-4-yl)-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyrimidin-2-yl)phenoxy)propyl(methyl) carbamate

A solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-dimethyl-isoxazol-4-yl)-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (136 mg, 0.2 mmol) in DMF (5 mL) stirred at roomtemperature was treated with NCS (53 mg, 0.4 mmol) and the reactionmixture further stirred at 45° C. for 1 h; the excess of reagent was thequenched by addition of saturated Na₂S₂O₃ aqueous solution (2 mL) andthe resulting mixture was diluted with EtOAc (20 mL), washed with water(20 mL) and brine (20 mL). The organic layer was dried over Na₂SO₄,filtered and concentrated. The residue was purified by chromatographiccolumn on silicagel (petroleum ether/EtOAc=30/1 to 2/1) to givetert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(5-chloro-4-(3,5-dimethyl-isoxazol-4-yl)-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (100 mg, 70% yield) as white solid. ESI-LCMS(m/z): 716.3 [M+1]⁺.

Step 2: Synthesis of1-(3-(5-chloro-4-(3,5-dimethylisoxazol-4-yl)-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

tert-Butyl2-(tert-butyldimethylsilyloxy)-3-(3-(5-chloro-4-(3,5-dimethylisoxazol-4-yl)-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (100 mg, 0.14 mmol) was treated with 4N HCl solutionin dioxane (4 mL) and the mixture was stirred at room temperature for 2h., concentrated under vacuum and the residue was purified bypreparative HPLC to give1-(3-(5-chloro-4-(3,5-dimethylisoxazol-4-yl)-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-olas a formic acid salt (white solid, 36 mg, 51% yield). ¹HNMR (500 MHz,CD₃OD) δ ppm: 8.56 (s, 1H), 7.99 (d, J=8.0 Hz, 1H), 7.95 (s, 1H), 7.41(t, J=8.0 Hz, 1H), 7.11 (dd, J=2.0 and 8.0 Hz, 1H), 4.30-4.26 (m, 1H),4.14-4.06 (m, 2H), 4.03-3.98 (m, 2H), 3.61 (d, J=7.0 Hz, 2H), 3.47-3.42(m, 2H), 3.30-3.27 (m, 1H), 3.22-3.16 (m, 1H), 2.77 (s, 3H), 2.44 (s,3H), 2.31 (s, 3H), 2.12-2.08 (m, 1H), 1.80-1.75 (m, 2H), 1.50-1.40 (m,2H); ESI-LCMS: 502.2 [M+1]⁺.

Example 13. Preparation of methyl4-(5-chloro-2-(2-chloro-5-(2-hydroxy-3-(methylamino)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-ylamino)piperidine-1-carboxylate

Step 1: Synthesis of 2-((3-bromophenoxy)methyl)oxirane

To a suspension of 3-bromophenol (100 g, 0.58 mol) and K₂CO₃ (240.7 g,1.74 mol) in MeCN (1 L) was added 2-(chloromethyl)oxirane (106.98 g,1.16 mol) slowly at room temperature and then the reaction mixture wasstirred at external temperature of 80° C. for 14 h. After being cooleddown to room temperature, the mixture was filtered and the filtrate wasconcentrated. The residue was purified by chromatographic column onsilica gel (petroleum ether/EtOAc=80/1 to 60/1) to give2-((3-bromophenoxy) methyl)oxirane (74 g, 62% yield) as colorless oil.ESI-LCMS (m/z): 228.7 [M+1]⁺.

Step 2: Synthesis of 1-(3-bromophenoxy)-3-(methylamino)propan-2-ol

To a solution of 2-((3-bromophenoxy)methyl)oxirane (56 g, 0.24 mol) inMeOH (150 mL) was added the 33% MeNH₂ solution in MeOH (150 mL) slowlyat 0° C.; the mixture was then stirred at room temperature for 12 h. andfinally concentrated under vacuum to give the 2-((3-bromophenoxy)methyl)oxirane (72 g, crude), which was used directly in the next step withoutfurther purification, assumed quantitative yield. ESI-LCMS (m/z): 260.1[M+1]⁺.

Step 3: Synthesis of tert-butyl3-(3-bromophenoxy)-2-hydroxypropyl(methyl) carbamate

To a solution of 1-(3-bromophenoxy)-3-(methylamino)propan-2-ol (0.24mol) and triethylamine (46.5 g, 0.46 mol) in DCM (1 L) was added asolution of Boc₂O (74.42 g, 0.34 mol) in DCM (100 mL) slowly at 0° C.;then the mixture was further stirred at room temperature for 3 h.,washed consecutively with water (300 mL×2), saturated NH₄Cl aqueoussolution (200 mL×2) and brine (300 mL×2). The organic phase was driedover Na₂SO₄, filtered and concentrated to give tert-butyl3-(3-bromophenoxy)-2-hydroxypropyl(methyl)carbamate tert-butyl3-(3-bromophenoxy)-2-hydroxypropyl(methyl)carbamate as a pale yellowoil, which was used directly in next step without further purification,assumed quantitative yield. ESI-LCMS (m/z): 382.1 [M+23]⁺.

Step 4: Synthesis of tert-butyl3-(3-bromophenoxy)-2-(tert-butyldimethylsilyloxy)propyl(methyl)carbamate

A solution of tert-butyl3-(3-bromophenoxy)-2-hydroxypropyl(methyl)carbamate (0.24 mol) andimidazole (33.47 g, 0.49 mol) in DCM (600 mL) stirred at 0° C. wastreated with slow addition of TBSCl (73.5 g, 0.49 mol). The mixture wasthen stirred at 35 C.° for 2 h., washed with water (300 mL×2) and brine(300 mL). The organic layer was dried over Na₂SO₄, filtered andconcentrated. And the resulting rhe residue was purified bychromatographic column on silica gel (petroleum ether/EtOAc=80/1 to60/1) to give tert-butyl3-(3-bromo-phenoxy)-2-(tert-butyl-dimethylsilyloxy)propyl(methyl)carbamate(100 g, 86% yield) as a pale yellow oil. ESI-LCMS: 496.1 [M+23]⁺.

Step 5: Synthesis of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4,6-di-chloro-pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

To a solution of tert-butyl3-(3-bromophenoxy)-2-(tert-butyldimethylsilyloxy)propyl(methyl)carbamate (20 g, 42 mmol) in dry THF (30 mL) stirred at −78° C.was added n-butyl lithium (18.4 mL, 2.5 M in hexane) over 10 min., themixture was further stirred for another 10 min. at −78° C. before4,6-dichloro-pyrimidine (7.5 g, 50.4 mmol) in THF (10 mL) was addedslowly over 10 min. The resulting mixture was stirred at sametemperature for 10 min., then quenched with HOAc (4 mL) and warmed to 0°C. slowly. DDQ (13 g, 58.8 mmol) was then added portionwise and theresulting mixture was stirred at room temperature for 10 min, dilutedwith CH₂Cl₂ (100 mL) and filtered through a pad of silica gel. Thefiltrate was concentrated and the residue was purified chromatographiccolumn on silicagel (petroleum ether/EtOAc=80/1) to afford tert-butyl2-(tert-butyldi-methylsilyloxy)-3-(3-(4,6-di-chloro-pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (10.0 g, 45% yield) as a white solid. ESI-LCMS(m/z): 563.7 [M+23]⁺.

Step 6: Synthesis of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

To a solution of tert-butyl2-(tert-butyldi-methylsilyloxy)-3-(3-(4,6-di-chloro-pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(8.0 g, 14.7 mmol) in degassed mixture of dioxane and H₂O (3/1, 150 mL)was added 3,5-dimethylisoxazol-4-ylboronic acid (2.09 g, 14.7 mmol),Pd(PPh₃)₄ (853 mg, 0.74 mmol) and Na₂CO₃ (4.7 g, 44.3 mmol). The systemwas purged with N₂ stream and heated at 100° C. for 12 h. After beingcooled down to room temperature, the mixture was diluted with water (100mL) and extracted with EtOAc (50 mL×2). The organic layers werecombined, dried over Na₂SO₄, filtered and concentrated. The residue waspurified by chromatographic column on silicagel (petroleumether/EtOAc=60/1 to 30/1) to give tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methyl-pyrimidin-2-yl)phenoxy)propyl(methyl)carbamateas a white solid (4.2 g, 46% yield). ESI-LCMS: 624.9 [M+23]⁺.

Step 7: Synthesis of methyl4-(2-(3-(3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyldimethylsilyloxy)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-ylamino)piperidine-1-carboxylate

A solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-di-methylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(100 mg, 0.16 mmol), methyl 4-aminopiperidine-1-carboxylatehydrochloride (130 mg, 0.66 mmol), triethylamine (67 mg, 0.66 mmol) andKI (15 mg, 0.083 mmol) in DMSO (2 mL) was placed in a microwave reactor,the temperature was set at 145° C. and irradiated for 1 h. After beingcooled down to room temperature, the mixture was diluted with EtOAc (30mL), washed with water (6 mL×2) and brine (6 mL). The organic layer wasdried over Na₂SO₄, filtered and concentrated. The residue was purifiedby preparative TLC (petroleum ether/EtOAc=1.5/1) to obtain methyl4-(2-(3-(3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyl-dimethylsilyloxy) propoxy) phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methyl-pyrimidin-4-ylamino)piperidine-1-carboxylate(96 mg, 80% yield) as a pale yellow solid. ESI-LCMS: 725.0 [M+1]⁺.

Step 8: Synthesis of methyl4-(2-(5-(3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyldimethylsilyloxy)propoxy)-2-chlorophenyl)-5-chloro-6-(3,5-dimethyl-isoxazol-4-yl)pyrimidin-4-ylamino)piperidine-1-carboxylate

A solution of methyl 4-(2-(3-(3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyl-dimethylsilyloxy)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-ylamino)piperidine-1-carboxylate (96 mg, 0.13 mmol) in DMF (3 mL) stirred atroom temperature was treated with NCS (35 mg, 0.26 mmol) solution in 0.5mL of DMF. The mixture was stirred at 45° C. for 30 min., and thencooled to room temperature, diluted with EtOAc (30 mL), washedconsecutively with water (10 mL×2), saturated Na₂S₂O₃ aqueous solution(10 mL) and brine (10 mL). The organic layer was dried over Na₂SO₄,filtered and concentrated. The residue was purified by preparative TLC(petroleum ether/EtOAc=1.5/1) to obtain then methyl4-(2-(5-(3-(tert-butoxycarbonyl(methyl)amino)-2-hydroxypropoxy)-2-chlorophenyl)-5-chloro-6-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-ylamino)piperidine-1-carboxylate (84 mg, 80% yield) as a pale yellow solid.ESI-LCMS: 792.7 [M+1]⁺.

Step 9: Synthesis of methyl4-(5-chloro-2-(2-chloro-5-(2-hydroxy-3-(methylamino)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-ylamino)piperidine-1-carboxylate

A solution of methyl4-(2-(5-(3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyl-dimethyl-silyloxy)propoxy)-2-chlorophenyl)-5-chloro-6-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-ylamino)piperidine-1-carboxylate (84 mg, 0.11 mmol) in 90% TFA aqueous solution(2 mL) was stirred at 35° C. for 1 h., concentrated under vacuum, theresidue was dissolved in MeOH (5 mL) and the pH adjusted to 9 withsaturated aqueous K₂CO₃ solution. The mixture was filtered and thefiltrate was concentrated. The residue was purified by preparative HPLCto give methyl4-(5-chloro-2-(2-chloro-5-(2-hydroxy-3-(methylamino)propoxy)phenyl)-6-(3,5-di-methylisoxazol-4-yl)pyrimidin-4-ylamino)piperidine-1-carboxylate as a formic acid salt(white solid, 25 mg, 37% yield). ¹HNMR (500 MHz, MeOD) δ ppm: 8.60 (brs,1H), 7.42 (d, J=9.0 Hz, 1H), 7.28 (d, J=3.0 Hz, 1H), 7.06 (dd, J=3.0 and8.0 Hz, 1H), 4.42-4.36 (m, 1H), 4.25-4.12 (m, 3H), 4.10-4.02 (m, 2H),3.70 (s, 3H), 3.23-3.18 (m, 1H), 3.14-3.07 (m, 1H), 3.04-2.90 (m, 2H),2.71 (s, 3H), 2.42 (s, 3H), 2.27 (s, 3H), 2.08-2.02 (m, 2H), 1.70-1.58(m, 2H); ESI-LCMS: 578.8 [M+1]⁺.

Example 14. Preparation of1-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-(hydroxymethyl)-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

Step 1: Synthesis of2,4-dichloro-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidine-5-carbaldehydeand4,6-dichloro-2-(tetrahydro-2H-pyran-4-ylamino)pyrimidine-5-carbaldehyde

To a mixture of 2,4,6-trichloropyrimidine-5-carbaldehyde (1.5 g, 7.2mmol) and NaHCO₃ (0.91 g, 10 mmol) in THF (100 mL) was addedtetrahydro-2H-pyran-4-amine (0.73 g, 7.2 mmol) slowly at 0° C. Themixture was warmed up to room temperature and stirred for 8 h. Thereaction mixture was filtered and the filtrate was concentrated. Theresidue was purified by chromatographic column on silicagel (petroleumether/EtOAc=10/1 to 1/1) to give2,4-dichloro-6-(tetrahydro-2H-pyran-4-ylamino) pyrimidine-5-carbaldehyde(1.0 g, 51% yield) as major product. The minor isomer4,6-dichloro-2-(tetrahydro-2H-pyran-4-ylamino)pyrimidine-5-carbaldehyde(400 mg, 21% yield) was also obtained. ESI-LCMS (m/z): 276.0 [M+1]⁺.

Step 2: Synthesis of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-5-formyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

To a solution of2,4-dichloro-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidine-5-carbaldehyde(0.4 g, 1.4 mmol) in degassed dioxane and H₂O (10/1, 25 mL) was addedtert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxa-borolan-2-yl)phenoxy)propyl(methyl)carbamate (830 mg, 1.6 mmol), K₂CO₃ (600 mg, 4.35 mmol) andPd(PPh₃)₄ (83 mg, 0.07 mmol). The system was purged with N₂ stream andthe mixture was stirred at 100° C. for 2 h. After being cooled down toroom temperature, the reaction mixture was diluted with water (50 mL)and extracted with EtOAc (50 mL×2). The organic layers were combined,dried over Na₂SO₄, filtered and concentrated. The residue was purifiedby chromatographic column on silicagel (petroleum ether/EtOAc=5/1 to1/1) to afford the tert-butyl 2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-5-formyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (710 mg, 77% yield) as major product. ESI-LCMS(m/z): 635.0 [M+1]⁺.

Step 3: Synthesis of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-dimethyl-isoxazol-4-yl)-5-formyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

To a solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-5-formyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(600 mg, 0.95 mmol) in degassed dioxane and H₂O (10/1, 50 mL) was addedPd₂(dba)₃ (92 mg, 0.10 mmol), tricyclohexylphosphine (80 mg, 0.30 mmol),KF (18 mg, 0.30 mmol) and3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) isoxazole(255 mg, 1.1 mmol). The system was purged with N₂ stream, placed in amicrowave reactor and irradiated for 1 h at 110° C. After being cooleddown to room temperature, the mixture was diluted with water (25 mL) andextracted with EtOAc (25 mL×2). The organic layers were combined, driedover Na₂SO₄, filtered and concentrated. The residue was purified bychromatographic column on silicagel (petroleum ether/EtOAc=5/1 to 1/1)to give tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-formyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (530 mg, 80% yield). ESI-LCMS (m/z): 696.0[M+1]⁺.

Step 4: tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-(hydroxymethyl)-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

A solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-formyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(200 mg, 0.29 mmol) in THF (10 mL) was treated with NaBH₄ (25 mg, 0.6mmol) and the mixture stirred at room temperature for 2 h, concentratedunder vacuum and the resulting residue was purified by preparative TLCto give tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-dimethyl-isoxazol-4-yl)-5-(hydroxymethyl)-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(180 mg, 91% yield). ESI-LCMS: 698.0 [M+1]⁺.

Step 5: Synthesis of1-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-(hydroxymethyl)-6-(tetra-hydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

tert-Butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-(hydroxymethyl)-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (80 mg, 0.11 mmol) was dissolved in a 2.5 N HCl solution inmethanol (10 mL), and the mixture was stirred at room temperature for 2h., concentrated under vacuum and purified by preparative HPLC to give1-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-(hydroxymethyl)-6-(tetrahydro-2H-pyran-4-yl-amino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-olas a TFA salt (34 mg, 51% yield). ¹HNMR (500 MHz, CD₃OD) δ ppm:7.43-7.40 (t, J=8.0 Hz, 1H), 7.18-7.10 (m, 3H), 4.46 (s, 2H), 4.43-4.38(m, 1H), 4.22-4.18 (m, 2H), 4.03-3.96 (m, 2H), 3.93-3.89 (m, 2H),3.50-3.45 (m, 2H), 3.20-3.06 (m, 1H), 2.66 (s, 3H), 2.60 (s, 3H), 2.41(s, 3H), 1.95-1.91 (m, 2H), 1.72-1.64 (m, 2H); LCMS: 484.0 [M+H]⁺.

Example 15. Preparation of1-(3-(5-(difluoromethyl)-4-(3,5-dimethylisoxazol-4-yl)-6-(tetra-hydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

Step 1: tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(5-(difluoromethyl)-4-(3,5-dimethylisoxazol-4-yl)-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-formyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (200 mg, 0.29 mmol) was treated withbis-(2-methoxyethyl)aminosulfur trifluoride (BAST, 5 mL, excess) and themixture was stirred at room temperature for 12 h, excess of reagentquenched by pouring the mixture into ice water (50 mL) and extractedwith DCM (25 mL×2). The combined organic layers were dried over Na₂SO₄,filtered and concentrated. The residue was purified by chromatographiccolumn on silicagel (petroleum ether/EtOAc=20/1 to 8/1) to givetert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(5-(difluoromethyl)-4-(3,5-dimethylisoxazol-4-yl)-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (35 mg, 18% yield).ESI-LCMS (m/z): 718 [M+1]⁺.

Step 2: Synthesis of1-(3-(5-(difluoromethyl)-4-(3,5-dimethylisoxazol-4-yl)-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

tert-Butyl2-(tert-butyldimethylsilyloxy)-3-(3-(5-(difluoromethyl)-4-(3,5-di-methylisoxazol-4-yl)-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(35 mg, 0.05 mmol) was treated with 2.5 N HCl solution in methanol (10mL), and the mixture was stirred at room temperature for 2 h.,concentrated under vacuum and the resulting residue purified bypreparative HPLC to give1-(3-(5-(difluoromethyl)-4-(3,5-dimethylisoxazol-4-yl)-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-olas a TFA salt (18 mg, 62% yield). ¹HNMR (500 MHz, CD₃OD) δ ppm:7.37-7.34 (m, 1H), 7.08-7.02 (m, 3H), 6.74-6.53 (t, J=53.0 Hz, 1H),4.41-4.36 (m, 1H), 4.21-4.16 (m, 2H), 4.02-3.90 (m, 4H), 3.47-3.43 (m,2H), 3.20-3.06 (m, 1H), 2.68 (s, 3H), 2.66 (s, 3H), 2.46 (s, 3H),1.94-1.91 (m, 2H), 1.65-1.59 (m, 2H); LCMS: 504 [M+H]⁺.

Example 16. Preparation of6-(3,5-Dimethyl-isoxazol-4-yl)-2-[3-(2-hydroxy-3-methylamino-propoxy)phenyl]pyrimidine-4-carboxylicacid (tetrahydro-pyran-4-ylmethyl)-amide

Step 1: Synthesis of phenyl2-(3-(3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyldimethylsilyloxy)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)pyrimidine-4-carboxylate

To a solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(122 mg, 0.20 mmol) in degassed MeCN (5 mL) was added phenyl formate (37mg, 0.30 mmol), xantphos (2 mg, 0.002 mmol), Pd(OAc)₂ (2 mg, 0.006 mmol)and Et₃N (1 mL). The system was purged with N₂ stream, the reactionvessel was sealed and the mixture was stirred at 80° C. for 2.5 h. Afterbeing cooled down to room temperature, the mixture was filtered througha pad of Celite and concentrated to give phenyl2-(3-(3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyldimethylsilyloxy)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl) pyrimidine-4-carboxylate, whichwas used for next reaction without further purification. Quantitativeyield. ESI-LCMS (m/z): 689.0 [M+1]⁺.

Step 2: Synthesis of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-di-methylisoxazol-4-yl)-6-((tetrahydro-2H-pyran-4-yl)methylcarbamoyl)pyrimidin-2-yl)phenoxy)propyl(methyl) carbamate

A solution of phenyl2-(3-(3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyl-dimethylsilyloxy)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)pyrimidine-4-carboxylate(0.2 mmol) in MeCN (3 mL) stirred at room temperature was treated with(tetrahydro-2H-pyran-4-yl)methanamine (30 mg, 0.34 mmol) and Et₃N (1mL). The mixture was further stirred at room temperature for 0.5 h.,concentrated and the residue was purified by preparative TLC to givetert-butyl2-(tert-butyldimethyl-silyloxy)-3-(3-(4-(3,5-dimethylisoxazol-4-yl)-6-((tetrahydro-2H-pyran-4-yl)methyl-carbamoyl)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(80 mg, 55% yield for 2 steps). ESI-LCMS (m/z): 710.3 [M+1]⁺.

Step 3: Synthesis of6-(3,5-dimethylisoxazol-4-yl)-2-(3-(2-hydroxy-3-(methyl-amino)propoxy)phenyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)pyrimidine-4-carboxamide

A solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-dimethyl-isoxazol-4-yl)-6-((tetrahydro-2H-pyran-4-yl)methylcarbamoyl)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(80 mg, 0.11 mmol) in MeOH (3 mL) was treated with 4N HCl in dioxane (1mL), and the mixture was stirred at room temperature for 1 h.,concentrated and the residue was dissolved in MeOH (5 mL) and treatedwith saturated K₂CO₃ aqueous solution till pH=9. The mixture wasfiltered, the filtrate was concentrated and the residue was purified bypreparative HPLC to give6-(3,5-dimethylisoxazol-4-yl)-2-(3-(2-hydroxy-3-(methyl-amino)propoxy)phenyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)pyrimidine-4-carboxamideas a formic acid salt (white solid, 11 mg, 20% yield). ¹HNMR (500 MHz,CD₃OD) δ ppm: 9.21 (brs, 1H), 8.26 (d, J=7.5 Hz, 1H), 8.17 (s, 1H), 8.04(d, J=3.5 Hz, 1H), 7.49 (t, J=7.5 Hz, 1H), 7.19 (d, J=8.0 Hz, 1H),4.36-4.30 (m, 1H), 4.22-4.14 (m, 2H), 4.02-3.98 (m, 2H), 3.50-3.42 (m,4H), 3.40-3.34 (m, 1H), 3.27-3.22 (m, 1H), 2.81 (s, 6H), 2.62 (s, 3H),2.06-1.97 (m, 1H), 1.78-1.70 (m, 2H), 1.48-1.38 (m, 2H); ESI-LCMS (m/z):396.3 [M+1]⁺.

Example 17. Preparation of1-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-((tetrahydro-2H-pyran-4-yl)methoxy)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

Step 1: Synthesis of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-di-methylisoxazol-4-yl)-5-methyl-6-((tetrahydro-2H-pyran-4-yl)methoxy)pyrimidin-2-yl)phenoxy)propyl(methyl) carbamate

A mixture of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(0.41 mmol), (tetrahydro-2H-pyran-4-yl)methanol (or any other alcohol orthiol, 0.81 mmol) and Cs₂CO₃ (330 mg, 1.01 mmol) in DMSO (5 mL) wasstirred at 120° C. for 1 h in a sealed tube. After being cooled down toroom temperature, the mixture was diluted with EtOAc (50 mL) and washedwith water (30 mL×3) followed by brine (50 mL). The organic phase wasdried over Na₂SO₄, filtered and concentrated. The residue was purifiedby automated chromatographic column eluted with 0% to 50%EtOAc/petroleum ether, 40 mL/min, to give tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-((tetra-hydro-2H-pyran-4-yl)methoxy)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamateas a yellow solid (170 mg, 60% yield). ESI-LCMS (m/z): 697.0 [M+1]⁺.

Step 2: Synthesis of1-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-((tetrahydro-2H-pyran-4-yl)methoxy)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

A solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-6-((tetrahydro-2H-pyran-4-yl)methoxy)pyrimidin-2-yl)phenoxy)propyl(methyl) carbamate (160 mg, 0.24 mmol) in DCM (6 mL) wastreated with 4N HCl solution in dioxane (2 mL) and the mixture wasstirred at room temperature for 2 h., concentrated and the residue wasdissolved in MeOH (5 mL) and treated with saturated NaHCO₃aqueoussolution till pH=8. The mixture was concentrated under vacuum and theresidue was purified by preparative HPLC to give 1-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-((tetrahydro-2H-pyran-4-yl)methoxy)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol as a formic acid salt(white solid, 97 mg, 75% yield). ¹HNMR (500 MHz, CD₃OD) δ ppm: 8.56(brs, 1H), 8.04 (d, J=8.0 Hz, 1H), 7.99 (s, 1H), 7.43 (t, J=8.0 Hz, 1H),7.12 (dd, J=8.0 and 2.0 Hz, 1H), 4.49 (d, J=6.5 Hz, 2H), 4.29-4.25 (m,1H), 4.15-4.06 (m, 2H), 4.05-4.00 (m, 2H), 3.56-3.49 (m, 2H), 3.29-3.25(m, 1H), 3.18-3.14 (m, 1H), 2.75 (s, 3H), 2.39 (s, 3H), 2.28 (s, 3H),2.26-2.23 (m, 1H), 2.14 (s, 3H), 1.86-1.82 (m, 2H), 1.62-1.52 (m, 2H).ESI-LCMS: 483.0 (M+1)+.

Example 18. Preparation of1-(3-(4-(5-cyclopropyl-3-methylisoxazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

Step A1: Synthesis of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

To a solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4,6-dichloro-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(2.2 g, 4.0 mmol) and triethylamine (610 mg, 6.0 mmol) in DMF (20 mL)was added tetrahydro-2H-pyran-4-amine (610 mg, 6.0 mmol) at roomtemperature. The mixture was then heated at 120° C. and stirred for 12h., cooled down to room temperature, diluted with EtOAc (30 mL) andsuccessively washed with H₂O (25 mL×2), saturated aqueous NH₄Cl solution(30 mL×2) and brine (30 mL). The organic layer was dried over Na₂SO₄,filtered and concentrated and the resulting residue was purified bychromatographic column on silicagel (petroleum ether/EtOAc=10/1 to 4/1)to give tert-butyl2-(tert-butyldimethyl-silyloxy)-3-(3-(4-chloro-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate as a white solid (1.9 g,Yeild: 76% yield). ESI-LCMS (m/z)=621.3 [M+1]⁺.

Step B1: Synthesis of the mixture of 5-cyclopropyl-3-methylisoxazole and3-cyclopropyl-5-methylisoxazole

A mixture of 1-cyclopropylbutane-1,3-dione (or any other suitable1,3-dione, 15.9 mmol), NH₂OH—HCl (2.2 g, 31.75 mmol) and K₂CO₃ (6.6 g,47.62 mmol). in EtOH (12 mL) was stirred under reflux for 12 h., cooledto room temperature filtered and concentrated to render a mixture of5-cyclopropyl-3-methylisoxazole and 3-cyclopropyl-5-methylisoxazole(ratio=4/1, determined by HNMR) as a yellow oil. Assumed quantitativeyield. ESI-LCMS (m/z): 124 [M+1]⁺.

Step B2: Synthesis of the mixture of4-bromo-5-cyclopropyl-3-methylisoxazole and4-bromo-3-cyclopropyl-5-methylisoxazole

A solution of 5-cyclopropyl-3-methylisoxazole and3-cyclo-propyl-5-methylisoxazole (15.9 mmol) in DMF (10 mL) was treatedwith NBS (3.1 g, 17.4 mmol) and the resulting mixture was stirred atroom temperature for 12 h., diluted with EtOAc (150 mL) and washed withH₂O (100 mL×3) followed by brine (50 mL). The organic layer was driedover Na₂SO₄, filtered and concentrated and the residue was purified byautomated chromatographic column on silicagel eluted with 0% to 8%EtOAc/petroleum ether to give a mixture of4-bromo-5-cyclopropyl-3-methyl-isoxazole and4-bromo-3-cyclopropyl-5-methylisoxazole as a yellow oil (2.5 g, 12.3mmol, 78% yield in two steps). ESI-LCMS (m/z): 201.9 [M+1]⁺.

Step B3: Synthesis of a mixture of5-cyclopropyl-3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazoleand3-cyclopropyl-5-methyl-4-(4,4,5,5-tetra-methyl-1,3,2-dioxaborolan-2-yl)isoxazole

To a mixture of 4-bromo-5-cyclopropyl-3-methylisoxazole and4-bromo-3-cyclopropyl-5-methylisoxazole (500 mg, 2.48 mmol) in dioxane(15 mL) was added4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (943 mg,3.71 mmol), KOAc (1.17 g, 7.43 mmol) and PdCl₂(dppf) (181 mg, 0.25mmol); the system was purged with N₂ stream, sealed and heated at 105°C. for 12 h. After being cooled down to room temperature, the mixturewas filtered through a pad of celite and concentrated to give a mixtureof5-cyclopropyl-3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazoleand3-cyclopropyl-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazoleas a yellow solid, which was used directly in next step without furtherpurification. ESI-LCMS (m/z): 250.1 [M+1]⁺.

Step 1: Synthesis of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(5-cyclo-propyl-3-methylisoxazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl) phenoxy)propyl(methyl)carbamate

To a solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(400 mg, 0.64 mmol) in degassed dioxane and H₂O (3/1, 4 mL) was added KF(37 mg, 0.64 mmol), Pd₂(dba)₃ (46 mg, 0.06 mmol), TCP (36 mg, 0.13 mmol)and5-cyclo-propyl-3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole(containing 30% of regioisomer:3-cyclopropyl-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxa-borolan-2-yl)isoxazole)(319 mg, 1.28 mmol). The system was purged with N₂ stream, the reactionvessel was sealed, placed in a microwave reactor and irradiated for 1 hat external temperature of 130° C. After being cooled down to roomtemperature, the mixture was diluted with EtOAc (25 mL) and washed withwater (20 mL) followed by brine (20 mL). The organic layer was driedover Na₂SO₄, filtered and concentrated and the residue was purified bychromatographic column on silicagel (petroleum ether/EtOAc=10/1 to 1/1)to give a mixture of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(5-cyclopropyl-3-methylisoxazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-yl-amino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate,along with its regiosiomer tert-butyl 2-(tertbutyldimethylsilyloxy)-3-(3-(4-(3-cyclopropyl-5-methyl-isoxazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (total: 200 mg, 44% yield). ESI-LCMS (m/z):708.7 [M+1]⁺.

Step 2: Synthesis of1-(3-(4-(5-cyclopropyl-3-methylisoxazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

A mixture of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(5-cyclo-propyl-3-methyl-isoxazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl (methyl)carbamate and tert-butyl2-(tert-butyldimethyl-silyloxy)-3-(3-(4-(3-cyclopropyl-5-methylisoxazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-yl-amino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (200 mg, 0.28 mmol) was dissolved in 2.5 N HClsolution in methanol (10 mL) and the mixture stirred at room temperaturefor 2 h., concentrated under vacuum, and the residue was purified bypreparative HPLC to give1-(3-(4-(5-cyclopropyl-3-methylisoxazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol along with the its regiosiomer1-(3-(4-(3-cyclopropyl-5-methylisoxazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol (isomeric ration: 2/1, total: 49 mg, 36% yield) as a whitesolid. ¹HNMR (500 MHz, CD₃OD) δ ppm: 7.94-7.91 (m, 2H), 7.37 (t, J=8.5Hz, 1H), 7.06 (dd, J=2.5 and 8.0 Hz, 1H), 4.54-4.49 (m, 1H), 4.19-4.14(m, 1H), 4.10-4.04 (m, 3H), 3.70-2.92 (m, 5H), 2.78 (s, 3H), 2.25 (s,3H), 2.13 (s, 3H), 2.12-2.05 (m, 1H), 1.97-1.77 (m, 4H), 1.12-1.07 (m,2H), 0.98-0.96 (m, 2H); ESI-LCMS: 494.3 [M+1]⁺.

Example 19. Preparation of1-(3-(4-(3,5-dimethylisothiazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

Step 1: Synthesis of pent-3-yn-2-one

A 100 mL round-bottom flask equipped with a reflux condenser, athermometer, an addition funnel and an argon inlet was loaded with AlCl₃(5.94 g, 0.045 mmol) and DCM (40 mL), and cooled to 0° C. A freshlyprepared solution of trimethyl(prop-1-ynyl)silane (5.0 g, 0.045 mol) andAcCl (3.2 mL, 0.045 mol) in 10 mL of DCM was added slowly with stirringat 0° C., once the addition was completed the cooling bath was removedand the reaction mixture was further stirred at room temperature for 3h., was poured into ice water and extracted with DCM (50 mL×3). Thecombined organic layers were dried over Na₂SO₄, filtered andconcentrated. The residue was distilled to give pent-3-yn-2-one (1.6 g,44% yield). ¹HNMR (500 MHz, CDCl₃) δ ppm: 2.30 (s, 3H), 2.01 (s, 3H).

Step 2: Synthesis of 3,5-dimethylisothiazole

A mixture of pent-3-yn-2-one (5.42 g, 0.066 mol) and H₂NOSO₃H (7.46 g,0.066 mol) in 40 mL of water was stirred at 0° C. for 30 min. ThenNaHCO₃ (5.54 g, 0.066 mol) followed by NaHS (4.1 g, 0.073 mol) wereslowly added. The cooling bath was removed and the reaction mixture wasstirred at room temperature for 12 h., then extracted with diethyl ether(50 mL×3). The combined organic layers were dried over Na₂SO₄, filteredand concentrated to give 3,5-dimethylisothiazole (4.27 g, 60% yield) asan oil. ESI-LCMS (m/z): 114.1 [M+1]⁺.

Step 3: Synthesis of 4-iodo-3,5-dimethylisothiazole

A mixture of 3,5-dimethylisothiazole (4.27 g, 0.038 mol) and I₂ (9.59 g,0.038 mol) was slowly added to HNO₃ (50 mL) with stirring at 0° C., thecooling bath was then removed and the mixture was further stirred atroom temperature for 12 h., poured into ice water and extracted withEtOAc (50 mL×3). The combined organic layers were dried over Na₂SO₄,filtered and concentrated. The residue was purified by chromatographiccolumn on silicagel to give 4-iodo-3,5-dimethylisothiazole (3.5 g, 33%yield). ESI-LCMS (m/z): 239.9 [M+1]⁺.

Step 4: Synthesis of 3,5-dimethylisothiazol-4-ylboronic acid

A solution of 4-iodo-3,5-dimethylisothiazole (100 mg, 0.41 mmol) in 5 mLof THF stirred at −15° C. under N₂ atmosphere, was treated with a 3 Msolution of EtMgBr in diethyl ether (0.42 mL, 1.25 mmol,), stirred atthe same temperature for 5 min and then B(OMe)₃ (131 mg, 1.25 mmol) wasadded. The final mixture was stirred at room temperature for 2 h.,quenched with slow addition of aqueous HCl, poured into ice water andextracted with ethyl acetate (20 mL×3). The combined organic layers weredried over Na₂SO₄, filtered and concentrated to give3,5-dimethylisothiazol-4-ylboronic acid (65 mg, crude), which was useddirectly without further purification. ESI-LCMS (m/z): 158.0 [M+1]⁺.

Step 5: Synthesis of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-di-methylisothiazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

A mixture of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(100 mg, 0.16 mmol), 3,5-dimethylisothiazol-4-ylboronic acid (50 mg,0.32 mmol), KF (10 mg, 0.17 mmol), Pd₂(dba)₃ (22 mg, 0.02 mmol) and TCP(13 mg, 0.05 mmol) in degassed dioxane and H₂O (3/1, 5.5 mL) was purgedwith N₂ stream, the reaction vessel was sealed, placed in a microwavereactor and irradiated for 1 h at external temperature of 130° C.,cooled down to room temperature, diluted with water (5 mL) and themixture was extracted with EtOAc (10 mL×3). The combined organic layerswas dried over Na₂SO₄, filtered and concentrated. The residue waspurified by preparative TLC to give tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-dimethylisothiazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl) carbamate (42 mg, 38% yield). ESI-LCMS (m/z): 698.0[M+1]⁺.

Step 6: Synthesis of1-(3-(4-(3,5-dimethylisothiazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

A solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-dimethyl-isothiazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(42 mg, 0.06 mmol) in 2.5N HCl solution in methanol (1.5 mL) was stirredat room temperature for 2 h., concentrated under vacuum and the residuewas dissolved in MeOH (5 mL) and treated with aqueous NH₄OH till pH=9.The resulting mixture was concentrated in vacuo and the residue waspurified by preparative HPLC to give1-(3-(4-(3,5-dimethylisothiazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-olas a formic acid salt (15 mg, 48% yield). ¹HNMR (500 MHz, CD₃OD) δ ppm:8.58 (brs, 1H), 7.96 (d, J=7.5 Hz, 1H), 7.89 (s, 1H), 7.39 (t, J=8.0 Hz,1H), 7.08 (dd, J=2.5 and 8.0 Hz, 1H), 4.58-4.51 (m, 1H), 4.32-4.25 (m,1H), 4.16-4.06 (m, 4H), 3.70-3.63 (m, 2H), 3.30-3.28 (m, 1H), 3.21-3.17(m, 1H), 2.77 (s, 3H), 2.42 (s, 3H), 2.31 (s, 3H), 2.13-2.08 (m, 2H),1.93 (s, 3H), 1.85-1.76 (m, 2H); ESI-LCMS (m/z): 484.2 [M+1]⁺.

Example 20. Preparation of1-(3-(4-(3,5-dimethyl-3H-1,2,3-triazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

Step 1: Synthesis of tert-butyl2-hydroxy-3-(3-(5-methyl-4-(prop-1-ynyl)-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

A solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(1.0 g, 1.61 mmol), Pd(MeCN)₂C₂ (42 mg, 0.16 mmol) and X-phos (230 mg,0.48 mmol) in Et₃N (10 ml) was treated with trimethyl(prop-1-ynyl)silane(360 mg, 3.22 mmol). The system was purged with N₂ stream and then TBAF(3.22 ml, 3.22 mmol) was added slowly at 0° C. The mixture was thenwarmed up to room temperature the reaction vessel was sealed, placed ina microwave reactor and irradiated for 3 h at external temperature of110° C. After being cooled down to room temperature, the mixture wasdiluted with water (50 ml) and extracted with EtOAc (50 ml×2). Theorganic layers were combined, dried over Na₂SO₄, filtered andconcentrated. The residue was purified by chromatographic column onsilicagel (petroleum ether/EtOAc=10/1 to 1/1) to give tert-butyl2-hydroxy-3-(3-(5-methyl-4-(prop-1-ynyl)-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (600 mg, 73% yield) asmajor product. ESI-LCMS (m/z): 511.0 [M+1]⁺.

Step 2: Synthesis of tert-butyl2-hydroxy-3-(3-(5-methyl-4-(5-methyl-3-((trimethylsilyl)methyl)-3H-1,2,3-triazol-4-yl)-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy) propyl(methyl)carbamate and tert-butyl2-hydroxy-3-(3-(5-methyl-4-(5-methyl-1-((trimethylsilyl)methyl)-1H-1,2,3-triazol-4-yl)-6-(tetra-hydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

To a solution of tert-butyl2-hydroxy-3-(3-(5-methyl-4-(prop-1-ynyl)-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(400 mg, 0.78 mmol) in degassed toluene (10 ml) was added(azidomethyl)trimethylsilane (1 g, 7.80 mmol) followed by ClCp*(PPh₃)₂Ru(176 mg, 0.24 mmol). The system was purged with N₂ stream, sealed andstirred at 90° C. for 24 h. The reaction mixture was cooled to roomtemperature, diluted with water (50 ml) and extracted with EtOAc (50ml×2). The organic layers were combined, dried over Na₂SO₄, filtered andconcentrated. The residue was purified by preparative HPLC to rendertert-butyl2-hydroxy-3-(3-(5-methyl-4-(5-methyl-3-((trimethylsilyl)methyl)-3H-1,2,3-triazol-4-yl)-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(62 mg, 12% yield) as major product. ESI-LCMS (m/z): 640.3 [M+1]⁺.

The regiosiomer tert-butyl2-hydroxy-3-(3-(5-methyl-4-(5-methyl-1-((trimethylsilyl)methyl)-1H-1,2,3-triazol-4-yl)-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl (methyl)carbamate (41 mg, 8% yield yield) was alsoisolated as minor product. ESI-LCMS (m/z): 640.3 [M+1]⁺.

Step 3: Synthesis of tert-butyl3-(3-(4-(3,5-dimethyl-3H-1,2,3-triazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-2-hydroxy-propyl(methyl)carbamate

A solution of tert-butyl2-hydroxy-3-(3-(5-methyl-4-(5-methyl-3-((trimethylsilyl)methyl)-3H-1,2,3-triazol-4-yl)-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl) carbamate (62 mg, 0.097 mmol) in THF (10 ml) wastreated with 1M TBAF in THF (0.2 mmol), slowly added at 0° C. Themixture was then warmed up to room temperature and stirred for 12 h.,diluted with water (25 ml) and extracted with EtOAc (25 ml×2). Theorganic layers were combined, dried over Na₂SO₄, filtered andconcentrated to give tert-butyl3-(3-(4-(3,5-dimethyl-3H-1,2,3-triazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-2-hydroxypropyl(methyl)carbamate(40 mg, crude), which was used directly without further purification.ESI-LCMS (m/z): 568.3 [M+1]⁺.

Step 4: Synthesis of1-(3-(4-(3,5-dimethyl-3H-1,2,3-triazol-4-yl)-5-methyl-6-(tetra-hydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

tert-Butyl3-(3-(4-(3,5-dimethyl-3H-1,2,3-triazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-2-hydroxypropyl(methyl)carbamate(40 mg, 0.07 mmol) was dissolved in a 2N HCl solution in methanol (10ml), and the mixture was stirred at room temperature for 2 h.,concentrated under vacuum and the resulting residue was purified bypreparative HPLC to give1-(3-(4-(3,5-dimethyl-3H-1,2,3-triazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-olas a formic acid salt (11 mg, 22% yield for 2 steps). ¹HNMR (500 MHz,CD₃OD) δ ppm: 8.57 (brs, 1H), 7.98 (d, J=8.0 Hz, 1H), 7.93 (s, 1H), 7.40(t, J=8.5 Hz, 1H), 7.09 (dd, J=2.0 and 8.5 Hz, 1H), 4.58-4.51 (m, 1H),4.27 (brs, 1H), 4.15-4.06 (m, 4H), 4.03 (s, 3H), 3.68-3.63 (m, 2H),3.30-3.23 (m, 1H), 3.19-3.12 (m, 1H), 2.74 (s, 3H), 2.27 (s, 3H),2.13-2.08 (m, 2H), 2.00 (s, 3H), 1.85-1.76 (m, 2H); ESI-LCMS (m/z):468.0 [M+H]⁺.

Example 21. Preparation of1-(3-(4-(3-(hydroxymethyl)-5-methylisoxazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

Step 1: Synthesis of (5-methylisoxazol-3-yl)methyl benzoate

Benzoyl chloride (3 g, 21.24 mmol) was slowly added to a stirredsolution of (5-methylisoxazol-3-yl)methanol (2.0 g, 17.7 mmol), Et₃N(4.9 mL, 35.3 mmol) and DMAP (216 mg, 1.76 mmol) in DCM (50 mL) at 0°C., after the addition was complete, the reaction mixture was warmed upto room temperature and further stirred for 16 h., washed with water (30mL), aqueous NH₄Cl solution (30 mL×2) and brine (30 mL). The organiclayer was dried over Na₂SO₄, filtered, concentrated under vacuum and theresulting residue was purified by chromatographic column on silicageleluted with 0% to 15% EtOAc/petroleum ether to give(5-methylisoxazol-3-yl)methyl benzoate as a white solid (3.4 g, 89%yield). ESI-LCMS: 218.1 [M+1]⁺.

Step 2: Synthesis of (4-bromo-5-methylisoxazol-3-yl)methyl benzoate

A solution of (5-methylisoxazol-3-yl)methyl benzoate (3.16 g, 14.5 mmol)and NBS (2.98 g, 16.7 mmol) in AcOH (30 mL) was treated withconcentrated H₂SO₄ (1.43 g, 14.5 mmol) slowly added at room temperatureand then the reaction mixture was heated at 110° C. for 1 h., cooleddown to room temperature, slowly added into iced saturatedNaHCO₃solution (400 mL) with stirring and extracted with DCM (200 mL×3).The combined organic layers were washed with brine (200 mL), dried overNa₂SO₄, filtered, concentrated under vacuum and the resulting residuewas purified by chromatographic column on silicagel eluted with 0% to10% EtOAc/petroleum ether, to give(4-bromo-5-methyl-isoxazol-3-yl)methyl benzoate as a white solid (3.53g, 83% yield). ESI-LCMS: 296.0 [M+1]⁺.

Step 3: Synthesis of(5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazol-3-yl)methyl benzoate

A suspension of (4-bromo-5-methylisoxazol-3-yl)methyl benzoate (600 mg,2.0 mmol), S-Phos (166 mg, 0.4 mmol),4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.59 g, 20.27 mmol), Pd(OAc)₂(46 mg, 0.20 mmol) and Et₃N (1.4 mL, 10.1 mmol) in toluene (30 mL) wasstirred under N₂ atmosphere at external temperature of 90° C. for 3 h.After being cooled down to room temperature, the reaction mixture wasfiltered, and the filtrate concentrated under vacuum to give(5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazol-3-yl)methylbenzoate as an oil (900 mg, crude), which was used in next-step withoutfurther purification. Assumed quantitative yield. ESI-LCMS: 344.3[M+1]⁺.

Step 4: Synthesis of(4-(2-(3-(3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyldimethylsilyloxy)propoxy)phenyl)-5-methyl-6-(tetrahydro-2H-pyran-4-yl-amino)pyrimidin-4-yl)-5-methylisoxazol-3-yl)methylbenzoate

A solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (300 mg, 0.48 mmol) indioxane and H₂O (3/1, 12 mL) was treated with(5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazol-3-yl)methylbenzoate (2 mmol, crude from previous step), TCP (135 mg, 0.48 mmol); KF(56 mg, 0.97 mmol) and Pd₂(dba)₃ (221 mg, 0.24 mmol). The system waspurged with N₂ stream, the vial sealed, placed in a microwave reactorand irradiated for 60 min. at external temperature of 110° C. Afterbeing cooled down to room temperature the mixture was diluted with water(30 mL) and extracted with EtOAc (30 mL×2). The combined organic layerswere washed with brine, dried over Na₂SO₄, filtered and concentrated,the resulting residue was purified by preparative TLC (petroleumether/EtOAc=2/1) to give(4-(2-(3-(3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyldimethyl-silyloxy)propoxy)phenyl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-4-yl)-5-methylisoxazol-3-yl)methylbenzoate as a yellow solid (280 mg, 74% yield). ESI-LCMS: 802.3 [M+1]⁺.

Step 5: Synthesis of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3-(hydroxyl-methyl)-5-methylisoxazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

A solution of (4-(2-(3-(3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyl-di-methylsilyloxy)propoxy)phenyl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-4-yl)-5-methylisoxazol-3-yl)methyl benzoate (140 mg, 0.17mmol) in MeOH (5 mL) was treated with a solution of NaOH (14 mg, 0.35mmol) in water (1 mL) and the reaction mixture was stirred at roomtemperature for 2 h. and then concentrated under vacuum. The residue wasdissolved in DCM (50 mL), washed with water (20 mL×3) and brine (20 mL).The organic phase was dried over Na₂SO₄, filtered and concentrated togive tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3-(hydroxymethyl)-5-methylisoxazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamateas a yellow solid (90 mg, 76% yield). ESI-LCMS: 698.3 [M+1]⁺.

Step 6: Synthesis of1-(3-(4-(3-(hydroxymethyl)-5-methylisoxazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

To a solution of tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3-(hydroxyl-methyl)-5-methylisoxazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(90 mg, 0.13 mmol) in DCM (2 mL) was added 4N HCl in dioxane (1 mL) andthe mixture was stirred at room temperature for 2 h, concentrated undervacuum and the residue was dissolved in MeOH (2 ml), treated withammonia till pH 7-8 and then concentrated again. The residue waspurified by preparative HPLC to give1-(3-(4-(3-(hydroxymethyl)-5-methylisoxazol-4-yl)-5-methyl-6-(tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl) phenoxy)-3-(methylamino) propan-2-ol as a formic acidsalt (white solid, 14 mg, 20% yield). ESI-LCMS: 484.2 [M+1]⁺. ¹HNMR (400MHz, CD₃OD) δ ppm: 8.54 (br s, 1H), 7.92 (d, J=7.6 Hz, 1H), 7.83 (s,1H), 7.40 (t, J=8.0 Hz, 1H), 7.09 (dd, J=2.4 and 8.0 Hz, 1H), 4.65 (s,2H), 4.55-4.45 (m, 1H), 4.30-4.22 (m, 1H), 4.13-4.02 (m, 4H), 3.67-3.59(m, 2H), 3.30-3.24 (m, 1H), 3.20-3.10 (m, 1H), 2.77 (s, 3H), 2.40 (s,3H), 2.10-2.00 (m, 5H), 1.83-1.70 (m, 2H).

Example 22. Preparation of1-{4-Chloro-3-[4-(5,7-dihydro-pyrrolo[3,4-b]pyridin-6-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-3-methylamino-propan-2-ol

Step 1: Synthesis of (R)-2-((3-bromophenoxy)methyl)oxirane

To a suspension of 3-bromophenol (100 g, 0.58 mol) and Cs₂CO₃ (379 g,1.16 mol) in THF (1500 mL) was added (R)-glycidyl nosylate (192 g, 0.74mol) at room temperature. The reaction mixture was heated at 40° C. andstirred at the same temperature for 16 h, cooled down to roomtemperature, filtered and concentrated. The residue was dissolved inwater (200 mL) and extracted with ethyl acetate (150 mL×3), the organiclayers were combined, dried over Na₂SO₄, filtered and concentrated togive (R)-2-((3-bromophenoxy)methyl)oxirane (160 g, crude), which wasused directly for the next step without further purification. ESI-LCMS(m/z): 228.7 [M+1]⁺.

Step 2: Synthesis of (R)-1-(3-bromophenoxy)-3-(methylamino)propan-2-ol

A solution of (R)-2-((3-bromophenoxy)methyl)oxirane (159 g, crude fromstep 1) in MeOH (500 mL) was treated with 33% MeNH₂ in MeOH (500 mL),added slowly with stirring at 0° C. After the addition was complete, thesolution was further stirred at room temperature for 16 h, the volatileswere then removed in vacuo to give the(R)-1-(3-bromophenoxy)-3-(methylamino)propan-2-ol (181 g, crude), whichwas used for the next step directly without further purification.ESI-LCMS (m/z): 260.0 [M+1]⁺.

Step 3: Synthesis of (R)-tert-butyl3-(3-bromophenoxy)-2-hydroxypropyl(methyl) carbamate

A solution of (R)-1-(3-bromophenoxy)-3-(methylamino)propan-2-ol (181 g,crude from step 2) and triethylamine (178 g, 1.76 mol) in DCM (1 L)stirred at 0° C. was treated with portion wise addition of a solution ofBoc₂O (289 g, 1.32 mol) in DCM (100 mL). Then the cooling bath wasremoved and the reaction mixture was further stirred at room temperaturefor 2 h., washed consecutively with water (300 mL×2), saturated NH₄Claqueous solution (200 mL×2) and brine (300 mL). The organic phase wasdried over Na₂SO₄, filtered and concentrated to give (R)-tert-butyl3-(3-bromophenoxy)-2-hydroxypropyl(methyl)carbamate (276 g, crude) aspale yellow oil, which was used into next step directly without furtherpurification. ESI-LCMS (m/z): 382.0 [M+23]⁺.

Step 4: Synthesis of (R)-tert-butyl3-(3-bromophenoxy)-2-(tert-butyldimethyl-silyloxy)propyl(methyl)carbamate

A solution of (R)-tert-butyl 3-(3-bromophenoxy)-2-hydroxypropyl(methyl)carbamate (276 g, crude from step 3) and imidazole (132 g, 1.94 mol) inDCM (1 L) stirred at 0° C. under N₂ atmosphere, was treated with slowaddition of TBSCl (189 g, 1.26 mol) and the reaction mixture was furtherstirred at room temperature for 16 h., washed with water (300 mL×2) andbrine (300 mL). The organic layer was dried over Na₂SO₄, filtered,concentrated and the resulting residue residue was purified bychromatographic column on silica gel (petroleum ether/EtOAc=80/1 to60/1) to give the (R)-tert-butyl3-(3-bromo-phenoxy)-2-(tert-butyldimethylsilyloxy)propyl(methyl)carbamate (105 g, 39% yield for 4 steps) as a pale yellow oil. ESI-LCMS:495.9 [M+23]⁺.

Step 5: Synthesis of (R)-tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4,6-dichloro-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

A solution of (R)-tert-butyl3-(3-bromophenoxy)-2-(tert-butyldimethylsilyloxy) propyl(methyl)carbamate (24 g, 50.58 mmol) in dry THF (100 mL), stirred at−78° C. under N₂ atmosphere was treated with slow addition of n-butyllithium (21.1 mL, 2.4 M in hexane) over 20 minutes. The mixture wasstirred for another 10 minutes at the same temperature followed by slowaddition of a solution of 4,6-dichloro-5-methyl-pyrimidine (9.1 g, 55.64mmol) in THF (20 mL) and further stirred at −78° C. for 30 minutes. DDQ(16.1 g, 70.9 mmol) was then added portion wise, the mixture warmed upto 0° C. and stirred for 30 minutes, concentrated and the residue wasdiluted with CH₂Cl₂ (300 mL), washed with 10% NaOH (50 mL), water (100mL×2) and brine (100 mL). The organic layer was dried over Na₂SO₄,filtered, concentrated and the residue was purified by chromatographiccolumn on silicagel eluted with petroleum ether/EtOAc=80/1 to 40/1 torender (R)-tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4,6-dichloro-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (10.8 g, 38% yield) as a white solid. ESI-LCMS (m/z): 578.2[M+23]⁺.

Step 6: Synthesis of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl) carbamate

To a solution of (R)-tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4,6-dichloro-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(10.8 g, 19.4 mmol) in degassed dioxane and H₂O (3/1, 240 mL) was added3,5-dimethylisoxazol-4-ylboronic acid (2.73 g, 19.4 mmol), Pd(PPh₃)₄(2.24 g, 1.94 mmol) and Na₂CO₃ (4.1 g, 38.81 mmol). The system waspurged with N₂ stream and the mixture was stirred at 100° C. for 1 h.,cooled down to room temperature, diluted with water (100 mL) andextracted with EtOAc (250 mL×2). The organic layers were combined andwashed with brine (200 mL), dried over Na₂SO₄, filtered, concentratedand the residue was purified by chromatographic column on silicagel,eluted with 0% to 15% EtOAc/petroleum ether, 50 min, to give tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl (methyl)carbamateas a white solid (7.1 g, 59% yield). ESI-LCMS: 639.3 [M+23]⁺.

Step 7: Synthesis of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

To a solution of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(7.1 g, 11.5 mmol) in DMF (100 mL) was added NCS (2.3 g, 17.25 mmol) andthe reaction mixture was stirred at 25° C. for 2 h., diluted with EtOAc(300 mL) and washed with water (200 mL×3) and brine (200 mL). Theorganic layer was dried over Na₂SO₄, filtered, concentrated and theresidue was purified by chromatographic column on silicagel, eluted with0% to 15% EtOAc/petroleum ether, to give tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamateas white solid (6.2 g, 83% yield). ESI-LCMS: 673.2 [M+23]⁺.

Step 8: tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-(3,5-di-methylisoxazol-4-yl)-5-methyl-6-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

A reaction pressure vessel was charged with a mixture of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (150 mg, 0.23 mmol); 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine (orany other suitably substituted primary or secondary amine, 0.34 mmol),KI (81 mg, 0.46 mmol) and n-BuOH (1.5 mL), capped, placed in a microwavereactor and irradiated for 60 min. at external temperature of 140° C.After being cooled down to room temperature the mixture was diluted withwater (50 mL) and extracted with EtOAc (40 mL×3). The organic layerswere combined, dried over Na₂SO₄, filtered and concentrated to givetert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-6-(5H-pyrrolo[3,4-b]pyridine-6(7H)-yl)pyrimidin-2-yl) phenoxy)propyl(methyl)carbamate as a brown solid (169mg, crude), which was used directly for the next step without furtherpurification. ESI-LCMS (m/z): 735.0 [M+1]⁺.

Step 9: Synthesis of(2R)-1-(4-chloro-3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

A solution of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-6-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)pyrimidin-2-yl) phenoxy)propyl (methyl)carbamate (169 mg, crude, fromstep 1) in 90% TFA (6.6 mL) was stirred at room temperature for 3 h, thesolvent was then removed in vacuo and the resulting residue wasdissolved in MeOH (3 ml), treated with ammonia till pH 7-8 andconcentrated. The residue was purified by preparative HPLC to give(2R)-1-(4-chloro-3-(4-(3,5-di-methylisoxazol-4-yl)-5-methyl-6-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)pyrimidin-2-yl)phenoxy)-3-(methylamino) propan-2-ol as a white solid (67 mg, 56% yield for 2 steps).ESI-LCMS (m/z): 520.8 [M+H]⁺. ¹HNMR (400 MHz, CD₃OD) δ ppm: 8.49 (d,J=4.4 Hz, 1H), 7.87 (d, J=7.6 Hz, 1H), 7.43-7.37 (m, 2H), 7.31 (d, J=2.8Hz, 1H), 7.05 (dd, J=3.2 and 8.8 Hz, 1H), 5.31 (s, 2H), 5.28 (s, 2H),4.15-4.08 (m, 1H), 4.05-3.97 (m, 2H), 2.84-2.75 (m, 2H), 2.47 (s, 3H),2.46 (s, 3H), 2.43 (s, 3H), 2.29 (s, 3H).

Example 23. Preparation of(R)-1-{4-Chloro-3-[5-chloro-4-(5,7-dihydro-pyrrolo[3,4-b]pyridine-6-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-yl]-phenoxy}-3-methyl-amino-propan-2-ol

Step 1: Synthesis of (R)-tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-di-methylisoxazol-4-yl)-6-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)pyrimidin-2-yl)phenoxy)propyl (methyl)carbamate

A reaction pressure vessel was charged with a mixture of (R)-tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(100 mg, 0.16 mmol); 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine (20 mg, 0.24mmol), triethylamine (34 mg, 0.33 mmol) and n-BuOH (3 mL), capped,placed in a microwave reactor and irradiated for 60 min. at externaltemperature of 140° C. After being cooled down to room temperature, themixture was diluted with water (20 mL) and extracted with EtOAc (20mL×3). The organic layers were combined, dried over Na₂SO₄, filtered andconcentrated. The crude was purified by preparative TLC with (petroleumether/EtOAc=3/1) to give (R)-tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-dimethylisoxazol-4-yl)-6-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate as a white solid (95 mg, 84% yield). ESI-LCMS(m/z): 687.3 [M+H]⁺.

Step 2: Synthesis of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(5-chloro-4-(3,5-dimethylisoxazol-4-yl)-6-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

A solution of (R)-tert-butyl 2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-dimethyl-isoxazol-4-yl)-6-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (95 mg, 0.14 mmol) in DMF (4 mL) was treated with NCS(110 mg, 0.83 mmol) and the reaction mixture was stirred at 45° C. for16 h. After being cooled down to room temperature, the mixture wasdiluted with EtOAc (30 mL) and washed with water (40 mL×2). The organiclayer was dried over Na₂SO₄, filtered and concentrated in vacuo and theresulting residue was purified by preparative TLC (petroleumether/EtOAc=1/1) to give tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(5-chloro-4-(3,5-di-methylisoxazol-4-yl)-6-(5H-pyrrolo[3,4-b]pyridine-6(7H)-yl)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate as a light yellow solid (50 mg, 48% yield). ESI-LCMS (m/z):755.3 [M+H]⁺.

Step 3: Synthesis of(R)-1-{4-Chloro-3-[5-chloro-4-(5,7-dihydro-pyrrolo[3,4-b]pyridine-6-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-yl]-phenoxy}-3-methyl-amino-propan-2-ol

A solution of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(5-chloro-4-(3,5-di-methylisoxazol-4-yl)-6-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (50 mg, 0.066 mmol) in 90% TFA (3 mL) was stirred atroom temperature for 16 h, the solvent was then removed in vacuo and theresulting residue was dissolved in MeOH (5 ml), treated with ammoniatill pH 7-8 and concentrated. The residue was purified by preparativeHPLC to give(2R)-1-(4-chloro-3-(5-chloro-4-(3,5-di-methylisoxazol-4-yl)-6-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-olas a white solid (10 mg, 29% yield). ESI-LCMS (m/z): 541.2 [M+H]⁺; ¹HNMR(400 MHz, CD₃OD) δ ppm: 8.51 (d, J=4.0 Hz, 1H), 7.89 (d, J=8.4 Hz, 1H),7.45-7.40 (m, 1H), 7.37 (d, J=2.8 Hz, 1H), 7.32-7.31 (d, 1H), 7.08 (dd,J=2.8 and 8.8 Hz, 1H), 5.44 (s, 2H), 5.41 (s, 2H), 4.16-4.10 (m, 1H),4.08-4.00 (m, 2H), 2.90-2.70 (m, 2H), 2.49 (s, 3H), 2.47 (s, 3H), 2.32(s, 3H).

Example 24. Preparation of methyl4-(5-chloro-2-(2-chloro-5-((R)-2-hydroxy-3-(methylamino)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-ylamino)piperidine-1-carboxylate

Step 1: Synthesis of (R)-methyl4-(2-(3-(3-(tert-butoxycarbonyl(methylamino))-2-(tert-butyldimethylsilyloxy)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-ylamino)piperidine-1-carboxylate

A reaction pressure vessel was charged with a mixture of (R)-tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-di-methylisoxazol-4-yl)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(850 mg, 1.41 mmol), methyl 4-amino piperidine-1-carboxylate HCl (or anyother suitable substituted primary or secondary amine, 5.65 mmol), Et₃N(714 mg, 7.06 mmol), KI (116 mg, 0.70 mmol) and DMSO (15 mL), capped,placed in a microwave reactor and irradiated for 60 min. at externaltemperature of 145° C., cooled down to room temperature, diluted withwater (50 mL) and extracted with EtOAc (50 mL×3). The organic layerswere combined, concentrated and the resulting residue was purified bypreparative TLC (petroleum ether/EtOAc=1.5/1) to give the (R)-methyl4-(2-(3-(3-(tert-butoxy-carbonyl(methyl)amino)-2-(tert-butyldimethylsilyloxy)propoxy)phenyl)-6-(3,5-di-methylisoxazol-4-yl)pyrimidin-4-ylamino)piperidine-1-carboxylate (880 mg, 86%yield) as a pale yellow solid. ESI-LCMS (m/z): 725.5 [M+1]⁺.

Step 2: Synthesis of methyl4-(2-(5-((R)-3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyldimethylsilyloxy)propoxy)-2-chlorophenyl)-5-chloro-6-(3,5-dimethyl-isoxazol-4-yl)pyrimidin-4-ylamino)piperidine-1-carboxylate

A solution of (R)-methyl4-(2-(3-(3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyldimethylsilyloxy)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl-amino)piperidine-1-carboxylate (800 mg,1.10 mmol) in DMF (8 mL) was treated with a solution of NCS (440 mg,3.31 mmol) in DMF (0.5 mL), the reaction flask was place in a heatingbath set at 45° C. and the mixture stirred for 16 h., cooled down toroom temperature, diluted with water (50 mL) and extracted with EtOAc(50 mL×3), The organic layers were combined, washed with aqueoussaturated Na₂S₂O₃ solution (30 mL) and brine (30 mL), then dried overNa₂SO₄, filtered and concentrated. The residue was purified bypreparative TLC (petroleum ether/EtOAc=1.5/1) to give4-(2-(5-((R)-3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyldimethylsilyloxy)propoxy)-2-chlorophenyl)-5-chloro-6-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-ylamino)piperidine-1-carboxylate (600 mg, 69% yield) as a pale yellow solid.ESI-LCMS (m/z): 793.4 [M+1]⁺. The side product from silyl estercleavage, methyl 4-(2-(5-((R)-3-(tert-butoxycarbonyl(methyl)amino)-2-hydroxylpropoxy)-2-chlorophenyl)-5-chloro-6-(3,5-di methylisoxazol-4-yl)pyrimidin-4-ylamino)piperidine-1-carboxylate] was alsoisolated (120 mg, 16% yield) as a pale yellow solid. ESI-LCMS (m/z):678.7 [M+1]⁺.

Step 3: Synthesis of methyl4-(5-chloro-2-(2-chloro-5-((R)-2-hydroxy-3-(methyl-amino)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-ylamino)piperidine-1-carboxylate

A solution of4-(2-(5-((R)-3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyldimethylsilyloxy)propoxy)-2-chlorophenyl)-5-chloro-6-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-yl-amino)piperidine-1-carboxylate (600 mg, 0.76 mmol) in 90%TFA (6 mL) was stirred at 35° C. for 3 h, the solvent was removed invacuo, and the residue was dissolved in MeOH (3 ml), treated withammonia till pH 7-8 and then concentrated again. The residue waspurified by preparative HPLC to give methyl4-(5-chloro-2-(2-chloro-5-((R)-2-hydroxy-3-(methylamino)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)pyrimidin-4-ylamino)piperidine-1-carboxylateas a formic acid salt (white solid, 385 mg, 81% yield). ESI-LCMS (m/z):579.2 [M+1]⁺; ¹HNMR (400 MHz, MeOD) δ ppm: 8.50 (br s, 1H), 7.43-7.46(d, J=9.2 Hz, 1H), 7.28-7.30 (d, J=3.2 Hz, 1H), 7.06-7.10 (dd, J=9.2 and3.2 Hz, 1H), 4.43-4.37 (m, 1H), 4.29-4.14 (m, 3H), 4.11-4.03 (m, 2H),3.71 (s, 3H), 3.29-3.13 (m, 2H), 2.96 (br s, 2H), 2.76 (s, 3H), 2.43 (s,3H), 2.29 (s, 3H), 2.06-2.03 (m, 2H), 1.70-1.59 (m, 2H).

Example 25. Preparation of(R)-1-{4-Chloro-3-[4-(5,7-dihydro-pyrrolo[3,4-d]pyrimidin-6-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-3-methylamino-propan-2-ol

Step 1: Synthesis of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-(5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

A reaction pressure vessel was charged with a mixture of(R)-(2-(tert-Butyl-dimethyl-silanyloxy)-3-{4-chloro-3-[4-chloro-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-propyl)-methyl-carbamicacid tert-butyl ester (120 mg, 0.18 mmol);6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine HCl (or any other suitablysubstituted secondary amine 0.28 mmol) and triethylamine (0.5 mL, 3.5mmol) in DMSO (2 mL), capped, placed in a microwave reactor andirradiated for 70 min. at external temperature of 140° C. After beingcooled down to room temperature, the mixture was diluted with water (20mL) and extracted with EtOAc (20 mL×3). The organic layers werecombined, dried over Na₂SO₄, filtered and concentrated. The residue waspurified by chromatographic column on silicagel to give(R)-(2-(tert-butyl-dimethyl-silanyloxy)-3-{4-chloro-3-[4-(5,7-dihydro-pyrrolo[3,4-d]pyrimidin-6-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-propyl)-methyl-carbamicacid tert-butyl ester (106 mg, 81% yield). ESI-LCMS (m/z): 735.8[M+H]⁺.

Step 2: Synthesis of(2R)-1-(4-chloro-3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-(5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

tert-Butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-6-(5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)pyrimidin-2-yl)phenoxy) propyl(methyl) carbamate (100 mg, 0.13 mmol) was treated with90% TFA (3 mL) and the mixture was stirred at room temperature for 16 h,concentrated in vacuo, the residue was dissolved in MeOH (2 ml) and theresulting solution was adjusted to pH 7-8 by the addition of ammonia,then concentrated again. The residue was purified by preparative HPLC togive(2R)-1-(4-chloro-3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-(5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol(45 mg, 64% yield). ESI-LCMS (m/z): 521.9 [M+H]⁺; ¹HNMR (400 MHz, CD₃OD)δ ppm: 9.12 (s, 1H), 8.82 (s, 1H), 7.42 (d, J=8.8 Hz, 1H), 7.32 (d,J=2.4 Hz, 1H), 7.066 (dd, J=2.8 and 8.4 Hz, 1H), 5.36 (s, 2H), 5.31 (s,2H), 4.15-4.09 (m, 1H), 4.07-4.00 (m, 2H), 2.87-2.72 (m, 2H), 2.48 (s,3H), 2.46 (s, 3H), 2.44 (s, 3H), 2.30 (s, 3H).

Example 26. Preparation of(2R)-1-(4-chloro-3-(4-(2-cyclopropyl-5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

Step 1: Synthesis of tert-butyl3-((dimethylamino)methylene)-4-oxopyrrolidine-1-carboxylate

A suspension of tert-butyl 3-oxopyrrolidine-1-carboxylate (10 g, 54.05mmol) in 1,1-dimethoxy-N,N-dimethylmethanamine (120 mL) was stirred at105° C. for 1 h., cooled down to room temperature, the solvent wasremoved in vacuo and the residue was purified by chromatographic columnon silicagel (DCM/MeOH=60/1 to 20/1) to give tert-butyl3-((di-methyl-amino)methylene)-4-oxopyrrolidine-1-carboxylate (10.78 g,83% yield). ESI-LCMS (m/z): 241.2[M+1]⁺; ¹HNMR (400 MHz, CDCl₃) δ ppm:7.26 (s, 1H), 4.57 (s, 2H), 3.86 (s, 2H), 3.09 (s, 6H), 1.48 (s, 9H).

Step 2: Synthesis of tert-butyl 2-cyclopropyl-5H-pyrrolo[3,4-d]pyrimidine-6(7H)-carboxylate

To a solution of tert-butyl3-((dimethylamino)methylene)-4-oxopyrrolidine-1-carboxylate (400 mg,1.67 mmol) in EtOH (15 mL) was added cyclopropane-carboximidamide HCl(or any other suitably substituted carboximidamide, 8.29 mmol) and Et₃N(1.01 g, 10 mmol). The mixture was stirred at 85° C. for 16 h., cooleddown to room temperature, the solvent was removed in vacuo and theresidue was purified by preparative TLC (petroleum ether/EtOAc=3/1) togive tert-butyl2-cyclopropyl-5H-pyrrolo[3,4-d]pyrimidine-6(7H)-carboxylate (280 mg, 64%yield) as a pale yellow solid. ESI-LCMS (m/z): 262.2[M+1]⁺.

Step 3: Synthesis of2-cyclopropyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine HCl

A solution of tert-butyl2-cyclopropyl-5H-pyrrolo[3,4-d]pyrimidine-6(7H)-carboxylate (280 mg,1.07 mmol) in MeOH (3 ml) was treated with 4N HCl in dioxane (5 ml) andthe mixture was stirred at room temperature for 2 h. and thenconcentrated in vacuo to give 2-cyclo-propyl-6, 7-dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride (240 mg, crude) as a yellow solid, whichwas used directly for the next step without further purification.ESI-LCMS (m/z): 162.1[M+1]⁺. ¹HNMR (400 MHz, DMSO-d6) δ ppm: 10.44 (brs, 2H), 8.67 (s, 1H), 4.54 (t, J=4.8 Hz, 2H), 4.43 (t, J=5.2 Hz, 2H),2.28-2.21 (m, 1H), 1.11-1.06 (m, 2H), 1.02-0.98 (m, 2H).

Step 4: Synthesis of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-(2-cyclopropyl-5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

A reaction pressure vessel was charged with a mixture of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (160 mg, 0.24 mmol),2-cyclopropyl-6,7-dihydro-5H-pyrrolo[3,4-d] pyrimidine HCl (240 mg,crude from step 3), Et₃N (148 mg, 1.47 mmol). KI (20 mg, 0.12 mmol) andDMSO (3 mL), capped, placed in a microwave reactor and irradiated for 60min. at external temperature of 145° C. After being cooled down to roomtemperature, the mixture was diluted with water (20 mL) and extractedwith EtOAc (20 mL×3). The organic layers were combined, dried overNa₂SO₄, filtered, concentrated and the resulting residue was purified bypreparative TLC (petroleum ether/EtOAc=2/1) to give tert-butyl(R)-2-(tert-butyl-dimethylsilyloxy)-3-(4-chloro-3-(4-(2-cyclopropyl-5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl) carbamate (160 mg, 84% yield) as a pale yellowsolid. ESI-LCMS (m/z): 776.3 [M+1]⁺.

Step 5: Synthesis of(2R)-1-(4-chloro-3-(4-(2-cyclopropyl-5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)-3-(methyl amino) propan-2-ol

A solution of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-(2-cyclopropyl-5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (160 mg, 0.21 mmol) in90% aqueous solution TFA (4 mL) was stirred at 35° C. for 2 h, thesolvent was then removed in vacuo, and the residue was dissolved in MeOH(3 ml), treated with ammonia till pH 7-8 and then concentrated again.The residue was purified by preparative HPLC to give(2R)-1-(4-chloro-3-(4-(2-cyclopropyl-5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol (45 mg, 38% yield) asa white solid. ESI-LCMS (m/z): 561.7 [M+1]⁺; ¹HNMR (400 MHz, CD₃OD) δppm: 8.56 (s, 1H), 7.38 (d, J=8.8 Hz, 1H), 7.29 (d, J=2.8 Hz, 1H), 7.02(dd, J=8.8 and 2.8 Hz, 1H), 5.23 (s, 2H), 5.17 (s, 2H), 4.13-4.04 (m,1H), 4.02-3.94 (m, 2H), 2.82-2.68 (m, 2H), 2.43 (s, 3H), 2.40 (s, 3H),2.39 (s, 3H), 2.30-2.20 (m, 4H), 1.15-1.06 (m, 4H).

Example 27. Preparation of(2R)-1-(4-chloro-3-(4-(3,5-dimethylisoxazol-4-yl)-6-(3-fluoro-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-5-methylpyrimidin-2-yl)phenoxy)-3-(methyl-amino)propan-2-ol

Step 1: Synthesis of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-(3,5-dimethylisoxazol-4-yl)-6-(3-fluoro-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

A reaction pressure vessel was charged with a mixture of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (120 mg, 0.18 mmol),3-fluoro-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine HCl salt (or any othersuitably substituted primary or secondary amine, 0.36 mmol),triethylamine (56 mg, 0.55 mmol) and n-BuOH (1.5 mL), capped, placed ina microwave reactor and irradiated for 90 min. at external temperatureof 145° C., cooled down to room temperature, the mixture was dilutedwith water (50 mL) and extracted with EtOAc (40 mL×3). The organiclayers were combined, dried over Na₂SO₄, concentrated and the residuewas purified by preparative TLC (petroleum ether/EtOAc=2/1) to givetert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-(3,5-di-methylisoxazol-4-yl)-6-(3-fluoro-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-5-methyl-pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate as a white solid (110 mg, 79% yield).ESI-LCMS (m/z): 752.8[M+H]⁺.

Step 2: Synthesis of(2R)-1-(4-chloro-3-(4-(3,5-dimethylisoxazol-4-yl)-6-(3-fluoro-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-5-methylpyrimidin-2-yl)phenoxy)-3-(methyl-amino)propan-2-ol

A solution of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-(3,5-dimethyl-isoxazol-4-yl)-6-(3-fluoro-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (110 mg, 0.14 mmol) in 4NHCl in dioxane (2 mL) was stirred at room temperature for 16 h., thesolvent was then removed in vacuo, and the residue was dissolved in MeOH(3 ml), treated with ammonia till pH 7-8 and then concentrated again.The residue was purified by preparative HPLC to give(2R)-1-(4-chloro-3-(4-(3,5-dimethylisoxazol-4-yl)-6-(3-fluoro-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-5-methylpyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol(35 mg, 45% yield). ESI-LCMS (m/z): 539.2 [M+H]⁺; ¹HNMR (400 MHz, CD₃OD)δ ppm: 8.42 (s, 1H), 7.71-7.69 (m, 1H), 7.44-7.41 (d, J=8.8 Hz, 1H),7.32-7.30 (d, J=2.8 Hz, 1H), 7.08-7.05 (dd, J=2.8 Hz and 8.8 Hz, 1H),5.32 (s, 2H), 5.25 (s, 2H), 4.16-4.09 (m, 1H), 4.06-3.99 (m, 2H),2.90-2.77 (m, 2H), 2.51 (s, 3H) 2.46 (s, 3H), 2.44 (s, 3H), 2.30 (s,3H).

Example 28. Preparation of(R)-1-{4-Chloro-3-[4-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-6-(1-cyclopropyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-5-yl)pyrimidin-2-yl]-phenoxy}-3-methylamino-propan-2-ol

Step 1: Synthesis of tert-butyl1-cyclopropyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate

To a solution of tert-butyl3-((dimethylamino)methylene)-4-oxopyrrolidine-1-carboxylate (100 mg,0.42 mmol) in MeOH (3 mL) was added cyclopropylhydrazine hydrochloride(or any other suitably substituted hydrazine, 0.63 mmol) followed byEt₃N (84 mg, 0.83 mmol), and the mixture was heated at 85° C. for 16 h.,cooled down to room temperature, diluted with water (20 mL) andextracted with EtOAc (20 mL×3). The organic layers were combined, driedover Na₂SO₄, filtered and concentrated to give tert-butyl1-cyclopropyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate as ayellow solid, which was used directly without further purification.Assumed quantitative yield. ESI-LCMS (m/z): 250.2 [M+1]⁺.

Step 2: Synthesis of1-cyclopropyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole HCl

A solution of tert-butyl1-cyclopropyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (0.42mmol) in 4N HCl in dioxane (2 mL) was stirred at room temperature for 16h. and then concentrated in vacuo to give1-cyclopropyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole as HCl salt,which was used directly for the next step without further purification.Assumed quantitative yield ESI-LCMS (m/z): 150.3 [M+1]⁺.

Step 3: Synthesis of(R)-(2-(tert-Butyl-dimethyl-silanyloxy)-3-{4-chloro-3-[4-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-6-(1-cyclopropyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-5-yl)-pyrimidin-2-yl]-phenoxy}-propyl)-methyl-carbamicacid tert-butyl ester

A reaction pressure vessel was charged with a mixture of tert-butyl(2R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (200 mg, 0.31 mmol), 1-cyclopropyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole HCl salt (0.42 mmol), KI (102 mg,0.62 mmol), Et₃N (62 mg, 0.62 mmol) and n-BuOH (3 mL), capped, placed ina microwave reactor and irradiated for 60 min. at external temperatureof 140° C. After being cooled down to room temperature, the mixture wasdiluted with water (20 mL) and extracted with EtOAc (20 mL×3). Theorganic layers were combined, dried over Na₂SO₄, filtered, concentratedand the residue was purified by preparative TLC (petroleumether/EtOAc=2/1) to obtain(R)-(2-(tert-butyl-dimethyl-silanyloxy)-3-{4-chloro-3-[4-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-6-(1-cyclopropyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-5-yl)-pyrimidin-2-yl]-phenoxy}-propyl)-methyl-carbamicacid tert-butyl ester (140 mg, 59% yield). ESI-LCMS (m/z): 764.4 [M+1]⁺.

Step 4: Synthesis of(R)-1-{4-Chloro-3-[4-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-6-(1-cyclopropyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-5-yl)pyrimidin-2-yl]-phenoxy}-3-methylamino-propan-2-ol

A solution of(R)-(2-(tert-Butyl-dimethyl-silanyloxy)-3-{4-chloro-3-[4-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-6-(1-cyclopropyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-5-yl)-pyrimidin-2-yl]-phenoxy}-propyl)-methyl-carbamicacid tert-butyl ester (140 mg, 0.18 mmol) in 4N HCl in dioxane (2 mL),was stirred at room temperature for 1 h, the solvent was then removed invacuo, and the residue was dissolved in MeOH (3 ml), treated withammonia till pH 7-8 and then concentrated again. The residue waspurified by preparative HPLC to give(R)-1-{4-Chloro-3-[4-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-6-(1-cyclopropyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-5-yl)pyrimidin-2-yl]-phenoxy}-3-methylamino-propan-2-olas a formic acid salt (white solid, 60 mg, 56% yield). ESI-LCMS (m/z):550.2 [M+1]⁺; ¹HNMR (400 MHz, CD₃OD) δ ppm: 8.56 (s, 1H), 7.45-7.43 (d,J=8.8 Hz, 1H), 7.33 (s, 1H), 7.29 (d, J=3.2 Hz, 1H), 7.08 (dd, J=3.2 and8.0 Hz, 1H), 5.15 (s, 2H), 5.01 (s, 2H), 4.28-4.22 (m, 1H), 4.11-4.03(m, 2H), 3.63-3.57 (m, 1H), 3.28-3.12 (m, 2H), 2.75 (s, 3H), 2.43 (s,6H), 2.29 (s, 3H), 1.14-1.05 (m, 4H).

Examples 29 and 30. Preparation of(2R)-1-{4-chloro-3-[4-(2,3-dimethyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-3-methylamino-propan-2-oland(2R)-1-{4-Chloro-3-[4-(1,3-dimethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-5-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-3-methylamino-propan-2-ol

Step 1: Synthesis of(R)-(2-(tert-Butyl-dimethyl-silanyloxy)-3-{4-chloro-3-[4-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-6-(3-methyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-5-yl)pyrimidin-2-yl]phenoxy}propyl)methyl-carbamicacid tert-butyl ester

A reaction pressure vessel was charged with a mixture of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (200 mg, 0.31 mmol);3-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole hydrochloride (74 mg,0.46 mmol), Et₃N (63 mg, 0.62 mmol) and n-BuOH (2 mL), capped, placed ina microwave reactor and irradiated for 60 min. at external temperatureof 140° C. After being cooled down to room temperature, the mixture wasdiluted with water (10 mL) and extracted with EtOAc (20 mL×2). Thecombined organic layers were washed with brine, dried over Na₂SO₄,filtered and concentrated. The residue was purified by preparative TLC(petroleum ether/EtOAc=1/1.5) to give(R)-(2-(tert-Butyl-dimethyl-silanyloxy)-3-{4-chloro-3-[4-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-6-(3-methyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-5-yl)pyrimidin-2-yl]phenoxy}propyl) methyl-carbamic acid tert-butyl ester as a light yellow solid(195 mg, 86% yield). ESI-LCMS (m/z): 738.3 [M+H]⁺.

Step 2:(R)-(2-(tert-Butyl-dimethyl-silanyloxy)-3-{4-chloro-3-[4-(2,3-dimethyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-propyl)-methyl-carbamicacid tert-butyl ester

To a solution of(R)-(2-(tert-Butyl-dimethyl-silanyloxy)-3-{4-chloro-3-[4-(3,5-di-methyl-isoxazol-4-yl)-5-methyl-6-(3-methyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-5-yl)pyrimidin-2-yl]phenoxy}propyl)methyl-carbamicacid tert-butyl ester (195 mg, 0.26 mmol) in dry THF (10 mL) stirred at0° C. under nitrogen atmosphere, was added NaH (19 mg, 60%, 0.46 mmol),stirred for 5 minutes and then treated with neat Mel (56 mg, 0.39 mmol).The mixture was further stirred at room temperature for 1 h., dilutedwith water (20 mL) and extracted with EtOAc (20 mL×3). The combinedorganic layers were dried over Na₂SO₄, filtered and concentrated. Theresidue was purified by preparative TLC (petroleum ether/EtOAc=1/1.5) togive(R)-(2-(tert-butyl-dimethyl-silanyloxy)-3-{4-chloro-3-[4-(2,3-dimethyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-propyl)-methyl-carbamicacid tert-butyl ester along with its inseparable regioisomer(R)-(2-(tert-butyl-dimethyl-silanyloxy)-3-{4-chloro-3-[4-(1,3-dimethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-5-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-propyl)-methyl-carbamicacid tert-butyl ester as a yellow solid (199 mg, 100% yield). ESI-LCMS(m/z): 752.3 [M+H]⁺.

Step 3: Synthesis of(2R)-1-{4-Chloro-3-[4-(2,3-dimethyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-3-methylamino-propan-2-ol

A solution of the mixture of regioisomers from previous step (199 mg,0.26 mmol) in 90% TFA (6 mL) was stirred at room temperature for 16 h;the solvent was then removed in vacuo and the resulting residue wasdissolved in MeOH (3 ml), treated with ammonia till pH 7-8 andconcentrated. The residue was purified by preparative HPLC to give(2R)-1-{4-chloro-3-[4-(2,3-dimethyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-6-(3,5-di-methyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-3-methylamino-propan-2-oland its inseparable regioisomer1-{4-Chloro-3-[4-(1,3-dimethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-5-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-3-methylamino-propan-2-ol(86 mg, 60% yield). The mixture (75 mg) was separated by HPLC to obtainpure(2R)-1-{4-chloro-3-[4-(2,3-dimethyl-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-3-methylamino-propan-2-ol(16 mg recovered). ESI-LCMS (m/z): 538.2 [M+H]⁺. ¹HNMR (400 MHz, CD₃OD)δ ppm: 7.28 (d, J=8.8 Hz, 1H), 7.16 (d, J=1.6 Hz, 1H), 6.92 (dd, J=1.2and 8.8 Hz, 1H), 4.86 (s, 2H), 4.84 (s, 2H), 4.05-3.95 (m, 1H),3.94-3.85 (m, 2H), 3.68 (s, 3H), 2.80-2.62 (m, 2H), 2.37 (s, 3H), 2.30(s, 3H), 2.28 (s, 3H), 2.21 (s, 3H), 2.16 (s, 3H); along with itsregioisomer(2R)-1-{4-Chloro-3-[4-(1,3-dimethyl-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-5-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-3-methylamino-propan-2-ol(24 mg). ESI-LCMS (m/z): 538.2 [M+H]⁺. ¹HNMR (400 MHz, CD₃OD) δ ppm:7.28 (d, J=8.4 Hz, 1H), 7.15 (d, J=2.0 Hz, 1H), 6.92 (dd, J=2.8 and 8.8Hz, 1H), 4.93 (s, 2H), 4.85 (s, 2H), 4.04-3.96 (m, 1H), 3.94-3.85 (m,2H), 3.66 (s, 3H), 2.78-2.60 (m, 2H), 2.35 (s, 3H), 2.29 (s, 3H), 2.28(s, 3H), 2.16 (s, 3H), 2.10 (s, 3H).

Example 31.-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-3-methyl-amino-propan-2-ol

Step 1: Synthesis of7-Cyclopropyl-2,7-diaza-spiro[3.5]nonane-2-carboxylic acid tert-butylester

To a solution of 2,7-Diaza-spiro[3.5]nonane-2-carboxylic acid tert-butylester (452 mg, 2.0 mmol) in MeOH and THF (1/1, 12 mL) was added(1-ethoxy-cyclo-propoxy)trimethylsilane (696 mg, 4.0 mmol), 4 Amolecular sieves (450 mg), HOAc (240 mg, 4.0 mmol) and NaBH₃CN (504 mg,8.0 mmol). The mixture was stirred at 80° C. for 16 h.; cooled down toroom temperature, filtered; the filtrate was diluted with water (40 mL)and extracted with EtOAc (50 mL×3). The organic layers were combined,dried over Na₂SO₄, filtered and concentrated to give 7-cyclopropyl-2,7-diaza-spiro[3.5]nonane-2-carboxylic acid tert-butyl ester asa white solid (550 mg, 100% yield), which was used for the next stepwithout further purification. ESI-LCMS (m/z): 267.0 [M+H]⁺.

Step 2: Synthesis of 7-Cyclopropyl-2,7-diaza-spiro[3.5]nonane HCl salt

7-Cyclopropyl-2,7-diaza-spiro[3.5]nonane-2-carboxylic acid tert-butylester (550 mg) was dissolved 4 N HCl in dioxane (6 ml) and the solutionwas stirred at room temperature for 1 h., and then concentrated in vacuoto give 7-cyclo propyl-2,7-diaza-spiro[3.5]nonane as HCl salt (550 mg,crude), which was used for the next step without further purification.ESI-LCMS (m/z): 167.1 [M+H]⁺.

Step 3: Synthesis of(R)-(2-(tert-Butyl-dimethyl-silanyloxy)-3-{4-chloro-3-[4-(7-cyclopropyl-2,7-diaza-spiro[3.5]non-2-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-propyl)-methyl-carbamicacid tert-butyl ester

A reaction pressure vessel was charged with a mixture of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (100 mg, 0.154 mmol); 7-cyclopropyl-2,7-diaza-spiro[3.5]nonaneHCl salt (93 mg, crude from step 2), triethylamine (78 mg, 0.77 mmol)and n-BuOH (3 mL), capped, placed in a microwave reactor and irradiatedfor 60 min. at external temperature of 140° C. After being cooled downto room temperature, the mixture was diluted with water (20 mL) andextracted with EtOAc (20 mL×3). The organic layers were combined, driedover Na₂SO₄, filtered and concentrated. The residue was purified bypreparative TLC (petroleum ether/EtOAc=1/1 to give(R)-(2-(tert-butyl-dimethyl-silanyloxy)-3-{4-chloro-3-[4-(7-cyclopropyl-2,7-diaza-spiro[3.5]non-2-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-propyl)-methyl-carbamicacid tert-butyl ester as a light yellow solid (80 mg, 67% yield).ESI-LCMS (m/z): 781.0 [M+H]⁺.

Step 4: Synthesis of(R)-1-{4-Chloro-3-[4-(7-cyclopropyl-2,7-diaza-spiro[3.5]non-2-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-3-methyl-amino-propan-2-ol

A solution of(R)-(2-(tert-Butyl-dimethyl-silanyloxy)-3-{4-chloro-3-[4-(7-cyclopropyl-2,7-diaza-spiro[3.5]non-2-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-propyl)-methyl-carbamicacid tert-butyl ester (80 mg) in 90% TFA (6.6 mL) was stirred at roomtemperature for 16 h, the solvent was then removed in vacuo and theresidue was dissolved in MeOH (5 ml), treated with ammonia till pH 7-8and concentrated. The residue was purified by preparative HPLC to give(R)-1-{4-chloro-3-[4-(7-cyclopropyl-2,7-diaza-spiro[3.5]non-2-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-3-methyl-amino-propan-2-olas a formic acid salt (white solid, 40 mg, 64% yield). ESI-LCMS (m/z):567.3 [M+H]⁺; ¹HNMR (400 MHz, CD₃OD) δ ppm: 8.53 (br s, 1H), 7.42 (d,J=8.8 Hz, 1H), 7.21 (d, J=2.4 Hz, 1H), 7.06 (dd, J=2.4 and 8.8 Hz, 1H),4.32-4.15 (m, 5H), 4.12-4.02 (m, 2H), 3.30-3.26 (m, 1H), 3.22-3.13 (m,1H), 3.08 (br s, 4H), 2.77 (s, 3H), 2.38 (s, 3H), 2.29-2.26 (m, 1H),2.25 (s, 3H), 2.17 (s, 3H), 2.03 (br s, 4H), 0.82-0.68 (m, 4H).

Example 32. Preparation of(R)-1-{4-Chloro-3-[4-(7-cyclopropyl-2,7-diaza-spiro[4.4]non-2-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-3-methyl-amino-propan-2-ol

Step 1: Synthesis of7-Cyclopropyl-2,7-diaza-spiro[4.4]nonane-2-carboxylic acid tert-butylester

To a solution of 2,7-diaza-spiro[4.4]nonane-2-carboxylic acid tert-butylester (260 mg, 1.15 mmol) in MeOH and THF (1/1, 10 mL) was added(1-ethoxy-cyclo-propoxy)trimethylsilane (300 mg, 1.73 mmol), 4 Amolecular sieves (260 mg), HOAc (69 mg, 1.15 mmol) and NaBH₃CN (145 mg,2.30 mmol). The mixture was stirred at 80° C. for 16 h., cooled down toroom temperature, filtered and the filtrate was diluted with water (30mL) and extracted with EtOAc (20 mL×3). The organic layers werecombined, dried over Na₂SO₄, filtered and concentrated to give7-cyclopropyl-2,7-diaza-spiro[4.4]nonane-2-carboxylic acid tert-butylester as a white solid (330 mg), which was used for the next stepwithout further purification. ESI-LCMS (m/z): 267.3 [M+H]⁺; ¹HNMR (400MHz, CD₃OD) δ ppm: 3.30-3.10 (m, 4H), 2.78-2.65 (m, 2H), 2.63-2.50 (m,2H), 1.85-1.58 (m, 5H), 1.35 (s, 9H), 0.40-0.29 (m, 4H).

Step 2: Synthesis of 2-Cyclopropyl-2,7-diaza-spiro[4.4]nonane TFA salt

7-Cyclopropyl-2,7-diaza-spiro[4.4]nonane-2-carboxylic acid tert-butylester (1.15 mmol) was dissolved in 4 N HCl in dioxane (6 ml), thesolution was stirred at room temperature for 4 h., and then concentratedin vacuo to give 2-cyclopropyl-2,7-diaza-spiro[4.4]nonane as HCl salt asa white solid, which was used directly in next step. Assumedquantitative yield. ESI-LCMS (m/z): 167.1 [M+H]⁺; ¹HNMR (400 MHz, CD₃OD)δ ppm: 3.58 (br s, 4H), 3.40-3.31 (m, 4H), 2.90-2.80 (m, 1H), 2.22-2.02(m, 4H), 0.96-0.92 (m, 2H), 0.90-0.85 (m, 2H).

Step 3: Synthesis of(R)-(2-(tert-Butyl-dimethyl-silanyloxy)-3-{4-chloro-3-[4-(7-cyclopropyl-2,7-diaza-spiro[4.4]non-2-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-propyl)-methyl-carbamicacid tert-butyl ester

A reaction pressure vessel was charged with a mixture of of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (110 mg, 0.16 mmol); 2-cyclopropyl-2,7-diaza-spiro[4.4]nonaneHCl salt (113 mg), triethylamine (85 mg, 0.84 mmol) and n-BuOH (3 mL),capped, placed in a microwave reactor and irradiated for 10 min. atexternal temperature of 140° C. After being cooled down to roomtemperature, the mixture was diluted with water (20 mL) and extractedwith EtOAc (20 mL×3). The organic layers were combined, dried overNa₂SO₄, filtered and concentrated in vacuo to give(R)-(2-(tert-Butyl-dimethyl-silanyloxy)-3-{4-chloro-3-[4-(7-cyclopropyl-2,7-diaza-spiro[4.4]non-2-yl)-6-(3,5-di-methyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-propyl)-methyl-carbamicacid tert-butyl ester as a brown solid (132 mg), which was used for thenext step without further purification. ESI-LCMS (m/z): 781.4 [M+H]⁺.

Step 4: Synthesis of(R)-1-{4-Chloro-3-[4-(7-cyclopropyl-2,7-diaza-spiro[4.4]non-2-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-3-methyl-amino-propan-2-ol

A solution of(R)-(2-(tert-butyl-dimethyl-silanyloxy)-3-{4-chloro-3-[4-(7-cyclopropyl-2,7-diaza-spiro[4.4]non-2-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-propyl)-methyl-carbamicacid tert-butyl ester (132 mg) in 90% TFA (6.6 mL) was stirred at 35° C.for 3 h, the solvent was removed in vacuo and the residue was dissolvedin MeOH (3 ml), treated with ammonia till pH 7-8 and concentrated. Theresidue was purified by preparative HPLC to give(R)-1-{4-Chloro-3-[4-(7-cyclopropyl-2,7-diaza-spiro[4.4]non-2-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-phenoxy}-3-methyl-amino-propan-2-olas a white solid (28 mg, 32% yield). ESI-LCMS (m/z): 567.3 [M+H]⁺; ¹HNMR(400 MHz, CD₃OD) δ ppm: 7.39 (d, J=8.8 Hz, 1H), 7.23 (d, J=2.8 Hz, 1H),7.03 (dd, J=3.2 and 8.8 Hz, 1H), 4.15-4.08 (m, 1H), 4.05-3.94 (m, 2H),3.91-3.83 (m, 2H), 3.82-3.70 (m, 2H), 2.95-2.72 (m, 6H), 2.48 (d, 3H),2.40 (d, 3H), 2.70 (s, 3H), 2.26 (s, 3H), 2.09-1.96 (m, 2H), 1.94-1.85(m, 2H), 1.80-1.74 (m, 1H), 0.53-0.42 (m, 4H).

Example 33. Preparation of(R)-2-[2-[2-Chloro-5-(2-hydroxy-3-methylamino-propoxy)-phenyl]-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-4-yl]-2,7-diaza-spiro[3.5]nonane-7-carboxylicacid methyl ester

Step 1: Synthesis of 2,7-Diaza-spiro[3.5]nonane-2,7-dicarboxylic acid2-tert-butyl ester 7-methyl ester

To a solution of 2,7-Diaza-spiro[3.5]nonane-2-carboxylic acid tert-butylester (226 mg, 1.0 mmol) and triethylamine (303 mg, 3 mmol) in CH₂Cl₂ (6mL) stirred at 0° C. under nitrogen atmosphere was added methylchloroformate (188 mg, 2 mmol) dropwise, and the mixture was furtherstirred at room temperature for 1 h., excess of reagent was quenchedwith saturated NaHCO₃solution (10 mL) and the mixture was then extractedwith EtOAc (20 mL×2). The combined organic phases were washed withsaturated NH₄Cl solution (20 mL) and brine (20 mL), dried over Na₂SO₄,filtered and concentrated to give2,7-diaza-spiro[3.5]nonane-2,7-dicarboxylic acid 2-tert-butyl ester7-methyl ester as a white solid, which was used for the next stepwithout further purification (assumed quantitative yield). ESI-LCMS(m/z): 307.2 [M+23]⁺.

Step 2: Synthesis of 2,7-Diaza-spiro[3.5]nonane-7-carboxylic acid methylester HCl salt

A solution of 2,7-Diaza-spiro[3.5]nonane-2,7-dicarboxylic acid2-tert-butyl ester 7-methyl ester (290 mg, 1.0 mmol, from step 1) inMeOH (2 mL) was treated with 4N HCl in dioxane (6 mL), and the mixturewas stirred at room temperature for 1 h., and then concentrated in vacuoto give 2,7-diaza-spiro[3.5]nonane-7-carboxylic acid methyl ester as HClsalt (530 mg, crude), which was used for the next step without furtherpurification. ESI-LCMS (m/z): 185.2 [M+H]⁺.

Step 3: Synthesis of(R)-2-[2-{5-[3-(tert-Butoxycarbonyl-methyl-amino)-2-(tert-butyl-dimethyl-silanyloxy)-propoxy]-2-chloro-phenyl}-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-4-yl]-2,7-diaza-spiro[3.5]nonane-7-carboxylicacid methyl ester

A reaction pressure vessel was charged with a mixture of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (120 mg, 0.18 mmol);2,7-diaza-spiro[3.5]nonane-7-carboxylic acid methyl ester HCl salt (100mg, crude from step 2), triethylamine (93 mg, 0.92 mmol). and n-BuOH (3mL), capped, placed in a microwave reactor and irradiated for 60 min. atexternal temperature of 140° C. After being cooled down to roomtemperature, the mixture was diluted with water (20 mL) and extractedwith EtOAc (20 mL×3). The organic layers were combined, dried overNa₂SO₄, filtered and concentrated to give(R)-2-[2-{5-[3-(tert-butoxycarbonyl-methyl-amino)-2-(tert-butyl-dimethyl-silanyloxy)-propoxy]-2-chloro-phenyl}-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-4-yl]-2,7-diaza-spiro[3.5]nonane-7-carboxylicacid methyl ester as a light yellow solid (147 mg, crude) which was usedfor the next step without further purification. ESI-LCMS (m/z): 798.8[M+H]⁺.

Step 4: Synthesis of(R)-2-[2-[2-Chloro-5-(2-hydroxy-3-methylamino-propoxy)-phenyl]-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-4-yl]-2,7-diaza-spiro[3.5]nonane-7-carboxylicacid methyl ester

A solution of(R)-2-[2-{5-[3-(tert-butoxycarbonyl-methyl-amino)-2-(tert-butyl-dimethyl-silanyloxy)-propoxy]-2-chloro-phenyl}-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-4-yl]-2,7-diaza-spiro[3.5]nonane-7-carboxylicacid methyl ester (147 mg, from step 2) in 90% TFA (6.6 mL) was stirredat room temperature for 16 h., the solvent was removed in vacuo and theresidue was dissolved in MeOH (5 ml), treated with ammonia till pH 7-8and concentrated. The residue was purified by preparative HPLC to give(R)-2-[2-[2-Chloro-5-(2-hydroxy-3-methylamino-propoxy)-phenyl]-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-4-yl]-2,7-diaza-spiro[3.5]nonane-7-carboxylicacid methyl ester as a white solid (65 mg, 60% yield for 2 steps).ESI-LCMS (m/z): 585.3 [M+H]⁺. ¹HNMR (500 MHz, CD₃OD) δ ppm: 8.53 (br s,1H), 7.42 (d, J=8.5 Hz, 1H), 7.20 (d, J=3.0 Hz, 1H), 7.06 (dd, J=3.0 and9.0 Hz, 1H), 4.36-4.25 (m, 1H), 4.19 (br s, 4H), 4.11-4.05 (m, 2H), 3.71(s, 3H), 3.53-3.48 (m, 4H), 3.30-3.25 (m, 1H), 3.20-3.14 (m, 1H), 2.77(s, 3H), 2.39 (s, 3H), 2.25 (s, 3H), 2.17 (s, 3H), 1.88-1.82 (m, 4H).

Example 34.phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-yl)-2,6-diazaspiro[3.4]octane-6-carboxylate

Step 1: Synthesis of 2-tert-butyl 6-methyl2,6-diazaspiro[3.4]octane-2,6-di-Carboxylate

To a solution of tert-butyl 2,6-diazaspiro[3.4]octane-2-carboxylate (100mg, 0.47 mmol) in DCM (2 mL) stirred at 0° C. was treated with Et₃N (95mg, 0.94 mmol) followed by slow addition of methyl chloroformate (89 mg,0.94 mmol), and the reaction mixture further stirred at room temperaturefor 16 h., diluted with EtOAc (20 mL) and consecutively washed with H₂O(20 mL), aqueous NH₄Cl solution (20 mL) and brine (20 mL). The organiclayer was dried over Na₂SO₄, filtered and concentrated to give2-tert-butyl 6-methyl 2,6-diazaspiro[3.4]octane-2,6-dicarboxylate (100mg, 78% yield) as a yellow solid. ESI-LCMS (m/z): 293.1 [M+Na]⁺.

Step 2: Synthesis of methyl 2,6-diazaspiro[3.4]octane-6-carboxylate TFAsalt

A solution of 2-tert-butyl 6-methyl2,6-diazaspiro[3.4]octane-2,6-dicarboxylate (100 mg, 0.37 mmol) in DCM(1 mL) was treated with neat TFA (1 mL), the resulting mixture wasstirred at room temperature for 1 h. and finally concentrated to givemethyl 2,6-diazaspiro[3.4]octane-6-carboxylate as TFA salt (62 mg,crude), which was used for the next step without further purification.ESI-LCMS (m/z): 171.2 [M+1]⁺.

Step 3: Synthesis of methyl2-(2-(5-((R)-3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyldimethylsilyloxy)propoxy)-2-chlorophenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-yl)-2,6-diazaspiro[3.4]octane-6-carboxylate

A reaction pressure vessel was charged with a mixture of tert-butyl(2R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (150 mg, 0.23 mmol); methyl2,6-diazaspiro[3.4]octane-6-carboxylate TFA salt (59 mg, crude from step2), Et₃N (47 mg, 0.46 mmol), KI (77 mg, 0.46 mmol) and n-BuOH (3 mL),capped, placed in a microwave reactor and irradiated for 120 min. atexternal temperature of 140° C. After being cooled down to roomtemperature, EtOAc (20 mL) was added, the mixture was washed with water(20 mL), aqueous NH₄Cl solution (20 mL) and brine (20 mL). The organiclayer was dried over Na₂SO₄, filtered, concentrated and the resultingresidue was purified by preparative TLC (petroleum ether/EtOAc=2/1) togive methyl2-(2-(5-((R)-3-(tert-butoxycarbonyl(methyl)amino)-2-(tertbutyl-dimethylsilyloxy)propoxy)-2-chlorophenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methyl-pyrimidin-4-yl)-2,6-diazaspiro[3.4]octane-6-carboxylate(100 mg, 55% yield) as a white solid. ESI-LCMS (m/z): 785.4 [M+1]⁺.

Step 4: Synthesis of methyl2-(2-(2-chloro-5-((R)-2-hydroxy-3-(methylamino)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-yl)-2,6-diaza-spiro[3.4]octane-6-carboxylate

A solution of methyl 2-(2-(5-((R)-3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyldimethylsilyloxy)propoxy)-2-chlorophenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-yl)-2,6-diazaspiro[3.4]octane-6-carboxylate(100 mg, 0.12 mmol) in DCM (1 mL) was treated with neat TFA (1 mL) andthe mixture was stirred at 45° C. for 5 h., the solvent was removed invacuo, the residue was dissolved in MeOH (2 ml), treated with ammoniatill pH 7-8 and concentrated. The crude residue was purified bypreparative HPLC to give methyl2-(2-(2-chloro-5-((R)-2-hydroxy-3-(methylamino)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methyl-pyrimidin-4-yl)-2,6-diazaspiro[3.4]octane-6-carboxylate(42 mg, 58% yield) as a white solid. ESI-LCMS (m/z): 571.2 [M+1]⁺; ¹HNMR(400 MHz, CD₃OD) δ ppm: 7.40 (d, J=8.4 Hz, 1H), 7.21 (d, J=3.2 Hz, 1H),7.05 (dd, J=2.8 and 8.2 Hz, 1H), 4.42-4.32 (m, 4H), 4.23-4.16 (m, 1H),4.04 (d, J=5.2 Hz, 2H), 3.72 (s, 3H), 3.66-3.62 (m, 2H), 3.53-3.46 (m,2H), 3.13-3.07 (m, 1H), 3.04-2.97 (m, 1H), 2.64 (s, 3H), 2.38 (s, 3H),2.28-2.20 (m, 6H), 2.16 (s, 2H).

Example 35. Preparation of(R)-1-(4-chloro-3-(4-(cis-1-cyclopropyl-3-fluoropiperidin-4-yl-amino)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)-3-(methyl-amino)propan-2-ol

Step 1: Synthesis of tert-butylcis-1-cyclopropyl-3-fluoropiperidin-4-yl-carbamate

To a solution of tert-butyl cis-3-fluoropiperidin-4-ylcarbamate (380 mg,1.74 mmol), (1-methoxycyclopropoxy)trimethylsilane (1.4 g, 8.72 mmol)and AcOH (209 mg, 3.5 mmol) in MeOH (10 mL), NaBH₃CN (439 mg, 6.97 mmol)was slowly added with stirring at room temperature; the reaction mixturewas then heated under reflux for 16 h., cooled down to room temperatureand the solvent was removed under vacuum. The residue was suspended inDCM (100 mL), washed with water (50 mL×2) and brine (60 mL), the organicphase was dried over Na₂SO₄, filtered and concentrated under vacuum togive tert-butyl cis-1-cyclopropyl-3-fluoropiperidin-4-yl-carbamate,which was used for the next step without further purification. Assumedquantitative yield. ¹HNMR (500 MHz, CDCl₃) δ ppm: 4.84 (d, J=8.0 Hz,1H), 4.69 (d, J=49.5 Hz, 1H), 3.75-3.60 (m, 1H), 3.37-3.30 (m, 1H),3.11-3.04 (m, 1H), 2.50-2.36 (m, 1H), 2.35-2.27 (m, 1H), 1.83-1.70 (m,2H), 1.47 (s, 9H), 1.27-1.39 (m, 1H), 0.53-0.40 (m, 4H).

Step 2: Synthesis of cis-1-cyclopropyl-3-fluoropiperidin-4-amine HCl

A solution of tert-butylcis-1-cyclopropyl-3-fluoropiperidin-4-ylcarbamate (510 mg, crude fromstep 1) in DCM (15 mL) was treated with 4N HCl in dioxane (5 mL); thefinal mixture was further stirred at room temperature for 1 h andconcentrated under vacuum to givecis-1-cyclopropyl-3-fluoropiperidin-4-amine HCl salt as a white solid(410 mg), which was used for the next step without further purification.ESI-LCMS: 159.3 [M+1]⁺.

Step 3: Synthesis of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-(cis-1-cyclopropyl-3-fluoropiperidin-4-ylamino)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

To a solution of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl) carbamate (300 mg, 0.46 mmol) intoluene (6 mL) was added t-BuONa (177 mg, 1.84 mmol), Pd(t-Bu₃P)₂ (71mg, 0.14 mmol) and cis-1-cyclopropyl-3-fluoropiperidin-4-aminehydrochloric acid (or any other suitably substituted primary amine, 0.92mmol). The system was purged with N₂ stream, sealed and heated at 100°C. for 16 h. After being cooled down to room temperature, the mixturewas diluted with water (20 mL) and extracted with EtOAc (20 mL×2). Thecombined organic layers were washed with brine, dried over Na₂SO₄,filtered and concentrated to render a residue which was purified bypreparative TLC (petroleum ether/EtOAc=2/1) to give tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-(cis-1-cyclopropyl-3-fluoropiperidin-4-ylamino)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate as a yellow solid (140mg, 39% yield). ESI-LCMS: 772.9 [M+1]⁺.

Step 4: Synthesis of(R)-1-(4-chloro-3-(4-(cis-1-cyclopropyl-3-fluoropiperidin-4-ylamino)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

A solution of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-(cis-1-cyclopropyl-3-fluoropiperidin-4-ylamino)-6-(3,5-dimethylisoxazol-4-yl)-5-methyl-pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (140 mg, 0.18 mmol) in DCM (5 mL) was treatedwith 4N HCl in dioxane (2 mL) and the reaction mixture was stirred atroom temperature for 1 h., the solvent was then removed in vacuo, theresulting residue was dissolved in MeOH (2 ml), treated with ammoniatill pH 7-8, concentrated and submitted to purification by preparativeHPLC to give(R)-1-(4-chloro-3-(4-(cis-1-cyclopropyl-3-fluoropiperidin-4-ylamino)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-olas a white solid (33 mg, 33% yield). ESI-LCMS: 559.2 [M+1]⁺; ¹HNMR (500MHz, DMSO-d6) δ ppm: 7.44 (d, J=9.0 Hz, 1H), 7.29 (d, J=3.5 Hz, 1H),7.05 (dd, J=3.5 and 9.0 Hz, 1H), 6.71 (d, J=7.0 Hz, 1H), 5.89 (d, J=4.5Hz, 1H), 4.93 (d, J=49.0 Hz, 1H), 4.33-4.12 (m, 2H), 4.00 (d, J=5.0 Hz,2H), 3.26-3.18 (m, 1H), 3.17-3.09 (m, 1H), 3.05-2.95 (m, 2H), 2.59 (s,3H), 2.45-2.35 (m, 2H), 2.33 (s, 3H), 2.19 (s, 3H), 2.07-1.96 (m, 5H),1.73-1.65 (m, 2H), 0.48-0.39 (m, 2H), 0.37-0.23 (m, 2H).

Example 36. Preparation of(2R)-1-(4-chloro-3-(4-(3,3-difluoro-1-methylpiperidin-4-yl-amino)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)-3-(methyl-amino)propan-2-ol

Step 1: Synthesis of tert-butyl4-(benzylamino)-3,3-difluoropiperidine-1-carboxylate

To a solution of tert-butyl 3,3-difluoro-4-oxopiperidine-1-carboxylate(1.0 g, 4.25 mmol) in DCM (15 mL) was treated with BnNH₂ (689 mg, 6.38mmol) followed by addition of NaBH(OAc)₃ (2.71 g, 12.76 mmol) and thesuspension was stirred at room temperature for 16 h., quenched withaqueous NaHCO₃solution (10 mL) and extracted with DCM (30 mL×2). Thecombined organic layers were washed with water (20 mL×3) and brine (20mL), dried over Na₂SO₄, filtered and concentrated. The resulting residuewas purified by preparative TLC (petroleum ether/EA=3/1) to givetert-butyl 4-(benzylamino)-3,3-difluoropiperidine-1-carboxylate (570 mg,41% yiled) as a colorless oil. ESI-LCMS (m/z): 327.2 [M+1]⁺.

Step 2: Synthesis of tert-butyl4-amino-3,3-difluoropiperidine-1-carboxylate

A solution of 4-(benzylamino)-3,3-difluoropiperidine-1-carboxylate (570mg, 1.74 mmol) in methanol (15 mL) was stirred at room temperature underH₂ atmosphere in the presence of 10% Pd—C (300 mg) for 16 h, thereaction mixture was then filtered through a pad of Celite and thefiltrate was concentrated to give tert-butyl4-amino-3,3-difluoropiperidine-1-carboxylate (380 mg, 91% yield) as acolorless oil. ¹HNMR (400 MHz, CD₃OD) δ ppm: 4.15-4.00 (m, 1H),3.91-3.83 (m, 1H), 3.20-2.84 (m, 3H), 1.83-1.74 (m, 1H), 1.49-1.38 (m,1H), 1.36 (s, 9H).

Step 3: Synthesis of tert-butyl4-(2-(2-chloro-5-(methoxymethoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-ylamino)-3,3-difluoropiperidine-1-carboxylate

A reaction pressure vessel was charged with a mixture of4-(6-chloro-2-(2-chloro-5-(methoxymethoxy)phenyl)-5-methyl-pyrimidin-4-yl)-3,5-dimethylisoxazole(250 mg, 0.63 mmol); tert-butyl 4-amino-3, 3-difluoropiperidine-1-carboxylate (300 mg, 1.27 mmol) and KF (111 mg, 1.90 mmol)in DMSO (7 mL), capped, placed in a microwave reactor and irradiated for6 h. at external temperature of 120° C. After being cooled down to roomtemperature, the mixture was diluted with EtOAc (60 mL), washed withwater (10 mL×3) and brine (10 mL). The organic layer was dried overNa₂SO₄, filtered and concentrated. The residue was purified bypreparative TLC (petroleum ether/EtOAc=2/1) to give tert-butyl4-(2-(2-chloro-5-(methoxymethoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-yl-amino)-3,3-difluoropiperidine-1-carboxylate(210 mg, 56% yield) as a white solid. ESI-LCMS (m/z): 594.2 [M+1]⁺.

Step 4: Synthesis of4-chloro-3-(4-(3,3-difluoropiperidin-4-ylamino)-6-(3,5-di-methylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenolhydrochloride

A solution of tert-butyl4-(2-(2-chloro-5-(methoxymethoxy)phenyl)-6-(3,5-di-methylisoxazol-4-yl)-5-methylpyrimidin-4-ylamino)-3,3-difluoropiperidine-1-carboxylate(210 mg, 1.45 mmol) in MeOH (10 mL) was treated with 4N HCl in dioxane(5 mL) and the mixture was stirred at room temperature for 2 h. andconcentrated in vacuo to give4-chloro-3-(4-(3,3-di-fluoropiperidin-4-ylamino)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenol HCl (320 mg, crude), which was used for the next step withoutfurther purification. Assumed quantitative yield. ESI-LCMS (m/z): 450.1[M+1]⁺.

Step 5: Synthesis of4-chloro-3-(4-(3,3-difluoro-1-methylpiperidin-4-ylamino)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenol

To a solution of4-chloro-3-(4-(3,3-difluoropiperidin-4-ylamino)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methylpyrimidin-2-yl)phenolHCl salt (320 mg, crude from previous step) in methanol (12 mL) wasadded aqueous HCHO solution (35%, 5 mL), AcOH (93 mg, 1.54 mmol) andNaBH₃CN (87 mg, 1.36 mmol), and the reaction mixture was stirred at roomtemperature for 2 h., quenched with saturated aqueous NaHCO₃solution (8mL) and extracted with EtOAc (30 mL×2). The combined organic layers werewashed with brine, dried over Na₂SO₄, filtered and concentrated to give4-chloro-3-(4-(3,3-difluoro-1-methyl-piperidin-4-ylamino)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenol (390 mg, crude), which wasused for the next step without further purification. Assumedquantitative yield. ESI-LCMS (m/z): 464.2 [M+1]⁺.

Step 6: Synthesis of2-(2-chloro-5-((R)-oxiran-2-ylmethoxy)phenyl)-N-(3,3-di-fluoro-1-methyl-piperidin-4-yl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-amine

To a solution of4-chloro-3-(4-(3,3-difluoro-1-methylpiperidin-4-ylamino)-6-(3,5-di-methylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenol(390 mg, crude from previous step) in THF (12 mL) was added(R)-oxiran-2-ylmethyl 3-nitrobenzenesulfonate (177 mg, 0.68 mmol) andCs₂CO₃ (443 mg, 1.36 mmol), and the mixture was stirred at 45° C. for 16h., cooled down to room temperature, diluted with water (30 mL) andextracted with EtOAc (30 mL×2). The combined organic layers were washedwith brine, dried over Na₂SO₄, filtered and concentrated. The residuewas purified by preparative TLC to give2-(2-chloro-5-((R)-oxiran-2-ylmethoxy)phenyl)-N-(3,3-di-fluoro-1-methylpiperidin-4-yl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-amine(140 mg, 76% yield for 3 steps). ESI-LCMS (m/z): 520.2 [M+1]⁺.

Step 7: Synthesis of(2R)-1-(4-chloro-3-(4-(3,3-difluoro-1-methylpiperidin-4-yl-amino)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)-3-(methyl-amino)propan-2-ol

A solution of2-(2-chloro-5-((R)-oxiran-2-ylmethoxy)phenyl)-N-(3,3-difluoro-1-methylpiperidin-4-yl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-amine(140 mg, 0.27 mmol) in MeOH (3 mL) was treated with 33% MeNH₂ in MeOH (5mL), and the mixture was stirred at room temperature for 16 h.,concentrated in vacuo and the resulting residue was purified bypreparative HPLC to give(2R)-1-(4-chloro-3-(4-(3,3-difluoro-1-methylpiperidin-4-ylamino)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)-3-(methyl-amino)propan-2-ol(46 mg, 31% yield) as a white solid. ESI-LCMS: 550.8 [M+1]⁺; ¹HNMR (400MHz, CD₃OD) δ ppm: 7.34 (d, J=9.2 Hz, 1H), 7.16 (d, J=3.2 Hz, 1H), 6.98(dd, J=3.2 and 8.8 Hz, 1H), 5.00-4.90 (m, 1H), 4.10-4.02 (m, 1H),3.99-3.90 (m, 2H), 3.18-3.09 (m, 1H), 2.94-2.87 (m, 1H), 2.79-2.73 (m,1H), 2.72-2.65 (m, 1H), 2.47-2.07 (m, 14H), 2.04-1.94 (m, 5H).

Example 37. Preparation of(R)-1-(4-chloro-3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-((2R,4R)-2-methyl-tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

Step 1: Synthesis ofcis-(+)-N-benzyl-2-methyl-tetrahydro-2H-pyran-4-amine

A solution of 2-methyl-tetrahydropyran-4-one (1.9 g, 16.6 mmol) andBnNH₂ (5.34 g, 49.9 mmol) in DCE (90 mL) was treated with NaBH(OAc)₃(10.6 g, 50.0 mmol) and the mixture was stirred at room temperature for16 h., diluted with water (60 mL), and extracted with DCM (50 mL×3). Thecombined organic layers were washed with brine, dried over Na₂SO₄,filtered and concentrated. The residue was purified by preparative TLC(petroleum ether/EA=3/1) to give cis-N-benzyl-2-methyl-tetrahydro-2H-pyran-4-amine (1.36 g, 39%) and trans-N-benzyl-2-methyl-tetrahydro-2H-pyran-4-amine (0.79 g, 23%). ESI-LCMS (m/z): 206.2 [M+H]⁺.

Step 2: Resolution of cis-N-benzyl-2-methyl-tetrahydro-2H-pyran-4-amine

A racemic mixture of cis-N-benzyl-2-methyl-tetrahydro-2H-pyran-4-amines(1.36 g) was resolved by chiral HPLC to obtain the isolated enantiomerscis-(+)-N-benzyl-2-methyl-tetrahydro-2H-pyran-4-amine (500 mg)cis-(−)-N-benzyl-2-methyl-tetrahydro-2H-pyran-4-amine (650 mg). Theconfiguration of cis-(+)-isomer was assumed to be (2R, 4R).

Step 3: Synthesis of (2R,4R)-2-methyl-tetrahydro-2H-pyran-4-amine

A mixture of cis-(+)-N-benzyl-2-methyl-tetrahydro-2H-pyran-4-amine (500mg, 2.4 mmol) and 10% Pd—C (200 mg) in 20 mL of MeOH was stirred at roomtemperature under H₂ atmosphere for 16 h., filtered through a pad ofCelite, the filtrate was treated with 4N HCl in dioxane (5 mL) andconcentrated to give (2R, 4R)-2-methyl-tetrahydro-2H-pyran-4-amine HCl,which was used for the next step without further purification. Assumedquantitative yield. ESI-LCMS (m/z): 116.1 [M+H]⁺.

Step 4: Synthesis of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-((2R,4R)-2-methyl-tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate

A reaction pressure vessel was charged with a mixture of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate(200 mg, 0.31 mmol), (2R,4R)-2-methyl-tetrahydro-2H-pyran-4-amine HCl(1.1 mmol), KI (30 mg, 0.18 mmol), Et₃N (1 mL, 7.1 mmol) and n-BuOH (5mL), capped, placed in a microwave reactor and irradiated for 4 h. atexternal temperature of 140° C. After being cooled down to roomtemperature, water (20 mL) was added and the mixture was extracted withEtOAc (20 mL×3). The combined organic layers were washed with brine,dried over Na₂SO₄, filtered and concentrated to give tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-((2R,4R)-2-methyl-tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (262 mg, crude), which was used for the next stepwithout further purification. ESI-LCMS (m/z): 730.3 [M+H]⁺.

Step 5: Synthesis of(R)-1-(4-chloro-3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-((2R,4R)-2-methyl-tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol

A solution of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-6-((2R,4R)-2-methyl-tetrahydro-2H-pyran-4-ylamino)pyrimidin-2-yl) phenoxy)propyl(methyl)carbamate (262 mg, crude fromprevious step) in MeOH (4 mL) was treated with 4N HCl in dioxane (2 mL)and the mixture was stirred at room temperature for 2 h., the solventwas then removed in vacuo, and the residue was dissolved in MeOH (2 ml),treated with ammonia till pH 7-8 and then concentrated again. Theresidue was purified by preparative HPLC to give(R)-1-(4-chloro-3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-((2R,4R)-2-methyl-tetra-hydro-2H-pyran-4-ylamino)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-ol as a formic acid salt (white solid, 102 mg, 59% yield for 2steps). ESI-LCMS (m/z): 515.8 [M+H]⁺; ¹HNMR (400 MHz, CD₃OD) δ ppm: 8.55(br s, 1H), 7.42 (d, J=8.8 Hz, 1H), 7.21 (d, J=2.8 Hz, 1H), 7.06 (dd,J=2.8 and 8.8 Hz, 1H), 4.51-4.41 (m, 1H), 4.30-4.20 (m, 1H), 4.12-4.00(m, 3H), 3.63-3.55 (m, 2H), 3.30-3.15 (m, 2H), 2.75 (s, 3H), 2.37 (s,3H), 2.24 (s, 3H), 2.12-1.99 (m, 5H), 1.72-1.60 (m, 1H), 1.45-1.34 (m,1H), 1.22 (d, J=6.0 Hz, 3H).

Example 38. Preparation of (S)-ethyl3-((2-(2-chloro-5-((R)-2-hydroxy-3-(methylamino)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-ylamino)methyl)morpholine-4-carboxylate

Step 1: Synthesis of (S)-ethyl3-((2-(5-((R)-3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyldimethylsilyloxy)propoxy)-2-chlorophenyl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methylpyrimidin-4-ylamino)methyl)morpholine-4-carboxylate

A reaction pressure vessel was charged with a mixture of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(4-chloro-3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)propyl(methyl)carbamate (120 mg, 0.18 mmol), (S)-ethyl3-(amino-methyl)morpholine-4-carboxylate HCl salt (82 mg, 0.36 mmol),Et₃N (0.5 mL, 3.5 mmol) and DMSO (2 mL), capped, placed in a microwavereactor and irradiated for 60 min. at external temperature of 140° C.,the mixture was then cooled down to room temperature, diluted with water(40 mL) and extracted with EtOAc (30 mL×3). The organic layers werecombined, dried over Na₂SO₄, filtered, concentrated and the cruderesidue was purified by chromatographic column on silicagel to give(R)-ethyl 3-((2-(5-((R)-3-(tert-butoxycarbonyl(methyl)amino)-2-(tert-butyldimethyl-silyloxy)propoxy)-2-chlorophenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-ylamino)methyl)morpholine-4-carboxylateas a white solid (81 mg, 54% yield). ESI-LCMS (m/z): 802.8 [M+H]⁺.

Step 2: Synthesis of (S)-ethyl3-((2-(2-chloro-5-((R)-2-hydroxy-3-(methylamino)propoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-ylamino)methyl)morpholine-4-carboxylate

A solution of (S)-ethyl3-((2-(5-((R)-3-(2-tert-butoxy-2-oxoethylamino)-2-(tert-butyldimethyl-silyloxy)propoxy)-2-chlorophenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-ylamino)methyl)morpholine-4-carboxylate(100 mg, 0.12 mmol) in 4N HCl in dioxane (4 mL), was stirred at roomtemperature for 16 h, the solvent was then removed in vacuo, and theresidue was dissolved in MeOH (10 ml), treated with ammonia till pH 7-8and then concentrated again. The residue was purified by preparativeHPLC to give (R)-ethyl3-((2-(2-chloro-5-((R)-2-hydroxy-3-(methylamino)propoxy)phenyl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methylpyrimidin-4-ylamino)methyl)morpholine-4-carboxylateas a formic acid salt (46 mg, 58% yield). ESI-LCMS (m/z): 589.3 [M+H]⁺;¹HNMR (500 MHz, MeOD) δ ppm: 8.56 (s, 1H), 7.42 (d, J=9.0 Hz, 1H), 7.25(br s, 1H), 7.06 (dd, J=3.5 and 9.0 Hz, 1H), 4.60-4.20 (m, 2H),4.13-3.60 (m, 10H), 3.53-3.40 (m, 2H), 3.27-3.24 (m, 1H), 3.18-3.12 (m,1H), 2.75 (s, 3H), 2.36 (s, 3H), 2.24 (s, 3H), 2.00 (s, 3H), 1.25-0.95(m, 3H).

Example 39. Preparation of1-{3-[4-(5,7-Dihydro-pyrrolo[3,4-b]pyridin-6-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methyl-pyrimidin-2-yl]-4-fluoro-phenoxy}-3-methylamino-propan-2-ol

Step 1: Synthesis of (R)-2-((3-bromo-4-fluorophenoxy)methyl)oxirane

To a solution of 3-bromo-4-fluorophenol (or any other suitablysubstituted 3-bromophenol, 130 mmol) in 200 ml of MeCN was added K₂CO₃(55 g, 398 mmol) and (R)-oxiran-2-ylmethyl 4-methylbenzenesulfonate(29.6 g, 130 mmol) and the mixture was stirred at 80° C. for 16 h.,cooled down to room temperature, filtered and concentrated to give(R)-2-((3-bromo-4-fluorophenoxy) methyl)oxirane (30 g, crude) as a paleyellow oil, which was used into next step without further purification.Assumed quantitative yield.

Step 2: Synthesis of(R)-1-(3-bromo-4-fluorophenoxy)-3-(methylamino)propan-2-ol

A solution of (R)-2-((3-bromo-4-fluorophenoxy)methyl)oxirane (30 g,crude from step 1) in MeOH (100 ml) stirred at 0° C. was treated withslow addition of 33% MeNH₂ in MeOH (100 ml), then further stirred atroom temperature for 2 h. After removal of volatiles in vacuo,(R)-1-(3-bromo-4-fluorophenoxy)-3-(methyl-amino)propan-2-ol (33 g,crude) was obtained as a pale yellow oil, which was used into next stepdirectly. ESI-LCMS (m/z): 279.1 [M+H]⁺. Assumed quantitative yield.

Step 3: Synthesis of (R)-tert-butyl3-(3-bromo-4-fluorophenoxy)-2-hydroxypropyl(methyl)carbamate

A solution of (R)-1-(3-bromo-4-fluorophenoxy)-3-(methylamino)propan-2-ol (33 g, crude from step 2) in 200 ml of DCM stirred 0° C. wastreated with portion wise addition of Boc₂O (29 g, 132 mmol) and thereaction mixture was further stirred at room temperature for 2 h., andconcentrated in vacuo to give (R)-tert-butyl 3-(3-bromo-4-fluorophenoxy)-2-hydroxypropyl(methyl)carbamate (44 g, crude) as pale yellowoil, which was used into next step directly. ESI-LCMS (m/z): 400.0[M+23]⁺. Assumed quantitative yield.

Step 4: Synthesis of (R)-tert-butyl3-(3-bromo-4-fluorophenoxy)-2-(tert-butyldimethylsilyloxy)propyl(methyl)carbamate

A solution of (R)-tert-butyl3-(3-bromo-4-fluorophenoxy)-2-hydroxylpropyl (methyl) carbamate (44 g,crude from step 3) and imidazole (27 g, 236 mmol) in 200 ml of DCM wastreated with a solution of TBSCl (22 g, 141 mmol) in DCM (50 ml), addedslowly from addition funnel and the reaction mixture was stirred at 35°C. under N₂ atmosphere for 16 h., then diluted with water (200 ml), theorganic layer was dried over Na₂SO₄, filtered, concentrated and theresulting residue was purified by chromatographic column on silica gel(petroleum ether/EtOAc=20/1) to obtain (R)-tert-butyl3-(3-bromo-4-fluorophenoxy)-2-(tert-butyldimethylsilyloxy)propyl(methyl)carbamate (47 g, 33% yield for 4 steps) as a pale yellow solid.ESI-LCMS (m/z): 515.1 [M+23]⁺.

Step 5: Synthesis of (R)-tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4,6-dichloro-5-methylpyrimidin-2-yl)-4-fluorophenoxy)propyl(methyl)carbamate

A solution of (R)-tert-butyl3-(3-bromo-4-fluorophenoxy)-2-(tert-butyldimethylsilyloxy)propyl(methyl)carbamate (10 g, 20 mmol) in dry THF (50 mL),stirred at −78° C. under N₂ atmosphere was treated with slow addition ofn-butyl lithium (10 mL, 2.5N in hexane) over a period of 30 min. Themixture was stirred for another 10 minutes at the same temperaturefollowed by slow addition of a solution of4,6-dichloro-5-methyl-pyrimidine (3.3 g, 20 mmol) in THF (20 mL) andfurther stirred at −78° C. for 30 minutes. DDQ (6.8 g, 30 mmol) was thenadded portion wise, the mixture warmed up to 0° C. and stirred for 30minutes, concentrated and the residue was diluted with CH₂Cl₂ (300 mL),washed with 10% NaOH (50 mL), water (100 mL×2) and brine (100 mL). Theorganic layer was dried over Na₂SO₄, filtered, concentrated and theresidue was purified by chromatographic column on silicagel eluted withpetroleum ether/EtOAc=15/1 to give (R)-tert-butyl 2-(tert-butyldimethylsilyloxy)-3-(3-(4,6-dichloro-5-methylpyrimidin-2-yl)-4-fluorophenoxy)propyl(methyl) carbamate (5.8 g, 51% yield) as a white solid. ESI-LCMS (m/z):595.9 [M+23]⁺.

Step 6: Synthesis oftert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)-4-fluorophenoxy)propyl(methyl) carbamate

To a solution of (R)-tert-butyl2-(tert-butyldimethylsilyloxy)-3-(3-(4,6-dichloro-5-methylpyrimidin-2-yl)-4-fluorophenoxy)propyl(methyl)carbamate(5.8 g, 10 mmol) in degassed dioxane and H₂O (5/1, 120 mL) was added3,5-dimethylisoxazol-4-yl boronic acid (1.2 g, 8.0 mmol), Pd(PPh₃)₄ (1.1g, 1.0 mmol) and Na₂CO₃ (2.2 g, 20 mmol). The system was purged with N₂stream and the mixture was stirred at 80° C. for 4 h., cooled down toroom temperature, diluted with water (100 mL) and extracted with EtOAc(250 mL×2). The organic layers were combined and washed with brine (200mL), dried over Na₂SO₄, filtered, concentrated and the residue waspurified by chromatographic column on silicagel, eluted with 1:5EtOAc:petroleum ether to givetert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-dimethyl-isoxazol-4-yl)-5-methylpyrimidin-2-yl)-4-fluorophenoxy)propyl(methyl)carbamate(3.7 g, 58% yield) as a light yellow solid. ESI-LCMS (m/z): 635.0[M+1]⁺.

Step 7: Synthesis of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)pyrimidin-2-yl)-4-fluorophenoxy)propyl(methyl)carbamate

A reaction pressure vessel was charged with a mixture of tert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)-4-fluorophenoxy)propyl(methyl)carbamate (110 mg, 0.17 mmol); 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine (orany other suitably substituted primary or secondary amine, 0.26 mmol),KI (61 mg, 0.35 mmol) and n-BuOH (1 mL), capped, placed in a microwavereactor and irradiated for 60 min. at external temperature of 140° C.After being cooled down to room temperature, the mixture was dilutedwith water (20 mL) and extracted with EtOAc (20 mL×3). The organiclayers were combined, dried over Na₂SO₄, filtered and concentrated togivetert-butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-(5H-pyrrolo[3,4-b]pyridine-6(7H)-yl)pyrimidin-2-yl)-4-fluoro-phenoxy) propyl (methyl) carbamate as a brownsolid (124 mg, crude), which was used for the next step without furtherpurification. ESI-LCMS (m/z): 719.0 [M+1]⁺.

Step 8: Synthesis of(2R)-1-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)pyrimidin-2-yl)-4-fluorophenoxy)-3-(methyl-amino)propan-2-ol

tert-Butyl(R)-2-(tert-butyldimethylsilyloxy)-3-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)pyrimidin-2-yl)-4-fluorophenoxy)propyl(methyl)carbamate (124 mg, crude, from step 1) was treated with90% TFA (5 mL) and the solution was stirred at room temperature for 3 h;concentrated under vacuo, the residue was dissolved in MeOH (5 ml) andthe resulting solution was treated with ammonia till pH 7-8 andconcentrated. The residue was purified by preparative HPLC to give(2R)-1-(4-chloro-3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)pyrimidin-2-yl)phenoxy)-3-(methylamino)propan-2-olas a white solid (62 mg, 71% yield for 2 steps). ESI-LCMS (m/z): 504.9[M+H]⁺; ¹HNMR (400 MHz, CD₃OD) δ ppm: 8.49 (d, J=4.0 Hz, 1H), 7.88 (d,J=7.6 Hz, 1H), 7.60 (dd, J=3.2 and 6.0 Hz, 1H), 7.40 (dd, J=4.8 and 7.6Hz, 1H), 7.20-7.05 (m, 2H), 5.30 (s, 2H), 5.26 (s, 2H), 4.18-4.11 (m,1H), 4.06-4.00 (m, 2H), 2.94-2.77 (m, 2H), 2.52 (s, 3H), 2.44 (s, 3H),2.43 (s, 3H), 2.31 (s, 3H).

Example 40. Preparation of(R)-4-{6-(3,5-Dimethyl-isoxazol-4-yl)-2-[5-(2-hydroxy-3-methyl-amino-propoxy)-2-trifluoromethyl-phenyl]-5-methyl-pyrimidin-4-ylamino}-piperidine-1-carboxylicacid methyl ester

Step 1: Synthesis of 2-bromo-4-methoxy-1-(trifluoromethyl)benzene

To a suspension of NaH (60%, 6.0 g, 0.15 mol) in dry DMF (50 mL) stirredat 0° C. under nitrogen atmosphere, was added CH₃OH (6.0 mL, 0.15 mol)dropwise via syringe. After gas evolution ceased, the suspension wasstirred at 0° C. for 20 minutes before2-bromo-4-fluoro-1-(trifluoromethyl)benzene (6.0 mL, 0.043 mol) wasadded dropwise over 5 minutes. The reaction mixture was allowed to warmup to room temperature and then heated at 60° C. for 2 h. After beingcooled down to room temperature the mixture was diluted with water (100mL), extracted with EtOAc (100 mL×2), the combined organic layers werewashed with water (100 mL×2) and brine (100 mL), dried over Na₂SO₄,filtered and concentrated. The residue was purified by chromatographiccolumn on silicagel (petroleum ether/EtOAc=100/1 to 30/1) to give2-bromo-4-methoxy-1-(trifluoromethyl)benzene as an oil (8.0 g, 73%yield). ¹HNMR (400 MHz, CD₃OD) δ ppm: 7.65 (d, J=8.4 Hz, 1H), 7.31 (d,J=2.0 Hz, 1H), 7.02 (dd, J=2.0 and 8.4 Hz, 1H), 3.86 (s, 3H).

Step 2: Synthesis of4,6-dichloro-2-(5-methoxy-2-(trifluoromethyl)phenyl)-5-methylpyrimidine

To a solution of 2-bromo-4-methoxy-1-(trifluoromethyl)benzene (5.0 g,19.6 mmol) in dry THF (50 mL) stirred at −78° C. under nitrogenatmosphere, was added n-Butyl lithium (8.9 mL, 2.4 M in hexane, 21.4mmol) over a period of 5 minutes, the mixture was stirred for another 10minutes at the same temperature before 4,6-dichloro-5-methylpyrimidine(4.5 g, 27.9 mmol) in THF (5 mL) was added slowly over 5 minutes. Theresulting mixture was stirred at −78° C. for 30 minutes, then quenchedwith HOAc (1.5 mL) and warmed to 0° C. slowly. DDQ (6.6 g, 29.1 mmol)was then added portion wise and the resulting mixture was stirred at 0°C. for 30 minutes, diluted with CH₂Cl₂ (100 mL), washed with 10% NaOH(50 mL×2) and brine (100 mL); the organic layer was dried over Na₂SO₄,filtered and concentrated. The residue was purified silica columnchromatography with (petroleum ether/EtOAc=100/1 to 30/1) to render4,6-dichloro-2-(5-methoxy-2-(trifluoromethyl) phenyl)-5-methylpyrimidine(1.0 g, 21% yield). ESI-LCMS (m/z): 337.0 [M+H]⁺.

Step 3: Synthesis of4-(6-chloro-2-(5-methoxy-2-(trifluoromethyl)phenyl)-5-methylpyrimidin-4-yl)-3,5-dimethylisoxazole

To a solution of4,6-dichloro-2-(5-methoxy-2-(trifluoromethyl)phenyl)-5-methyl-pyrimidine(1.4 g, 4.1 mmol) in degassed dioxane and water (50 mL, 5/1) was added3,5-dimethylisoxazol-4-ylboronic acid (831 mg, 5.9 mmol), Na₂CO₃ (1.2 g,11.8 mmol) and Pd(PPh₃)₄ (335 mg, 0.29 mmol). The flask was evacuatedand refilled with N₂ three times, then heated at 100° C. for 2 h. Afterbeing cooled down to room temperature, the mixture was diluted withwater (50 mL) and extracted with EtOAc (40 mL×2). The combined organiclayers were washed with brine (50 mL×2), dried over Na₂SO₄, filtered andconcentrated. The residue was purified by preparative TLC (petroleumether/EtOAc=5/1) to give 4-(6-chloro-2-(5-methoxy-2-(trifluoromethyl)phenyl)-5-methyl-pyrimidin-4-yl)-3,5-dimethylisoxazole (1.0 g,60% yield). ESI-LCMS (m/z): 398.1 [M+H]⁺.

Step 4: Synthesis of3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)-4-(trifluoromethyl)phenol

A solution of4-(6-chloro-2-(5-methoxy-2-(trifluoromethyl)phenyl)-5-methyl-pyrimidin-4-yl)-3,5-dimethylisoxazole(700 mg, 1.7 mmol) in DCM (4 mL) stirred at 0° C. was treated with slowaddition of BBr3 (1.5 mL, 16.5 mmol), and the mixture was furtherstirred at room temperature for 2 h, cooled down to 0° C. and quenchedby slow addition of water (20 mL), extracted with EtOAc (20 mL×2), thecombined organic layers were washed with aqueous NaHCO₃solution (20 mL)and brine (20 mL), dried over Na₂SO₄, filtered and concentrated. Theresidue was purified by preparative TLC (petroleum ether/EtOAc=5/1) togive3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)-4-(trifluoromethyl)phenol (220 mg, 32% yield). ESI-LCMS (m/z): 384.1 [M+H]⁺.

Step 5: Synthesis of methyl4-(6-(3,5-dimethylisoxazol-4-yl)-2-(5-hydroxy-2-(trifluoromethyl)phenyl)-5-methylpyrimidin-4-ylamino)piperidine-1-carboxylate

A reaction pressure vessel was charged with a mixture of3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)-4-(trifluoromethyl)phenol(170 mg, 0.44 mmol); methyl 4-aminopiperidine-1-carboxylate HCl (200 mg,1.03 mmol), TEA (0.5 mL, 3.5 mmol) and KI (145 mg, 0.88 mmol) in DMSO (2mL), capped, placed in a microwave reactor and irradiated for 45 min. atexternal temperature of 145° C. After being cooled down to roomtemperature, the mixture was diluted with water (20 mL) and extractedwith EtOAc (15 mL×2); the combined organic layers were washed withaqueous NH₄Cl solution (20 mL) and brine (20 mL), dried over Na₂SO₄,filtered and concentrated. The residue was purified by preparative TLC(petroleum ether/EtOAc=2/1) to give methyl4-(6-(3,5-dimethylisoxazol-4-yl)-2-(5-hydroxy-2-(trifluoromethyl)phenyl)-5-methylpyrimidin-4-ylamino)piperidine-1-carboxylateas a yellow solid (77 mg, 34% yield). ESI-LCMS (m/z): 505.8 [M+H]⁺.

Step 6: Synthesis of methyl 4-(6-(3,5-dimethylisoxazol-4-yl)-5-methyl-2-(5-((R)-oxiran-2-ylmethoxy)-2-(trifluoromethyl)phenyl)pyrimidin-4-ylamino)piperidine-1-carboxylate

To a solution of methyl4-(6-(3,5-dimethylisoxazol-4-yl)-2-(5-hydroxy-2-(trifluoro-methyl)phenyl)-5-methylpyrimidin-4-ylamino)piperidine-1-carboxylate(77 mg, 0.15 mmol) and (R)-oxiran-2-ylmethyl 3-nitrobenzenesulfonate (73mg, 0.3 mmol) in THF (10 mL) was added Cs₂CO₃ (98 mg, 0.3 mmol) and themixture was stirred at 40° C. for 16 h, cooled down to room temperature,diluted with water (20 mL) and extracted with EtOAc (20 mL×2). Thecombined organic layers were washed with brine, dried over Na₂SO₄,filtered and concentrated to give methyl 4-(6-(3,5-dimethylisoxazol-4-yl)-5-methyl-2-(5-((R)-oxiran-2-ylmethoxy)-2-(trifluoromethyl)phenyl)pyrimidin-4-ylamino)piperidine-1-carboxylate as a brown solid (83 mg,crude), which was used for the next step without further purification.ESI-LCMS (m/z): 561.9[M+H]⁺.

Step 7: Synthesis of methyl4-(6-(3,5-dimethylisoxazol-4-yl)-2-(5-((R)-2-hydroxy-3-(methylamino)propoxy)-2-(trifluoromethyl)phenyl)-5-methylpyrimidin-4-yl-amino)piperidine-1-carboxylate

A solution of4-(6-(3,5-dimethylisoxazol-4-yl)-2-(5-hydroxy-2-(trifluoromethyl)phenyl)-5-methylpyrimidin-4-ylamino)piperidine-1-carboxylate (83 mg,crude from previous step) in 33% MeNH₂ in MeOH (5 mL) was stirred at 35°C. for 16 h.; concentrated in vacuo and the resulting residue waspurified by preparative HPLC to give methyl4-(6-(3,5-dimethylisoxazol-4-yl)-2-(5-((R)-2-hydroxy-3-(methylamino)propoxy)-2-(trifluoromethyl)phenyl)-5-methylpyrimidin-4-ylamino)piperidine-1-carboxylate as aformic acid salt (36 mg, 37% yield for 2 steps). ESI-LCMS (m/z): 593.3[M+H]⁺; ¹HNMR (400 MHz, CD₃OD) δ ppm: 8.56 (br s, 1H), 7.75 (d, J=9.2Hz, 1H), 7.20 (br s, 2H), 4.50-4.35 (m, 1H), 4.30-4.10 (m, 4H), 3.70 (s,3H), 3.30-3.10 (m, 2H), 3.00-2.85 (m, 2H), 2.74 (s, 3H), 2.35 (s, 3H),2.21 (s, 3H), 2.08-1.98 (m, 6H), 1.65-1.50 (m, 2H).

Example 41. Preparation of(R)-1-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-(5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)pyrimidin-2-yl)-4-(trifluoromethyl)phenoxy)-3-(methyl-amino)propan-2-ol

Step 1: Synthesis of 3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-(5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)pyrimidin-2-yl)-4-(trifluoromethyl)phenol

A reaction pressure vessel was charged with a mixture of3-(4-chloro-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)-4-(trifluoromethyl)phenol(76 mg, 0.20 mmol); 6,7-dihydro-5H-pyrrolo [3,4-d]pyrimidine HCl (93 mg,0.59 mmol), Et₃N (0.3 mL, 2.1 mmol) and KI (66 mg, 0.40 mmol) in DMSO (2mL), capped, placed in a microwave reactor and irradiated for 45 min. atexternal temperature of 145° C. After being cooled down to roomtemperature, the mixture was diluted with water (20 mL) and extractedwith EtOAc (15 mL×2). The combined organic layers were washed with brine(10 mL), dried over Na₂SO₄, filtered and concentrated. The residue waspurified by preparative TLC (petroleum ether/EtOAc=5/1) to give3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-(5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)pyrimidin-2-yl)-4-(trifluoromethyl)phenol as a yellow solid (72 mg, 77%yield). ESI-LCMS (m/z): 469.2 [M+H]⁺.

Step 2: Synthesis of3,5-dimethyl-4-(5-methyl-2-(5-((R)-oxiran-2-ylmethoxy)-2-(trifluoromethyl)phenyl)-6-(5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)pyrimidin-4-yl)isoxazole

A solution of3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-(5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)pyrimidin-2-yl)-4-(trifluoromethyl)phenol (72 mg, 0.15 mmol) in THF (10 mL) was treated with(R)-(−)-Glycidyl nosylate (79 mg, 0.30 mmol) and Cs₂CO₃ (98 mg, 0.30mmol), and the mixture was stirred at 40° C. for 16 h, diluted withEtOAc (20 mL), and consecutively washed with water (20 mL×2) and brine(20 mL). The organic phase was dried over Na₂SO₄, filtered andconcentrated to give3,5-dimethyl-4-(5-methyl-2-(5-((R)-oxiran-2-yl-methoxy)-2-(trifluoromethyl)phenyl)-6-(5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)pyrimidin-4-yl)isoxazole as a brown solid (70 mg, crude), which was usedfor the next step without further purification. ESI-LCMS (m/z): 525.2[M+H]⁺.

Step 3: Synthesis of(R)-1-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-(5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)pyrimidin-2-yl)-4-(trifluoromethyl)phenoxy)-3-(methylamino)propan-2-ol

A solution of3,5-dimethyl-4-(5-methyl-2-(5-((R)-oxiran-2-ylmethoxy)-2-(trifluoromethyl)phenyl)-6-(5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)pyrimidin-4-yl) isoxazole(70 mg, crude, from step 2) in 33% MeNH₂ in MeOH (5 mL) was stirred at35° C. for 16 h, concentrated, and the resulting residue was purified bypreparative HPLC to give(R)-1-(3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-(5H-pyrrolo[3,4-d]pyrimidin-6(7H)-yl)pyrimidin-2-yl)-4-(trifluoromethyl)phenoxy)-3-(methylamino)propan-2-olas a white solid (10 mg, 11% yield for 2 steps). ESI-LCMS (m/z):556.3[M+H]⁺; ¹HNMR (400 MHz, CD₃OD) δ ppm: 9.11 (s, 1H), 8.81 (s, 1H),7.75 (d, J=9.2 Hz, 1H), 7.26 (d, J=2.4 Hz, 2H), 7.20 (dd, J=2.0 and 9.2Hz, 1H), 5.33 (s, 2H), 5.28 (s, 2H), 4.20-4.05 (m, 3H), 2.91-2.75 (m,2H), 2.49 (s, 3H), 2.46 (s, 3H), 2.41 (s, 3H), 2.26 (s, 3H).

Example 42. Preparation of (R)-1-(4-chloro-3-(4-((2S,4S)-1-cyclopropyl-2-methylpiperidin-4-ylamino)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)-3-(di-methylamino)propan-2-ol

Step 1: Synthesis of (2S,4R)-tert-butyl2-methyl-4-(methylsulfonyloxy)piperidine-1-carboxylate

To a solution of (2S,4R)-tert-butyl4-hydroxy-2-methylpiperidine-1-carboxylate (500 mg, 2.32 mmol) and Et₃N(352 mg, 3.48 mmol) in DCM (15 mL) at 0° C. was added MsCl (318 mg, 2.78mmol) dropwise, and the mixture was stirred to room temperature for 3 h.After the reaction was complete, water (30 mL) was added and the mixturewas extracted by DCM (30 mL×2). The combined organic layers were washedwith aqueous NH₄Cl solution and brine, dried over Na₂SO₄, filtered andconcentrated to give (2S,4R)-tert-butyl2-methyl-4-(methylsulfonyloxy)piperidine-1-carboxylate, which was usedfor the next step without further purification. Assumed quantitativeyield. ESI-LCMS (m/z): 238.1 [(M−56)+1]⁺.

Step 2: Synthesis of (2S, 4S)-tert-butyl4-azido-2-methylpiperidine-1-carboxylate

To a solution of (2S,4R)-tert-butyl2-methyl-4-(methylsulfonyloxy)piperidine-1-carboxylate (700 mg, crudefrom step 1) in DMF (5 mL) was added NaN₃ (300 mg, 4.6 mmol). Themixture was heated at 80° C. for 16 h., cooled down to room temperature,diluted with water (30 mL) and extracted with EtOAc (30 mL×2). Thecombined organic layers were washed with brine, dried over Na₂SO₄,filtered and concentrated to obtain (2S,4S)-tert-butyl4-azido-2-methylpiperidine-1-carboxylate, which was used for the nextstep without further purification. Assumed quantitative yield. ESI-LCMS(m/z): 185.1 [(M−56)+1]⁺.

Step 3: Synthesis of (2S,4S)-tert-butyl4-amino-2-methylpiperidine-1-carboxylate

To a solution of (2S,4S)-tert-butyl4-azido-2-methylpiperidine-1-carboxylate (450 mg, crude from step 2) inMeOH (20 mL) was added 10% Pd—C (85 mg) and the mixture was stirred atroom temperature for 16 h under H₂ atmosphere, filtered through a pad ofCelite and the filtrate was concentrated to give (2S,4S)-tert-butyl4-amino-2-methyl-piperidine-1-carboxylate, which was used for the nextstep without further purification. Assumed quantitative yield. ESI-LCMS(m/z): 159.1 [(M−56)+1]⁺.

Step 4: Synthesis of 1-bromo-3-(methoxymethoxy)benzene

A solution of 3-bromophenol (30 g, 0.17 mol) and DIPEA (33.6 g, 0.26mol) in DCM (300 mL) stirred at 0° C. was treated with dropwise additionof methoxymethyl bromide (27.9 g, 225 mmol) and the reaction mixture wasfurther stirred at room temperature for 16 h., washed with water (200mL×2), aqueous NH₄Cl solution (200 mL) and brine (200 mL). The organiclayer was dried over Na₂SO₄, filtered and concentrated to render1-bromo-3-(methoxy-methoxy)benzene (38 g) as a yellow oil. ¹HNMR (400MHz, CDCl₃) δ ppm: 7.28-7.22 (m, 2H), 7.20-7.17 (m, 1H), 7.06-7.02 (m,1H), 5.21 (s, 2H), 3.37 (s, 3H).

Step 5: Synthesis of4,6-dichloro-2-(3-(methoxymethoxy)phenyl)-5-methyl-pyrimidine

To a solution of 1-bromo-3-(methoxymethoxy)benzene (20 g, 92.5 mmol) indry THF (100 mL) stirred at −78° C. under N₂ atmosphere, was addedn-butyl lithium (42 mL, 2.4 M in hexane, 101 mmol) over a period of 10minutes, the mixture was stirred for another 10 minutes at −78° C.before a solution of 4,6-dichloro-5-methylpyrimidine (18 g, 111 mmol) inTHF (20 mL) was added slowly over 10 minutes. The resulting mixture wasstirred at same temperature for 30 minutes, then quenched with HOAc (20mL) and warmed to 0° C. slowly. DDQ (30 g, 130 mmol) was then addedportionwise and resulting mixture was stirred at for 0° C. for 30minutes, diluted with CH₂Cl₂ (300 mL), washed with 10% NaOH (100 mL×2)and brine (100 mL). The organic layer was dried over Na₂SO₄, filtered,concentrated and the residue was purified chromatographic column onsilicagel eluted with (petroleum ether/EtOAc=80/1) to afford the4,6-dichloro-2-(3-(methoxymethoxy)phenyl)-5-methylpyrimidine (10.2 g,37% yield) as a white solid. ESI-MS (m/z): 299.1 [M+1]⁺.

Step 6: Synthesis of4-(6-chloro-2-(3-(methoxymethoxy)phenyl)-5-methyl-pyrimidin-4-yl)-3,5-dimethylisoxazole

To a solution of4,6-dichloro-2-(3-(methoxymethoxy)phenyl)-5-methylpyrimidine (10 g, 33.5mmol) and 3,5-dimethylisoxazol-4-ylboronic acid (4.72 g, 33.5 mmol) indegassed dioxane and H₂O (3/1, 80 mL) was added Pd(PPh₃)₄ (1.9 g, 1.6mmol) and Na₂CO₃ (10.6 g, 0.1 mol). The flask was evacuated andback-filled with dry N₂ three times, then heated at 80° C. for 2 h.After being cooled down to room temperature, the mixture was dilutedwith water (30 mL) and extracted with EtOAc (50 mL×2). The organiclayers were combined, dried over Na₂SO₄, filtered and concentrated. Theresidue was purified by chromatographic column on silicagel (petroleumether/EtOAc=30/1) to afford4-(6-chloro-2-(3-(methoxymethoxy)phenyl)-5-methylpyrimidin-4-yl)-3,5-di-methylisoxazole (4.7 g, 39% yield) as a whitesolid. ESI-MS (m/z): 360.1 [M+1]⁺.

Step 7: Synthesis of4-(6-chloro-2-(2-chloro-5-(methoxymethoxy)phenyl)-5-methylpyrimidin-4-yl)-3,5-dimethylisoxazole

To a solution of4-(6-chloro-2-(3-(methoxymethoxy)phenyl)-5-methylpyrimidin-4-yl)-3,5-dimethylisoxazole(5.0 g, 13.9 mmol) in DMF (50 mL) was added NCS (2.4 g, 18.1 mmol), andthe mixture was stirred at 45° C. for 2 h. After being cooled down toroom temperature, EtOAc (200 mL) was added, and the mixture was washedwith water (100 mL×3), aqueous Na₂SO₃ solution (100 mL×1) and brine (200mL). The organic phase was dried over Na₂SO₄, filtered and concentrated.The residue was purified by chromatographic column on silicagel(petroleum ether/EtOAc=20/1) to afford4-(6-chloro-2-(2-chloro-5-(methoxymethoxy)phenyl)-5-methylpyrimidin-4-yl)-3,5-di-methylisoxazole(4.7 g, 87% yield) as a white solid. ESI-MS (m/z): 394.1 [M+1]⁺.

Step 8: Synthesis of (2S,4S)-tert-butyl4-(2-(2-chloro-5-(methoxymethoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-ylamino)-2-methylpiperidine-1-carboxylate

A reaction pressure vessel was charged with a mixture of4-(6-chloro-2-(2-chloro-5-(methoxymethoxy)phenyl)-5-methyl-pyrimidin-4-yl)-3,5-dimethylisoxazole (600 mg, 1.5 mmol), (2S,4S)-tert-butyl4-amino-2-methyl piperidine-1-carboxylate (or any other suitablysubstituted primary or secondary amine, 2.3 mmol), Et₃N (230 mg, 2.2mmol) and DMSO (5 mL), capped, placed in a microwave reactor andirradiated for 60 min. at external temperature of 135° C. After beingcooled down to room temperature, water (30 mL) was added and the mixturewas extracted by EtOAc (30 mL×2). The combined organic layers werewashed with brine, dried over Na₂SO₄, concentrated and the residue waspurified by preparative TLC (petroleum ether/EtOAc=1/1) to obtain the(2S,4S)-tert-butyl4-(2-(2-chloro-5-(methoxymethoxy)phenyl)-6-(3,5-dimethyl-isoxazol-4-yl)-5-methylpyrimidin-4-ylamino)-2-methylpiperidine-1-carboxylate(730 mg, 84% yield). ESI-LCMS (m/z): 571.8 [M+1]⁺.

Step 9: Synthesis of4-chloro-3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-((2S,4S)-2-methylpiperidin-4-ylamino)pyrimidin-2-yl)phenolHCl

To a solution of (2S,4S)-tert-butyl4-(2-(2-chloro-5-(methoxymethoxy)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-ylamino)-2-methylpiperidine-1-carboxylate(730 mg, 1.2 mmol) in MeOH (5 mL) was added 4N HCl in dioxane (5 mL) andthe mixture was stirred at room temperature for 2 h. and concentratedunder vacuo to give4-chloro-3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-((2S,4S)-2-methylpiperidin-4-ylamino)pyrimidin-2-yl)phenolHCl salt (750 mg, crude, purity: 93% at 254 nm), which was used for thenext step without further purification. ESI-LCMS (m/z): 427.9 [M+1]⁺.

Step 10: Synthesis of4-chloro-3-(4-((2S,4S)-1-cyclopropyl-2-methylpiperidin-4-ylamino)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenol

To a solution of4-chloro-3-(4-(3,5-dimethylisoxazol-4-yl)-5-methyl-6-((2S,4S)-2-methylpiperidin-4-ylamino)pyrimidin-2-yl)phenol HCl (400 mg crude from step 9)in MeOH (10 mL) was added (1-ethoxycyclopropoxy)trimethylsilane (450 mg,2.5 mmol), AcOH (0.3 mL, 5.2 mmol) and NaBH₃CN (164 mg, 2.5 mmol). Themixture was heated at 80° C. for 16 h., cooled down to room temperatureand quenched with slow addition of aqueous NaHCO₃solution (30 mL), thenextracted with EtOAc (30 mL×3). The combined organic layers were washedwith brine, dried over Na₂SO₄, filtered and concentrated. The residuewas triturated with petroleum ether/EtOAc (4/1, 15 mL×2) to give4-chloro-3-(4-((2S,4S)-1-cyclopropyl-2-methyl-piperidin-4-yl-amino)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenol(220 mg, 54%). ESI-LCMS (m/z): 467.8 [M+1]⁺.

Step 11: Synthesis of2-(2-chloro-5-((R)-oxiran-2-ylmethoxy)phenyl)-N-((2S,4S)-1-cyclopropyl-2-methylpiperidin-4-yl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-amine

A solution of4-chloro-3-(4-((2S,4S)-1-cyclopropyl-2-methyl-piperidin-4-yl-amino)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenol(110 mg, 0.23 mmol) in THF (10 mL) and (R)-oxiran-2-ylmethyl3-nitrobenzenesulfonate (115 mg, 0.44 mmol) was treated with Cs₂CO₃ (153mg, 0.47 mmol), and the mixture was heated at 40° C. for 16 h., dilutedwith water (30 mL) and the mixture was extracted with EtOAc (30 mL×2).The combined organic layers were washed with brine, dried over Na₂SO₄,filtered and concentrated to give 2-(2-chloro-5-((R)-oxiran-2-ylmethoxy)phenyl)-N-((2S,4S)-1-cyclopropyl-2-methylpiperidin-4-yl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-amine (250 mg, crude), which was usedfor the next step without further purification. ESI-LCMS (m/z): 523.9[M+1]⁺.

Step 12: Synthesis of(R)-1-(4-chloro-3-(4-((2S,4S)-1-cyclopropyl-2-methyl-piperidin-4-ylamino)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)-3-(dimethyl amino)propan-2-ol

A solution of 2-(2-chloro-5-((R)-oxiran-2-ylmethoxy)phenyl)-N-((2S,4S)-1-cyclo-propyl-2-methylpiperidin-4-yl)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-4-amine(125 mg, crude from step 11) in MeOH (10 mL) was treated with 40 wt %dimethylamine solution in water (3 mL), and the reaction mixture wasstirred at 40° C. for 2 h., the volatiles were then removed in vacuo andthe resulting residue was purified by preparative HPLC to give(R)-1-(4-chloro-3-(4-((2S,4S)-1-cyclo-propyl-2-methylpiperidin-4-ylamino)-6-(3,5-dimethylisoxazol-4-yl)-5-methylpyrimidin-2-yl)phenoxy)-3-(dimethylamino)propan-2-ol as a white solid (47 mg, 71%yield). ESI-LCMS (m/z): 568.9 [M+1]⁺; ¹HNMR (400 MHz, CD₃OD) δ ppm: 7.40(d, J=8.8 Hz, 1H), 7.21 (d, J=3.2 Hz, 1H), 7.06-7.02 (m, 1H), 4.35-4.23(m, 1H), 4.15-4.08 (m, 1H), 4.07-4.01 (m, 1H), 3.99-3.94 (m, 1H),3.20-3.12 (m, 1H), 2.60-2.40 (m, 2H), 2.37 (s, 3H), 2.35 (s, 6H), 2.23(m, 3H), 2.12-2.03 (m, 2H), 2.01 (s, 3H), 1.72-1.57 (m, 2H), 1.50-1.35(m, 1H), 1.29 (d, J=6.4 Hz, 2H), 0.75-0.60 (m, 2H), 0.56-0.47 (m, 1H),0.40-0.30 (m, 1H).

Bioloical Assays General Materials

S-adenosylmethionine (SAM), S-adenosylhomocysteine (SAH), bicine,Tween20, dimethylsulfoxide (DMSO), bovine skin gelatin (BSG), sodiumbutyrate and Tris(2-carboxyethyl)phosphine hydrochloride solution (TCEP)were purchased from Sigma-Aldrich at the highest level of puritypossible. ³H-SAM was purchase from American Radiolabeled Chemicals witha specific activity of 80 Ci/mmol. 384-well streptavidin Flashplateswere purchased from PerkinElmer.

Substrates

Peptide representative of human histone H3 residues 16-30 wassynthesized with an N-terminal linker-affinity tag motif and aC-terminal amide cap by 21^(st) Century Biochemicals. The peptide waspurified by high-performance liquid chromatography (HPLC) to greaterthan 95% purity and confirmed by liquid chromatography mass spectrometry(LC-MS). The sequence was Biot-Ahx-PRKQLATKAARKSAP-amide and contained amonomethylated arginine at position 26 (SEQ ID NO.:1).

Molecular Biology

Human CARM1 (PRMT4) (NM_199141.1) transcript clone was amplified from anHEK 293 cDNA library, incorporating a flanking 5′ sequence encoding aFLAG tag (MDYKDDDDK) (SEQ ID NO.:2) fused directly to Ala 2 of CARM1 and3′ sequence encoding a hexa His sequence (EGHHHHHH) (SEQ ID NO.:3) fuseddirectly to Ser 608. The gene sequence encoding isoform1 containing adeletion of amino acids 539-561 was amplified subsequently and subclonedinto pFastBacMam (Viva Biotech).

Protein Expression

Recombinant baculovirus were generated according to Bac-to-Bac kitinstructions (Life Technologies). Protein over-expression wasaccomplished by infecting exponentially growing HEK 293F cell culture at1.3×10⁶cell/ml with virus (MOI=10) in the presence of 8 mM sodiumbutyrate. Infections were carried out at 37° C. for 48 hours, harvestedby centrifugation, and stored at −80° C. for purification.

Protein Purification

Expressed full-length human Flag- and His-tagged CARM1 protein waspurified from cell paste by anti-flag M2 affinity chromatography withresin equilibrated with buffer containing 20 mM Tris, 150 mM NaCl, 5%glycerol, pH 7.8. Column was washed with 500 mM NaCl in buffer A andFlag-CARM1-His was eluted with 200 ug/ml FLAG peptide in buffer A.Pooled fractions were dialyzed in 20 mM Tris, 150 mM NaCl, 5% glyceroland 1 mM DTT, pH 7.8. The purity of recovered protein was 94.

Predicted Translations

Flag-CARM1-His (SEQ ID NO.: 4)MDYKDDDDKAAAAAAVGPGAGGAGSAVPGGAGPCATVSVFPGARLLTIGDANGEIQRHAEQQALRLEVRAGPDSAGIALYSHEDVCVFKCSVSRETECSRVGKQSFIITLGCNSVLIQFATPNDFCSFYNILKTCRGHTLERSVFSERTEESSAVQYFQFYGYLSQQQNMMQDYVRTGTYQRAILQNHTDFKDKIVLDVGCGSGILSFFAAQAGARKIYAVEASTMAQHAEVLVKSNNLTDRIVVIPGKVEEVSLPEQVDIIISEPMGYMLFNERMLESYLHAKKYLKPSGNMFPTIGDVHLAPFTDEQLYMEQFTKANFWYQPSFHGVDLSALRGAAVDEYFRQPVVDTFDIRILMAKSVKYTVNFLEAKEGDLHRIEIPFKFHMLHSGLVHGLAFWFDVAFIGSIMTVWLSTAPTEPLTHWYQVRCLFQSPLFAKAGDTLSGTCLLIANKRQSYDISIVAQVDQTGSKSSNLLDLKNPFFRYTGTTPSPPPGSHYTSPSENMWNTGSTYNLSSGMAVAGMPTAYDLSSVIASGSSVGHNNLIPLGSSGAQGSGGGSTSAHYAVNSQFTMGGPAISMASPMSIPTNTMHYGSEGHHHHH H

General Procedure for CARM1 Enzyme Assays on Peptide Substrates

The assays were all performed in a buffer consisting of 20 mM Bicine(pH=7.6), 1 mM TCEP, 0.005% BSG, and 0.002% Tween 20, prepared on theday of use. Compounds in 100% DMSO (1 ul) were spotted into apolypropylene 384-well V-bottom plates (Greiner) using a Platemate Plusoutfitted with a 384-channel head (Thermo Scientific). DMSO (1 ul) wasadded to Columns 11, 12, 23, 24, rows A-H for the maximum signal controland 1 ul of SAH, a known product and inhibitor of CARM1, was added tocolumns 11, 12, 23, 24, rows I-P for the minimum signal control. Acocktail (40 ul) containing the CARM1 enzyme was added by MultidropCombi (Thermo-Fisher). The compounds were allowed to incubate with CARM1for 30 min at room temperature, then a cocktail (10 ul) containing³H-SAM and peptide was added to initiate the reaction (final volume=51ul). The final concentrations of the components were as follows: CARM1was 0.25 nM, ³H-SAM was 30 nM, peptide was 250 nM, SAH in the minimumsignal control wells was 1 mM, and the DMSO concentration was 2%. Theassays were stopped by the addition of non-radiolabeled SAM (10 ul) to afinal concentration of 300 uM, which dilutes the ³H-SAM to a level whereits incorporation into the peptide substrate is no longer detectable. 50ul of the reaction in the 384-well polypropylene plate was thentransferred to a 384-well Flashplate and the biotinylated peptides wereallowed to bind to the streptavidin surface for at least 1 hour beforebeing washed once with 0.1% Tween20 in a Biotek ELx405 plate washer. Theplates were then read in a PerkinElmer TopCount plate reader to measurethe quantity of ³H-labeled peptide bound to the Flashplate surface,measured as disintegrations per minute (dpm) or alternatively, referredto as counts per minute (cpm).

%  inhibition  calculation${\%\mspace{14mu}{inh}} = {100 - {\left( \frac{{dpm}_{cmpd} - {dpm}_{\min}}{{dpm}_{\max} - {dpm}_{\min}} \right) \times 100}}$

where dpm=disintegrations per minute, cmpd=signal in assay well, and minand max are the respective minimum and maximum signal controls.

parameter  IC 50  fit$Y = {{Bottom} + \frac{\left( {{Top} - {Bottom}} \right)}{\left( {1 + \left( \frac{X}{{IC}_{50}} \right)^{{Hill}\mspace{14mu}{Coefficient}}} \right.}}$

where top and bottom are the normally allowed to float, but may be fixedat 100 or 0 respectively in a 3-parameter fit. The Hill Coefficientnormally allowed to float but may also be fixed at 1 in a 3-parameterfit. Y is the % inhibition and X is the compound concentration.

RKO Methylation Assay

RKO adherent cells were purchased from ATCC (American Type CultureCollection), Manassas, Va., USA. DMEM/Glutamax medium,penicillin-streptomycin, heat inactivated fetal bovine serum, 0.05%trypsin and D-PBS were purchased from Life Technologies, Grand Island,N.Y., USA. Odyssey blocking buffer, 800CW goat anti-rabbit IgG (H+L)antibody, and Licor Odyssey infrared scanner were purchased from LicorBiosciences, Lincoln, Nebr., USA. Asymmetric di-methyl PABP1 antibodywas purchased from Cell Signaling Technology, Danvers, Mass., USA.Methanol was purchased from VWR, Franklin, Mass., USA. 10% Tween 20 waspurchased from KPL, Inc., Gaithersburg, Md., USA. Paraformaldehyde (PFA)was purchased from EM Sciences. DRAQ5 was purchased from BiostatusLimited, Leicestershire, UK.

RKO adherent cells were maintained in growth medium (DMEM/Glutamaxmedium supplemented with 10% v/v heat inactivated fetal bovine serum and100 units/mL penicillin-streptomycin) and cultured at 37° C. under 5%CO₂.

Cell treatment, In Cell Western (ICW) for detection of asymmetricdi-methyl PABP1 and DNA content: RKO cells were seeded in assay mediumat a concentration of 30,000 cells per mL to a poly-D-lysine coated 384well culture plate (BD Biosciences 356697) with 50 μL per well. Compound(100 nL) from a 96-well source plate was added directly to 384 well cellplate. Plates were incubated at 37° C., 5% CO₂ for 48 hours. After twodays of incubation, plates were brought to room temperature outside ofthe incubator for ten minutes and blotted on paper towels to remove cellmedia. Cells were fixed for 20 minutes at room temperature by adding 50ul of 8% PFA followed by aspiration of supernatant with the Biotek EL406plate washer. Cells were then permeabilized by addition of 50 μL of icecold 100% methanol directly to each well and incubated for 30 min atroom temperature. After 30 min, plates were transferred to a BiotekEL406 plate washer and washed 2 times with 100 μL per well of washbuffer (1×PBS). Next 60 μL per well of Odyssey blocking buffer (OdysseyBuffer with 0.1% Tween 20 (v/v)) were added to each plate and incubated1 hour at room temperature. Blocking buffer was removed and 20 μL perwell of primary antibody was added (asymmetric-methyl PABP1) diluted1:400 in Odyssey buffer with 0.1% Tween 20 (v/v)) and plates wereincubated overnight (16 hours) at 4° C. Plates were washed 5 times with100 μL per well of wash buffer. Next 20 μL per well of secondaryantibody was added (1:800 800CW goat anti-rabbit IgG (H+L) antibody,1:2000 DRAQ5 in Odyssey buffer with 0.1% Tween 20 (v/v)) and incubatedfor 1 hour at room temperature. The plates were washed 5 times with 100μL per well wash buffer then 2 times with 100 μL per well of water.Plates were allowed to dry at room temperature then imaged on the LicorOdyssey machine which measures integrated intensity at 700 nm and 800 nmwavelengths. Both 700 and 800 channels were scanned.

Calculations.

First, the ratio for each well was determined by:

$\left( \frac{{asymmetric}\mspace{14mu}{di}\text{-}{methyl}\mspace{14mu}{PABP}\; 1\mspace{14mu} 800\mspace{14mu}{nm}\mspace{14mu}{value}}{{DRAQ}\; 5\mspace{14mu} 700\mspace{14mu}{nm}\mspace{14mu}{value}} \right)$

Each plate included fourteen control wells of DMSO only treatment(minimum inhibition) as well as fourteen control wells for maximuminhibition treated with 20 μM of a reference compound. The average ofthe ratio values for each control type was calculated and used todetermine the percent activation for each test well in the plate.Reference compound was serially diluted three-fold in DMSO for a totalof nine test concentrations, beginning at 20 μM.

Percent inhibition was determined and IC₅₀ curves were generated usingtriplicate wells per concentration of compound.

${{Percent}\mspace{14mu}{Inhibition}} = {100 - \left( {\left( \frac{\begin{matrix}{\left( {{Minimum}\mspace{14mu}{Inhibition}\mspace{14mu}{Ratio}} \right) -} \\\left( {{Individual}\mspace{14mu}{Test}\mspace{14mu}{Sample}\mspace{14mu}{Ratio}} \right)\end{matrix}}{\begin{matrix}{\left( {{Minimum}\mspace{14mu}{Inhibition}\mspace{14mu}{Ratio}} \right) -} \\\left( {{Maximum}\mspace{14mu}{Inhibition}\mspace{14mu}{Ratio}} \right)\end{matrix}} \right)*100} \right)}$

Human Myeloma Cell Line Proliferation Assay

Human Multiple Myeloma cell lines NCI-H929 (FIG. 1A) and U266B1 (FIG.1B) were treated with varying doses of 304-1a (medium grey data points),23-3 (light grey data points), and 113-3 (black data points) in a 14-dayproliferation assay. At the end of the experiment, total cell number wasdetermined for each cell line for different doses of 304-1a, 23-3, and113-3. As shown below, all compounds tested decreased the proliferationof these cell lines, at potencies consistent with that seen for thebiochemical and cell-based (PABP1me2a) ICW (In Cell Western) assays.

TABLE 3 Biochemical potencies # Biochem IC₅₀  1-1 A  2-1 A  3-1 A  4-1 E 5-1 D  6-1 B  7-1 B  8-1 B  9-1 A 10-1 A 11-1 A 12-1 B 13-1 A 14-1 A15-1 A 16-1 B 17-1 C 18-1 A 19-1 A 20-1 A 21-1 B 22-1 A 23-1 B 24-1 A25-1 A 26-1 A 27-1 B 28-1 B 29-1 A 30-1 B 31-1 B 32-1 A 33-1 A 34-1 A35-1 B 36-1 A 37-1 A 38-1 B 39-1 B 40-1 B 41-1 A 42-1 A 43-1 B 44-1 B45-1 A 46-1 A 47-1 B 48-1 A 49-1 A 50-1 A 51-1 B 52-1 B 53-1 A 54-1 B55-1 A 56-1 A 57-1 A 58-1 B 59-1 A 60-1 A 61-1 C 62-1 A 63-1 B 64-1 A65-1 B 66-1 B 67-1 B 68-1 B 69-1 B 70-1 A 71-1 A 72-1 B 73-1 B 74-1 B75-1 B  1-2 B  2-2 A  3-2 B  4-2 A  5-2 A  6-2 A  7-2 B  8-2 A  9-2 B10-2 B 11-2 B 12-2 B 13-2 B 14-2 A 15-2 A 16-2 A  1-1a A  2-1a B  3-1a A 4-1a A  5-1a A  6-1a A  7-1a A  8-1a A  9-1a A  10-1a A  11-1a A  12-1aA  13-1a A  14-1a A  15-1a A  16-1a A  17-1a A  18-1a A  19-1a A  20-1aA  21-1a A  22-1a B  23-1a A  24-1a B  25-1a B  26-1a C  27-1a A  28-1aA  29-1a A  30-1a A  31-1a A  32-1a A  33-1a A  34-1a A  35-1a A  36-1aA  37-1a B  38-1a A  39-1a A  40-1a A  41-1a A  42-1a A  43-1a A  44-1aA  45-1a A  46-1a B  47-1a A  48-1a C  49-1a A  50-1a A  51-1a A  52-1aB  53-1a A  54-1a A  55-1a A  56-1a A  57-1a A  58-1a B  59-1a A  60-1aA  61-1a A  62-1a C  63-1a C  64-1a B  65-1a B  66-1a A  67-1a A  68-1aA  69-1a A  70-1a A  71-1a A  72-1a A  73-1a B  74-1a A  75-1a A  76-1aA  77-1a A  78-1a A  79-1a A  80-1a A  81-1a A  82-1a A  83-1a B  84-1aA  85-1a A  86-1a A  87-1a A  88-1a A  89-1a A  90-1a A  91-1a A  92-1aA  93-1a A  94-1a A  95-1a A  96-1a A  97-1a A  98-1a A  99-1a A 100-1aA 101-1a A 102-1a A 103-1a A 104-1a A 105-1a A 106-1a A 107-1a A 108-1aA 109-1a A 110-1a A 111-1a A 112-1a A 113-1a D 114-1a A 115-1a A 116-1aA 117-1a A 118-1a A 119-1a A 120-1a A 121-1a A 122-1a C 123-1a B 124-1aA 125-1a A 126-1a A 127-1a A 128-1a B 129-1a A 130-1a B 131-1a A 132-1aA 133-1a A 134-1a A 135-1a A 136-1a A 137-1a A 138-1a A 139-1a A 140-1aA 141-1a A 142-1a A 143-1a A 144-1a A 145-1a A 146-1a A 147-1a A 148-1aA 149-1a A 150-1a A 151-1a A 152-1a A 153-1a A 154-1a A 155-1a A 156-1aA 157-1a A 158-1a B 159-1a A 160-1a A 161-1a A 162-1a A 163-1a A 164-1aA 165-1a A 166-1a A 167-1a A 168-1a A 169-1a A 170-1a A 171-1a A 172-1aA 173-1a A 174-1a A 175-1a A 176-1a A 177-1a A 178-1a A 179-1a A 180-1aB 181-1a A 182-1a A 183-1a A 184-1a A 185-1a A 186-1a A 187-1a A 188-1aA 189-1a A 190-1a A 191-1a A 192-1a A 193-1a A 194-1a A 195-1a A 196-1aA 197-1a A 198-1a A 199-1a A 200-1a A 201-1a A 202-1a A 203-1a A 204-1aA 205-1a A 206-1a A 207-1a A 208-1a A 209-1a A 210-1a A 211-1a A 212-1aA 213-1a B 214-1a B 215-1a A 216-1a A 217-1a A 218-1a A 219-1a A 220-1aA 221-1a A 222-1a B 223-1a C 224-1a A 225-1a A 226-1a A 227-1a A 228-1aA 229-1a A 230-1a A 231-1a A 232-1a A 233-1a A 234-1a A 235-1a A 236-1aA 237-1a A 238-1a A 239-1a A 240-1a A 241-1a A 242-1a A 243-1a A 244-1aA 245-1a A 246-1a A 247-1a A 248-1a A 249-1a A 250-1a A 251-1a A 252-1aA 253-1a A 254-1a A 255-1a A 256-1a A 257-1a A 258-1a A 259-1a A 260-1aA 261-1a A 262-1a A 263-1a A 264-1a A 265-1a A 266-1a A 267-1a A 268-1aA 269-1a A 270-1a A 271-1a A 272-1a A 273-1a A 274-1a A 275-1a A 276-1aA 277-1a A 278-1a A 279-1a A 280-1a A 281-1a A 282-1a A 283-1a A 284-1aA 285-1a A 286-1a A 287-1a A 288-1a A 289-1a A 290-1a A 291-1a A 292-1aA 293-1a A 294-1a A 295-1a A 296-1a A 297-1a A 298-1a A 299-1a A 300-1aA 301-1a A 302-1a A 303-1a A 304-1a A 305-1a A 306-1a A 307-1a A 308-1aA 309-1a A 310-1a — 311-1a — 312-1a — 313-1a — 314-1a — 315-1a — 316-1a— 317-1a — 318-1a — 319-1a — 320-1a — 321-1a — 322-1a — 323-1a — 324-1a— 325-1a — 326-1a — 327-1a — 328-1a — 329-1a — 330-1a — 331-1a A 332-1aA 333-1a B 334-1a A 335-1a A 336-1a B 337-1a B 338-1a A 339-1a A 340-1aA 341-1a A 346-1a B 347-1a B 348-1a B 349-1a B 350-1a A 351-1a A 352-1aA 353-1a B 354-1a B 355-1a A 356-1a A 357-1a B 358-1a A 359-1a A 360-1aB 361-1a B 362-1a A 363-1a B 364-1a B 365-1a B 366-1a A 367-1a A 368-1aA 369-1a A 370-1a A 371-1a C 372-1a C 373-1a B 374-1a B 375-1a C 376-1aA 377-1a A 378-1a A 379-1a A 380-1a B 381-1a A 382-1a A 383-1a C 384-1aB 385-1a B 386-1a D 387-1a B 388-1a B 389-1a B 390-1a A 391-1a A 392-1aA 393-1a B 394-1a A 395-1a B 396-1a A 397-1a A 398-1a A 399-1a B 400-1aB 401-1a B 402-1a D 403-1a D 404-1a B 405-1a B 406-1a B 407-1a B 408-1aA 409-1a B 410-1a B 412-1a A 413-1a B 414-1a B 415-1a A 416-1a D 418-1aB 419-1a B 420-1a B 421-1a A 422-1a A 423-1a B 424-1a A 425-1a A 426-1aB 427-1a A 428-1a B 429-1a A 430-1a B 431-1a B 432-1a B 433-1a B 434-1aA 435-1a A 436-1a A 437-1a A 438-1a B 439-1a A 440-1a A 441-1a A 442-1aA 443-1a A 445-1a A 446-1a A 447-1a A 448-1a A 449-1a A 450-1a B 451-1aB 452-1a A 453-1a B 454-1a A 455-1a A 456-1a A 457-1a A 458-1a A 459-1aB 460-1a B 461-1a A 462-1a A 463-1a A 464-1a A 465-1a A 466-1a A 467-1aA 468-1a A 469-1a A 470-1a A 471-1a A 472-1a B 475-1a A 478-1a — 479-1a— 480-1a — 481-1a — 482-1a A 483-1a A 484-1a A 485-1a A 486-1a A 487-1aA 488-1a A 489-1a A 490-1a A 491-1a A 492-1a A 493-1a A 494-1a B 495-1aA 496-1a A 497-1a B 498-1a A 499-1a A 500-1a A 501-1a A 502-1a A 503-1aA 504-1a A 505-1a A 506-1a A 507-1a A 508-1a A 509-1a B 510-1a A 511-1aA 512-1a A 513-1a A 514-1a A 515-1a B 516-1a A 517-1a A 518-1a B 519-1aA 520-1a B 521-1a A 522-1a A 523-1a B 524-1a A 525-1a A 526-1a A 527-1aB 528-1a A 529-1a A 530-1a B 531-1a A 532-1a B 533-1a B 534-1a B 535-1aB 536-1a A 537-1a A 538-1a A 539-1a B 540-1a B 541-1a A 542-1a A 543-1aA 544-1a A 545-1a B 546-1a B 547-1a B 548-1a A 549-1a A 550-1a B 551-1aB 552-1a B 553-1a B 554-1a B 555-1a B 556-1a B 557-1a B 558-1a A 559-1aA 560-1a A 561-1a A 562-1a A 563-1a A 564-1a A 565-1a A 566-1a A 567-1aA 568-1a A 569-1a A 570-1a A 571-1a A 572-1a A 573-1a A 574-1a A 575-1aA 576-1a A 577-1a A 578-1a A 579-1a A 580-1a A 581-1a A 582-1a B 583-1aB 584-1a B 585-1a B 586-1a B 587-1a B 588-1a B 589-1a B 590-1a B 591-1aB 592-1a B 593-1a B 594-1a B 595-1a B 596-1a B 597-1a B 598-1a B 599-1aB 600-1a B 601-1a B 602-1a B 603-1a C 604-1a C 605-1a C 606-1a C 607-1aD 608-1a D 609-1a A 610-1a A 611-1a A 612-1a A 613-1a A 614-1a A 615-1aA 616-1a A 617-1a A 618-1a A 619-1a A 620-1a A 621-1a A 622-1a A 623-1aA 624-1a A 625-1a B 626-1a C 627-1a B 628-1a B 629-1a B 630-1a B 631-1aC 632-1a A 635-1a C 636-1a B 637-1a B 638-1a B 639-1a B 640-1a B 641-1aB 642-1a C 643-1a C 644-1a A 645-1a C 646-1a B 647-1a B 648-1a B 649-1aB 650-1a B 651-1a B 652-1a A 653-1a C 654-1a B 655-1a B 656-1a B 657-1aA 658-1a A 659-1a B 660-1a C 661-1a B 662-1a B 663-1a B 664-1a B 665-1aA 666-1a B 667-1a B 668-1a B 669-1a A 670-1a B 671-1a B 672-1a B 673-1aB 674-1a B 675-1a B 676-1a C 677-1a E 678-1a B 679-1a C 680-1a B 681-1aC 682-1a A 683-1a B 684-1a C 685-1a C 686-1a B 687-1a B  1-3 A  2-3 A 3-3 A  4-3 A  5-3 A  6-3 A  7-3 A  8-3 A  9-3 A 10-3 A 11-3 A 12-3 A13-3 A 14-3 A 15-3 A 16-3 A 17-3 A 18-3 A 19-3 A 20-3 A 21-3 A 22-3 A23-3 A 24-3 A 25-3 A 26-3 A 27-3 A 28-3 A 29-3 A 30-3 A 31-3 A 32-3 A33-3 A 34-3 A 35-3 A 36-3 A 37-3 A 38-3 A 39-3 A 40-3 A 41-3 A 42-3 A43-3 A 44-3 A 45-3 A 46-3 A 47-3 A 48-3 A 49-3 A 50-3 B 51-3 B 52-3 B53-3 A 54-3 A 55-3 A 56-3 A 57-3 A 58-3 A 59-3 A 60-3 A 61-3 A 62-3 A63-3 A 64-3 A 65-3 A 66-3 A 67-3 A 68-3 A 69-3 A 70-3 A 71-3 A 72-3 A73-3 A 74-3 A 75-3 A 76-3 A 77-3 A 78-3 B 79-3 D 80-3 B 81-3 C 82-3 A83-3 A 84-3 A 85-3 A 86-3 A 87-3 A 88-3 A 89-3 A 90-3 A 91-3 A 92-3 A93-3 A 94-3 A 95-3 A 96-3 A 97-3 A 98-3 A 99-3 A 100-3  A 101-3  A102-3  A 103-3  A 104-3  A 105-3  A 106-3  A 107-3  D 108-3  A 109-3  A110-3  A 111-3  A 112-3  A 113-3  A 114-3  A 115-3  A 116-3  A 117-3  A118-3  A 119-3  A 120-3  A 121-3  A 122-3  A 123-3  B 124-3  A 125-3  A126-3  A 127-3  A 128-3  A 129-3  A 130-3  A 131-3  A 132-3  A 133-3  A134-3  A 135-3  A 136-3  A 137-3  A 138-3  A 139-3  A 140-3  A 141-3  A142-3  A 143-3  A 144-3  A 145-3  A 146-3  A 147-3  A 148-3  A 149-3  A150-3  A 151-3  A 152-3  A 153-3  A 154-3  A 155-3  A 156-3  A 157-3  A158-3  A 159-3  A 160-3  A 161-3  A 162-3  A 163-3  A 164-3  A 165-3  B166-3  B 167-3  A 168-3  A 169-3  A 170-3  A 171-3  A 172-3  A 173-3  A174-3  A 175-3  A 176-3  A 177-3  A 178-3  A 179-3  A 180-3  A 181-3  A182-3  A 183-3  A 184-3  A 185-3  A 186-3  A 187-3  A 188-3  A 189-3  A190-3  A 191-3  A 192-3  A 193-3  B 194-3  A 195-3  A 196-3  A 197-3  A198-3  A 199-3  A 200-3  A 201-3  A 202-3  A 203-3  A 204-3  A 205-3  A206-3  A 207-3  A 208-3  A 209-3  A 210-3  A 211-3  A 212-3  A 213-3  A214-3  A 215-3  A 216-3  A 217-3  A 218-3  A 219-3  A 220-3  A 221-3  A222-3  A 223-3  A 224-3  A 225-3  A 226-3  A 227-3  A 228-3  A 229-3  A230-3  A 231-3  A 232-3  A 233-3  A 234-3  A 235-3  A 236-3  A 237-3  A238-3  A 239-3  A 240-3  A 241-3  A 242-3  A 243-3  A 244-3  A 245-3  A246-3  A 247-3  A 248-3  A 249-3  A 250-3  A 251-3  A 252-3  A 253-3  A254-3  A 255-3  A 256-3  A 257-3  A 258-3  A 259-3  A 260-3  A 261-3  A262-3  B 263-3  A 264-3  A 265-3  A 266-3  A 267-3  A 268-3  A 269-3  A270-3  A 271-3  — 272-3  A 273-3  A 274-3  A 275-3  A 276-3  A 277-3  A278-3  A 279-3  A 280-3  A 281-3  A 282-3  A 283-3  A 284-3  A 285-3  A286-3  A 287-3  A 288-3  A 289-3  A 290-3  A 291-3  A 292-3  A 293-3  A294-3  A 295-3  A 296-3  A 297-3  A Classification codes for biochemicalpotencies: A: IC₅₀ < 0.1 uM B: 0.1 uM ≤ IC₅₀ < 1 uM C: 1 uM ≤ IC₅₀ < 3uM D: 3 uM ≤ IC₅₀ < 10 uM E: 10 uM < IC₅₀

TABLE 4 Cellular potencies # Cellular IC₅₀  3-1 B 26-1 C 33-1 A 40-1 B41-1 C 51-1 C 52-1 C 70-1 C  1-1a A  2-1a C  3-1a C  4-1a C  5-1a C 6-1a A  7-1a C  8-1a C  9-1a B  10-1a C  11-1a B  12-1a C  13-1a B 14-1a C  15-1a C  16-1a B  17-1a A  18-1a A  19-1a C  20-1a B  21-1a B 22-1a C  23-1a C  24-1a C  25-1a C  26-1a C  27-1a C  28-1a A  29-1a C 30-1a A  31-1a B  32-1a C  33-1a B  34-1a A  35-1a B  36-1a C  37-1a C 38-1a B  39-1a B  40-1a C  41-1a C  42-1a C  43-1a C  44-1a B  45-1a A 46-1a C  47-1a A  48-1a C  49-1a B  50-1a A  51-1a C  52-1a C  53-1a C 54-1a A  55-1a A  56-1a A  57-1a C  58-1a B  59-1a C  60-1a C  61-1a C 62-1a C  63-1a C  64-1a C  65-1a C  66-1a A  67-1a C  68-1a B  69-1a C 70-1a A  71-1a A  72-1a A  73-1a C  74-1a B  75-1a A  76-1a C  77-1a A 78-1a B  79-1a A  80-1a C  81-1a A  82-1a A  83-1a C  84-1a A  85-1a A 86-1a B  87-1a A  88-1a A  89-1a A  90-1a A  91-1a A  92-1a A  93-1a A 94-1a A  95-1a C  96-1a A  97-1a A  98-1a A  99-1a A 100-1a B 101-1a A102-1a A 103-1a A 104-1a A 105-1a B 106-1a B 107-1a A 108-1a A 109-1a C110-1a B 111-1a B 112-1a C 113-1a C 114-1a C 115-1a A 116-1a B 117-1a C118-1a A 119-1a A 120-1a A 121-1a A 122-1a C 123-1a B 124-1a B 125-1a A126-1a B 127-1a A 128-1a B 129-1a C 130-1a C 131-1a A 132-1a A 133-1a A134-1a A 135-1a A 136-1a A 137-1a A 139-1a A 140-1a A 141-1a A 142-1a A143-1a A 144-1a A 145-1a B 146-1a A 147-1a A 148-1a A 149-1a A 150-1a B151-1a A 152-1a A 153-1a A 154-1a A 155-1a A 156-1a B 157-1a A 158-1a B159-1a C 160-1a C 161-1a A 162-1a A 163-1a A 164-1a A 165-1a A 166-1a A167-1a A 168-1a A 169-1a A 170-1a A 171-1a A 172-1a A 173-1a A 174-1a A175-1a B 176-1a A 177-1a B 178-1a C 179-1a A 180-1a C 181-1a A 182-1a A183-1a A 184-1a A 185-1a A 186-1a A 187-1a A 188-1a A 189-1a A 190-1a A191-1a A 192-1a A 193-1a A 194-1a A 195-1a A 196-1a A 197-1a A 198-1a A199-1a A 200-1a A 201-1a A 202-1a A 203-1a A 204-1a A 205-1a A 206-1a A207-1a A 208-1a A 209-1a B 210-1a A 211-1a A 212-1a A 213-1a C 214-1a B215-1a A 216-1a A 217-1a A 218-1a A 219-1a A 220-1a A 221-1a A 222-1a C223-1a C 224-1a A 225-1a A 226-1a A 227-1a A 228-1a A 229-1a A 230-1a A231-1a A 232-1a A 233-1a C 234-1a A 235-1a A 236-1a A 237-1a C 238-1a C239-1a A 240-1a A 241-1a A 242-1a A 243-1a A 244-1a A 245-1a A 246-1a B247-1a A 248-1a A 249-1a A 250-1a A 251-1a A 252-1a A 253-1a A 254-1a A255-1a A 256-1a A 257-1a A 258-1a B 259-1a A 260-1a A 261-1a A 262-1a A263-1a A 264-1a B 265-1a A 266-1a A 267-1a C 268-1a C 269-1a A 270-1a A271-1a A 273-1a C 274-1a A 275-1a C 276-1a A 277-1a A 278-1a A 279-1a A280-1a C 281-1a C 282-1a A 283-1a A 284-1a A 285-1a A 286-1a A 287-1a A288-1a A 289-1a B 290-1a A 291-1a C 292-1a A 293-1a A 294-1a A 295-1a A296-1a B 297-1a B 298-1a C 299-1a A 300-1a A 301-1a B 302-1a A 303-1a A304-1a A 305-1a A 306-1a A 307-1a C 308-1a A 309-1a A 310-1a — 311-1a —312-1a — 313-1a — 314-1a — 315-1a — 316-1a — 317-1a — 318-1a — 319-1a —320-1a — 321-1a — 322-1a — 323-1a — 324-1a — 325-1a — 326-1a — 327-1a —328-1a — 329-1a — 330-1a — 331-1a B 332-1a C 333-1a C 334-1a C 335-1a B336-1a C 337-1a B 338-1a C 339-1a C 340-1a C 341-1a C 346-1a C 347-1a C348-1a C 349-1a C 350-1a C 351-1a B 352-1a C 353-1a C 354-1a C 355-1a C356-1a C 357-1a C 358-1a C 359-1a C 360-1a C 361-1a C 364-1a C 365-1a C366-1a C 367-1a B 368-1a A 369-1a C 370-1a B 371-1a C 372-1a C 373-1a C374-1a C 375-1a C 376-1a B 377-1a C 378-1a C 379-1a C 380-1a C 382-1a C383-1a C 384-1a C 385-1a C 386-1a C 387-1a C 388-1a C 389-1a C 390-1a B391-1a C 392-1a B 393-1a C 394-1a A 395-1a C 396-1a C 397-1a C 398-1a C399-1a C 400-1a B 401-1a C 402-1a C 403-1a C 404-1a C 405-1a C 406-1a B407-1a C 408-1a B 409-1a C 410-1a B 411-1a — 412-1a C 413-1a C 414-1a C415-1a C 416-1a C 417-1a A 418-1a C 419-1a C 420-1a B 421-1a B 422-1a C423-1a C 424-1a C 425-1a C 426-1a C 427-1a A 428-1a C 429-1a C 430-1a C431-1a C 432-1a C 433-1a B 434-1a A 435-1a C 436-1a A 437-1a B 438-1a C439-1a B 440-1a C 441-1a B 442-1a C 443-1a C 445-1a C 446-1a A 447-1a C448-1a A 449-1a A 450-1a C 451-1a C 452-1a C 453-1a B 454-1a B 455-1a A456-1a A 457-1a C 458-1a A 459-1a C 460-1a C 461-1a C 462-1a C 463-1a A464-1a A 465-1a A 466-1a A 467-1a A 468-1a B 469-1a B 470-1a A 471-1a A472-1a C 475-1a B 478-1a — 479-1a — 480-1a — 481-1a — 482-1a A 483-1a A484-1a A 485-1a A 486-1a A 487-1a A 488-1a A 489-1a A 490-1a A 491-1a A492-1a A 493-1a A 494-1a A 495-1a A 496-1a A 497-1a A 498-1a A 499-1a A500-1a A 501-1a A 502-1a A 503-1a A 504-1a A 505-1a A 506-1a A 507-1a A508-1a A 509-1a B 510-1a B 511-1a B 512-1a B 513-1a B 514-1a B 515-1a B516-1a B 517-1a B 518-1a B 519-1a B 520-1a B 521-1a B 522-1a B 523-1a B524-1a B 525-1a B 526-1a B 527-1a B 528-1a B 529-1a B 530-1a B 531-1a B532-1a B 533-1a B 534-1a B 535-1a B 536-1a B 537-1a B 538-1a C 539-1a C540-1a C 541-1a C 542-1a C 543-1a C 544-1a C 545-1a C 546-1a C 547-1a C548-1a C 549-1a C 550-1a C 551-1a C 552-1a C 553-1a C 554-1a C 555-1a C556-1a C 557-1a C 558-1a C 559-1a C 560-1a C 561-1a C 562-1a C 563-1a C564-1a C 565-1a C 566-1a C 567-1a C 568-1a C 569-1a C 570-1a C 571-1a C572-1a C 573-1a C 574-1a C 575-1a C 576-1a C 577-1a C 578-1a C 579-1a C580-1a C 581-1a C 582-1a C 583-1a C 584-1a C 585-1a C 586-1a C 587-1a C588-1a C 589-1a C 590-1a C 591-1a C 592-1a C 593-1a C 594-1a C 595-1a C596-1a C 597-1a C 598-1a C 599-1a C 600-1a C 601-1a C 602-1a C 603-1a C604-1a C 605-1a C 606-1a C 607-1a C 608-1a C 609-1a C 610-1a C 611-1a C612-1a C 613-1a C 614-1a C 615-1a C 616-1a C 617-1a C 618-1a C 619-1a C620-1a C 621-1a C 622-1a C 623-1a C 624-1a C 625-1a C 626-1a D 627-1a D628-1a D 629-1a D 630-1a D 631-1a D 632-1a D 635-1a D 636-1a D 637-1a D638-1a D 639-1a D 640-1a D 641-1a D 642-1a D 643-1a D 644-1a D 645-1a D646-1a D 647-1a C 648-1a D 649-1a D 650-1a D 651-1a D 652-1a D 653-1a D654-1a D 655-1a D 656-1a D 657-1a D 658-1a D 659-1a D 660-1a D 661-1a D662-1a D 663-1a D 664-1a D 665-1a D 666-1a D 667-1a D 668-1a D 669-1a D670-1a D 671-1a D 672-1a C 673-1a C 674-1a D 675-1a D 676-1a D 677-1a D678-1a D 679-1a D 680-1a D 681-1a D 682-1a D 683-1a D 684-1a D 685-1a D686-1a D 687-1a D  1-3 D  2-3 A  3-3 A  4-3 A  5-3 B  6-3 A  7-3 A  8-3A  9-3 A 10-3 A 11-3 B 12-3 A 13-3 A 14-3 A 15-3 B 16-3 A 17-3 A 18-3 C19-3 A 20-3 A 21-3 A 22-3 A 23-3 A 24-3 A 25-3 A 26-3 A 27-3 A 28-3 A29-3 A 30-3 A 31-3 A 32-3 A 33-3 A 34-3 B 35-3 A 36-3 A 37-3 A 38-3 A39-3 A 40-3 A 41-3 A 42-3 A 43-3 A 44-3 A 45-3 A 46-3 A 47-3 C 48-3 A49-3 A 50-3 D 51-3 D 52-3 D 53-3 A 54-3 A 55-3 A 56-3 A 57-3 A 58-3 A59-3 A 60-3 A 61-3 A 62-3 A 63-3 A 64-3 A 65-3 A 66-3 A 67-3 A 68-3 A69-3 A 70-3 A 71-3 C 72-3 A 73-3 A 74-3 A 75-3 A 76-3 A 77-3 A 78-3 D79-3 D 80-3 D 81-3 D 82-3 A 83-3 A 84-3 A 85-3 A 86-3 A 87-3 A 88-3 A89-3 A 90-3 A 91-3 A 92-3 A 93-3 A 94-3 A 95-3 A 96-3 A 97-3 A 98-3 A99-3 A 100-3  A 101-3  A 102-3  A 103-3  A 104-3  A 105-3  A 106-3  A107-3  D 108-3  A 109-3  A 110-3  A 111-3  A 112-3  A 113-3  A 114-3  A115-3  A 116-3  A 117-3  A 118-3  A 119-3  A 120-3  A 121-3  A 122-3  A123-3  C 124-3  A 125-3  A 126-3  A 127-3  A 128-3  A 129-3  A 130-3  A131-3  A 132-3  A 133-3  A 134-3  A 135-3  A 136-3  A 137-3  A 138-3  A139-3  A 140-3  A 141-3  A 142-3  A 143-3  A 144-3  A 145-3  C 146-3  A147-3  A 148-3  A 149-3  A 150-3  A 151-3  A 152-3  A 153-3  A 154-3  A155-3  A 156-3  A 157-3  A 158-3  A 159-3  A 160-3  A 161-3  A 162-3  A163-3  B 164-3  A 165-3  D 166-3  D 167-3  A 168-3  A 169-3  A 170-3  A171-3  A 172-3  A 173-3  A 174-3  A 175-3  A 176-3  A 177-3  A 178-3  A179-3  A 180-3  A 181-3  A 182-3  A 183-3  A 184-3  A 185-3  A 186-3  A187-3  C 188-3  A 189-3  A 190-3  A 191-3  A 192-3  A 193-3  D 194-3  A195-3  A 196-3  A 197-3  A 198-3  A 199-3  A 200-3  A 201-3  A 202-3  A203-3  A 204-3  A 205-3  A 206-3  A 207-3  A 208-3  A 209-3  A 210-3  A211-3  A 212-3  A 213-3  A 214-3  A 215-3  A 216-3  A 217-3  A 218-3  A219-3  A 220-3  A 221-3  A 222-3  A 223-3  A 224-3  A 225-3  A 226-3  A227-3  A 228-3  A 229-3  A 230-3  A 231-3  A 232-3  A 233-3  A 234-3  A235-3  A 236-3  A 237-3  A 238-3  A 239-3  A 240-3  A 241-3  A 242-3  A243-3  A 244-3  A 245-3  A 246-3  A 247-3  A 248-3  A 249-3  A 250-3  A251-3  A 252-3  A 253-3  A 254-3  B 255-3  B 256-3  B 257-3  A 258-3  A259-3  A 260-3  A 261-3  A 262-3  D 263-3  A 264-3  A 265-3  A 266-3  A267-3  A 268-3  A 269-3  A 270-3  A 271-3  — 272-3  A 273-3  B 274-3  A275-3  A 276-3  A 277-3  A 278-3  C 279-3  C 280-3  A 281-3  A 282-3  A283-3  A 284-3  A 285-3  A 286-3  A 287-3  A 288-3  A 289-3  A 290-3  A291-3  A 292-3  A 293-3  A 294-3  A 295-3  A 296-3  A 297-3  AClassification codes for cellular potencies: A: IC₅₀ < 5 uM B: 5 uM ≤IC₅₀ < 10 uM C: 10 uM ≤ IC₅₀ < 20 uM D: ≥20 uM

Other Embodiments

The foregoing has been a description of certain non-limiting embodimentsof the invention. Those of ordinary skill in the art will appreciatethat various changes and modifications to this description may be madewithout departing from the spirit or scope of the present invention, asdefined in the following claims.

1-35. (canceled)
 36. A compound of Formula (I-h):

or a pharmaceutically acceptable salt thereof, wherein: X is —O—, —S—, or —CH₂—; R¹ and R^(1a) are each independently hydrogen or optionally substituted C₁₋₄ aliphatic; each of R^(2a), R^(2b), R^(2c), and R^(2d) is independently hydrogen, halogen, —CN, —NO₂, —C(═O)R^(A2), —C(═O)OR^(A2), —C(═O)N(R^(A2))₂, —OR^(A2), —SR^(A2), —N(R^(A2))₂, —S(═O)R^(A2), —S(═O)₂R^(A2), optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, wherein each instance of R^(A2) is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R^(A2) groups attached to the same nitrogen atom are joined to form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring; G₈ is C—R⁸ or N; G₁₀ is C—R¹⁰ or N; G₁₁ is C—R¹¹ or N; G₁₂ is C—R¹² or N; provided at least two instances of G₈, G₁₀, G₁₁, or G₁₂ is N; each instance of R⁸, R¹⁰, R¹¹, and R¹² is independently selected from the group consisting of hydrogen, halo, —CN, —NO₂, —C(═O)R′, —C(═O)OR′, —C(═O)N(R′)₂, optionally substituted alkyl, and -L¹-R³; each instance of R′ is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R′ groups attached to the same nitrogen are joined to form an optionally substituted heterocyclyl ring or optionally substituted heteroaryl ring; each instance of L¹ and L² is independently a bond, —O—, —N(R^(L))—, —S—, —C(O)—, —C(O)O—, —C(O)S—, —C(O)N(R^(L))—, —C(O)N(R^(L))N(R^(L))—, —OC(O)—, —OC(O)N(R^(L))—, —NR^(L)C(O)—, —NR^(L)C(O)N(R^(L))—, —NR^(L)C(O)N(R^(L))N(R^(L))—, —NR^(L)C(O)O—, —SC(O)—, —C(═NR^(L))—, —C(═NNR^(L))—, —C(═NOR^(L))—, —C(═NR^(L))N(R^(L))—, —NR^(L)C(═NR^(L))—, —C(S)—, —C(S)N(R^(L))—, —NR^(L)C(S)—, —S(O)—, —OS(O)₂—, —S(O)₂O—, —SO₂—, —N(R^(L))SO₂—, —SO₂N(R^(L))—, —N(R^(L))SO₂N(R^(L))—, an optionally substituted C₁₋₁₀ saturated or unsaturated hydrocarbon chain, wherein one or more moieties selected from the group consisting of —O—, —N(R^(L))—, —S—, —C(O)—, —C(O)O—, —C(O)S—, —C(O)N(R^(L))—, —C(O)N(R^(L))N(R^(L))—, —OC(O)—, —OC(O)N(R^(L))—, —NR^(L)C(O)—, —NR^(L)C(O)N(R^(L))—, —NR^(L)C(O)N(R^(L))N(R^(L))—, —NR^(L)C(O)O—, —SC(O)—, —C(═NR^(L))—, —C(═NNR^(L))—, —C(═NOR^(L))—, —C(═NR^(L))N(R^(L))—, —NR^(L)C(═NR^(L))—, —C(S)—, —C(S)N(R^(L))—, —NR^(L)C(S)—, —S(O)—, —OS(O)₂—, —S(O)₂O—, —SO₂—, —N(R^(L))SO₂—, —SO₂N(R^(L))—, and —N(R^(L))SO₂N(R^(L))— is optionally and independently present between two carbon atoms of the hydrocarbon chain, and optionally and independently present at one or both ends of the hydrocarbon chain; each R^(L) is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group, or R^(L) and R³ taken together form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring, or R^(L) and R¹³ taken together form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring; R³ is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, provided when R³ is hydrogen, then L¹ is not a bond; and R¹³ is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.
 37. The compound or pharmaceutically acceptable salt of claim 36, wherein: X is O; R¹ is optionally substituted C₁₋₄ aliphatic; R^(1a) is hydrogen; G₁₀ is C—R¹⁰; and G₁₁ is C—R¹¹.
 38. The compound of claim 36, having the structure of Formula (I-1-A) or Formula (I-1-A′):

or a pharmaceutically acceptable salt thereof, wherein: m is 0 or 1; R¹ is hydrogen, methyl, ethyl, n-propyl, isopropyl, or cyclopropyl; R^(1a) is hydrogen; R^(2a), R^(2b), and R^(2d) are hydrogen; R^(2c) is hydrogen or halogen; R³ is a cyclic or acyclic moiety; R¹⁰ is hydrogen, optionally substituted alkyl, optionally substituted C₃₋₄cycloalkyl, or halogen; each instance of R^(13A) is independently optionally substituted alkyl; L¹ is a bond, —N(R^(L))—, —NR^(L)C(O)O—, —NR^(L)C(O)N(R^(L))—, —N(R^(L))—, —N(R^(L))SO₂N(R^(L))—, —NR^(L)—(CH₂)_(x)—C(O)O—, —NR^(L)—(CH₂)_(x)—O—, —NR^(L)C(O)N(R^(L))—, —NR^(L)—(CH₂)_(x)—, —(CH₂)_(x)—NR^(L), —NR^(L)C(O)O(CH₂)_(x)—, —NR^(L)C(O)NR^(L)(CH₂)_(x)—, or —NR^(L)(CH₂)_(x)NR^(L)C(O)—; and Q is N; Y is O; and W is CH or CR^(3A); or Q is N, Y is S, and W is CH or CR^(13A).
 39. The compound or pharmaceutically acceptable salt of claim 38, wherein: R^(2c) is halogen; L¹ is a bond or —N(R^(L))—; Q is N; Y is O; and W is CH or CR^(13A).
 40. The compound or pharmaceutically acceptable salt of claim 39, wherein: R¹ is methyl; R^(2c) is chloro; L¹ is a bond; R³ is a cyclic moiety; R¹⁰ is methyl; W is CR^(13A); and each R^(13A) is methyl.
 41. The compound of claim 36, having the structure of Formula (I-1-A) or Formula (I-1-A′):

or a pharmaceutically acceptable salt thereof, wherein: m is 1; R¹ is hydrogen, methyl, ethyl, n-propyl, isopropyl, or cyclopropyl; R^(1a) is hydrogen; R^(2a), R^(2d), and R^(2d) are hydrogen; R^(2c) is hydrogen, chloro or fluoro; W is CH or CR^(13A); Y is O or S; R¹⁰ is hydrogen, methyl, or chloro; each R^(13A) is optionally substituted alkyl; and R^(L) and R³ taken together form an optionally substituted heterocyclic ring, an optionally substituted heterocyclic ring which is fused to an optionally substituted aromatic ring, an optionally substituted heterocyclic ring which is fused to an optionally substituted heteroaromatic ring, an optionally substituted bicyclic heterocyclic ring system, an optionally substituted ortho-fused heterocyclic ring system, an optionally substituted spiro-fused heterocyclic ring system, or an optionally substituted bridged heterocyclic ring system.
 42. The compound or pharmaceutically acceptable salt of claim 41, wherein: R¹ is methyl; R^(2c) is chloro; W is CR^(13A); Y is O; R¹⁰ is methyl; and each R^(13A) is methyl.
 43. The compound of claim 36, having the structure of Formula (I-1-Aa6) or Formula (I-1-Aa6′):

or a pharmaceutically acceptable salt thereof, wherein: m is 1; each n is independently 0 or 1; R¹ is hydrogen, methyl, ethyl, n-propyl, isopropyl, or cyclopropyl; R^(1a) is hydrogen; R^(2a), R^(2d), and R^(2d) are hydrogen; R^(2c) is hydrogen, chloro or fluoro; each R^(3A) is independently an optionally substituted C₁₋₆ alkyl; R^(3B) is —CO₂R^(aa), wherein R^(aa) is C₁₋₁₀ alkyl; R¹⁰ is hydrogen, methyl, or chloro; each R^(13A) is optionally substituted alkyl; W is CH or CR^(3A); and Y is O or S.
 44. The compound or pharmaceutically acceptable salt of claim 43, wherein: each n is 0; R¹ is methyl; R^(2c) is chloro; R^(3B) is —CO₂Me; W is CR^(13A); Y is O; R¹⁰ is methyl; and each R^(13A) is methyl.
 45. The compound of claim 36, having the structure of Formula (I-1-Aa7) or Formula (I-1-Aa7′):

or a pharmaceutically acceptable salt thereof, wherein: m is 1; n is 0 or 1; R¹ is hydrogen, methyl, ethyl, n-propyl, isopropyl, or cyclopropyl; R^(1a) is hydrogen; R^(2a), R^(2d), and R^(2d) are hydrogen; R^(2c) is hydrogen, chloro or fluoro; R^(3A) is optionally substituted C₁₋₆ alkyl; R¹⁰ is hydrogen, methyl, or chloro; each R^(13A) is optionally substituted alkyl; W is CH or CR^(3A); and Y is O or S.
 46. The compound or pharmaceutically acceptable salt of claim 45, wherein: n is 0; R¹ is methyl; R^(2c) is chloro; W is CR^(13A); Y is O; R¹⁰ is methyl; and each R^(13A) is methyl.
 47. A pharmaceutical composition comprising a compound of claim 36, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
 48. A method of treating a CARM1-mediated disorder, comprising administering to a subject in need thereof an effective amount of a compound of claim 36, or a pharmaceutically acceptable salt thereof.
 49. The method of claim 48, wherein the disorder is a proliferative disorder or a metabolic disorder.
 50. The method of claim 49, wherein the disorder is cancer.
 51. The method of claim 50, wherein the cancer is associated with E2F1 upregulation.
 52. The method of claim 50, wherein the cancer is breast cancer, prostate cancer, or colorectal cancer.
 53. The method of claim 52, wherein the breast cancer is ERα-dependent breast cancer.
 54. The method of claim 52, wherein the prostate cancer is castration-resistant prostate cancer.
 55. The method of claim 52, wherein the cancer is colorectal cancer associated with dysregulated WNT/β-catenin signaling. 